US 20180142003A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2018/0142003 A1**

LOGTENBERG et al. (43) **Pub. Date: May 24, 2018**

(54) **ANTIBODY PRODUCING NON-HUMAN ANIMALS**

(71) Applicant: **Merus N.V.**, Utrecht (NL)

(72) Inventors: **Ton LOGTENBERG**, Driebergen (NL); **Mark THROSBY**, Utrecht (NL); **Robert A. KRAMER**, Utrecht (NL); **Rui Daniel PINTO**, Utrecht (NL); **Cornelis A. DE KRUIF**, De Bilt (NL); **Erwin HOUTZAGER**, Zeist (NL)

(73) Assignee: **Merus N.V.**, Utrecht (NL)

(21) Appl. No.: **15/866,374**

(22) Filed: **Jan. 9, 2018**

Related U.S. Application Data

(60) Division of application No. 12/589,181, filed on Oct. 19, 2009, which is a continuation of application No. 12/459,285, filed on Jun. 29, 2009, now abandoned.

(60) Provisional application No. 61/133,274, filed on Jun. 27, 2008.

Publication Classification

(51) **Int. Cl.**


C07K 16/12	(2006.01)
C12P 21/00	(2006.01)
A01K 67/027	(2006.01)
C12N 15/85	(2006.01)
C07K 16/24	(2006.01)
C07K 14/47	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/1282*** (2013.01); ***C12P 21/00*** (2013.01); ***A01K 67/027*** (2013.01); ***C12N 15/8509*** (2013.01); *C07K 2317/24* (2013.01); ***C07K 16/248*** (2013.01); ***C07K 14/47*** (2013.01); *A01K 2267/01* (2013.01); *A01K 2227/105* (2013.01); *A01K 2217/206* (2013.01); *A01K 2217/15* (2013.01); *A01K 2217/075* (2013.01); *A01K 2217/052* (2013.01); *A01K 2207/15* (2013.01); ***A01K 67/0278*** (2013.01)

(57) **ABSTRACT**

Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.





SfiI
ExtMVH-1 & -2
MVH-1 to -25
BsteII
ExtMCHγ1
MCHγ1
VH
CHγ1
MJH-Rev1 to 4
ExtMJH-Rev1 to 4
BstEII
MCHγ1-Rev
ExtMCH-Rev
NotI
SfiI
ExtMVH-1 & -2
MVH-1 to -35
VH's
CH1
MJH-Rev1 to 4
ExtMJH-Rev1 to 4
BstEII

Fig. 1



V_H amplification
(4 reactions)
Intermediate step
(2 reactions)
Site introduction
(8 reactions)
MVH-1 to -25
MJH-Rev1
ExtMJH-Rev1&2
ExtMVH-1
ExtMVH-2
A_1
B_1
MJH-Rev2
ExtMJH-Rev2int
A_2
B_2
MJH-Rev3
A_3
B_3
MJH-Rev4
A_4
B_4
ExtMJH-Rev3
ExtMJH-Rev4

Fig. 2




MV1043
6772 bp
F1 origin
Bla promoter
Amp
ColE1
LacZ promoter
g3 leader
O12 VK/JK1
Ck
rbs
PelB leader
stuffer 1.2kb
CH1
His Tag
Myc Tag
Amber stop
Gene III protein

Fig. 3



Mouse kappa silencing strategy Merus

13181 bp

Fig. 4



To be deleted: part2
Igl-J3
Igl-J3p
Igl-C3
Igl-J1
Igl-C1
Igl-V1
Igl-C4
Igl-J4
Igl-C2
Igl-J2
Igl-V3
To be deleted: part1
Igl-V2
Mouse lambda silencing strategy Merus
234987 bp

Fig. 5



stop
rat CK allele a ORF
IGKV1-39 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak

Fig. 6



stop
rat CK allele a ORF
IGLV2-14 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak

Fig. 7



3' enhancer
stop
rat CK allele a ORF
Intron enhancer
IGKV1-39 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak
IGKV1-39 promoter

Fig. 8



3' enhancer
stop
rat CK allele a ORF
Intron enhancer
IGLV2-14 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak
IGKV1-39 promoter

Fig. 9



3' enhancer
stop
rat CK allele a ORF
IGKV1-39 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak
IGKV1-39 promoter

Fig. 10



IGKV1-39 rearranged ORF
IGKV1-39 leader part 2
IGKV1-39 leader intron
IGKV1-39 leader part 1
Kozak
IGKV1-39 promoter
rat CK allele a ORF
stop
truncated 3' enhancer

Fig. 11

Fig. 12

human germline IGKV1-39/J DNA

```
  1   GAC ATC CAG ATG ACC CAG AGC CCC AGC AGC CTG AGC GCC AGC GTG GGC GAC AGA GTG ACC ATC ACC TGC AGA GCC AGC
 79   CAG AGC ATC AGC AGC TAC CTG AAC TGG TAT CAG CAG AAG CCC GGC AAG GCC CCC AAG CTG CTG ATC TAC GCC GCC AGC
157   TCC CTG CAG AGC GGC GTG CCC AGC AGA TTC AGC GGC AGC GGC TCC GGC ACC GAC TTC ACC CTG ACC ATC AGC AGC CTG
235   CAG CCC GAG GAC TTC GCC ACC TAC TAC TGC CAG CAG AGC TAC AGC ACC CCC CCC ACC TTC GGC CAG GGC ACC AAG GTG
313   GAG ATC AAG
```

human germline IGKV1-39/J Protein

```
  1   DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA
 51   ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ
101   GTKVEIK
```

human germline IGLV2-14/J DNA

```
  1   CAG TCT GCC CTG ACC CAG CCC GCC TCT GTG TCT GGC AGC CCT GGC CAG AGC ATC ACC ATC AGC TGC ACC GGC ACC AGC
 79   AGC GAC GTG GGC GGC TAC AAC TAC GTG TCC TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATG ATC TAC GAG
157   GTG TCC AAC AGA CCC AGC GGC GTG AGC AAC AGA TTC AGC GGC AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC
235   GGC CTC CAG GCT GAG GAC GAG GCC GAC TAC TAC TGC AGC AGC TAC ACC AGC AGC TCC ACC CTG GTG TTT GGC GGC GGA
313   ACA AAG CTG ACC GTG CTG
```

human germline IGLV2-14/J Protein

```
  1   QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI
 51   YEVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTLV
101   FGGGTKLTVL
```

Rat IGCK allele a DNA

```
  1   AGA GCC GAC GCC GCT CCC ACC GTG TCC ATC TTC CCC CCC AGC ATG GAA CAG CTG ACC TCT GGC GGA GCC ACC GTG GTC
 79   TGC TTC GTG AAC AAC TTC TAC CCC AGA GAC ATC AGC GTG AAG TGG AAG ATC GAC GGC AGC GAG CAG AGG GAC GGC GTG
157   CTG GAC AGC GTG ACC GAC CAG GAC AGC AAG GAC TCC ACC TAC AGC ATG AGC AGC ACC CTG AGC CTG ACC AAG GTG GAG
235   TAC GAG AGG CAC AAC CTG TAC ACC TGC GAG GTG GTG CAC AAG ACC AGC TCC AGC CCC GTG GTC AAG TCC TTC AAC CGG
313   AAC GAG TGT
```

Fig. 12, contd.

Rat IGCK allele a protein

```
  1   RADAAPTVSI FPPSMEQLTS GGATVVCFVN NFYPRDISVK WKIDGSEQRD
 51   GVLDSVTDQD SKDSTYSMSS TLSLTKVEYE RHNLYTCEVV HKTSSSPVVK
101   SFNRNEC
```

IGKV1-39/J-Ck

```
  1   GGT ACC GCG GCC GCC ACC ATG GAC ATG AGA GTG CCC GCC CAG CTC CTG GGG CTC CTG CTA CTC TGG CTC CGA GGT AAG
 79   GAT GGA GAA CAC TAG GAA TTT ACT CAG CCA GTG TGC TCA GTA CTG ACT GGA ACT TCA GGG AAG TTC TCT GAT AAC ATG
157   ATT AAT AGT AAG AAT ATT TGT TTT TAT GTT TCC AAT CTC AGG TGC CAG ATG TGA CAT CCA GAT GAC CCA GAG CCC CAG
235   CAG CCT GAG CGC CAG CGT GGG CGA CAG AGT GAC CAT CAC CTG CAG AGC CAG CCA GAG CAT CAG CAG CTA CCT GAA CTG
313   GTA TCA GCA GAA GCC CGG CAA GGC CCC CAA GCT GCT GAT CTA CGC CGC CAG CTC CCT GCA GAG CGG CGT GCC CAG CAG
391   ATT CAG CGG CAG CGG CTC CGG CAC CGA CTT CAC CCT GAC CAT CAG CAG CCT GCA GCC CGA GGA CTT CGC CAC CTA CTA
469   CTG CCA GCA GAG CTA CAG CAC CCC CCC CAC CTT CGG CCA GGG CAC CAA GGT GGA GAT CAA GAG AGC CGA CGC CGC TCC
547   CAC CGT GTC CAT CTT CCC CCC CAG CAT GGA ACA GCT GAC CTC TGG CGG AGC CAC CGT GGT CTG CTT CGT GAA CAA CTT
625   CTA CCC CAG AGA CAT CAG CGT GAA GTG GAA GAT CGA CGG CAG CGA GCA GAG GGA CGG CGT GCT GGA CAG CGT GAC CGA
703   CCA GGA CAG CAA GGA CTC CAC CTA CAG CAT GAG CAG CAC CCT GAG CCT GAC CAA GGT GGA GTA CGA GAG GCA CAA CCT
781   GTA CAC CTG CGA GGT GGT GCA CAA GAC CAG CTC CAG CCC CGT GGT CAA GTC CTT CAA CCG GAA CGA GTG TTG AGC TAG
859   CGA GCT C
```

IGLV2-14/J-Ck

```
  1   GGT ACC GCG GCC GCC ACC ATG GAC ATG AGA GTG CCC GCC CAG CTC CTG GGG CTC CTG CTA CTC TGG CTC CGA GGT AAG
 79   GAT GGA GAA CAC TAG GAA TTT ACT CAG CCA GTG TGC TCA GTA CTG ACT GGA ACT TCA GGG AAG TTC TCT GAT AAC ATG
157   ATT AAT AGT AAG AAT ATT TGT TTT TAT GTT TCC AAT CTC AGG TGC CAG ATG TCA GTC TGC CCT GAC CCA GCC CGC CTC
235   TGT GTC TGG CAG CCC TGG CCA GAG CAT CAC CAT CAG CTG CAC CGG CAC CAG CAG CGA CGT GGG CGG CTA CAA CTA CGT
313   GTC CTG GTA TCA GCA GCA CCC CGG CAA GGC CCC CAA GCT GAT GAT CTA CGA GGT GTC CAA CAG ACC CAG CGG CGT GAG
391   CAA CAG ATT CAG CGG CAG CAA GAG CGG CAA CAC CGC CAG CCT GAC CAT CAG CGG CCT CCA GGC TGA GGA CGA GGC CGA
469   CTA CTA CTG CAG CAG CTA CAC CAG CAG CTC CAC CCT GGT GTT TGG CGG CGG AAC AAA GCT GAC CGT GCT GAG AGC CGA
547   CGC CGC TCC CAC CGT GTC CAT CTT CCC CCC CAG CAT GGA ACA GCT GAC CTC TGG CGG AGC CAC CGT GGT CTG CTT CGT
625   GAA CAA CTT CTA CCC CAG AGA CAT CAG CGT GAA GTG GAA GAT CGA CGG CAG CGA GCA GAG GGA CGG CGT GCT GGA CAG
703   CGT GAC CGA CCA GGA CAG CAA GGA CTC CAC CTA CAG CAT GAG CAG CAC CCT GAG CCT GAC CAA GGT GGA GTA CGA GAG
781   GCA CAA CCT GTA CAC CTG CGA GGT GGT GCA CAA GAC CAG CTC CAG CCC CGT GGT CAA GTC CTT CAA CCG GAA CGA GTG
859   TTG AGC TAG CGA GCT C
```

Fig. 12, contd.

VkP-IGKV1-39/J-Ck

```
   1 GGC CGG CCC ACA TGA AAC AAT GGG AAC CAT GTG ACA ATC ACA GAG GTG TTG TTA CTA TAG CAA AAG GGA TTG TTA CTC
  79 TCC ACA TCC CTT TAA GTA ACT TGA AGG CCT GAT AGA CCC ACC CTC TAA GAC TTC ATT AGA CAT TCC CTA CGA ATG GTT
 157 ATA CTC TCC TGT ATA CTC CCA ATA CAA CTC TAA AAT ATA TTA TTC CAT ATA GTC CTT AGG TTT GTA TTA AAG TTT GAC
 235 TTT TTT CCT TCA AAA TAT CTC TTG TCA CAA CAG CGG CTC TAG AGA GAA ATA CAT TCC CTC CAG GCA AAT CTA TGC TGC
 313 GCT GGT CTG ACC TGG GAC CCT GGG GAC ATT GCC CCT GTG CTG AGT TAC TAA GAT GAG CCA GCC CTG CAG CTG TGC TCA
 391 GCC TGC CCC ATG CCC TGC TGA TTG ATT TGC ATG TTC CAG AGC ACA GCC CCC TGC CCT GAA GAC TTT TTT ATG GGC TGG
 469 TCG CAC CCT GTG CAG GAG TCA GTC TCA GTC AGG AGC CAC CAT GGA CAT GAG AGT GCC CGC CCA GCT CCT GGG GCT CCT
 547 GCT ACT CTG GCT CCG AGG TAA GGA TGG AGA ACA CTA GGA ATT TAC TCA GCC AGT GTG CTC AGT ACT GAC TGG AAC TTC
 625 AGG GAA GTT CTC TGA TAA CAT GAT TAA TAG TAA GAA TAT TTG TTT TTA TGT TTC CAA TCT CAG GTG CCA GAT GTG ACA
 703 TCC AGA TGA CCC AGA GCC CCA GCA GCC TGA GCG CCA GCG TGG GCG ACA GAG TGA CCA TCA CCT GCA GAG CCA GCC AGA
 781 GCA TCA GCA GCT ACC TGA ACT GGT ATC AGC AGA AGC CCG GCA AGG CCC CCA AGC TGC TGA TCT ACG CCG CCA GCT CCC
 859 TGC AGA GCG GTG TGC CCA GCA GAT TCA GCG GCA CCG GCT CCG GCA CCG ACT TCA CCC TGA CCA TCA GCA GCC TGC AGC
 937 CCG AGG ACT TCG CCA CCT ACT ACT GCC AGC AGA GCT ACA GCA CCC CCC CCA CCT TCG GCC AGG GCA CCA AGG TGG AGA
1015 TCA AAC GTA AGT ACA CTT TTC TCA TCT TTT TTT ATG TGT AAG ACA CAG GTT TTC ATG TTA GGA GTT AAA GTC AGT TCA
1093 GAA AAT CTT GAG AAA ATG GAG AGG GCT CAT TAT CAG TTG ACG TGG CAT ACA GTG TCA GAT TTT CTG TTT ATC AAG CTA
1171 GTG AGA TTA GGG GCA AAA AGA GGC TTT AGT TGA GAG GAA AGT AAT TAA TAC TAT GGT CAC CAT CCA AGA GAT TGG ATC
1249 GGA GAA TAA GCA TGA GTA GTT ATT GAG ATC TGG GTC TGA CTG CAG GTA GCG TGG TCT TCT AGA CGT TTA AGT GGG AGA
1327 TTC GGA GGG GAT GAG GAA TGA AGG AAC TTC AGG ATA GAA AAG GGC TGA AGT CAA GTT CAG CTC CTA AAA TGG ATG TGG
1405 GAG CAA ACT TTG AAG ATA AAC TGA ATG ACC CAG AGG ATG AAA CAG CGC AGA TCA AAG AGG GGC CTG GAG CTC TGA GAA
1483 GAG AAG GAG ACT CAT CCG TGT TGA GTT TCC ACA AGT ACT GTC TTG AGT TTT GCA ATA AAA GTG GGA TAG CAG AGT TGA
1561 GTG AGC CGT AGG CTG AGT TCT CTC TTT TGT CTC CTA AGT TTT TAT GAC TAC AAA AAT CAG TAG TAT GTC CTG AAA TAA
1639 TCA TTA AGC TGT TTG AAA GTA TGA CTG CTT GCC ATG TAG ATA CCA TGG CTT GCT GAA TAA TCA GAA GAG GTG TGA CTC
1717 TTA TTC TAA AAT TTG TCA CAA AAT GTC AAA ATG AGA GAC TCT GTA GGA AGG AGT CCT TGA CAG ACA GCT CAA GGG GTT
1795 TTT TTC CTT TGT CTC ATT TCT ACA TCA AAG TAA ATT TGA AAT GAT CTT TTT TAT TAT AAG AGT AGA AAT ACA GTT GGG
1873 TTT GAA CTA TAT GTT TTA ATG GCC ACG GTT TTG TAA GAC ATT TGG TCC TTT GTT TTC CCA GTT ATT ACT CGA TTG TAA
1951 TTT TAT ATC GCC AGC AAT GGA CTG AAA CGG TCC GCA ACC TCT TCT TTA CAA CTG GGT GAC CTC GCG GCT GTG CCA GCC
2029 ATT TGG CGT TCA CCC TGC CGC TAA GGG CCA TGT GAA CCC CCG CGG TAG CAT CCC TTG CTC CGC GTG GAC CAC TTT CCT
2107 GAG GCA CAG TGA TAG GAA CAG AGC CAC TAA TCT GAA GAG AAC AGA GAT GTG ACA GAC TAC ACT AAT GTG AGA AAA ACA
2185 AGG AAA GGG TGA CTT ATT GGA GAT TTC AGA AAT AAA ATG CAT TTA TTA TTA TAT TCC CTT ATT TTA ATT TTC TAT TAG
2263 GGA ATT AGA AAG GGC ATA AAC TGC TTT ATC CAG TGT TAT ATT AAA AGC TTA ATG TAT ATA ATC TTT TAG AGC TAA AAT
2341 CTA CAG CCA GCA AAA GTC ATG GTA AAT ATT CTT TGA CTG AAC TCT CAC TAA ACT CCT CTA AAT TAT ATG TCA TAT TAA
2419 CTG GTT AAA TTA ATA TAA ATT TGT GAC ATG ACC TTA ACT GGT TAG GTA GGA TAT TTT TCT TCA TGC AAA AAT ATG ACT
2497 AAT AAT AAT TTA GCA CAA AAA TAT TTC CCA ATA CTT TAA TTC TGT GAT AGA AAA ATG TTT AAC TCA GCT ACT ATA ATC
2575 CCA TAA TTT TGA AAA CTA TTT ATT AGC TTT TGT GTT TGA CCC TTC CCT AGC CAA AGG CAA CTA TTT AAG GAC CCT TTA
2653 AAA CTC TTG AAA CTA CTT TAG AGT CAT TAA GTT ATT TAA CCA CTT TTA ATT ACT TTA AAA TGA TGT CAA TTC CCT TTT
2731 AAC TAT TAA TTT ATT TTA AGG GGG CAA AGG CTG CTC ATA ATT CTA TTG TTT TTC TTG GTA AAG AAC TCT CAG TTT TCG
2809 TTT TTA CTA CCT CTG TCA CCC AAG AGT TGG CAT CTC AAC AGA GGG GAC TTT CCG AGA GGC CAT CTG GCA GTT GCT TAA
2887 GAT CAG AAG TGA AGT CTG CCA GTT CCT CCC AGG CAG GTG GCC CAG ATT ACA GTT GAC CTG TTC TGG TGT GGC TAA AAA
2965 TTG TCC CAT GTG GTT ACA AAC CAT TAG ACC AGG GTC TGA TGA ATT GCT CAG AAT ATT TCT GGA CAC CCA AAT ACA GAC
```

Fig. 12, contd.

```
3043 CCT GGC TTA ACG CCC TGT CCA TAC AGT AGG TTT AGC TTG GCT ACA CCA AAG GAA GCC ATA CAG AGG CTA ATA TCA GAG
3121 TAT TCT TGG AAG AGA CAG GAG AAA ATG AAA GCC AGT TTC TGC TCT TAC CTT ATG TGC TTG TGT TCA GAC TCC CAA ACA
3199 TCA GGA GTG TCA GAT AAA CTG GTC TGA ATC TCT GTC TGA AGC ATG GAA CTG AAA AGA ATG TAG TTT CAG GGA AGA AAG
3277 GCA ATA GAA GGA AGC CTG AGA ATA TCT TCA AAG GGT CAG ACT CAA TTT ACT TTC TAA AGA AGT AGC TAG GAA CTA GGG
3355 AAT AAC TTA GAA ACA ACA AGA TTG TAT ATA TGT GCA TCC TGG CCC CAT TGT TCC TTA TCT GTA GGG ATA ACC GTG CTT
3433 TTT TGT GTG TCT GTA TAT AAC ATA ACT GTT TAC ACA TAA TAC ACT GAA ATG GAG CCC TTC GTT ACT TCA TAC CAT
2511 CCT CTG TCC TTC CTT CCT CAG GGG CCC ACG CCG CTC CCA CCG TGT CCA TCT TCC CCC CCA GCA TGG AAC ACC TGA CCT
3589 CTG GCG CCA CCG TGG TCT GCT TCC TGA ACA ACT TCT ACC CCA GAC ACA TCA GCG TGA AGT GGA AGA TCG ACG GCA
3667 GGG AGC AGA AGG ACG GCG TGC TGG ACA GCC TGA CCG ACC AGG ACA GCA AGG ACT CCA CCT GCA TGA GCA GCA CCC
3745 TGA GCC TGA CCA AGG TGG AGT ACC AGA GGC ACA ACC TGT ACA CCT GCG AGG TGG TGC ACA AGA CCA GCT CCA GCC CCG
3823 TGG TCA AGT CCT TCA ACC GGA ACG AGT GTT GAA GAC AAA GGT CCT GAG ACG CCA CCA GCT CCC CAG CTC CAT CCT
3901 ATC TTC CCT TCT AAG GTC TTG GAG GCT TCC CCA GCG ACC TAC CAC TGT GAC GGT CCA AAC CTC CTC CCC ACC
3979 TCC TTC TCC TCC CTT TCC TTG GCT TTT ATC ATG CTA ATA TTT GCA GAA AAT ATT CAA TAA AGT GAG TCT TTC
4057 CAC TTG AGA TCT CTG CTA AAT GGT AGT AAT CAG TTG TTT TTC CAG TTA CCT GGG TTT CTC TTC TAA AGA
4135 AGT TAA ATG TTT AGT TGC CCT GAA ATC CAC CAC ACT TAA AGG ATA AAT AAA ACC CTC CAC TTG CCC TGG TTG GCT GTC
4213 CAC TAC ATG GCA GTC CTT TCT AAG GTT CAC GAG TAC TAT TCA TGG CTT ATT TCT CTG GGC CAT GGT AGC TTT GAG GTC
4291 GCA TAC TTC CCA GTT TTC CCC TAA GTC GTC AAA GTC CTG AAG GGG GAC AGT CTT TAC AAG CAC ATG TTC TGT AAT
4369 CTG ATT CAA CCT ACC CAC TAA ACT TGG CGA AGC AAA GTA GAA TCA TTA TCA CAG GAA GCA AGG GCA ACC TAA ATG TGC
4447 AAG CAA TAG GAA AAT GTG GAA GCC CAT CAT AGT ACT TGG ACT TCA TCT GCT TTT GTG CCT TCA CTA AGT TTT TAA ACA
4525 TGA GCT GGC TCC TAT CTG CCA TTG GCA AGC CTG GGC ACT ACC CAC AAC CTA CTT CAA GGA CCT CTA TAC CGT GAG ATT
4603 ACA CAC ATA CAT CAA AAT TTG GGA AAA GTT CTA CCA AGC TGA GAG CTG ATC ACC CCA CTC TTA GGT GCT TAT CTC TGT
4681 ACA CCA GAA ACC TTA AGA AGC AAC CAG TAT TGA GAG ACT CAT TTA TGA AAG TCT AAA GAA TGA ATC ATA GCC CAA AAC GTC
4759 CAC CAA CAG TTA AAT TAT GAC ATG TTC ACA ATT GAG CTA TTA CTT AAT AAG GAG AAT TAA TAA AAT AAA ACT TAA CAG
4837 CAT AGT TTA ATC TCA TAA ACA AGA TAA TAA GCA AAA CAA AAC ATT TTT TCA TCA AAA CAA AAG CAG GTA AAA
4915 TTT AAA ATT AAG AGA GAC ATA AGT TTT GAG GTA GCA AGA TGG AAA CTC TGG GGC TTG GGG AAT GTT CTG TCT CTC TGT
4993 ATG GGA TGT GAA ATT GGG ATC CAT AAA AGA GTA TAT GTT CTT CCT GTA TAT ATT GTA TAC TTC ATA ATA ACT TCA
5071 CCT AAA GAA ATA TCT AAT ACC CAG TGC ATA CAT AAA AGA GGA TAC AAG GAA TGA ATC ATA CGT CAA GGC CAG AAA GAC
5149 AAT AAA GTA GGG GAT CCA GGA TCA AAT CTC CCA CAA CCT TGA GCC TTC TAC TAT TCT GCC TTC CAG AGC TCA AAG TAC
5227 AAA ACA CAT AAT TCA AAC ACA TGA TCC CTC CTT GGG GTC TCT TCC TTC ATG CAT CGA ATT AGA AAT AGC CAT GTA TAA
5305 AAT GAG ATA GAA GAG ACC TTC ATC AAC AGG TCA AAG AAT ATA GGT AAT TTT GTC TGG GTA TGA AGA GCC CAC GTA TCA
5383 AAG GTT ACA TTA GGG AAG GAG GAC ACT AAC AGT GAC TTT CAT TCT CCC CCT CTT CCT GGA GGC CCC TGC ATT TAG
5461 TCC CTC GTG GGC TCA TCC ACT CAG CAC ACA TTT ACT AAG CAT CTT CTC AGC CTA CAC TCT GAA GGC AGT GCA GAA TAA
5539 TGT TAG TGT CCC TTC CCC CAG TTA ATA TGC AGT CCA GTT TCC CTG CTC CTC CCC TTT CTC AGT CCA CAT AAG GAT GAT
5617 GGG AAA GGA CAG TCA CCA AAT AGG AGA GGG CAA CCC TTT GCC TTC CTA CCT CTT GAG AAT GTA CAT TAT TAT CCA CTT
5695 TTT GAA ACT TCT TTT AAT TGC TTT TTA ATT TGT CTT TTC AAA TAG CAT AAC CTT GTT CAT CCA TTT CTG GGA ACC
5773 AAA TTT ATC AAT CAA CAG TGC CTC TAA TCT GGC TAT TAA TAC AAA AAT GCC TCC TCA AAB TAT ATA TGT TCC AGT CTT
5851 ATC TAA AAC AGA ACC CAC AAT AAA AAA GAA GAA ATA ATA CAT ATA AGC ATT TAT TTA ACA CTG CTG AAA TTA TAC CAT TAG AGA ACT CTT GTG CTT
5929 TGT GAA AAA AAT ATA ATC TAA TGT CAC ATG CTG TAT TCT TTT TAT TTA ACA CTG CTG AAA TTA TAC CAT TAG AGA GAA
6007 AGA GGA CAG ATC ACT GAT CCT AGG ATC TAG GGA TGT TAC AGA TAA GAA AAC AAA TGT GAC AAB GAG CTG TCA CAA GGA
6085 GGA TCT TCA AGG TCA CAG AAT CAC TGT CTT GAT TTC AGT GGT GGT TAC ATA CAT TTA AAT ATG TGA TAA AAT GTT GTT
6163 GAA CTA TAT TCA TAT ATT GTA CCA ATG TCA AAT GCT TAA TTT TGG CTC TAT AGT ATA ATT ATG CAC TAA ATA ACT ATT
```

Fig. 12, contd.

Fig. 12, contd.




Fig. 12, contd.

```
12637 CCA TAT CTC CCC ACC CAT CCC CCA TAC CAG ACT GGT TAT TGA TTT TCA TGG TGA CTG GCC TGA GAA GAT TAA AAA AAG
12715 TAA TGC TAC CTT ATT GGG AGT GTC CCA TGG ACC AAG ATA GCA ACT GTC ATA GCT ACC GTC ACA CTG CTT TGA TCA AGA
12793 AGA CCC TTT GAG GAA CTG AAA ACA GAA CCT TAG GCA CAT CTG TTG CTT TCG CTC CCA TCC TCC TCC AAC AGC CTG GGT
12871 GGT GCA CTC CAC ACC CTT TCA AGT TTC CAA AGC CTC ATA CAC CTG CTC CCT ACC CCA GCA CCT GGC CAA GGC TGT ATC
12949 CAG CAC TGG GAT GAA AAT GAT ACC CCA CCT CCA TCT TGT TTG ATA TTA CTC TAT CTC AAG CCC CAG GTT AGT CCC CAG
13027 TCC CAA TGC TTT TGC ACA GTC AAA ACC CAA CTT GGA ATA ATC AGT ATC CTT GAA GAG TTC TGA TAT GGT CAC TGG GCC
13105 CAT ATA CCA TGT AAG ACA TGT GGA AAA GAT GTT TCA TGG GGC CCA GAC ACG TTC TAG AAG TAC CTG AGA GTG GCA AAA
13183 AAT AGT TGT GCT AAA TAG TTT GGC CAC CTT TAG GCT GAG AGA CTA GGA AAT ACA GCG ATG GAC TAT ATC AGC ATT GCA
13261 GGA TAG TTG TCA GTA AAC ACC CCA CAA CCC ATA ACA GAA GTA TTC TCT TCT TTC TAT ATC CCT TTT CCA TCC ATG TAG
13339 ATG GCT GTC TTG ATA TTT GTT CTA GAC GGC CGG CC
```

VkP-IGKV1-39/J-Ck-Δ1

```
    1 GGC CGG CCC ACA TGA AAC AAT GGG AAC CAT GTG ACA ATC ACA GAG GTG TTG TTA CTA TAG CAA AAG GGA TTG TTA CTC
   79 TCC ACA TCC CTT TAA GTA ACT TGA AGG CCT GAT AGA CCC ACC CTC TAA GAC TTC ATT AGA CAT TCC CTA CGA ATG GTT
  157 ATA CTC TCC TGT ATA CTC CCA ATA CAA CTC TAA AAT ATA TTA TTC CAT ATA GTC CTT AGG TTT GTA TTA AAG TTT GAC
  235 TTT TTT CCT TCA AAA TAT CTC TTG TCA CAA CAG CGG CTC TAG AGA GAA ATA CAT TCC CTC CAG GCA AAT CTA TGC TGC
  313 GCT GGT CTG ACC TGG GAC CCT GGG GAC ATT GCC CCT GTG CTG AGT TAC TAA GAT GAG CCA GCC CTG CAG CTG TGC TCA
  391 GCC TGC CCC ATG CCC TGC TGA TTG ATT TGC ATG TTC CAG AGC ACA GCC CCC TGC CCT GAA GAC TTT TTT ATG GGC TGG
  469 TCG CAC CCT GTG CAG GAG TCA GTC TCA GTC AGG AGC CAC CAT GGA CAT GAG AGT GCC CGC CCA GCT CCT GGG GCT CCT
  547 GCT ACT CTG GCT CCG AGG TAA GGA TGG AGA ACA CTA GGA ATT TAC TCA GCC AGT GTG CTC AGT ACT GAC TGG AAC TTC
  625 AGG GAA GTT CTC TGA TAA CAT GAT TAA TAG TAA GAA TAT TTG TTT TTA TGT TTC CAA TCT CAG GTG CCA GAT GTG ACA
  703 TCC AGA TGA CCC AGA GCC CCA GCA GCC TGA GCG CCA GCG TGG GCG ACA GAG TGA CCA TCA CCT GCA GAG CCA GCC AGA
  781 GCA TCA GCA GCT ACC TGA ACT GGT ATC AGC AGA AGC CCG GCA AGG CCC CCA AGC TGC TGA TCT ACG CCG CCA GCT CCC
  859 TGC AGA GGS GCG TGC CCA GCA GAT TCA GCG GCA GCG GCT CCG GCA CCG ACT TCA CCC TGA CCA TCA GCA GCC TGC AGC
  937 CCG AGG ACT TCG CCA CCT ACT ACT GCC AGC AGA GCT ACA GCA CCC CCC CCA CCT TCG GCC AGG GCA CCA AGG TGG AGA
 1015 TCA AAC GTA AGT ACA CTT TTC TCA TCT TTT TTT ATG TGT AAG ACA CAG GTT TTC ATG TTA GGA GTT AAA GTC AGT TCA
 1093 GAA AAT CTT GAG AAA ATG GAG AGG GCT CAT TAT CAG TTG ACG TGG CAT ACA GTG TCA GAT TTT CTG TTT ATC AAG CTA
 1171 GTG AGA TTA GGG GCA AAA AGA GCC TTT AGT TGA GAG GAA AGT AAT TAA TAC TAT GGT CAC CAT CCA AGA GAT TGG ATC
 1249 GGA GAA TAA GCA TGA GTA GTT ATT GAG ATC TGG GTC TGA CTG CAG GTA GCG TGG TCT TCT AGA CGT TTA AGT GGG AGA
 1327 TTT GGA GGS GAT GAG GAA TGA AGG AAC TTC AGG ATA GAA AAG GGC TGA AGT CAA GTT CAG CTC CTA AAA TGG ATG TGG
 1405 GAG CAA ACT TTG AAG ATA AAC TGA ATG ACC CAG AGG ATG AAA CAG CGC AGA TCA AAG AGG GGC CTG GAG CTC TGA GAA
 1483 GAG AAG GAG ACT CAT CCG TGT TGA GTT TCC ACA AGT ACT GTC TTG AGT TTT GCA ATA AAA GTG GGA TAG CAG AGT TGA
 1561 GTG AGC CGT AGG CTG AGT TCT CTC TTT TGT CTC CTA AGT TTT TAT GAC TAC AAA AAT CAG TAG TAT GTC CTG AAA TAA
 1639 TCA TTA AGC TGT TTG AAA GTA TGA CTG CTT GCC ATG TAG ATA CCA TGG CTT GCT GAA TAA TCA GAA GAG GTG TGA CTC
 1717 TTA TTC TAA AAT TTG TCA CAA AAT GTC AAA ATG AGA GAC TCT GTA GGA ACG AGT CCT TGA CAG ACA GCT CAA GGG GTT
 1795 TTT TTC CTT TGT CTC ATT TCT ACA TGA AAG TAA ATT TGA AAT GAT CTT TTT TAT TAT AAG AGT AGA AAT ACA GTT GGG
 1873 TTT GAA CTA TAT GTT TTA ATG GCC ACG GTT TTG TAA GAC ATT TGG TCC TTT GTT TTC CCA GTT ATT ACT CGA TTG TAA
 1951 TTT TAT ATC GCC AGC AAT GGA CTG AAA CGG TCC GCA ACC TCT TCT TTA CAA CTG GGT GAC CTC GCG GCT GTG CCA GCC
 2029 ATT TGG CGT TCA CCC TGC CGC TAA GGG CCA TGT GAA CCC CCG CGG TAG CAT CCC TTG CTC CGC GTG GAC CAC TTT CCT
 2107 GAG GCA CAG TGA TAG GAA CAG AGC CAC TAA TCT GAA GAG AAC AGA GAT GTG ACA GAC TAC ACT AAT GTG AGA AAA ACA
```

Fig. 12, contd.




Fig. 12, contd.




Fig. 12, contd.




Fig. 12, contd.

```
11779 CAT TTA ACA GAT TAG GAG ATG AAA CGG TAG ACT CTG TGT AGT TGT ACA CCC CTG TGA TCC CAT CGC TAG GAA GAC TGA
11857 GGC AGG AAG TCC TCG AGC TCA AAC CAG CTT AGG CTA CAC AGA GAA ACT ATC TAA AAA ATA ATT ACT AAC CAC TTA ATA
11935 GGA GAT TGG ATG TTA AGA TCT GGT CAC TAA GAG GCA GAA TTG AGA TTC GAA GCC AGT ATT TTC TAC CTG GTA TGT TTT
12013 AAA TTG CAG TAA GGA TCT AAG TGT AGA TAT ATA ATA ATA AGA TTC TAT TGA TCT CTG CAA CAA CAG AGA GTG TTA GAT
12091 TTG TTT GGA AAA AAA TAT TAT CAG CCA ACA TCT TCT ACC ATT TCA GTA TAG CAC AGA GTA CCC ACC CAT ATC TCC CCA
12169 CCC ATC CCC CAT ACC AGA CTG GTT ATT GAT TTT CAT GGT GAC TGG CCT GAG AAG ATT AAA AAA AGT AAT GCT ACC TTA
12247 TTG GGA GTG TCC CAT GGA CCA AGA TAG CAA CTG TCA TAG CTA CCG TCA CAC TGC TTT GAT CAA GAA GAC CCT TTG AGC
12325 AAC TGA AAA CAG AAC CTT AGG CAC ATC TGT TGC TTT CGC TCC CAT CCT CCT CCA ACA GCC TGG GTG GTG CAC TCC ACA
12403 CCC TTT CAA GTT TCC AAA GCC TCA TAC ACC TGC TCC CTA CCC CAG CAC CTG GCC AAG GCT GTA TCC AGC ACT GGG ATG
12481 AAA ATG ATA CCC CAC CTC CAT CTT GTT TGA TAT TAC TCT ATC TCA AGC CCC AGG TTA GTC CCC AGT CCC AAT GCT TTT
12559 GCA CAG TCA AAA CTC AAC TTG GAA TAA TCA GTA TCC TTG AAG AGT TCT GAT ATG GTC ACT GGG CCC ATA TAC CAT GTA
12637 AGA CAT GTG GAA AAG ATG TTT CAT GGG GCC CAG ACA CGT TCT AGA AGT ACC TGA GAG TGG CAA AAA ATA GTT GTG CTA
12715 AAT AGT TTG GCC ATC TTT AGG CTG AGA GAC TAG GAA ATA CAG CGA TGG ACT ATA TCA GCA TTG CAG GAT AGT TGT CAG
12793 TAA ACA CCC CAC AAC CCA TAA CAG AAG TAT TCT CTT CTT TCT ATA TCC CTT TTC CAT CCA TGT AGA TGG CTG TCT TCA
12871 TAT TTG TTC TAG ACG GCC GGC C
```

VkP-IGKV1-39/J-Ck-Δ2

```
   1 GGC CGG CCC ACA TGA AAC AAT GGG AAC CAT GTG ACA ATC ACA GAG GTG TTG TTA CTA TAG CAA AAG GGA TTG TTA CTC
  79 TCC ACA TCC CTT TAA GTA ACT TGA AGG CCT GAT AGA CCC ACC CTC TAA GAC TTC ATT AGA CAT TCC CTA CGA ATG GTT
 157 ATA CTC TCC TGT ATA CTC CCA ATA CAA CTC TAA AAT ATA TTA TTC CAT ATA GTC CTT AGG TTT GTA TTA AAG TTT GAC
 235 TTT TTT CCT TCA AAA TAT CTC TTG TCA CAA CAG CGG CTC TAG AGA GAA ATA CAT TCC CTC CAG GCA AAT CTA TGC TGC
 313 GCT GGT CTG ACC TGG GAC CCT GGG CAC ATT GCC CCT GTG CTG AGT TAC TAA GAT GAG CCA GCC CTG CAG CTG TGC TCA
 391 GCC TGC CCC ATG CCC TGC TGA TTG ATT TGC ATG TTC CAG AGC ACA GCC CCC TGC CCT GAA GAC TTT TTT ATG GGC TGG
 469 TCG CAC CCT GTG CAG GAG TCA GTC TCA GTC AGG AGC CAC CAT GGA CAT GAG AGT GCC CGC CCA GCT CCT GGG GCT CCT
 547 GCT ACT CTG GCT CCG AGG TAA GGA TGG AGA ACA CTA GGA ATT TAC TCA GCC AGT GTG CTC AGT ACT GAC TGG AAC TTC
 625 AGG GAA GTT CTC TGA TAA CAT GAT TAA TAG TAA GAA TAT TTG TTT TTA TGT TTC CAA TCT CAG GTG CCA GAT GTG ACA
 703 TCC AGA TGA CCC AGA GCC CCA GCA GCC TGA GCG CCA GCG TGG GCG ACA GAG TGA CCA TCA CCT GCA GAG CCA GCC AGA
 781 GCA TCA GCA GCT ACC TGA ACT GGT ATC AGC AGA AGC CCG GCA AGG CCC CCA AGC TGC TGA TCT ACG CGG CCA GCT CCC
 859 TGC AGA GCG GCG TGC CCA GCA GAT TCA GCG GCA GCG GCT CCG GCA CCG ACT TCA CCC TGA CCA TCA GCA GCC TGC AGC
 937 CCG AGG ACT TCG CCA CCT ACT ACT GCC AGC AGA GCT ACA GCA CCC CCC CCA CCT TCG GCC AGG GCA CCA AGG TGG AGA
1015 TCA AAC GTA AGT ACA CTT TTC TCA TCT TTT TTT ATG TGT AAG ACA CAG GTT TTC ATG TTA GGA GTT AAA GTC AGT TCA
1093 GAA AAT CTT GAG AAA ATG GAG AGG GCT CAT TAT CAG TTG ACG TGG CAT ACA GTG TCA GAT TTT CTG TTT ATC AAG CTA
1171 GTG AGA TTA GGG GCA AAA AGA GGC ITT AGT TGA GAG GAA AGT AAT TAA TAC TAT GGT CAC CAT CCA AGA GAT TGG ATC
1249 GGA GAA TAA GCA TGA GTA GTT ATT GAG ATC TGG GTC TGA CTG CAG GTA GCG TGG TCT TCT AGA CGT TTA AGT GGG AGA
1327 TTT GGA GGG GAT GAG GAA TGA AGG AAC TTC AGG ATA GAA AAG GGC TGA AGT CAA GTT CAG CTC CTA AAA TGG ATG TGG
1405 GAG CAA ACT TTG AAG ATA AAC TGA ATG ACC CAG AGG ATG AAA CAG CGC AGA TCA AAG AGG GGC CTG GAG CTC TGA GAA
1483 GAG AAG GAG ACT CAT CCG TGT TGA GTT TCC ACA AGT ACT GTC TTG AGT TTT GCA ATA AAA GTG GGA TAG CAG AGT TGA
1561 GTG AGC CGT AGG CTG AGT TCT CTC TTT TGT CTC CTA AGT TTT TAT GAC TAC AAA AAT CAG TAG TAT GTC CTG AAA TAA
1639 TCA TTA AGC TGT TTG AAA GTA TGA CTG CTT GCC ATG TAG ATA CCA TGG CTT GCT GAA TAA TCA GAA GAG GTG TGA CTC
1717 TTA TTC TAA AAT TTG TCA CAA AAT GTC AAA ATG AGA GAC TCT GTA GGA ACG AGT CCT TGA CAG ACA GCT CAA GGG GTT
```

Fig. 12, contd.




Fig. 12, contd.

```
4993 CAT CCA CTC AGC ACA CAT TTA CTA AGC ATC TTC TCA GCC TAC ACT CTG AAG GCA GTG CAG AAT AAT GTT AGT GTC CCT
5071 TCC CCC AGT TAA TAT GCA GTC CAG TTT CCC TGC TCC TTC CCT TTC TCA GTC CAC ATA AGG ATG ATG GGA AAG GAC AGT
5149 CAC CAA ATA GGA GAG GGC AAC CCT TTG CCT TCC TAC CTC TTG AGA ATG TAC ATT ATT ATC CAC TTT TTG AAA CTT CTT
5227 TTA ATT GCT TTT TTT TAA TTT GTC TTT TCA AAT AGC ATA ACC TTG TTC ATC CAT TTC TGG GAA CCA AAT TTA TCA ATC
5305 AAC AGT GCC TCT AAT CTG GCT ATT AAT ACA AAA ATG CCT CCT CAA AAT ATA TAT GTT CGA GTC TTA TCT AAA ACA GAA
5383 CCC ACA ATA AAA AAG AAG AAA GAA TAC ATA TAA GCA TTT ATA TAA TTC TGA GCA ACC TTG TGC TTT GTG AAA AAA ATA
5461 TAA TCT AAT GTC ACA TGC TGT ATT CTT TTT ATT TAA CAC TGG TGA AAT TAT ACC ATT AGA GAG AAA GAG GAC AGA TCA
5539 CTG ATC CTA GGA TCT AGG GAT GTT ACA GAT AAG AAA ACA AAT GTG ACA AAG AGC TGT CAC AAG GAG GAT CTT CAA GGT
5617 CAC AGA ATC ACT GTC TTG ATT TCA GTG GTG GTT ACA TAC ATT TAA ATA TGT GAT AAA ATG TTG TTG AAC TAT ATT CAT
5695 ATA TTG TAC CAA TGT CAA ATG CTT AAT TTT GGC TCT ATA GTA TAA TTA TGC ACT AAA TAA CTA TTT GGA CAA AGA AAA
5773 TGA TGT TTA CAT CAA AGG TGA GGC CAT ATT TGT TAG GAA CAT AAC TTA AAA ACC ATT TTG GAT AAC TAA TGA AAA GCC
5851 ATT TTG TGT GCC TTG GCA TAT CAT GCC TAA GCT GTC ACC AGA TAG ATC TAA TAA GAC CTA AGC CTC AGA AGC AAG CCC
5929 CTG CCC AGC AAG CAG GCA GCA CAG ATA AGA GCT AAA CCC AGG ACA GGC CAT GAT ATG CTA ATG AAC TAC CTT CAA GGT
6007 GGT GTT GCT GAC CTA GTG AAC CAG CCC CAA GCT GTG AGC CCC AAT AGC ACA AAG CTA CTG CCC AAA GAA ATT ATA CAA
6085 AAA TTG GAA CTT TGG GAA TGG TGT GCA GGA TCG CTC TGC TGT ATG CCT GGA ACA CAG CTT CTC TAT GTT TTG TAT TGA
6163 TAC CAG TCT AGA AGC TTC CAA AAC TTT CTC ACT GAA GAA GAT TCC CCA TGT GGG ACC CCT ACA GAC TCT TTT GCC CAA
6241 ACA ACT GCT TCC CTC CTG GTG TGA TCA TGG ACC AAG ATA GCA ACT GTC ATA GCT ACC GTC ACA CTG CTT TGA TCA AGA
6319 AGA CCC TTT GAG GAA CTG AAA ACA GAA CCT TAG GCA CAT CTG TTG CTT TCG CTC CCA TCC TCC TCC AAC AGC ATG GCT
6397 GTC TTC ATA TTT GTT CTA GAC GGC CGG CC
```

VkP-IGLV2-14/J-Ck

```
   1 GGC CGG CCC ACA TGA AAC AAT GGG AAC CAT GTG ACA ATC ACA GAG GTG TTG TTA CTA TAG CAA AAG GGA TTG TTA CTC
  79 TCC ACA TCC CTT TAA GTA ACT TGA AGG CCT GAT AGA CCC ACC CTC TAA GAC TTC ATT AGA CAT TCC CTA CGA ATG GTT
 157 ATA CTC TCC TGT ATA CTC CCA ATA CAA CTC TAA AAT ATA TTA TTC CAT ATA GTC CTT AGG TTT GTA TTA AAG TTT GAC
 235 TTT TTT CCT TCA AAA TAT CTC TTG TCA CAA CAG CGG CTC TAG AGA GAA ATA CAT TCC CTC CAG GCA AAT CTA TGC TGC
 313 GCT GGT CTG ACC TGG GAC CCT GGG GAC ATT GCC CCT GTG CTG AGT TAC TAA GAT GAG CCA GCC CTG CAG CTG TGC TCA
 391 GCC TGC CCC ATG CCC TGC TGA TTG ATT TGC ATG TTC CAG AGC ACA GCC CCC TGC CCT GAA GAC TTT TTT ATG GGC TGG
 469 TCG CAC CCT GTG CAG GAG TCA GTC TCA GTC AGG AGC CAC CAT GGA CAT GAG AGT GCC CGC CCA GCT CCT GGG GCT CCT
 547 GCT ACT CTG GCT CCG AGG TAA GGA TGG AGA ACA CTA GGA ATT TAC TCA GCC AGT GTG CTC AGT ACT GAC TGG AAC TTC
 625 AGG GAA GTT CTC TGA TAA CAT GAT TAA TAG TAA GAA TAT TTG TTT TTA TGT TTC CAA TCT CAG GTG CCA GAT GTC AGT
 703 CTG CCC TGA CCC AGC CCG CCT CTG TGT CTG GCA GCC CTG GCC AGA GCA TCA CCA TCA GCT GCA CCG GCA CCA GCA GCG
 781 ACG TGG GCG GCT ACA ACT ACG TGT CCT GGT ATC AGC AGC ACC CCG GCA AGG CCC CCA AGC TGA TGA TCT ACG AGG TGT
 859 CCA ACA GAC CCA GCG GCG TGA GCA ACA GAT TCA GCG GCA GCA AGA GCG GCA ACA CCG CCA GCC TGA CCA TCA GCG GCC
 937 TCC AGG CTG AGG ACG AGG CCG ACT ACT ACT GCA GCA GCT ACA CCA GCA GCT CCA CCC TGG TGT TTG GCG GCG GAA CAA
1015 AGC TGA CCG TGC TGC GTA AGT ACA CTT TTC TCA TCT TTT TTT ATG TGT AAG ACA CAG GTT TTC ATG TTA GGA GTT AAA
1093 GTC AGT TCA GAA AAT CTT GAG AAA ATG GAG AGG GCT CAT TAT CAG TTG ACG TGG CAT ACA GTG TCA GAT TTT CTG TTT
1171 ATC AAG CTA GTG AGA TTA GGG GCA AAA AGA GGC TTT AGT TGA GAG GAA AGT AAT TAA TAC TAT GGT CAC CAT CCA AGA
1249 GAT TGG ATC GGA GAA TAA GCA TGA GTA GTT ATT GAG ATC TGG GTC TGA CTG CAG GTA GCG TGG TCT TCT AGA CGT TTA
1327 AGT GGG AGA TTT GGA GGG GAT GAG GAA TGA AGG AAC TTC AGG ATA GAA AAG GGC TGA AGT CAA GTT CAG CTC CTA AAA
1405 TGG ATG TGG GAG CAA ACT TTG AAG ATA AAC TGA ATG ACC CAG AGG ATG AAA CAG CGC AGA TCA AAG AGG GGC CTG GAG
1483 CTC TGA GAA GAG AAG GAG ACT CAT CCG TGT TGA GTT TCC ACA AGT ACT GTC TTG AGT TTT GCA ATA AAA GTG GCA TAG
```

Fig. 12, contd.

Fig. 12, contd.




Fig. 12, contd.

Fig. 12, contd.

```
11155 CGT GTA ACT CTC CTG TGA CTG AGT ATC TCA CBA AAC GTT CTA CCT GCC AAA CCT GGA TGA GCC CTT TGT CTT TCT GAA
11233 GCT ATG AGG CTC TCT ACA TAG ACT CAA GAA GGA AAT GAC AGG GAG GAG GTA ATA ATG AAG TGG GGA AGG CTG ACA TTA
11311 GCA TTG CTC CTG TGT GGC TCC TTA ATT TCT CAT ACT TCA CAC TGA GAT GTT ATT AAC TGT GAC TCA TAG GTG AAG AAG
11388 CCA GAG CTA AGG TTC TCA TAT TTG AGT GTT ATA GAA TGA GTA GAG CAG TAG TTC TCA AAC TAT GGG TCA TGA CTC CTT
11467 TAT GGG TCA AAC TAC CCT TTC ACA CAG GTT GCA TAT CAG ATA TCC TAA TTT TAT ATA CAT ATA TAT ATG CAT ATG TAT
11545 ATA TAT ATA TTT CAC AAC AGT AGC AAA ATT ATT TAG TAA TCA TTT TAT AGT TGT GGG TCA TGG CAA CAT GAG GAA CTG
11623 TAT TAA AGG GTT GCA GCA TTA GGA ATG TTG AGA CCC ACT GTA ATA GAG AAT GAG GCT TAA GGC AGG GCT ATA AAG CCC
11701 AAT GGA CCA TGT GCC TTT TCC AAC ATT TGC CAC ATG GTA AGC TCT GTA TAG ACT TTT TAA AGA ACA TTG GTT TGT AAT
11779 TTT AAA TGG ATA AGG GTC TTC ACT GTC TAT CAC CCA TCT ATA TAA TAA ATA CAT AAG TTT TGA TTC CAC CAT GGA TTC
11857 AAA TGC AAA AAT CCT CAA CCT AAG ACA TAG CAG TGA AAC ATT GAT GAC CAA ATA GGA AAT CCA TGT AGA GAC CTT CTA
11935 TCT TCT GAT GGC TCC ACA GGC ACC ATC TTG CAA CAG AGT TCT ACT TTG CTA CCA GTA ATG AAT ACA GTG TCT CAA CTC
12013 CTG CCA TTG AAT CTT CAG GAA GCC CCT GAA ATG ACT TGT ACT ACA CCA TTT CTT AAA GAC AGA AAA GCT AAG ACT TAG
12091 AGG GAA TAA ATG TCA TGC CTG AGA TCA TGC AAC CAA TTA AGT CCA ACT TGG CCT GAT CAA GAG GCA CAA TTC AAA AGC
12169 AAT GTT GTT CCT TCA CTA GCT CTT GTG TAT GGT TGC TGA TTC CGG AAG CAA AGT ATC AGT GAA TAT CCC TAG TGG GAA
12247 AAG ACT TGG AAA TCA AAT GTC TCA TTT AAC AGA TTA GGA GAT GAA ACG GTA GAC TCT GTG TAG TTG TAC ACC CCT GTG
12325 ATC CCA TCG CTA GGA AGA CTG AGG CAG GAA GTC CTC GAG CTC AAA CCA GCT TAG GCT ACA CAG AGA AAC TAT CTA AAA
12403 AAT AAT TAC TAA CTA CTT AAT AGG AGA TTG GAT GTT AAG ATC TGG TCA CTA AGA GGC AGA ATT GAG ATT CGA AGC CAG
12481 TAT TTT CTA CCT GGT ATG TTT TAA ATT GCA GTA AGG ATC TAA GTG TAG ATA TAT AAT AAT AAG ATT CTA TTG ATC TCT
12559 GCA ACA ACA GAG AGT GTT AGA TTT GTT TGG AAA AAA ATA TTA TCA GCC AAC ATC TTC TAC CAT TTC AGT ATA GCA CAG
12637 AGT ACC CAC CCA TAT CTC CCC ACC CAT CCC CCA TAC CAG ACT GGT TAT TGA TTT TCA TGG TGA CTG GCC TGA GAA GAT
12715 TAA AAA AAG TAA TGC TAC CTT ATT GGG AGT GTC CCA TGG ACC AAG ATA GCA ACT GTC ATA GCT ACC GTC ACA CTG CTT
12793 TGA TCA AGA AGA CCC TTT GAG GAA CTG AAA ACA GAA CCT TAG GCA CAT CTG TTG CTT TCG CTC CCA TCC TCC TCC AAC
12871 AGC CTG GGT GGT GCA CTC CAC ACC CTT TCA AGT TTC CAA AGC CTC ATA CAC CTG CTC CCT ACC CCA GCA CCT GGC CAA
12949 GGC TGT ATC CAG CAC TGG GAT GAA AAC GAT ACC CCA CCT CCA TCT TGC TTG ATA TTA CTC TAT CTC AAG CCC CAG GTT
13027 AGT CCC CAG TCC CAA TGC TTT TGC ACA GTC AAA ACT CAA CTT GGA ATA ATC AGT ATC CTT GAA GAG TTC TGA TAT GGT
13105 CAC TGG GCC CAT ATA CCA TGT AAG ACA TGT GGA AAA GAT GTT TCA TGG GGC CCA GAC ACG TTC TAG AAG TAC CTG AGA
13183 GTG GCA AAA AAT AGT TGT GCT AAA TAG TTT GGC CAT CTT TAG GCT GAG AGA CTA GGA AAT ACA GCG ATG GAC TAT ATC
13261 AGC ATT GCA GGA TAG TTG TCA GTA AAC ACC CCA CAA CCC ATA ACA GAA GTA TTC TCT TCT TTC TAT ATC CCT TTT CCA
13339 TCC ATG TAG ATG GCT GTC TTC ATA TTT GTT CTA GAC GGC CGG CC
```

pSELECT-hGKV1-39/J-Ck

```
   1    GCG GCC GCA ATA AAA TAT CTT TAT TTT CAT TAC ATC TGT GTG TTG GTT TTT TGT GTG AAT CGT AAC TAA CAT ACG CTC
  79    TCC ATC AAA ACA AAA CGA AAC AAA ACA AAC TAG CAA AAT AGG CTG TCC CCA GTG CAA GTG CAG GTG CCA GAA CAT TTC
 157    TCT ATC GAA GGA TCT GCG ATC GCT CCG GTG CCC GTC AGT GGG CAG AGC GCA CAT CGC CCA CAG TCC CCG AGA AGT TGG
 235    GGG GAG GGG TCG GCA ATT GAA CGG GTG CCT AGA GAA GGT GGC GCG GGG TAA ACT GGG AAA GTG ATG TCG TGT ACT GGC
 313    TCC GCC TTT TTC CCG AGG GTG GGG GAG AAC CGT ATA TAA GTG CAG TAG TCG CCG TGA ACG TTC TTT TTC GCA ACG GGT
 391    TTG CCG CCA GAA CAC AGC TGA AGC TTC GAG GGG CTC GCA TCT CTC CTT CAC GCG CCC GCC GCC CTA CCT GAG GCC GCC
 469    ATC CAC GCC GGT TGA GTC GCG TTC TGC CGC CTC CCG CCT GTG GTG CCT CCT GAA CTG CGT CCG CCG TCT AGG TAA GTT
 547    TAA AGC TCA GGT CGA GAC CGG GCC TTT GTC CGG CGC TCC CTT GGA GCC TAC CTA GAC TCA GCC GGC TCT CCA CGC TTT
 625    GCC TGA CCC TGC TTG CTC AAC TCT ACG TCT TTG TTT CGT TTT CTG TTC TGC GCC GTT ACA GAT CCA AGC TGT GAC CGG
```

Fig. 12, contd.

```
   703  CGC CTA CCT GAG ATC ACC GGC GTG TCG AGG CCA CCA TGG ACA TGA GAG TGC CCG CCC AGC TCC TGG GGC TCC TGC TAC
   781  TCT GGC TCC GAG GTA AGG ATG GAG AAC ACT AGG AAT TTA CTC AGC CAG TGT GCT CAG TAC TGA CTG GAA CTT CAG GGA
   859  AGT TCT CTG ATA ACA TGA TTA ATA GTA AGA ATA TTT GTT TTT ATG TTT CCA ATC TCA GGT GCC AGA TGT GAC ATC CAG
   937  ATG AGC CAG AGC CCC AGC GCC CTG AGC GTG GGC GAC AGA GTG ACC ACC ATC ACC TGC AGA GCC AGC CAG AGC ATC
  1015  AGC AGC TAC CTG AAC TGG TAT CAG CAG AAG CCC GGC AAG GCC CCC AAG CTG CTG ATC TAC GCC GCC AGC TCC CTG CAG
  1093  AGC GGC GTG CCC AGC AGA TTC AGC GGC AGC GGC TCC GGC ACC GAC TTC ACC CTG ACC ATC AGC AGC CTG CAG CCC GAG
  1171  GAC TTC GCC ACC TAC TAC TGC CAG CAG AGC TAC AGC ACC CCC ACC TTC GGC CAG GGC ACC AAG GTG GAG ATC AAG
  1249  AGA GCC GAC GCC GCT CCC ACC GTG TCC ATC TTC CCC CCC AGC ATG GAA CAG CTG ACC TCT GGC GGA GCC ACC GTG GTC
  1327  TGC TTC GTG AAC AAC TTC TAC CCC AGA GAC ATC AGC GTG AAG TGG AAG ATC GAC GGC AGC GAG CAG AGG GAC GGC GTG
  1405  CTG GAC AGC GTG ACC GAC CAG GAC AGC AAG GAC TCC ACC TAC AGC ATG AGC AGC ACC CTG ACC CTG AGC AAG GCC GAC
  1483  TAC GAG AAG CAC AAG GTG TAC GCC TGC GAG GTG CAC AAG ACC AGC TCC CCC GTG GTC AAC TCC TTC AAC CGG GGC
  1561  AAC GAG TGT TGA GCT AGC TGG CCA GAC ATG ATA AGA TAC ATT GAT GAG TTT GGA CAA ACC ACA ACT AGA ATG CAC TGA
  1639  AAA AAA TGC TTT ATT TGT GAA ATT TCT GAT GCT ATT GCT TTA TTT GTA ACC ATT ATA AGC TGC AAT AAA CAA GTT AAC
  1717  AAC AAC AAT TGC ATT CAT TTT ATG TTT CAG GTT CAG GGG GAG GTG TGG CAG GTT TTT TAA AGC AAG TAA AAC CTC TAC
  1795  AAA TGT GGT ATG GAA TTC TAA AAT ACA GCA TAG CAA AAC TTT AAC CTC CAA ATC AAG CCC AGC AGT TCA GGC AGG TCT TGC AAC GTG ACA CCC
  1873  GAG GGA TGA ATA AGC CAT CAG GGG CTG TTG CCA ATG TGC ATT AGC TGT TTG CAG CCT CAC CTT CTT CCA TTG TTG GAG
  1951  AGT TTA AGA TAT AGT GTA TTT TCC CAA GGT TTG AAC TAG CTC TTC ATT TCT TTA TGT TTC AAA TGC ACT GAC CTC CCA
  2029  CAT TCC CTT TTT AGT AAA ACA TTC AGA AAT AAT TTA AAT ACA TCA TTG CAA TGA AAA TAA ATG TTT TTT ATT AGG CAG
  2107  AAT CCA GAT GCT CAA GGC GCT TCA TAA TAT CCC CCA GTT TAG TAG TTG GAC TTA GGG AAC AAA GGA ACC TTT AAT AGA
  2185  AAT TGG ACA GCA AGA AAG CGA GCT TCT AGC GAA TTC TCG ACT CAT TCC TTT GCC CTC GGA CGA GTG CTG GGG CGT CGG
  2263  TTT CCA CTA TCG GCG AGT ACT TCT ACA CAG CCA TCG GTC CAG ACG GCC GCG CTT CTG CGG GCG ATT TGT GTA CGC CCG
  2341  ACA GTC CCG GCT CCG GAT CGG ACG ATT GCG TCG CAT CGA CCC TGC GCC CAA GCT GCA TCA TCG AAA TTG CCG TCA ACC
  2419  AAG CTC TGA TAG AGT TGG TCA AGA CCA ATG CGG AGC ATA TAC GCC CGG AGC CGC GGC CTC CAG ATC AGA TCC GCC GCA GCG
  2497  CTC CGC TCG AAG TAG CGC GTC TGC TGC TCC ATA CAA GCC AAC CAC GGC CTC CAG AAG AAG ATG TTG GCG ACC TCG TAT
  2575  TGG GAA TCC CCG AAC ATC GCC TCG CTC CAG TCA ATG ACC GCT GTT ATG CGG CCA TTG TCC GTC TCA TCG AGA ACA TTG TTG GAG
  2653  CCG AAA TCC GCG TGC ACG AGG TGC CGG ACT TCG GGG CAG TCC TCG GCC CAA AGC ATC AGC TCA TCG AGA GCC TGC GCG
  2731  ACG GAC GCA CTG ACG GTG TCG TCC ATC ACA GTT TGC CAG TGA TAC ACA TGG CGA TCA GCA ATC GCC CAT ATG AAA TCA
  2809  CGC CAT GTA GTG TAT TGA CCG ATT CCT TGC GGT CCG AAT GCG CCC AAC CCG CTC GTC TGG CTA AGA TCG GCC GCA GCG
  2887  ATC GCA TCC ATG AGC TCC GCG ACG GGT TGC AGA ACA GCG GGC AGT TCG GTT TCA GGC AGG TCT TGC AAC GTG ACA CCC
  2965  TGT GCA CGG CGG GAG ATG CAA TAG GTC AGG CTC TCG CTG CTG AAT TCC CCA ATG TCA AGC ACT TCC GGA ATC GGG AGC GCG
  3043  GCC GAT GCA AAG TGC CGA TAA ACA TAA CGA TCT TTG TAG AAA CCA TCG GCG CAG CTA TTT ACC CGC AGG ACG ACA TAT CCA
  3121  CGC CCT CCT ACA TCG AAG CTG AAA GCA CGA GAT TCT TCG CCC TCC GAG AGC TGC ATC AGG TCG GAG ACG CTG TCG AAC
  3199  TTT TCG ATC AGA AAC TTC TCG ACA GAC GTC GCG GTG AGT TCA GGC TTT TTC ATG ATG GCC CTC CTA TAC TGA GTC GTA
  3277  TTA TAC TAT GCC GAT ATA CTA TGC CGA TGA TTA ATT GTC AAA ACA GCG TGG ATG GCG TCT CCA GCT TAT CTG ACG GTT
  3355  CAC TAA ACG AGC TCT GCT TAT ATA GAC CTC CCA CGG TAC ACG CCT ACC GCC CAT TTG CGT CAA TGG GGC GGA GTT GTT
  3433  ACG ACA TTT TGG AAA GTC CCG TTG ATT TAC TAG TCA AAA CAA ACT CCC ATT GAC GTC AAT GGG GTG GAG ACT TGG AAA
  3511  TCC CCG TGA GTC AAA CCG CTA TCC ACG CCC ATT GAT GTA CTG CCA AAA CCG CAT CAT CAT GGT AAT AGC GAT GAC TAA
  3589  TAC GTA GAT GTA CTG CCA AGT AGG AAA GTC CCA TAA GGT CAT GTA CTG GGC ATA ATG CCA GCC GGC CCA TTT ACC GTC
  3667  ATT GAC GTC AAT AGG GGG CGT ACT TGG CAT ATG ATA CAC TTG ATG TAC TGC CAA GTG GGC AGT TTA CCG TAA ATA CTC
  3745  CAC CCA TTG ACG TCA ATG GAA AGT CCC TAT TGG CGT TAC TAT GGG AAC ATA CGT CAT TAT TGA CGT CAA TGG GCG GGG
  3823  GTC GTT GGG CGG TCA GCC AGG CGG GCC ATT TAC CGT AAG TTA TGT AAC GCC TGC AGG TTA ATT AAG AAC ATG TGA GCA
```

Fig. 12, contd.

```
3801    AAA GGC CAG CAA AAG GCC AGG AAC CGT AAA AAG GCC GCG TTG CTG GCG TTT TTC CAT AGG CTC CGC CCC CCT GAC GAG
3979    CAT CAC AAA AAT CGA CGC TCA AGT CAG AGG TGG CGA AAC CCG ACA GGA CTA TAA AGA TAC CAG GCG TTT CCC CCT GGA
4057    AGC TCC CTC GTG CGC TCT CCT GTT CCG ACC CTG CCG CTT ACC GGA TAC CTG TCC GCC TTT CTC CCT TCG GGA AGC GTG
4135    GCG CTT TCT CAT AGC TCA CGC TGT AGG TAT CTC AGT TCG GTG TAG GTC GTT CGC TCC AAG CTG GGC TGT GTG CAC GAA
4213    CCC CCC GTT CAG CCC GAC CGC TGC GCC TTA TCC GGT AAC TAT CGT CTT GAG TCC AAC CCG GTA AGA CAC GAC TTA TCG
4291    CCA CTG GCA GCA GCC ACT GGT AAC AGG ATT AGC AGA GCG AGG TAT GTA GGC GGT GCT ACA GAG TTC TTG AAG TGG TGG
4369    CCT AAC TAC GGC TAC ACT AGA AGA ACA GTA TTT GGT ATC TGC GCT CTG CTG AAG CCA GTT ACC TTC GGA AAA AGA GTT
4447    GGT AGC TCT TGA TCC GGC AAA CAA ACC ACC GCT GGT AGC GGT GGT TTT TTT GTT TGC AAG CAG CAG ATT ACG CGC AGA
4525    AAA AAA GGA TCT CAA GAA GAT CCT TTG ATC TTT TCT ACG GGG TCT GAC GCT CAG TGG AAC GAA AAC TCA CGT TAA GGG
4603    ATT TTG GTC ATG GCT AGT TAA TTA ACA TTT AAA TCA
```

pSelect-IGLV2-14/J-Ck

```
   1    GCG GCC GCA ATA AAA TAT CTT TAT TTT CAT TAC ATC TGT GTG TTG GTT TTT TGT GTG AAT CGT AAC TAA CAT ACG CTC
  79    TCC ATC AAA ACA AAA CGA AAC AAA ACA AAC TAG CAA AAT AGG CTG TCC CCA GTG CAA GTG CAG GTG CCA GAA CAT TTC
 157    TCT ATC GAA GGA TCT GCG ATC GCT CCG GTG CCC GTC AGT GGG CAG AGC GCA CAT CGC CCA CAG TCC CCG AGA AGT TGG
 235    GGG GAG GGG TCG GCA ATT GAA CGG GTG CCT AGA GAA GGT GGC GCG GGG TAA ACT GGG AAA GTG ATG TCG TGT ACT GGC
 313    TCC GCC TTT TTC CCG AGG GTG GGG GAG AAC CGT ATA TAA GTG CAG TAG TCG CCG TGA ACG TTC TTT TTC GCA ACG GGT
 391    TTG CCG CCA GAA CAC AGC TGA AGC TTC GAG GGG CTC GCA TCT CTC CTT CAC GCG CCC GCC GCC CTA CCT GAG GCC GCC
 469    ATC CAC GCC GGT TGA GTC GCG TTC TGC CGC CTC CCG CCT GTG GTG CCT CCT GAA CTG CGT CCG CCG TCT AGG TAA GTT
 547    TAA AGC TCA GGT CGA GAC CGG GCC TTT GTC CGG CGC TCC CTT GGA GCC TAC CTA GAC TCA GCC GGC TCT CCA CGC TTT
 625    GCC TGA CGC TGC TTG CTC AAC TCT ACG TCT TTG TTT CGT TTT CTG TTC TGC GCC GTT ACA GAT CCA AGC TGT GAC CGG
 703    CGC CTA CCT GAG ATC ACC GGC GTG TCG ACG CCA CCA TGG ACA TGA GAG TGC CCG CCC AGC TCC TGG GGC TCC TGC TAC
 781    TCT GGC TCC GAG GTA AGG ATG GAG AAC ACT AGG AAT TTA CTC AGC CAG TGT GCT CAG TAC TGA CTG GAA CTT CAG GGA
 859    AGT TCT CTG ATA ACA TGA TTA ATA GTA AGA ATA TTT GTT TTT ATG TTT CCA ATC TCA GGT GCC AGA TGT CAG TCT GCC
 937    CTG ACC CAG CCC GCC TCT GTG TCT GGC AGC CCT GGC CAG AGC ATC ACC ATC AGC TGC ACC GGC ACC AGC AGC GAC GTG
1015    GGC GGC TAC AAC TAC GTG TCC TGG TAT CAG CAG CAC CCC GGC AAG GCC CCC AAG CTG ATG ATC TAC GAG GTG TCC AAC
1093    AGA CCC AGC GGC GTG AGC AAC AGA TTC AGC GGC AGC AAG AGC GGC AAC ACC GCC AGC CTG ACC ATC AGC GGC CTC CAG
1171    GCT GAG GAC GAG GCC GAC TAC TAC TGC AGC AGC TAC ACC AGC AGC TCC ACC CTG GTG TTT GGC GGC GGA ACA AAG CTG
1249    ACC GTG CTG AGA GGC GAC GCC GCT CCC ACC GTG TCC ATC TTC CCC CCC AGC ATG GAA CAG CTG ACC TCT GGC GGA GCC
1327    ACC GTG GTC TGC TTC GTG AAC AAC TTC TAC CCC AGA GAC ATC AGC GTG AAG TGG AAG ATC GAC GGC AGC GAG CAG AGG
1405    GAC GGC GTG CTG GAC AGC GTG ACC GAC CAG GAC AGC AAG GAC TCC ACC TAC AGC ATG AGC AGC ACC CTG ACC CTG ACC
1483    AAG GTG GAG TAC GAG AGG CAC AAC CTG TAC ACC TGC GAG GTG GTG CAC AAG ACC AGC TCC AGC CCC GTG GTC AAG TCC
1561    TTC AAC CGG AAC GAG TGT TGA GCT AGC TGG CCA GAC ATG ATA AGA TAC ATT GAT GAG TTT GGA CAA ACC ACA ACT AGA
 937    CTG ACT CAG CCT GCC TCC GTG TCT GGG TCT CCT GGA CAG TCG ATC ACC ATC TCC TGC ACT GGA ACC AGC AGT GAC GTT
1015    GGT GGT TAT AAC TAT GTC TCC TGG TAC CAA CAG CAC CCA GGC AAA GCC CCC AAA CTC ATG ATT TAT GAG GTC AGT AAT
1093    CGG CCC TCA GGG GTT TCT AAT CGC TTC TCT GGC TCC AAG TCT GGC AAC ACG GCC TCC CTG ACC ATC TCT GGG CTC CAG
1171    GCT GAG GAC GAG GCT GAT TAT TAC TGC AGC TCA TAT ACA AGC AGC AGC ACT CTC GTA TTC GGC GGA GGG ACC AAG CTG
1249    ACC GTC CTA CGG GCT GAT GCT GCA CCA ACT GTA TCC ATC TTC CCA CCA TCC ATG GAA CAG TTA ACA TCT GGA GGT GCC
1327    ACA GTC GTG TGC TTC GTG AAC AAC TTC TAT CCC AGA GAC ATC AGT GTC AAG TGG AAG ATT GAT GGC AGT GAA CGA CGA
1405    GAT GGT GTC CTG GAC AGT GTT ACT GAT CAG GAC AGC AAA GAC AGC ACG TAC AGC ATG AGC AGC ACC CTC TCG TTG ACC
```

Fig. 12, contd.




Fig. 12, contd.




Fig. 12, contd.




Fig. 12, contd.

```
6319 GTC TTA ATA AGA ATT CAC TGG CCG TCG TTT TAC AAC GTC GTG ACT GGG AAA ACC CTG GCG TTA CCC AAC TTA ATC GCC
6397 TTG CAG CAC ATC CCC CTT TCG CCA GCT GGC GTA ATA GCG AAG AGG CCC GCA CCG ATC GCC CTT CCC AAC AGT TGC GCA
6475 GCC TGA ATG GCG AAT GGC GCC CGA TGC GGT ATT TTC TCC TTA CGC ATC TGT GCG GTA TTT CAC ACC GCA TAC GTC AAA
6553 GCA ACC ATA GTA CGC GCC CTG TAG CGG CGC ATT AAG CGC GGC GGG TGT GGT GGT TAC GCG CAG CGT GAC CGC TAC ACT
6631 TGC CAG CGC CTT AGC GCC CGC TCC TTT CGC TTT CTT CCC TTC CTT TCT CGC CAC GTT CGC CGG CTT TCC CCG TCA AGC
6709 TCT AAA TCG GGG GCT CCC TTT AGG GTT CCG ATT TAG TGC TTT ACG GCA CCT CGA CCC CAA AAA A
```

MV1057

```
   1 TAC TCT TCC TTT TTC AAT ATT ATT GAA GCA TTT ATC AGG GTT ATT GTC TCA TGA GCG GAT ACA TAT TTG AAT GTA TTT
  79 AGA AAA ATA AAC AAA TAG GGG TTC CGC GCA CAT TTC CCC GAA AAG TGC CAC CTG ACG TCG ACG GAT CGG GAG ATC TCC
 157 CGA TCC CCT ATG GTG CAC TCT CAG TAC AAT CTG CTC TGA TGC CGC ATA GTT AAG CCA GTA TCT GCT CCC TGC TTG TGT
 235 GTT GGA GGT CGC TGA GTA GTG CGC GAG CAA AAT TTA AGC TAC AAC AAG GCA AGG CTT GAC CGA CAA TTG CAT GAA GAA
 313 TCT GCT TAG GGT TAG GCG TTT TGC GCT GCT TCG CTA GGT GGT CAA TAT TGG CCA TTA GCC ATA TTA TTC ATT GGT TAT
 391 ATA GCA TAA ATC AAT ATT GGC TAT TGG CCA TTG CAT ACG TTG TAT CCA TAT CAT AAT ATG TAC ATT TAT ATT GGC TCA
 469 TGT CCA ACA TTA CCG CCA TGT TGA CAT TGA TTA TTG ACT AGT TAT TAA TAG TAA TCA ATT ACG GGG TCA TTA GTT CAT
 547 AGC CCA TAT ATG GAG TTC CGC GTT ACA TAA CTT ACG GTA AAT GGC CCG CCT GGC TGA CCG CCC AAC GAC CCC CGC CCA
 625 TTG ACG TCA ATA ATG ACG TAT GTT CCC ATA GTA ACG CCA ATA GGG ACT TTC CAT TGA CGT CAA TGG GTG GAG TAT TTA
 703 CGG TAA ACT GCC CAC TTG GCA GTA CAT CAA GTG TAT CAT ATG CCA AGT ACG CCC CCT ATT GAC GTC AAT GAC GGT AAA
 781 TGG CCC GCC TGG CAT TAT GCC CAG TAC ATG ACC TTA TGG GAC TTT CCT ACT TGG CAG TAC ATC TAC GTA TTA GTC ATC
 859 GCT ATT ACC ATG GTG ATG CGG TTT TGG CAG TAC ATC AAT GGG CGT GGA TAG CGG TTT GAC TCA CGG GGA TTT CCA AGT
 937 CTC CAC CCC ATT GAC GTC AAT GGG AGT TTG TTT TGG CAC CAA AAT CAA CGG GAC TTT CCA AAA TGT CGT AAC AAC TCC
1015 GCC CCA TTG ACG CAA ATG GGC GGT AGG CGT GTA CGG TGG GAG GTC TAT ATA AGC AGA GCT CGT TTA GTG AAC CGT CAG
1093 ATC GCC TGG AGA CGC CAT CCA CGC TGT TTT GAC CTC CAT AGA AGA CAC CGG GAC CGA TCC AGC CTC CGC GGC CGG GAA
1171 CGG TGC ATT GGA AGC TTG GTA CCG GTG AAT TGG CCG GCC CGC GCC GTC GAG GTT ATC GAT CCG ACC GAC GCG TTC GCG
1249 AGA GGC CGC AAT TCC CTA GCC ACC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA CTG CTG CTG GCC CAG CCG GCC
1327 ATG GGG CGG AGA ATG GCC GGA ACT GGG CGG AGT TAG GGG CGG GAT GGG CGG AGT TAG GGG CGG GAC TAT GGT TGC TGA
1405 CTA ATT GAG ATC CGG ATC CGC TGG CAC GAC AGG TTT CCC GAC TGG AAA GCG GGC AGT GAG CGC AAC GCA ATT AAT GTG
1483 AGT TAG CTC ACT CAT TAG GCA CCC CAG GCT TTA CAC TTT ATG CTT CCG GCT CGT ATG TTG TGT GGA ATT GTG AGC GGA
1561 TAA CAA TTT CAC ACA GGA AAC AGC TAT GAC CAT GAT TAC GCC AAG CTT GGG CTG CAG GTT CTT TCC GCC TCA GAA GCC
1639 ATA GAG CCC ACC GCA TCC CCA GCA TGC CTG CTA TTG TCT TCC CAA TCC TCC CCC TTG CTG TCC TGC CCC ACC CCA CCC
1717 CCC AGA ATA GAA TGA CAC CTA CTC AGA CAA TGC GAT GCA ATT TCC TCA TTT TAT TAG GAA AGG ACA GTG GGA GTG GCA
1795 CCT TCC AGG GTC AAG GAA GGC ACG GGG GAG GGG CAA ACA ACA GAT GGC TGG CAA CTA GAA GGC ACA GTC GAG GCT GAT
1873 CAG CGA GCT CTA GAT CAT CGA TGC ATG GGG TCG TGC GCT CCT TTC GGT CGG GCG CTG CGG GTC GTG GGG CGG GCG TCA
1951 GGC ACC GGG CTT GCG GGT CAT GCA CCA GGT GCG CGG TCC TTC GGG CAC CTC GAC GTC GGC GGT GAC GGT GAA GCC GAG
2029 CCG CTC GTA GAA GGG GAG GTT GCG GGG CGC GGA GGT CTC CAG GAA GGC GGG CAC CCC GGC GCG CTC GGC CGC CTC CAC
2107 TCC GGG GAG CAC GAC GGC GCT GCC CAG ACC CTT GCC CTG GTG GTC GGG CGA GAC CCC GAC GGT GGC CAG GAA GCA CGC
2185 GGG CTC CTT GGG CCG GTG CGG CGC CAG GAG GCC TTC CAT CTG TTG CTG CGC GGC CAG CCG GGA ACC GCT CAA CTC GGC
2263 CAT GCG CGG GCC GAT CTC GGC GAA CAC CGC CCC CGC TTC GAC GCT CTC CGG CGT GGT CCA GAC CGC CAC CGC GGC GCC
2341 GTC GTC CGC GAC CCA CAC CTT GCC GAT GTC GAG CCC GAC GCG CGT GAG GAA GAG TTC TTG CAG CTC GGT CAC CGT CTC
2419 CAG TGC TAG CAC CAA GGG CCC ATC GGT CTT CCC CCT GGC ACC CTC CTC CAA GAG CAC CTC TGG GGG CAC AGC GGC CCT
```

Fig. 12, contd.

```
2497 GGC CTG CCT GGT CAA GGA CTA CTT CCC CGA ACC GGT GAC GGA GTC GTG GAA CTC AGG CGC CCT GAC CAG CGG CGT GCA
2575 CAC CTT CCC GGC TGT CCT ACA GTC CTC AGG ACT CTA CTC CCT CAG CAG CGT CGT GAC CGT GCC CTC CAG CAG CTT GGG
2653 CAC CCA GAC CTA CAT CTG CAA CGT GAA TCA CAA GCC CAG CAC CAA GGT GGA CAA GAG AGT TGG TGA GAG GCC AGC
2731 ACA GGG AGG GAG GGT GTC TGC TGG AAG CCA GGC TCA GCG CTC CTG CCT GGA CGC ATC CCG GCT ATG CAG TCC CAG TCC
2809 AGG GCA GCA AGC CAG GCC CCG TCT GGC TCT TCA GCC GGA GGC CTC TGC CCG CCC CAC TCA TGC TCA GGG AGA GGG TCT
2887 TCT GGC TTT TTC CCC AGG CTC TGG GCA GGC ACA GGC TAG GTG CCC CTA ACC CAG GCC CTG CAC ACA AAG GGG CAG GTG
2965 CTG GGC TCA GAC CTG CCA AGA GCC ATA TCC GGG AGG ACC CTG CCC CTG ACC TAA GCC CAC CCC AAA GGC CAA ACT CTC
3043 CAC TCC CTC AGC TCG GAC ACC TTC TCT CCT CCC AGA TTC CAG TAA CTC CCA ATC TTC TCT CTG CAG AGC CCA AAT CTT
3121 GTC ACA AAA CTC ACA CAT GCC CAC CGT GCC CAG CAC CTG AGG TCA CAT GCG TGG TGG TGG ACG TGA GCC ACG AAG ACC CTG
3199 AAC CCA AGG ACA CCC TCA TGA TCT CCC GGA CCC CTG AGG TCA CAT GCG TGG TGG TGG ACG TGA GCC ACG AAG ACC CTG
3277 AGG TCA AGT TCA ACT GGT ACG TGG ACG GCG TGG AGG TGC ATA ATG CCA AGA CAA AGC CGC GGG AGG AGC AGT ACA ACA
3355 GCA CGT ACC GTG TGG GCG TCC TCC GCG TCC TGC ACC AGG ACT GGC TGA ATG GCA AGG AGT ACA AGT GCA AGG TCT
3433 CCA ACA AAG CCC TCC CAG AGA AAA CCA TCT CCA AAG CCA AAG GGC AGC CCC GAG AAC CAC AGG TGT ACA
3511 CCC TGC CCC CAT CCC GGG AGG AGA TGA CCA AGA ACC AGG TCA GCC TGA CCT GCC TGG TCA AAG GCT TCT ATC CCA GCG
3589 ACA TCG CCG TGG AGT GGG AGA GCA ATG GGC AGC AGA ACA ACT ACG CCA CCT CCG TGC TGG ACT CCG ACG GCT TCT
3667 GCT CCT TCT TCC TCT ATA GCA AGC TCA CCG TGG ACA AGA GCA GGT GGC AGC AGG GGA ACG TCT TCT CAT GCA TGA
3745 TGC ATG AGG CTC TGC ACA ACC ACT ACA CGC AGA AGA GCC TCT CCC TGT CTC CGG GTA AAT GAG TTT AAC GGA TCT TAA
3823 TTA ATC CGA GCT CGG TAC CAA GCT TAA GTT TAA ACC GCT GAT CAG CCT CGA CTG TGC CTT CTA GTT GCC AGC CAT CTG
3901 TTG TTT GCC CCT CCC CCG TGC CTT CCT TGA CCC TGG AAG GTG CCA CTC CCA CTG TCC TTT CCT AAT AAA ATG AGG AAA
3979 TTG CAT CGC ATT GTC TGA GTA GGT GTC ATT CTA TTC TGG GGG GTG GGG TGG GCC AGG ACA GCA GGG AGG ATT GGG
4057 AAG ACA ATA GCA GCC ATG GGG CGG TGG GCT CTA TGG CTT CTG AGG CGG ATA AAA GAA CGA GGC GCT CTA GGG
4135 GGT ATC CCC ACG CGC CCT GTA GCG GCG CAT TAA GCG CGG CGG GTG TGG TGG TTA CGC GCA GCG TGA CCG CTA CAC TTG
4213 CCA GCG CCT AGC GCC CGC TCC TTT CCC TTT CTT CCC TTC CTT TCT CGC CAC GTT CGC CGG CTT TCC CCG TCA AGC TCT
4291 AAA TCG GGG GCT CCC TTT AGG GTT CGA TTT AAG TGC TTT ACG GCA CCT CGA CCC CAA AAA ACT TGA TTA GGG TGA TGG
4369 TTC ACG TAG TGG GCC ATC GCC CTG ATA GAC GGT TTT TCG CCC TTT GAC GTT GGA GTC CAC GTT CTT TAA TAG TGG ACT
4447 CTT GTT CCA AAC TGG AAC AAC ACT CAA CCC TAT CTC GGT CTA TTC TTT TGA TTT ATA AGG GAT TTT GCC GAT TTC GGC
4525 CTA TTG GTT AAA AAA TGA GCT GAT TTA ACA AAA ATT TAA CGC GAA TTA ATT CTG TGG AAT GTG TGT CAG TTA GGG TGT
4603 GGA AAG TCC CCA GGC TCC GCA GCA AGG AGT ATG CAA AGC ATG CAT CTC AAT TAG TCA GCA ACC ATA GTC CCG CCC CTA ACT
4681 TCC CCA GGC TCC CCA GCA GGC AGA ACT ATG CAA AGC ATG CAT CTC AAT TAG TCA GCA ACC ATA GTC CCG CCC CTA ACT
4759 CCG CCC ATC CCG CCC CTA ACT CCG CCC AGT TCC GCC CAT TCT CCG CCC CAT GGC TGA CTA ATT TTT TTT ATT TAT GCA
4837 GAG GCC GAG CGC GCC TCT GCC TCT GAG CTA TTC CAG AAG TAG TGA GGA GGC TTT TTT GGA GGC CTA GGC TTT TGC AAA
4915 AAG CTC CCG GGA GTT TGG ATA TCC ATT TTC GGA TCT GAT CAA GAG ACA GGA TGA GGA TCG TTT CGC ATG ATT GAA CAA
4993 GAT GCA TTG CAC GCA GGT TCT CCG GCC GCT TGG GTG GAG AGG CTA TTC GGC TAT GAC TGG GCA CAA CAG ATC GGC
5071 TGC TCT GAT GCC GCT GTG TTC CGG CTG TCA GCG CAG GGG CGC CCG GTT CTT TTT GTC AAG ACC GAC CTG TCC GGT GCC
5149 CTG AAT GAA CTG CAG GAC GAG GCA GCG CGG CTA TCG TGG CTG GCC ACG ACG GGC GTT CCT TGC GCA GCT GTG CTC GAC
5227 GTT GTC ACT GAA GGG GGA AGC GAC TGG CTG CTA TTG GGC GAA GTG CCG GGG CAG GAT CTC CTG TCA TCT CAC CTT GCT
5305 CCT GCC GAG AAA GTA TCC ATC ATG GCT GAT GCA ATG CGG CGG CTG CAT ACG CTT GAT CCG GCT ACC TGC CCA TTC GAC
5383 CAC CAA GCG AAA CAT CGC ATC GAG CGA GCA CGT ACT CGG ATG GAA GCC GGT CTT GTC GAT CAG GAT GAT CTG GAC GAA
5461 GAG CAT CAG GGG CTC GCC CCA GCC GAA CTG TTC GCC AGG CTC AAG GCG CGC CAT TTT CGA TTC ATC GAC TGT GGC CGG CTG
5539 ACC CAT CGC GAT GCC TGC TTG CCG AAT ATC ATG GTG GAA AAT GCC GCC TTT TCT GGA TTC ATC GAC TGT GGC CGG CTG
5617 GGT GTG GCG GAC CGC TAT CAG GAC ATA GCG TTG GCT ACC CGT GAT ATT GCT GAA GAG CTT GGC GGC GAA TGG GCT GAC
```

Fig. 12, contd.

```
5695 CGC TTC CTC GTC CTT TAC GGT ATC GCC GCT CCC GAT TCG CAG CGC ATC GCC TTC TAT CGC CTT CTT GAC GAG TTC TTC
5753 TGA GCG GGA CTC TCG GGT TCG GTG CTA CGA GAT TTC GAT TCC ACC GCC GCC TTC TAT GAA AGG TTG GGC TTC GGA ATC
5811 GTT TTC CGG GAC GCC GGC ATG ATC GTC CAG CGC GGG GAT CTC GAT CCC AAG ATC GAC TTC ATC GCC CAC CCC AAC TTG TTT
5869 ATT GCA GCT TAC AAA TAC AGC AAT AAT GCC ATC ACA AAT TTC ACA AAT AAA GCA TTT TTT TCA CTG CAT TCT
5927 AGT TGT TAT AAT GGT TAC AAA AAA TAC AGC ATC ACA AAT TTC ACA AAT AAA GCA TTT TTT TCA CTG CAT TCT
5985 TCA TGG TCA TAG CTG TTT CCT GTG TGA AAT TGT TAT CCG CTC ACA TTA ATT GCG TTG CGC TCA CTG CCC GCT TTC CAG TCG GGA
6043 TGT AAA GCC TGG CGT TTC GCC TAA TGA GCT GAT GCT TTC GTG TAG GTA TCT CAG TTC GGT GTA GGT CGT TCG CTC CAA GCT
6101 AAC CTG TGG TGC CAG AAT TGC ATG AAG AAT CTG CTT AGG GTT AGG CGT TTT GCG CTG CTT CGC GAG GTG TCA GCT CTT GCT
6159 GGC CAT TAG CCA TAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
6217 AIC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
6275 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
6333 CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT
6391 TCC ATT GAC GTC AAT GGG TGG AGT ATT TAC GGT AAA CTG CCC ACT TGG CAG TAC ATC AAG TGT ATC ATA TGC CAA GTA
6449 CGC CCC GCC CTA TTG ACG TCA ATG ACG GTA AAT GGC CCG CCT GGC ATT ATG CCC AGT ACA TGA CCT TAT GGG ACT TTC CTA
6507 GGC CAT TAG CCA TAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
6565 AIC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
6623 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
6681 CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT
6739 TCC ATT GAC GTC AAT GGG TGG AGT ATT TAC GGT AAA CTG CCC ACT TGG CAG TAC ATC AAG TGT ATC ATA TGC CAA GTA
6797 CGC CCC GCC CTA TTG ACG TCA ATG ACG GTA AAT GGC CCG CCT GGC ATT ATG CCC AGT ACA TGA CCT TAT GGG ACT TTC CTA
6855 AGC GGC ACC GAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
6913 ATC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
6971 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
7029 CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT
7087 TCC ATT GAC GTC AAT GGG TGG AGT ATT TAC GGT AAA CTG CCC ACT TGG CAG TAC ATC AAG TGT ATC ATA TGC CAA GTA
7145 CGC CCC GCC CTA TTG ACG TCA ATG ACG GTA AAT GGC CCG CCT GGC ATT ATG CCC AGT ACA TGA CCT TAT GGG ACT TTC CTA
7203 GGC CAT TAG CCA TAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
7261 AIC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
7319 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
7377 CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT
7435 TCC ATT GAC GTC AAT GGG TGG AGT ATT TAC GGT AAA CTG CCC ACT TGG CAG TAC ATC AAG TGT ATC ATA TGC CAA GTA
7493 CGC CCC GCC CTA TTG ACG TCA ATG ACG GTA AAT GGC CCG CCT GGC ATT ATG CCC AGT ACA TGA CCT TAT GGG ACT TTC CTA
7551 GGC CAT TAG CCA TAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
7609 AIC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
7667 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
7725 CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT
7783 TCC ATT GAC GTC AAT GGG TGG AGT ATT TAC GGT AAA CTG CCC ACT TGG CAG TAC ATC AAG TGT ATC ATA TGC CAA GTA
7841 CGC CCC GCC CTA TTG ACG TCA ATG ACG GTA AAT GGC CCG CCT GGC ATT ATG CCC AGT ACA TGA CCT TAT GGG ACT TTC CTA
7899 GGC CAT TAG CCA TAT TCA TTG GTT ATA TAG CAT AAA TCA ATA TTG GCT ATT GGC CAT TGC ATA CGT TGA GTT CTT CGG TGT
7957 AIC ATA ATA TGT ACA TTT ATA TTG GCT CAT GTC CAA CAT TAC CGC CAT GTT GAC ATT GAT TAT TGA CTA GTT ATT AAT
8015 AGT AAT CAA TTA CGG GGT CAT TAG TTC ATA GCC CAT ATA TGG AGT TCC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC
```

Fig. 12, contd.




Fig. 13A



Final Targeting Vector
pA
F3
5' D neo
bpA
amp
pCAGGS-IgVk1-39 Final Seq(SJ0110)
8179 bp
CAGGS promoter
FRT
pA
synthetic intron
loxP
IgVk1-39
mini ORF Fluc
pA
loxP

Fig. 13B

```
   1 atccaggcgc ggatcaataa aagatcatta ttttcaatag atctgtgtgt tggtttttg
  61 tgtgccttgg gggaggggga ggccagaatg aggcgcggcc aaggggagg gggaggccag
 121 aatgaccttg ggggaggggg aggccagaat gaccttgggg gaggggagg ccagaatgag
 181 gcgcggatcc ggagaagttc ctattccgaa gttcctattc ttcaaatagt ataggaactt
 241 cgctcgaggg atcggccatt gaacaagatg gattgcacgc aggttctccg gccgcttggg
 301 tggagaggct attcggctat gactgggcac aacagacaat cggctgctct gatgccgccg
 361 tgttccggct gtcagcgcag gggcgcccgg ttctttttgt caagaccgac ctgtccggtg
 421 ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg acgggcgttc
 481 cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg ctattgggcg
 541 aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa gtatccatca
 601 tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca ttcgaccacc
 661 aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt gtcgatcagg
 721 atgatctgga cgaagagcat cagggctcg cgccagccga actgttcgcc aggctcaagg
 781 cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc ttgccgaata
 841 tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg ggtgtggcgg
 901 accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt ggcggcgaat
 961 gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag cgcatcgcct
1021 tctatcgcct tcttgacgag ttcttctgag gggatcgatc cgctgtaagt ctgcagaaat
1081 tgatgatcta ttaaacaata aagatgtcca ctaaaatgga agttttcct gtcatacttt
1141 gttaagaagg gtgagaacag agtacctaca ttttgaatgg aaggattgga gctacggggg
1201 tgggggtggg gtgggattag ataaatgcct gctctttact gaaggctctt tactattgct
1261 ttatgataat gtttcatagt tggatatcat aatttaaaca agcaaaacca aattaagggc
1321 cagctcattc ctcccactca tgatctatag atctatagat ctctcgtggg atcattgttt
1381 ttctcttgat tcccactttg tggttctaag tactgtggtt tccaaatgtg tcagtttcat
1441 agcctgaaga acgagatcag cagcctctgt tccacataca cttcattctc agtattgttt
1501 tgccaagttc taattccatc agaagctgac tctagatggc gcgtatgcag gttttcgaca
1561 ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
1621 tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga
1681 cccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt
1741 ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt
1801 gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca
1861 ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
1921 catcgctatt accatggtcg aggtgagccc cacgttctgc ttcactctcc ccatctcccc
1981 cccctcccca cccccaattt tgtatttatt tatttttaa ttatttgtg cagcgatggg
2041 ggcgggggggg gggggggcgc gcgccaggcg gggcggggcg gggcgagggg cggggcgggg
2101 cgaggcggag aggtgcggcg gcagccaatc agagcggcgc gctccgaaag tttcctttta
2161 tggcgaggcg gcggcggcgg cggccctata aaaagcgaag cgcgcggcgg gcgggagtcg
2221 ctgcgttgcc ttcgccccgt gccccgctcc gcgccgcctc gcgccgcccg ccccggctct
```

Fig. 13B, contd.

```
2281 gactgaccgc gttactccca caggtgagcg ggcgggacgg cccttctcct ccgggctgta
2341 attagcgctt ggtttaatga cggctcgttt cttttctgtg gctggctgaa agccttaaag
2401 ggctccggga gggccctttg tgcgggggag agcggctcgg ggggtgcgtg cgtgtgtgtg
2461 tgcgtgggga gcgccgcgtg cggcccgcgc tgcccggcgg ctgtgagcgc tgcgggcgcg
2521 gcgcgggggt ttgtgcgctc cgcgtgtgcg cgaggggagc gcggccgggg gcggtgcccc
2581 gcggtgcggg ggggctgcga ggggaacaaa ggctgcgtgc ggggtgtgtg cgtgggggag
2641 tgagcagggg gtgtgggcgc ggcggtcggg ctgtaacccc ccccctgcacc cccctccccg
2701 agttgctgag cacggccccg cttcgggtgc ggggctccgt gcgggggcgtg gcgcgggggt
2761 cgccgtgccg gcgcgggggt ggcggcaggt ggggtgtccg ggcgggggcgg ggccgcctcg
2821 ggccggggag ggctcggggg agggcgcggg cggccccgga gcgccggcgg ctgtcgaggc
2881 gcggcgagcc gcagccattg cctttatgg taatcgtgcg agagggtgca gggacttcct
2941 ttgtcccaaa tctgtgcgga gccgaaatct gggaggcgcc gccgcacccc ctctagcggg
3001 cgcggggcga agcggtgcgg cgccggcagg aaggaaatgg gcggggaggg ccttcgtgcg
3061 tcgccgcgcc gccgtccctt tctcccttcc cagcctcggg gctgtccgcg gggggacggc
3121 tgccttcggg ggggacgggg cagggcgggg ttcggcttct ggcgtgtgac cggcggctct
3181 agaagcgttg gggtgagtac tccctctcaa aagcgggcat gacttctgcg ctaagattgt
3241 cagtttccaa aaacgaggag gatttgatat tcacctggcc cgcggtgatg cctttgaggg
3301 tggccgcgtc catctggtca gaaaagacaa tctttttgtt gtcaagcttg aggtgtggca
3361 ggcttgagat ctggccatac acttgagtga cattgacatc cactttgcct ttctctccac
3421 aggtgtccac tccccagggcg gcctccggag cgatcgccga tccgcctagg caattgttta
3481 aatcggccgg ccataacttc gtataatgta tgctatacga agttatggat cctcacagta
3541 ggtggccatcg ttcctttctg actgcccgcc ccccgcatgc cgtcccgcga tattgagctc
3601 cgaacctctc gccctgccgc cgccggtgct ccgtcgccgc cgcgccgcca tggaatcgaa
3661 gccaccatgg atcttaccgg aaaactcgac gcaagaaaaa tcagagagat cctcataaag
3721 gtcaagaagg gcggaaagat cgccgtgtaa ttctagaccg gttcgagatc caggcgcgga
3781 tcaataaaag atcattattt tcaatagatc tgtgtgttgg ttttttgtgt gccttggggg
3841 aggggaggc cagaatgagg cgcggccaag ggggaggggg aggccagaat gaccttgggg
3901 gagggggagg ccagaatgac cttgggggag ggggaggcca gaatgaggcg cgcctccgt
3961 cgacctataa cttcgtataa tgtatgctat acgaagttat ggcggccgcc accatggaca
4021 tgagagtgcc cgcccagctc ctgggctcc tgctactctg gctccgaggt aaggatggag
4081 aacactagga atttactcag ccagtgtgct cagtactgac tggaacttca gggaagttct
4141 ctgataacat gattaatagt aagaatattt gttttatgt ttccaatctc aggtgccaga
4201 tgtgacatcc agatgaccca gagccccagc agcctgagcg ccagcgtggg cgacagagtg
4261 accatcacct gcagagccag ccagagcatc agcagctacc tgaactggta tcagcagaag
4321 ccgggcaagg ccccaagct gctgatctac gccgccagct cctgcagag cggcgtgccc
4381 agcagattca gcggcagcgg ctccggcacc gacttcaccc tgaccatcag cagcctgcag
4441 ccggaggact tcgccaccta ctactgccag cagagctaca gcaccccccc caccttcggc
```

Fig. 13B, contd.

4501 cagggcacca aggtggagat caagagagcc gacgccgctc ccaccgtgtc catcttcccc
4561 cccagcatgg aacagctgac ctctggcgga gccaccgtgg tctgcttcgt gaacaacttc
4621 taccccagag acatcagcgt gaagtggaag atcgacggca gcgagcagag ggacggcgtg
4681 ctggacagcg tgaccgacca ggacagcaag gactccacct acagcatgag cagcaccctg
4741 agcctgacca aggtggagta cgagaggcac aacctgtaca cctgcgaggt ggtgcacaag
4801 accagctcca gccccgtggt caagtccttc aaccggaacg agtgttgagc tagcttaaga
4861 tttaaatagg ccggccgcgt cgacctcgag atccaggcgc ggatcaataa aagatcatta
4921 ttttcaatag atctgtgtgt tggtttttg tgtgccttgg gggaggggga ggccagaatg
4981 aggcgcggcc aaggggagg gggaggccag aatgaccttg ggggaggggg aggccagaat
5041 gaccttgggg gaggggagg ccagaatgag gcgcgccccc gggtaccgag ctcgaattag
5101 tggatcctca cagtaggtgg catcgttcct ttctgactgc ccgccccccg catgccgtcc
5161 cgcgatattg agctccgaac ctctcgccct gccgccgccg gtgctccgtc gccgccgcgc
5221 cgccatggaa tcgcgccggt aaccgaagtt cctatacttt ctagagaata ggaacttcgg
5281 aataggaact tcaagccggt acccagcttt tgttcccttt agtgagggtt aatttcgagc
5341 ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaatttcca
5401 cacaacatac gagccgggag cataaagtgt aaagcctggg gtgcctaatg agtgagctaa
5461 ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag
5521 ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc
5581 gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct
5641 cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg
5701 tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc
5761 cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga
5821 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct
5881 cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg
5941 gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag
6001 ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat
6061 cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac
6121 aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac
6181 tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttaccttc
6241 ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt
6301 tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc
6361 ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg
6421 agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca
6481 atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca
6541 cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag
6601 ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac
6661 ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc

Fig. 13B, contd.

6721 agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct
6781 agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc
6841 gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg
6901 cgagttacat gatccccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc
6961 gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat
7021 tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag
7081 tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat
7141 aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg
7201 cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca
7261 cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga
7321 aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc
7381 ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata
7441 tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg
7501 ccacctaaat tgtaagcgtt aatatttttgt taaaattcgc gttaaatttt tgttaaatca
7561 gctcattttt taaccaatag gccgaaatcg gcaaaatccc ttataaatca aaagaataga
7621 ccgagatagg gttgagtgtt gttccagttt ggaacaagag tccactatta aagaacgtgg
7681 actccaacgt caaagggcga aaaaccgtct atcagggcga tggcccacta cgtgaaccat
7741 cacctaatc aagttttttg gggtcgaggt gccgtaaagc actaaatcgg aaccctaaag
7801 ggagcccccg atttagagct tgacggggaa agccggcgaa cgtggcgaga aaggaaggga
7861 agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt agcggtcacg ctgcgcgtaa
7921 ccaccacacc cgccgcgctt aatgcgccgc tacagggcgc gtcccattcg ccattcaggc
7981 tgcgcaactg ttgggaaggg cgatcggtgc gggcctcttc gctattacgc cagctggcga
8041 aaggggatg tgctgcaagg cgattaagtt gggtaacgcc agggttttcc cagtcacgac
8101 gttgtaaaac gacggccagt gagcgcgcgt aatacgactc actatagggc gaattgggggg
8161 taactaagta aggatcgag



Rosa26 target
ATG
SA
PGK-Hyg^R
F3
FRT
Site specific recombination
by FLP^e (RMCE)
Δ 5' neo^R-pA
CAGGSprom
STOP
IgVκ1-39-pA
Exchange vector
Exchanged Rosa26 locus
ATG
SA
Δ 5' neo^R-pA
CAGGSprom
STOP
IgVκ1-39-pA
Rosa26-IgVκ1-39 locus, after Cre-mediated recombination
ATG
SA
Δ 5' neo^R-pA
CAGGSprom
IgVκ1-39-pA
loxP

Fig. 13C

Fig. 14A




Fig. 14B




Fig. 14C



2683/1
2683/3
2683/6
2683/8
WT
TT5
6.4kb (RMCE)
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95

Fig. 15A



pA
F3
5′ D neo
bpA
amp
pCAGGS-IgVI2-14 Final
Seq(SJ0111)
8188 bp
CAGGS promoter
FRT
pA
synthetic intron
loxP
IgVI2-14
mini ORF Fluc
pA
loxP

Fig. 15B

```
   1 atccaggcgc ggatcaataa aagatcatta ttttcaatag atctgtgtgt tggtttttg
  61 tgtgccttgg gggaggggga ggccagaatg aggcgcggcc aaggggagg gggaggccag
 121 aatgaccttg ggggaggggg aggccagaat gaccttgggg gaggggagg ccagaatgag
 181 gcgcggatcc ggagaagttc ctattccgaa gttcctattc ttcaaatagt ataggaactt
 241 cgctcgaggg atcggccatt gaacaagatg gattgcacgc aggttctccg gccgcttggg
 301 tggagaggct attcggctat gactgggcac aacagacaat cggctgctct gatgccgccg
 361 tgttccggct gtcagcgcag gggcgcccgg ttcttttttgt caagaccgac ctgtccggtg
 421 ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg acgggcgttc
 481 cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg ctattgggcg
 541 aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa gtatccatca
 601 tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca ttcgaccacc
 661 aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt gtcgatcagg
 721 atgatctgga cgaagagcat cagggctcg cgccagccga actgttcgcc aggctcaagg
 781 cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc ttgccgaata
 841 tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg ggtgtggcgg
 901 accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt ggcggcgaat
 961 gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag cgcatcgcct
1021 tctatcgcct tcttgacgag ttcttctgag gggatcgatc cgctgtaagt ctgcagaaat
1081 tgatgatcta ttaaacaata aagatgtcca ctaaaatgga agtttttcct gtcatacttt
1141 gttaagaagg gtgagaacag agtacctaca ttttgaatgg aaggattgga gctacgggcg
1201 tggggtggg gtgggattag ataaatgcct gctctttact gaaggctctt tactattgct
1261 ttatgataat gtttcatagt tggatatcat aatttaaaca agcaaaacca aattaagggc
1321 cagctcattc ctcccactca tgatctatag atctatagat ctctcgtggg atcattgttt
1381 ttctcttgat tcccactttg tggttctaag tactgtggtt tccaaatgtg tcagtttcat
1441 agcctgaaga acgagatcag cagcctctgt tccacataca cttcatctc agtattgttt
1501 tgccaagttc taattccatc agaagctgac tctagatggc gcgtatgcag gttttcgaca
1561 ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc atagcccata
1621 tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga
1681 cccccgcccc ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt
1741 ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt
1801 gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca
1861 ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt
1921 catcgctatt accatggtcg aggtgagccc cacgttctgc ttcactctcc ccatctcccc
1981 cccctccccc ccccccaatt tgtatttatt tatttttaa ttattttgtg cagcgatggg
2041 ggcgggggggg gggggggcgc gcgccaggcg gggcgggcg gggcgagggg cggggcgggg
2101 cgaggcggag aggtgcggcg gcagccaatc agagcggcgc gctccgaaag tttcctttta
```

Fig. 15B, contd.

2161 tggcgaggcg gcggcggcgg cggccctata aaaagcgaag cgcgcggcgg gcgggagtcg
2221 ctgcgttgcc ttcgccccgt gccccgctcc gcgccgcctc gcgccgcccg ccccggctct
2281 gactgaccgc gttactccca caggtgagcg ggcgggacgg cccttctcct ccgggctgta
2341 attagcgctt ggtttaatga cggctcgttt cttttctgtg gctgcgtgaa agccttaaag
2401 ggctccggga gggccctttg tgcgggggga agcggctcgg gggtgcgtg cgtgtgtgtg
2461 tgcgtgggga gcgccgcgtg cggcccgcgc tgcccgggcg ctgtgagcgc tgcgggcgcg
2521 gcgcgggggct ttgtgcgctc cgcgtgtgcg cgaggggagc gcggccgggg gcggtgcccc
2581 gcggtgcggg ggggctgcga ggggaacaaa ggctgcgtgc ggggtgtgtg cgtgggggag
2641 tgagcagggg gtgtgggcgc ggcggtcggg ctgtaacccc cccctgcacc cccctccccg
2701 agttgctgag cacggcccgg cttcgggtgc ggggctccgt gcgggcgtg gcgcgggggct
2761 cgccgtgccg ggcgggggtg ggcggcaggt ggggtgtccg ggcgggcggg ggccgcctcg
2821 ggccgggggag ggctcggggg aggggcgcgg cggccccgga gcgccggcgg ctgtcgaggc
2881 gcggcgagcc gcagccattg ccttttatgg taatcgtgcg agagggcgca gggacttcct
2941 ttgtcccaaa tctgtgcgga gccgaaatct gggaggcgcc gccgcacccc ctctagcggg
3001 cgcggggcga agcggtgcgg cgccggcagg aaggaaatgg gcggggaggg ccttcgtgcg
3061 tcgccgcgcc gccgtcccct tctccctctc cagcctcggg gctgtccgcg gggggacggc
3121 tgccttcggg gggacggggg cagggcgggg ttcggcttct ggcgtgtgac cggcggctct
3181 agaagcgttg gggtgagtac tccctctcaa aagcgggcat gacttctgcg ctaagattgt
3241 cagtttccaa aaacgaggag gatttgatat tcacctggcc cgcggtgatg cctttgaggg
3301 tggccgcgtc catctggtca gaaaagacaa tcttttttgtt gtcaagcttg aggtgtggca
3361 ggcttgagat ctggccatac acttgagtga cattgacatc cactttgcct ttctctccac
3421 aggtgtccac tcccagggcg gcctccggag cgatcgccga tccgcctagg caattgttta
3481 aatcggccgg ccataacttc gtataatgta tgctatacga agttatggat cctcacagta
3541 ggtggcatcg ttcctttctg actgcccgcc ccccgcatgc cgtcccgcga tattgagctc
3601 cgaacctctc gcctgccgc cgccggtgct ccgtcgccgc cgcgccgcca tggaatcgaa
3661 gccaccatgg atcttaccgg aaaactcgac gcaagaaaaa tcagagagat cctcataaag
3721 gtcaagaagg gcggaaagat cgccgtgtaa ttctagaccg gttcgagatc caggcgcgga
3781 tcaataaaag atcattattt tcaatagatc tgtgtgttgg tttttgtgt gccttggggg
3841 aggggaggc cagaatgagg cgcggccaag ggggaggggg aggccagaat gaccttgggg
3901 gaggggaggg ccagaatgac cttgggggag ggggaggcca gaatgaggcg cgccctccgt
3961 cgacctataa cttcgtataa tgtatgctat acgaagttat ggcggccgcc accatggacs
4021 tgagagtgcc cgcccagctc ctgggctcc tgctactctg gctccgaggt aaggatggag
4081 aacactagga atttactcag ccagtgtgct cagtactgac tggaacttca gggaagttct
4141 ctgatgacat gattgatagt aagaatattt gtttttatgt ttccaatctc aggtgccaga
4201 tgtcagtctg ccctgacccc gcccgcctct gtgtctggca gccctggcca gagcatcacc
4261 atcagctgca ccggcaccag cagcgacgtg ggcggctaca actacgtgtc ctggtatcag
4321 cagcaccccg gcaaggcccc caagctgatg atctacgagg tgtccaacag acccagcggc

Fig. 15B, contd.

```
4381 gtgagcaaca gattcagcgg cagcaagagc ggcaacaccg ccagcctgac catcagcggc
4441 ctccaggctg aggacgaggc cgactactac tgcagcagct acaccagcag ctccaccctg
4501 gtgtttggcg gcggaacaaa gctgaccgtg ctgagagccg acgccgctcc caccgtgtcc
4561 atcttccccc ccagcatgga acagctgacc tctggcggag ccaccgtggt ctgcttcgtg
4621 aacaacttct accccagaga catcagcgtg aagtggaaga tcgacggcag cgagcagagg
4681 gacggcgtgc tggacagcgt gaccgaccag gacagcaagg actccacctа cagcatgagc
4741 agcaccctga cgctgaccaa ggtggagtac gagaggcaca acctgtacac ctgcgaggtg
4801 gtgcacaaga ccagctccag ccccgtggtc aagtccttca accggaacga gtgttgagct
4861 agcttaagat ttaaataggc cggccgcgtc gacctcgaga tccaggcgcg gatcaataaa
4921 agatcattat tttcaataga tctgtgtgtt ggtttttgt gtgccttggg ggagggggag
4981 gccagaatga ggcgcggcca agggggaggg ggaggccaga atgaccttgg gggaggggga
5041 ggccagaatg accttggggg aggggggaggc cagaatgagg cgcgcccccg ggtaccgagc
5101 tcgaattagt ggatcctcac agtaggtggc atcgttcctt tctgactgcc cgccccccgc
5161 atgccgtccc gcgataattga gctccgaacc tctcgccctg ccgccgcggg tgctccgtcg
5221 ccgccgcgcc gccatggaat cgcgccggta accgaagttc ctatacttтc tagagaatag
5281 gaacttcgga ataggaactt caagccggta cccagctttt gttccctтta gtgagggtta
5341 atttcgagct tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc
5401 acaattccac acaacatacg agccgggagc ataaagtgta aagcctgggg tgcctaatga
5461 gtgagctaac tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg
5521 tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg
5581 cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg
5641 gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga
5701 aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg
5761 gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag
5821 aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc
5881 gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg
5941 ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt
6001 cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc
6061 ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc
6121 actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg
6181 tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca
6241 gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc
6301 ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat
6361 cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt
6421 ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt
6481 tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc
6541 agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc
```

Fig. 15B, contd.

6601 gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata
6661 ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg
6721 gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc
6781 cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct
6841 acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa
6901 cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt
6961 cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca
7021 ctgcataatt ctcttactgt catgccatcc gtaagatgct ttctgtgac tggtgagtac
7081 tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca
7141 atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt
7201 tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc
7261 actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca
7321 aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata
7381 ctcatactct tccttttttca atattattga agcatttatc agggttattg tctcatgagc
7441 ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc
7501 cgaaaagtgc cacctaaatt gtaagcgtta atattttgtt aaaattcgcg ttaaattttt
7561 gttaaatcag ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa
7621 aagaatagac cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa
7681 agaacgtgga ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac
7741 gtgaaccatc accctaatca agtttttggg ggtcgaggtg ccgtaaagca ctaaatcgga
7801 accctaaagg gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa
7861 aggaagggaa gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc
7921 tgcgcgtaac caccacaccc gccgcgctta atgcgccgct acagggcgcg tcccattcgc
7981 cattcaggct gcgcaactgt tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc
8041 agctggcgaa aggggatgt gctgcaaggc gattaagttg ggtaacgcca gggttttccc
8101 agtcacgacg ttgtaaaacg acggccagtg agcgcgcgta atacgactca ctataggcg
8161 aattgggggt aactaagtaa ggatcgag



Rosa26 target
PGK-Hyg^R
ATG
SA
F3
FRT
Site specific recombination
by FLP^e (RMCE)
Δ 5' neo^R-pA
CAGGSprom
STOP
IgVλ2-14-pA
Exchange vector
Exchanged Rosa26 locus
Rosa26-IgVλ2-14 locus, after Cre-mediated recombination
loxP

Fig. 15C



Regions
Kd
Germline
Best receptor Kd (μM)
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTF

Fig. 16A



Allotype count
10
5
0
10
20
30
40
50
60
70
80
90
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTF

Fig. 16B



Regions
Kd
Germline
Best receptor Kd (μM)
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTF

Fig. 16C



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
DR1
DR4
DR7
DR8
DR9
DR11(5)
DR12(5)
DR13(6)
DR14(6)
DR15(2)
DR16(2)
DR17(3)
DR51
DR52
DR53
DQ2
DQ4
DQ5(1)
DQ6(1)
DQ7(3)
DQ8(3)
DQ9(3)
DPw1
DPw2
DPw3
DPw4
DPw6

Fig. 17




Jκ1-Jκ5
MiEκ
Cκ
3'Eκ
Mouse Genomic Locus
Jκ1-Jκ5
Puro
Tk
Targeting Vector
SA 4.5 kb
LA 8.0 kb
Jκ1-Jκ5
Puro
Targeted Allele
(after homologous
recombination)
Jκ1-Jκ5
Constitutive KO Allele
(after Flp recombination)
mouse Igk exons
mouse Igk enhancers
F3

Fig. 18A

Fig. 18B


AmpR
NotI (1772)
pgk_tk_pa
sa
Igk-J1
Igk-J2
Igk-J3
Igk-J4
Igk-J5
F3
pIgKappa Finalseq_(ML0065)
20691 bp
Ia
CAGGS Puro pA
F3



Mouse Genomic Locus
V2
V3
J2-C2-J4-C4
V1
J3-C3-J1-C1
1st Targeting Vector
Puro
Tk
SA 4.5 kb
LA 9.6 kb
Igl V2-V3 Targeted Allele (after homologous recombination)
Puro
Constitutive KO Allele (after Flp recombination)
mouse Igl exons
FRT
F3
attB/attP

Fig. 19A



Igl V2-V3 Targeted Allele (after first targeting)
J2-C2-J4-C4
V1
J3-C3-J1-C1
Puro
2nd Targeting Vector
Neo
Tk
SA ~3.0 kb
LA ~7.0 kb
Igl V1-V2-V3 Targeted Allele (after second targeting)
J2-C2-J4-C4
J3-C3-J1-C1
Puro
Neo
Constitutive KO Allele (after Flp recombination)
J2-C2-J4-C4
J3-C3-J1-C1
mouse Igl exons
FRT
F3
attB/attP

Fig. 19B

Fig. 20A



amp
FRT
pA
F3
5' D neo
pA
pA hGH*
pVkP-O12_Final(ML0100)
19118 bp
VkP-O12

Fig. 20B




amp
pA
FRT
F3
5' D neo
pA
pA hGH*
pVkP-O12-del1_Final(ML0102)
18637 bp
VkP-O12-del1

Fig. 20C



pVkP-O12-del2_Final(ML104)



Rosa26 target
Exchange vector
Exchanged Rosa26 locus
ATG
SA
F3
PGK-Hyg^R
FRT
Site specific recombination
by FLP^e (RMCE)
Δ 5' neo^R-pA
VkP-O12 transgene
ATG
SA
Δ 5' neo^R-pA
VkP-O12 transgene

Fig. 21A



Rosa26 target
Exchange vector
Exchanged Rosa26 locus
PGK-Hyg^R
FRT
F3
Site specific recombination
by FLP^e (RMCE)
VkP-O12-del1 transgene
Δ 5' neo^R-pA
ATG
SA
VkP-O12-del1 transgene
Δ 5' neo^R-pA
ATG
SA

Fig 21B



Rosa26 target
Exchange vector
Exchanged Rosa26 locus
ATG
SA
PGK-Hyg^R
F3
FRT
Site specific recombination
by FLP^e (RMCE)
VkP-O12-del2 transgene
Δ 5' neo^R-pA
ATG
SA
Δ 5' neo^R-pA
VkP-O12-del2 transgene

Fig 21C



MV1057
10293 bp
CMV-long
MCS
Kozak sequence
Mouse VH signal peptide
stuffer 1kb
VH: (IgG1) ending part
CH1
Intron [CH1-Hinge]
Hinge
CH2
CH3
Stop
BGH p(A)
f1 ori
SV40
Neo
SV40 p(A)
CMV long
MCS
TCR alpha chain leader
VL: O12 (VKI/JK1)
Intron [VL-CL]
CL: CD46 (CK)
Stop
BGH p(A)
ColE1
Amp

Fig 22



Mice
Cell populations
T cells
WT
CD19 Cre
CD19 Cre HuVk1
<APC-A>: CD4
<FITC-A>: CD3
60
39.1
T cells
220609 st11 #_007
Event Count: 10055
58.2
40.8
T cells
220609 st11 #_009
Event Count: 24247
62.3
36.8
T cells
220609 st11 #_103
Event Count: 19929

Fig. 23



Mice
Cell populations
CD4+ T cells
CD8+ T cells
WT
CD19 Cre
CD19 Cre HuVk1
CD4 T cells
220609 st11 #_007
Event Count: 8033
CD8 T cells
220609 st11 #_007
Event Count: 3034
CD4 T cells
220609 st11 #_009
Event Count: 14121
CD8 T cells
220609 st11 #_009
Event Count: 9904
CD4 T cells
220609 st11 #_103
Event Count: 12406
CD8 T cells
220609 st11 #_103
Event Count: 7327
99.4
0.61
99.6
0.38
99.5
0.53
99.4
0.58
99.2
0.8
99.5
0.52
Cells
<PE-A>: cKappa rat

Fig. 23, contd.



Mice
Cell populations
CD11b+ & NK1.1+ myeloid & NK cells
WT
CD19 Cre
CD19 Cre HuVk1
<PE-Cy7-A>: NK11
<Alexa Fluor 700-A>: CD11b
<PE-A>: cKappa rat
Cells
6.43
7.8
7.17
95.3
4.68
96
4.05
95.1
4.91
CD11b pos
220609 st11 #_007
Event Count: 2351
CD11b pos
220609 st11 #_009
Event Count: 5413
CD11b pos
220609 st11 #_103
Event Count: 4688
1st gate
220609 st11 #_007
Event Count: 38582
1st gate
220609 st11 #_009
Event Count: 60388
1st gate
220609 st11 #_103
Event Count: 85118

Fig. 23, contd.



Mice
Cell populations
Spleen lymphocytes
WT
CD19 Cre
CD19 Cre
HuVk1
SSC-A
FSC-A
0
1000
2000
3000
4000
90
92.7
93.9
Live gate
220609 st1 #002_002
Event Count: 86632
Live gate
220609 st1 #005_005
Event Count: 101383
Live gate
220609 st1 #006_006
Event Count: 88613

Fig. 24



Mice
Cell populations
Spleen lymphocytes
B220+ /CD19+ B cells
WT
CD19 Cre
CD19 Cre HuVk1
<PerCP-Cy5-5-A>: CD19
<Alexa Fluor 700-A>: B220
% of Max
<PE-A>: cKappa rat
B cell
Ctrl
WT
CD19-Cre
HuVk1
54.7
37
50.9
98.5
1.46
Lymphocyte gate
220609 st1 #002_002
Event Count: 77945
220609 st1 #005_005
Event Count: 93980
220609 st1 #006_006
Event Count: 83203

Fig. 24, contd.



Mice
Cell populations
Peritoneal lymphocytes
WT
CD19 Cre
CD19 Cre HuVk1
SSC-A
FSC-A
<PerCP-Cy5-5-A>: CD19
<Alexa Fluor 700-A>: B220
32.9
49.6
29.6
33.6
23.8
35.4
Live gate
220609 st5 #049
Event Count: 249606
Lymphocyte gate
220609 st5 #049
Event Count: 82004
Live gate
220609 st5 #053_053
Event Count: 271464
Lymphocyte gate
220609 st5 #053_053
Event Count: 80377
Live gate
220609 st5 #054_054
Event Count: 309205
Lymphocyte gate
220609 st5 #054_054
Event Count: 73513

Fig. 25



Mice
Cell populations
B220+ /CD19+ B cells
CD5+ B1 cells
WT
CD19 Cre
CD19 Cre HuVk1
<Alexa Fluor 700-A>: B220
<APC-A>: CD5
<PE-A>: cKappa rat
% of Max
61.4
29.4
57.3
30.3
44.2
45.3
94
6
Ctrl
WT
CD19-Cre
CD19-Cre HuVk1
B cell gate
220609 st5 #049
Event Count: 40702
220609 st5 #053_053
Event Count: 26971
220609 st5 #054_054
Event Count: 26958
B1 B cell

Fig. 25, contd.



Mice
Cell populations
Bone marrow cells
BM lymphocytes
WT
CD19 Cre
CD19 Cre
HuVk1
SSC-A
FSC-A
<Alexa Fluor 700-A>: B220
<PE-Cy7-A>: IgM
45.9
43.6
45.6
43.2
49
48.7
Live gate
220609 st2 #018_018
Event Count: 175478
Lymphocyte gate
220609 st2 #018_018
Event Count: 80462
Live gate
220609 st2 #022_022
Event Count: 227803
Lymphocyte gate
220609 st2 #022_022
Event Count: 103828
Live gate
220609 st2 #023_023
Event Count: 176909
Lymphocyte gate
220609 st2 #023_023
Event Count: 86573

Fig. 26A




Fig. 26A, contd.



Mice
Cell populations
Pro- & pre- B cells
immature B cells
WT
CD19 Cre
CD19 Cre HuVk1
% of Max
Ctrl
WT
CD19-Cre
CD19-Cre HuVk1
99.6
0.45
96.6
3.3
<PE-A>: cKappa rat
Pro- pre- B cell
immature- B cell

Fig. 26B




Fig. 26B, contd.



Mice
Cell populations
Circulating lymphocytes
CD19 Cre
<Pacific Blue-A>: dapi
FSC-A
19.3
Ungated
Tube_002
Event Count: 136909
<PerCP-Cy5-5-A>: CD19
<Alexa Fluor 700-A>: B220
42.3
Live gate
Tube_002
Event Count: 26472
CD19 Cre
HuVk1
<Pacific Blue-A>: dapi
FSC-A
19.3
Ungated
Tube_003
Event Count: 490420
<PerCP-Cy5-5-A>: CD19
<Alexa Fluor 700-A>: B220
42.3
Live gate
Tube_003
Event Count: 37311

Fig. 27



Mice
Cell populations
B220+ /CD19+ B cells
B220+ /CD19+ B cells
CD19 Cre
CD19 Cre HuVk1
Rat Ckappa (transgene)
<PE-A>: Ckappa rat
<APC-A>: cKappa mouse
<PE-Cy7-A>: IgM
0.45
4.96
11.4
83.1
0.27
7.7
11
81.1
6.31
59.2
9.35
25.1
5.57
68
5.56
20.9
B cell
Tube_002
Event Count: 11207
B cell
Tube_002
Event Count: 11207
B cell
Tube_003
Event Count: 17569
B cell
Tube_003
Event Count: 17569
Mouse CKappa
IgM

Fig. 27, contd.




FIG. 28

	Stainings					Mixtures				
	#	Facs tubes #	Monoclonal	Work dilution		volume	1st step	2nd step	3rd step	Final dilution
A										
Spleen	1	1-8	CD21^{FITC}	640		320		0.50		
			Ckappa rat^{PE}	160			2.00			
			CD19$^{PerCP-Cy5.5}$	640				0.50		
			CD23^{PE-Cy7}	50	1:20			6.40		1000
			DAPI							
			Ckappa mouse$^{BIO-APC}$	100	1:50			3.20	APC	5000
			Clambda mouse$^{BIO-APC}$	100	1:30			3.20	APC	3000
			B220$^{Alex-700}$	160				2.00		
			FC block	400				0.80		
Spleen	2	9-16	IgD^{FITC}	640		640		1.00		
BM		17-24	Ckappa rat^{PE}	160			4.00			
			CD19$^{PerCP-Cy5.5}$	500				1.28		
			IgM^{PE-Cy7}	640				1.00		
			DAPI							
			Ckappa mouse$^{BIO-APC}$	100	1:50			6.40	APC	5000
			Clambda mouse$^{BIO-APC}$	100	1:30			6.40	APC	3000
			B220$^{Alex-700}$	160				4.00		
			FC block	400				1.60		
Spleen	3	25-32	Ckappa mouse^{FITC}	400		320		0.80		
			Ckappa rat^{PE}	160			2.00			
			CD19$^{PerCP-Cy5.5}$	500				0.64		
			IgM^{PE-Cy7}	640				0.50		
			DAPI							
			Clambda mouse$^{BIO-APC}$	100	1:30			3.20	APC	3000
			B220$^{Alex-700}$	160				2.00		
			FC block	400				0.80		
Spleen	4	33-40	Ckappa mouse^{FITC}	400		640		1.60		
		41-48	lambda^{FITC}	600				1.07		
PP			Ckappa rat^{PE}	160			4.00			
			CD19$^{PerCP-Cy5.5}$	500				1.28		

FIG. 29A

			IgM^{PE-Cy7}	640				1.00		
			DAPI							
			IgD^{A647}	1280				0.50		
			B220$^{Alex-700}$	160				4.00		
			PNA$^{BIO-SAV-APC-Cy7}$	300				2.13	APC-Cy7	
			FC block	400				1.60		
PC	5	49-56	IgM^{FITC}	160		320		2.00		
			Ckappa rat^{PE}	160			2.00			
			CD19$^{PerCP-Cy5.5}$	500				0.64		
			Ckappa mouse$^{BIO-PE-Cy7}$	100	1:50			3.20	PE-Cy7	5000
			Clambda mouse$^{BIO-PE-Cy7}$	100	1:30			3.20	PE-Cy7	3000
			DAPI							
			CD5^{APC}	320				1.00		
			B220$^{Alex-700}$	160				2.00		
			FC block	400				0.80		
BM	6	57-64	IgM^{FITC}	160		640		4.00		
			Ckappa rat^{PE}	160			4.00			
			CD19$^{PerCP-Cy5.5}$	500				1.28		
			Ckappa mouse$^{BIO-PE-Cy7}$	100	1:50			6.40	PE-Cy7	5000
			Clambda mouse$^{BIO-PE-Cy7}$	100	1:30			6.40	PE-Cy7	3000
			DAPI							
			CD25^{APC}	80				8.00		
			B220$^{Alex-700}$	160				4.00		
			FC block	400				1.60		
RAT spleen										
	7	144	Ckappa rat^{PE}	160		80	0.5			
			rat B220^{FITC}	160			0.5			
Spleen	8	97-104	cyt CD3^{FITC}	320		320		1		
			cyt Ckappa rat^{PE}	80			4.00			
			cyt CD11c$^{PE-TexasRED}$	75				4.27		
			cyt NK1.1$^{BIO-PE-Cy7}$	200				1.6	PE-Cy7	
			cyt CD19$^{PerCP-Cy5.5}$	320				1		
			cyt CD4^{APC}	500				0.64		
			cyt CD11b$^{Alex-700}$	50				6.40		

FIG. 29B

ANTIBODY PRODUCING NON-HUMAN ANIMALS

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is a divisional of U.S. patent application Ser. No. 12/589,181, filed Oct. 19, 2009, pending, which application is a continuation of U.S. patent application Ser. No. 12/459,285, filed Jun. 29, 2009, abandoned, which applications claim the benefit, under 35 U.S.C. § 119(e), to U.S. Provisional Patent Application Ser. No. 61/133,274, filed Jun. 27, 2008, for "Antibody Producing Non-Human Mammals," the entire contents of each of which are hereby incorporated herein by this reference.

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(C) OR (E)—SEQUENCE LISTING SUBMITTED AS ASCII TEXT FILE

[0002] Pursuant to 37 C.F.R. § 1.821(c) or (e), files containing a TXT version and a PDF version of the Sequence Listing have been submitted concomitant with this application, the contents of which are hereby incorporated by reference.

TECHNICAL FIELD

[0003] The invention relates to the production and use of non-human animals capable of producing antibodies or derivatives thereof, which are expressed from at least partially exogenous nucleic acids (transgenes). Transgenes to produce such transgenic animals and methods to produce such heterologous antibodies; methods and vectors for producing such transgenic animals are disclosed.

BACKGROUND

[0004] B cells mediate humoral immunity by producing specific antibodies. The basic structural subunit of an antibody (Ab) is an immunoglobulin (Ig) molecule. Ig molecules consist of a complex of two identical heavy (H) and two identical light (L) polypeptide chains. At the amino terminus of each H chain and L chain is a region that varies in amino acid sequence named the variable (V) region. The remaining portion of the H and L chains is relatively constant in amino acid sequence and is named the constant (C) region. In an Ig molecule, the H and L chain V regions (VH and VL) are juxtaposed to form the potential antigen-binding site. The genes that encode H and L chain V regions are assembled somatically from segments of germline DNA during precursor B (pre-B) cell differentiation: V, D and J gene segments for the H chain and V and J gene segments for the L chain. Within Ig V regions are three regions of greatest amino acid sequence variability that interact to form the antigen-recognition site and are thus referred to as complementarity determining regions (CDRs).

[0005] The V gene segment encodes the bulk of the V region domain, including CDR1 and CDR2. Diversity in CDR1 and CDR2 derives from sequence heterogeneity among multiple different germline-encoded V segments. CDR3 is encoded by sequences that are formed by the joining of H chain V, D, and J gene segments and L chain V and J segments and by mechanisms that create nucleotide sequence heterogeneity where these segments are combined. Additional diversity may be derived from pairing of different H and L chain V regions. Collectively these processes yield a primary repertoire of antibodies encoded by germline gene segments and expressed by newly formed B cells.

[0006] An additional source of antibody diversity is imposed on top of the diversity generated by recombination of Ig gene segments. B cells are able to introduce mutations into the antibody V regions that they express, a process called somatic hypermutation. Thus, when an animal first encounters an antigen, the antigen binds to a specific B cell which happens to carry antibodies which have a V domain which binds the antigen. This primary response may activate this B cell to go on to secrete the cognate antibody. These activated B cells can also now target a somatic mutation process to their rearranged antibody gene segments and thus allow the production of daughter cells which make variants of the antibodies of the primary response. A selection process amplifies those variant B cell descendants which make an antibody of improved affinity of the antigen. In B cells, somatic hypermutations are targeted to a restricted genomic region including both the rearranged VH and VL genes. Thus somatic mutation allows affinity maturation—the production and selection of high affinity antibodies. Therefore, somatic mutation is important for the generation of high affinity antibodies.

[0007] The exquisite specificity and high affinity of antibodies and the discovery of hybridoma technology allowing the generation of monoclonal antibodies (mAbs) has generated great expectations for their utilization as targeted therapeutics for human diseases. MAbs are identical because they are produced by a single B cell and its progeny. MAbs are made by fusing the spleen cells from a mouse that has been immunized with the desired antigen with myeloma cells to generate immortalized hybridomas. One of the major impediments facing the development of in vivo applications for mAbs in humans is the intrinsic immunogenicity of non-human Igs. Patients respond to therapeutic doses of mouse mAbs by making antibodies against the mouse Ig sequences (Human Anti Mouse Antibodies; HAMA), causing acute toxicity, alter their biodistribution and accelerate clearance, thus reducing the efficacy of subsequent administrations (Mirick et al. (2004), *Q. Nucl. Med. Mol. Imaging* 48:251-257).

[0008] To circumvent the generation of HAMA, antibody humanization methods have been developed in an attempt to produce mAbs with decreased immunogenicity when applied to humans. These endeavors have yielded various recombinant DNA-based approaches aimed at increasing the content of human amino acid sequences in mAbs while retaining the specificity and affinity of the parental non-human antibody. Humanization began with the construction of mouse-human chimeric mAbs (S. L. Morrison et al. (1984), *Proc. Natl. Acad. Sci. USA* 81:6851-5), in which the Ig C regions in murine mAbs were replaced by human C regions. Chimeric mAbs contain 60-70% of human amino acid sequences and are considerably less immunogenic than their murine counterparts when injected into humans, albeit that a human anti-chimeric antibody response was still observed (W. Y. Hwang et al. (2005), *Methods* 36:3-10).

[0009] In attempts to further humanize murine mAbs, CDR grafting was developed. In CDR grafting, murine antibodies are humanized by grafting their CDRs onto the VL and VH frameworks of human Ig molecules, while retaining those murine framework residues deemed essential for specificity and affinity (P. T. Jones et al. (1986), *Nature* 321:522). Overall, CDR-grafted antibodies consist of more

than 80% human amino acid sequences (C. Queen et al. (1989), *Proc. Natl. Acad. Sci. U.S.A.* 86:10029; P. Carter et al. (1992), *Proc. Natl. Acad. Sci. U.S.A.* 89:4285). Despite these efforts, CDR-grafted, humanized antibodies were shown to still evoke an antibody response against the grafted V region (W. Y. Hwang et al. (2005), *Methods* 36:3).

[0010] Subsequently to CDR grafting, humanization methods based on different paradigms such as resurfacing (E. A. Padlan et al. (1991), *Mol. Immunol.* 28:489), superhumanization (P. Tan D. A. et al. (2002), *J. Immunol.* 169:1119), human string content optimization (G. A. Lazar et al. (2007), *Mol. Immunol.* 44:1986) and humaneering have been developed in an attempt to further decrease the content of non-human sequences in therapeutic mAbs (J. C. Almagro et al. (2008), *Frontiers in Bioscience* 13:1619). As in CDR grafting approaches, these methods rely on analyses of the antibody structure and sequence comparison of the non-human and human mAbs in order to evaluate the impact of the humanization process into immunogenicity of the final product. When comparing the immunogenicity of chimeric and humanized antibodies, humanization of variable regions appears to decrease immunogenicity further (W. Y. Hwang et al. (2005), *Methods* 36:3-10).

[0011] De-immunization is another approach developed to reduce the immunogenicity of chimeric or mouse antibodies. It involves the identification of linear T-cell epitopes in the antibody of interest, using bioinformatics, and their subsequent replacement by site-directed mutagenesis to human or non-immunogenic sequences (WO 9852976 A1, the contents of which are incorporated by this reference). Although de-immunized antibodies exhibited reduced immunogenicity in primates, compared with their chimeric counterparts, some loss of binding affinity was observed (M. Jain et al. (2007), *Trends in Biotechnol.* 25:307).

[0012] The development of phage display technology complemented and extended humanization approaches in attempts to obtain less immunogenic mAbs for therapy in humans. In phage display, large collections ("libraries") of human antibody VH and VL regions are expressed on the surface of filamentous bacteriophage particles. From these libraries, rare phages are selected through binding interaction with antigen; soluble antibody fragments are expressed from infected bacteria and the affinity of binding of selected antibodies is improved by mutation (G. Winter et al. (1994), *Annu. Rev. Immunol.* 12:433). The process mimics immune selection, and antibodies with many different bindings specificities have been isolated using this approach (H. R. Hoogenboom et al. (2005), *Nat. Biotechnol.* 23:1105). Various sources of H and L chain V regions have been used to construct phage display libraries including those isolated from non-immune or immune donors. In addition, phage display libraries have been constructed of V regions that contain artificially randomized synthetic CDR regions in order to create additional diversity. Often, antibodies obtained from phage display libraries are subjected to in vitro affinity maturation to obtain high affinity antibodies (H. R. Hoogenboom et al. (2005), *Nat. Biotechnol.* 23:1105).

[0013] The creation of transgenic mouse strains producing human antibodies in the absence of mouse antibodies has provided another technology platform for the generation of specific and high affinity human mAbs for application in humans. In these transgenic animals, the endogenous mouse antibody machinery is inactivated and replaced by human Ig loci to substantially reproduce the human humoral immune system in mice (A. Jakobovits et al. (2007), *Nat. Biotechnol.* 25:1134; N. Lonberg (2005), *Nat. Biotechnol.* 23:1117). B cell development as well as Ig diversification by recombination of gene segments is faithfully reproduced in these mice, leading to a diverse repertoire of murine B cells expressing human Igs. By immunizing these mice with antigens, it was further demonstrated that these transgenic animals accumulated somatic mutations in the V regions of both heavy and light chains to produce a wide diversity of high-affinity human mAbs (N. Lonberg (2005), *Nat. Biotechnol.* 23:1117).

[0014] The question, whether "fully human" mAbs such as derived from phage display libraries or transgenic mice are less immunogenic than humanized mAbs cannot be answered yet, because full immunogenicity data are available for just two human mAbs. An anti-tumor necrosis factor mAb, developed from phage-displayed human libraries induced antibody responses in 12% of patients—at the higher end of the incidence of anti-antibody responses of the humanized antibodies (W. Y. Hwang et al. (2005), *Methods* 36:3-10).

[0015] Evaluation of the immunogenicity of the first registered human mAb generated by the transgenic approach demonstrated that mAb treatment resulted in the generation of antibodies in approximately 5.5% of treated cancer patients (A. Jakobovits et al. (2007), *Nat. Biotechnol.* 25:1134; J. A. Lofgren et al. (2007), *J. Immunol.* 178:7467).

DISCLOSURE OF THE INVENTION

[0016] Disclosed are a method and means for producing antibodies that are specific for their targets, but are less immunogenic. Described herein, the reduction of immunogenicity is at least partially achieved by providing a transgenic non-human mammal comprising, at least in its B cell lineage, a nucleic acid encoding at least an immunoglobulin light chain or heavy chain, wherein the heavy- or light chain encoding sequence is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations, preferably such a non-human animal is a rodent, more specifically a mouse. In certain embodiments, the nucleic acid encodes a human, human-like, or humanized immunoglobulin chain.

[0017] In the remainder of this specification, mice are typically used as examples of the non-human mammals. The transgenic, non-human, mammalian hosts are capable of mounting an immune response to an antigen, where the response produces antibodies having primate, particularly human, variable regions. Various transgenic hosts may be employed, particularly murine, lagomorpha, ovine, avine, porcine, equine, canine, feline, or the like. Mice have been used for the production of B-lymphocytes for immortalization for the production of antibodies. Since mice are easy to handle, can be bred in large numbers, and are known to have an extensive immune repertoire, mice will usually be the animal of choice. Therefore, in the following discussion, the discussion will refer to mice, but it should be understood that other animals, particularly non-primate mammals, may be readily substituted for the mice, following the same procedures.

[0018] The reason for preventing rearrangements and hypermutation is that in this manner a non-immunogenic polypeptide can be chosen beforehand knowing that this polypeptide chain will remain non-immunogenic. At least one of the chains of the resulting immunoglobulin is thus

less immunogenic. The resulting antibody needs to have (usually) both a light- and a heavy chain. The non-immunogenic chain must therefore be capable of pairing with the other chain. The other chain may be an endogenous chain, an exogenous chain or a hybrid of both. For human therapy, the non-immunogenic chain should be as close to human as possible.

[0019] A means for rendering a gene encoding an immunoglobulin chain (or chains) resistant to DNA rearrangement and/or mutation is of course removal of all genetic elements responsible for the rearrangement and/or mutation. The drawback thereof is that the variability of the two chains is eliminated, whereas the invention preferably retains the variability in one chain (preferably the heavy chain) and inhibits and/or prevents the rearrangement-mutation of the other chain (preferably the light chain).

[0020] The elements for rearrangement and/or hypermutation characterized so far are located within the loci for immunoglobulins. Therefore the means for rendering the immunoglobulin encoding sequence resistant to DNA rearrangement and/or mutation is inserting the gene in a locus outside the immunoglobulin loci.

[0021] Thus, described herein, a transgenic non-human mammal is provided wherein the light/heavy chain encoding sequence is integrated in the genome of the non-human mammal in a locus outside the immunoglobulin loci. Preferably the insertion is in a locus that is resistant to gene silencing. Described herein, the integration is in the Rosa-locus or a comparable locus.

[0022] In certain embodiments, provided is an expression cassette that can be inserted into a Rosa locus or comparable locus with a means that allows expression of the immunoglobulin chain(s) essentially limited to cells of B cell lineage, preferably with a means that allows expression of the light chain encoding nucleic acid during a certain stage of the development of B cells. The term "essentially limited expression" indicates that expression is predominantly in cells of the B-cell lineage, but that lower levels of expression in other cells, as compared to the level of expression in B-cells, is possible. In certain embodiments, the term "essentially limited expression" indicates that the expression is exclusively present in cells of the B-cell lineage. Such means typically and preferably include B cell (developmental stage) specific promoters such as CD19, CD20, μHC (all V-genes), VpreB1, VpreB2, VpreB3, λ5, Igα, Igβ, κLC (all genes), λLC (all genes), BSAP (Pax5). Although it is very well possible to direct the expression of the DNA rearrangement and/or mutation resistant chain by such promoters, they are relatively weak. A strong promoter will typically be required to ensure adequate surface expression of the B cell receptor (made up of the membrane attached Ig H and L chain) and to compete with the expression and pairing of endogenous chains (if present) through allelic exclusion. Such a promoter, however is usually not tissue specific. To confer tissue specificity, an indirect system employing Cre/lox or the like is preferred. The desired chain is put under control of a strong promoter inhibited by an element that can be removed by the action of a Cre-protein, leading to activation of the desired immunoglobulin encoding gene. This system is described in detail in F. T. Wunderlich (2004), "Generation of inducible Cre systems for conditional gene inactivation in mice," Inauguraldissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln; on the internet at deposit.ddb.de/cgi-bin/dokserv?idn=97557230x&dok_var=d1&dok_ext=pdf&filename=97557230x.pdf.

[0023] Preferably the immunoglobulin chain produced in a manner resistant to rearrangements and hypermutation is a light chain capable of pairing with different heavy chains encoded by the non-human mammal. The light chain will then be the same (and less immunogenic) in all antibodies, but variety in specificity is retained through rearrangements and hypermutations in the heavy chains. It may in that case be preferable to silence at least one of the endogenous loci encoding a light chain, although allelic exclusion may render this unnecessary.

[0024] According to this embodiment, preferably the endogenous kappa (κ) light chain locus is functionally silenced.

[0025] If the endogenous κ light chain locus is silenced, but also for other reasons, it is preferred that the resistant light chain is a κ light chain, preferably a light chain that has a germline-like sequence. Described herein such a light chain would lead to an antibody with reduced immunogenicity. The preferred germline sequence is based on the human IGKV1-39 (O12) as this light chain is very frequently observed in the human repertoire (de Wildt et al. 1999, *J. Mol. Biol.* 285(3):895 and has superior thermodynamic stability, yield and solubility (Ewert et al. 2003, *J. Mol. Biol.* 325(3):531).

[0026] The following gives more specific embodiments of the expression cassette with which the non-human animal can be provided described herein. Although this is typically advantageous for immunoglobulins, other genes of interest are also contemplated.

[0027] Thus, provided in a specific embodiment is a transgenic non-human mammal wherein the light chain encoding nucleic acid comprises in 5'-3' direction: a B cell specific promoter, a leader, a rearranged human V gene, optionally a mouse κ-intron enhancer (MoEκi), a constant region (κ) and optionally a (truncated) mouse κ-3' enhancer (MoEκ3'). Neuberger identified and examined a novel B-cell specific enhancer located downstream of the kappa constant region (Neuberger, EP 00469025 B1, the contents of which are incorporated herein by this reference). This enhancer has been shown to play a crucial role in the expression of kappa genes as removal of the 808 bp enhancer strongly reduced expression. Deletion of the 3' kappa enhancer also strongly reduced the level of somatic hypermutations (SHM). In transgenic and cell expression studies, it has been revealed that reduced, mutated or deleted 3' kappa enhancers not only lowered expression levels, but also decreased the level of somatic hypermutations. Currently, it cannot be determined whether the 3' kappa enhancer is involved in SHM processes, expression regulation or both (review V. H. Odegard et al. (2006), *Nat. Rev. Immunol.* 6:573; M. Inlay et al. (2002), *Nat. Immunol.* 3:463).

[0028] Detailed expression studies using engineered variants of the 3' kappa enhancer indicated that a 50 nucleotide region is sufficient to drive expression. However for proper expression a reduced sequence of 145 nucleotides is preferred (EP04690251; K. B. Meyer et al. (1990), *Nucleic Acids Res.* 18(19):5609-15).

[0029] Thus, the invention in one aspect provides a nucleic acid for insertion into the genome of a non human animal that is an expression cassette for the expression of a desired proteinaceous molecule in cells developing into mature B cells during a certain stage of development, the

cassette comprising means for preventing silencing of expression of the desired proteinaceous molecule after introduction into a host cell, and means for timing expression of the desired proteinaceous molecule with the desired developmental stage of the host cell.

[0030] An expression cassette is defined as a nucleic acid that has been provided with means for introduction into the genome of a host cell, such as sequences which allow for homologous recombination with a certain site in the genome. Usually the nucleic acid will be DNA, typically double stranded. Typically the expression cassette will be provided to the cell in a vector from which it is transferred to the genome of the cell. The expression cassette further comprises all elements necessary for expression of the gene in a host cell, although in certain embodiments some of such elements may be present on a second nucleic acid to be introduced, whereby these elements act in trans. Elements necessary for expression in a host cell include promoters, enhancers and other regulatory elements. Only those elements are necessary that are not provided by the host cell.

[0031] The expression of the gene of interest should not be silenced in the genome of the host cell, especially not in the development stage where expression is required. This can be done by various means, such as insertion into the endogenous locus or by providing the cassette with nucleic acid elements that prevent silencing (Kwaks et al. (2006), *Trends Biotechnol.* 24(3):137-142, which is incorporated herein by reference). It is preferred that the expression cassette is inserted in a locus that is not silenced in the host cells (EP 01439234; which is incorporated herein by reference).

[0032] The means for prevention of silencing comprise STabilizing Anti-Repression-sequences (STAR®-sequences) and Matrix Attachment Regions (MARs). A STAR sequence is a nucleic acid sequence that comprises a capacity to influence transcription of genes in cis. Typically, although not necessarily, a STAR sequence does not code by itself for a functional protein element. In one embodiment one STAR element is used. Preferably, however, more than one STAR element is used. In a particularly preferred embodiment an expression cassette described herein is provided with two STAR sequences; one STAR sequence at the 5' side of the coding sequence of the immunoglobulin gene and one STAR sequence at the 3' side of the coding sequence of the immunoglobulin gene. MARs are DNA sequences that are involved in anchoring DNA/chromatin to the nuclear matrix and they have been described in both mammalian and plant species. MARs possess a number of features that facilitate the opening and maintenance of euchromatin. MARs can increase transgene expression and limit position-effects.

[0033] Expression from the cassette should only occur during a certain period in the development of a cell, in particular a developing B cell, more in particular a B cell in a transgenic non-human animal, in particular a mouse. In this particular case the developmental period is chosen such that the expression of the gene from the cassette (typically a light- or heavy chain-like polypeptide) does not significantly interfere with the normal differentiation and/or maturation of the cell and when applicable, allows for pairing of the polypeptide chain produced with its counterpart.

[0034] This may, in one embodiment, be achieved by providing a nucleic acid described herein, wherein the means for timing expression is a promoter of which the activity is essentially limited to the certain stage of development. In a developing B cell, which, e.g., after immunization is maturing and/or differentiating, the expression of the gene of interest, when it is one of the polypeptide chains of an immunoglobulin, must not interfere (significantly) with the maturation and/or differentiation and it needs to be timed such that the resulting polypeptide can pair with its counterparts. Therefore, provided is a nucleic acid described herein wherein the certain stage starts at a stage immediately preceding or coinciding with the onset of the expression of light chain molecules by the cells at a certain stage of development into a mature B cell. This may be achieved by selecting a promoter which is active only during the suitable period. Such a promoter may be a CD19 promoter, the Ig-α promoter, the Ig-β promoter, the μhc (all genes) promoter, the Vk promoter or analogues or homologues thereof.

[0035] In a specific embodiment, the promoter as disclosed above does not drive the expression of the gene of interest directly. Instead it drives the expression of a gene of which the product activates in trans the expression of the gene of interest. Such an activating gene may be a gene encoding a so-called Cre recombinase or Cre-like protein. The expression cassette for the gene of interest may, e.g., be provided with a sequence that inhibits expression of the gene of interest. The sequence can be removed by the action of the Cre recombinase, which is under control of the desired promoter (active during the proper stage of development). In this embodiment a set of expression cassettes is required.

[0036] Therefore, provided is a set of nucleic acids that are expression cassettes, wherein one nucleic acid comprises an expression cassette encoding a Cre-like protein under control of a promoter active during the desired stage of development of the host cell and the second nucleic acid comprises a sequence encoding a desired proteinaceous molecule under control of a constitutive promoter which can be activated by the action of a Cre-like protein. The activation is preferably achieved by removal of a stop sequence flanked by loxP sites. The Cre/lox system is described in detail in Rajewsky et al. (1996), *J. Clin. Invest.* 98:600-603, which is incorporated herein by reference. Such systems are reviewed in F. T. Wunderlich (2004), "Generation of inducible Cre systems for conditional gene inactivation in mice," Inauguraldissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln; on the World Wide Web at deposit.ddb.de/cgi-bin/dokserv?idn=97557230x&dok_var=d1&dok_ext=pdf&filename=97557230x.pd, which is incorporated herein by reference.

[0037] Further provided is a transgenic non-human animal that has been provided with an expression cassette hereof, wherein the desired proteinaceous molecule is a polypeptide chain of an immunoglobulin. A preferred polypeptide chain is a light chain. A more preferred polypeptide is a germline or germline-like light chain. A most preferred polypeptide is encoded by the immunoglobulin kappa variable 1-39 (IGKV1-39, also known as O12) gene segment, preferably the rearranged germline kappa light chain IGKV1-39*01/IGKJ1*01 (nomenclature according to the IMGT database, at [worldwideweb].imgt.org).

[0038] In certain embodiments, the polypeptide chain is rendered essentially incapable of rearrangement and/or of excluded of any sequence modification such as normally operating on Ig during the process of B cell affinity maturation. Therefore, provided is a transgenic non-human animal that has been provided with an expression cassette

described herein, wherein the rearrangement and/or sequence modifications are prevented by the absence of elements at least partially responsible for somatic hypermutation such as, for example, the MoEκi enhancer.

[0039] A preferred expression cassette described herein comprises means for prevention of silencing. In one embodiment, the means for prevention of silencing are means for insertion into a locus in the genome of the host cell that is resistant to silencing. The means for insertion are preferably means for homologous recombination into the site resistant to silencing. A preferred locus when the non-human animal is a mouse is the rosa-locus.

[0040] A further preferred expression cassette described herein comprises in 5'-3' direction: a Vκ promoter, a mouse leader, a human V gene, optionally a MoEκi enhancer, a rat constant region (Cκ) and optionally a (truncated) MoEκ3' enhancer.

[0041] Yet a further preferred expression cassette described herein comprises in 5'-3' direction: a Vκ promoter, a human leader, a human V gene, optionally a MoEκi enhancer, a rat constant region (Cκ) and optionally a (truncated) MoEκ3' enhancer.

[0042] Certain antibodies produced as described herein may be be used in human therapeutics and diagnostics. Thus, provided is a method for producing a desired antibody comprising exposing a non-human mammal described herein to an antigen such that an antibody response is induced and isolating the antibodies specific for the antigen.

[0043] In certain embodiments, provided are methods for producing a desired antibody comprising exposing a non-human mammal described herein to an antigen such that an antibody response is induced and isolating cells producing such antibodies, culturing and optionally immortalizing the cells and harvesting the antibodies.

[0044] In certain embodiments, provided is a method for producing a desired antibody comprising exposing a non-human mammal described herein to an antigen such that an antibody response is induced and isolating a nucleic acid encoding at least part of such an antibody, inserting the nucleic acid or a copy or a derivative thereof in an expression cassette and expressing the antibody in a host cell.

[0045] The methods for producing antibodies from transgenic mice are known to a person skilled in the art. Particularly preferred are methods for production of mixtures of antibodies from one cell, whereby the nucleic acids encoding these antibodies have been derived from mice described herein.

[0046] These so-called oligoclonics are disclosed in WO04106375 and WO05068622, which are incorporated herein by reference.

[0047] Described herein are transgenic non-human mammals, preferably mice, capable of generating specific and high affinity hybrid mouse-human antibodies with preferably human immunoglobulin light chain variable (VL) regions in or near germline configuration and preferably murine immunoglobulin heavy chain variable (VH) regions that may have accumulated somatic mutations during the process of antigen-driven affinity maturation. It is envisaged that the murine VH regions of the hybrid antibodies may be subjected to humanization procedures to yield mAbs that have reduced immunogenicity when applied in humans based on germline or near-germline VL regions and murine VH regions that have been humanized.

[0048] In particular, we have shown that transgenic mice that harbor a DNA expression construct that encodes a rearranged human VL region under the control of cis-acting genetic elements that provide timely and regulated expression of the transgene on a significant proportion of B cells during B cell development, yet lack elements that direct the somatic hypermutation machinery to the transgene, are capable of generating specific and high affinity mouse-human hybrid antibodies with essentially unmutated L chains. It is shown that the rearranged human transgene is capable of pairing with a diversity of endogenous murine immunoglobulin H chains to form mouse-human hybrid immunoglobulins expressed on the surface of B cells and to sufficiently facilitate murine B cell development to obtain a sizeable and diverse peripheral B cell compartment.

[0049] In certain embodiments, the transgene expression construct harbors the coding sequences of a human rearranged L chain V region under the control of a human VL promoter to direct B-cell specific expression. In addition, the construct harbors the murine 3' Ck enhancer sequence for B cell specific and inducible and high level expression of the transgene. Furthermore, the construct is designed to lack regulatory elements that facilitate the recruitment of the somatic hypermutation machinery to the transgene, such as the intron enhancer and the 3' C-kappa enhancer.

[0050] In a related embodiment, the rearranged human VL gene is inserted in the murine Rosa26 locus by site-specific integration. The Rosa26 locus is useful in the context of the "targeted transgenesis" approach for efficient generation of transgenic organisms (such as mice) with a predictable transgene expression pattern.

[0051] In certain embodiments, the rearranged human VL region is selected for its capacity to pair with many different murine VH genes so as to ensure the generation of a population of B cells with a diverse VH gene repertoire. A method of obtaining such VL regions comprises amplifying a repertoire of rearranged VH genes from the B cells of mice and a repertoire of human rearranged germline VL regions from the B cells of humans and cloning them into phagemid display vectors to prepare diverse libraries of hybrid immunoglobulins in bacteria. By nucleotide sequence analysis of collections of unselected and antigen-selected VH/VL pairs, human germline VL genes that pair with many different murine VH genes are identified. A collection of human germline VL genes with this capacity is described.

[0052] In one embodiment, it is shown that upon immunization with antigen, the B cells are capable of mounting an immune response, leading to the generation of B cells that secrete hybrid antibodies with high specificity and affinity. The V regions encoding these antibodies are characterized by the human transgenic light chain that harbors no or very few mutations and a murine heavy chain that harbors a variable number of mutations introduced by the somatic hypermutation machinery.

[0053] In a related embodiment, strategies to obtain high affinity hybrid monoclonal antibodies from the transgenic mice by hybridoma and display technologies are contemplated as well as procedures to humanize the murine VH regions to obtain less immunogenic antibodies for application in humans.

[0054] In one embodiment, provided is an immunoglobulin L chain transgene construct comprising DNA sequences that encode a human immunoglobulin VL region in combination with a light chain constant region (CL) of an animal

immunoglobulin protein, which sequences are operably linked to transcription regulatory sequences that, when integrated in a non-human transgenic animal, produce an Ig VL-CL polypeptide with a human VL region that is not or marginally subject to somatic hypermutation. The Ig VL is capable of pairing with rearranged VH-CH polypeptides that are generated during B cell development in the non-human transgenic animal, with the VH-CH polypeptides retaining the capacity to undergo somatic hypermutation upon stimulation. The CL region may be of any animal species and is generally capable of pairing with the CH regions of the non-human transgenic animal.

[0055] Also included is the use of a transgene construct as above in producing a transgenic non-human animal capable of the production of hybrid antibodies consisting of VL-CL polypeptides and VH-CH polypeptides in which the VL region is of human origin and the CL, VH and CH may be of any animal species, including human. Upon immunization, these transgenic animals are capable of generating high affinity antibodies encoded by somatically hypermutated VH genes and essentially non-mutated VL genes encoded by the transgene.

[0056] In another aspect, provided is a process for the production of a transgenic non-human animal capable of the production of hybrid antibodies in response to antigenic challenge, comprising functionally disrupting the endogenous immunoglobulin light chain locus and inserting into the animal genome a transgene construct of the invention.

[0057] Included is the use of animals obtainable by this process in the production of B cells that produce immunoglobulin having human VL light chain. In another aspect of the invention there is provided a process for the production of B cells that produce immunoglobulin having human VL and binding to a selected antigen, comprising challenging an animal obtainable by a process as above with the antigen and screening for B cells from the animal that bind the antigen. Further included is B cells obtainable by this process and hybridomas obtainable by immortalizing such B cells, e.g., hybridomas obtained by fusing B cells as above with myeloma cells. Also included is a process for producing monoclonal antibody comprising cultivating such a hybridoma. In yet a further aspect, provided is the use of the above B cells in producing a hybridoma or corresponding monoclonal antibody.

[0058] Described herein is a process for the production of immunoglobulin having human VL chain and binding to a selected antigen, comprising challenging an animal obtainable as above with the antigen and obtaining immunoglobulin there from.

[0059] In one strategy, as an individual step, a rearranged VL region encoded by human germline V and J gene segments and a light chain constant region of any animal species but preferably a murine constant region is introduced into the mouse germ line. The transgene DNA may be introduced into the pronuclei of fertilized oocytes or embryonic stem cells. The integration may be random or homologous depending on the particular strategy to be employed. For example, the VL transgene may be introduced by random insertion, resulting in mice that bear one or multiple copies of the transgene in the genome. Alternatively, the human VL transgene may be targeted to a specific genomic locus using site-specific recombination as described in the art.

[0060] In certain embodiments, the VL transgene is targeted to the murine ROSA26 locus which is a suitable integration site allowing strong and predictable expression of inserted transgenes (European Patent Office document EP 1,439,234 A1, the contents of which are incorporated herein by this reference). The targeting vector allows insertion of a single copy of a gene expression cassette, thus avoiding modulation of transgene expression by the arrangement of multiple copies. By choosing the autosomal Rosa26 locus as insertion site, the expression pattern of the inserted transgene in the non-human animal is predictable. Furthermore, random X inactivation and/or modulation by chromosomal position effects are avoided. This also eliminates the need to generate and analyze multiple transgenic strains for any given transgene. Finally, the Rosa26 targeting vector for the site-specific integration can be used for multiple gene expression cassettes. Thus, it may be envisaged that two or more different rearranged germline human VL regions are inserted into the Rosa26 locus to further increase the diversity of the repertoire of hybrid or human antibodies.

[0061] In another embodiment, a rearranged human VL region may be targeted to the murine Ig kappa or lambda light chain locus so as to functionally inactivate the endogenous locus or mice containing the rearranged human VL region may be bred with mice that lack functional kappa or lambda Ig loci or both. Thus, by using transformation, using repetitive steps or in combination with breeding, transgenic animals may be obtained which are able to produce antibodies harboring the human VL transgene in the substantial absence of endogenous host immunoglobulin light chains.

[0062] In one embodiment, a human VL transgene is selected for its capacity to pair with a substantial portion of murine VH regions to form a diverse repertoire of functional mouse-human hybrid antibodies expressed on the surface of B cells. By a substantial portion of murine VH regions is meant that the human VL pairs with at least with 0.1% of the murine VH regions generated during B cell development, more preferably with at least 1% and most preferably with at least 10%. Methods to identify human VL genes with this characteristic include randomly pairing a repertoire of human VL regions with a repertoire of murine VH regions, co-expression of VH and VL regions in appropriate eukaryotic or prokaryotic expression vectors and screening for human VL regions that pair with a substantial portion of murine VH regions. In one embodiment, phagemid vectors may be used to direct expression of mouse-human antibody fragments in bacterial cells or to the surface of filamentous phage and analysis of binding capacity of antibody fragments by methods known in the art.

[0063] In another embodiment, a human VL transgene is selected for its capacity to pair with a substantial portion of human VH regions to form a diverse repertoire of human antibodies expressed on the surface of B cells. By a substantial portion of human VH regions is meant that the human VL pairs with at least with 0.1% of the human VH regions generated during B cell development, more preferably with at least 1% and most preferably with at least 10%.

[0064] In the latter embodiment, the human VL transgenic mice are crossed with mice that harbor functional rearranged or non-rearranged human H chain immunoglobulin loci and functionally inactivated endogenous H chain Ig loci as described in the art. The functional inactivation of the two copies of each of the three host Ig loci (heavy chain, kappa and lambda light chain), where the host contains the human

IgH and the rearranged human VL transgene would allow for the production of purely human antibody molecules without the production of host or host human chimeric antibodies. Such a host strain, by immunization with specific antigens, would respond by the production of mouse B-cells producing specific human antibodies, which B-cells are subsequently fused with mouse myeloma cells or are immortalized in any other manner for the continuous stable production of human monoclonal antibodies. Alternatively, the population of B cells is used as a source of VH regions that can be obtained by constructing cDNA libraries or by PCR amplification using primers for human VH regions as is known in the art.

[0065] A human rearranged VL gene is reconstructed in an appropriate eukaryotic or prokaryotic microorganism and the resulting DNA fragments can be introduced into pronuclei of fertilized mouse oocytes or embryonic stem cells. Various constructs that direct B cell specific expression of VL transgenes have been described in the art and have the following general format: a leader sequence and relevant upstream sequences to direct B cell specific expression of the transgene, a coding sequence of a human VL transgene, an enhancer sequence that directs B cell specific and high level expression of the transgene and a murine constant region gene. In a preferred format, the enhancer is the C-kappa 3' enhancer because it directs high level expression in B-lineage cells, but does not recruit somatic hypermutation when used in transgene constructs.

[0066] In one embodiment, animals, preferably mice, comprising one or multiple copies of the transgene in the genome are isolated and analyzed for stable expression. Animals are selected that show stable expression of the transgene over longer periods of time, preferably in B-cells. If required, different animal lines comprising independent insertions of one or multiple copies of the transgene, preferably on different chromosomes, are crossed to obtain animals with different insertions of one or multiple copies of the transgene to increase expression of the transgene in animals, preferably in B-cells.

[0067] Further provided is progeny of a transgenic non-human animal described herein, the progeny comprising, at least in its B-cell lineage, a heavy- or light chain encoding sequence together with a means that renders the sequence resistant to DNA rearrangements and/or somatic hypermutations.

[0068] Further provided is progeny of a transgenic non-human animal described herein, the progeny comprising an expression cassette for the expression of a desired proteinaceous molecule in cells during a certain stage of development in cells developing into mature B cells.

[0069] In addition, provided is a cell that is isolated from a transgenic non-human animal described herein, the cell comprising a heavy- or light chain encoding sequence together with a means that renders the sequence resistant to DNA rearrangements and/or somatic hypermutations. In addition, provided is a cell that is isolated from a transgenic non-human animal described herein, the cell comprising an expression cassette for the expression of a desired proteinaceous molecule in cells during a certain stage of development in cells developing into mature B cells. A cell described herein, preferably an antibody-producing B-cell or a cell that is capable of differentiating or maturating into an antibody-producing B-cell, can be used for in vitro production of antibodies, as is known to the skilled person, for example, from Gascan et al. 1991, *J. Exp. Med.* 173:747-750. Methods for immortalization of a cell described herein are known in the art and include the generation of hybridomas, for example, by fusion with a myeloma cell, transformation with Epstein Barr Virus; expression of the signal transducer of activation and transcription (STAT), activation via CD40 and IL4 receptor signaling, and/or expression of Bcl6 (Shvarts et al. 2002, *Genes Dev.* 16: 681-686).

[0070] In a separate step, the mouse endogenous Kappa and Lambda light chain loci are rendered essentially non-functional such that at least the majority of B cells in the transgenic mice bear Ig receptors that contain the transgenic human VL region. Inactivation of the endogenous mouse immunoglobulin loci is achieved by targeted disruption of the appropriate loci by homologous recombination in mouse embryonic stem cells. The targeted disruption comprises alteration of the genomic sequence such that substantially no functional endogenous mouse immunoglobulin Kappa and/or Lambda light chain is produced. The term "substantially no functional endogenous mouse immunoglobulin" indicates that the endogenous Kappa and/or Lambda light chain loci are functionally silenced such that the level of functional protein expression of the endogenous Kappa and/or Lambda light chain loci, preferably the endogenous Kappa light chain locus, is reduced to about 20% of the level of expression in a reference mouse, more preferred to about 10%, more preferred to about 5%, more preferred to about 2% and more preferred to about 1%. In a most preferred embodiment, the level of functional protein expression of the endogenous Kappa and/or Lambda light chain loci is reduced to 0%. The level of functional protein expression can be determined by means known to the skilled person, including western blotting and pairing with a mouse heavy chain. The reference mouse is a mouse in which the endogenous Kappa and/or Lambda light chain loci is not disrupted. The alteration comprises mutation and/or deletion of gene sequences that are required for functional expression of the endogenous immunoglobulin genes. Alternatively, the alteration comprises insertion of a nucleic acid into the endogenous mouse immunoglobulin Kappa and/or Lambda light chain loci such that the functional expression of the endogenous immunoglobulin genes is reduced. In one embodiment, the nucleic acid comprises a silencing element resulting in transcriptional silencing of the endogenous immunoglobulin gene. In a further embodiment, or in addition, the nucleic acid comprises a sequence that disrupts splicing and/or translation of the endogenous immunoglobulin gene, for example, by introducing an exon that renders a frame shift in the coding sequence, or that comprises a premature stop codon. In each case chimeric animals are generated which are derived in part from the modified embryonic stem cells and are capable of transmitting the genetic modifications through the germ line. The mating of mouse strains with human immunoglobulin loci to strains with inactivated mouse loci yields animals which produce antibodies comprising essentially only human light chains.

[0071] A construct for homologous recombination is prepared by means known in the art and any undesirable sequences are removed, e.g., procaryotic sequences. Any convenient technique for introducing a construct for homologous recombination into a target cell may be employed. These techniques include spheroplast fusion, lipofection, electroporation, calcium phosphate-mediated DNA transfer or direct microinjection. After transformation

or transfection of the target cells, target cells are selected by means of positive and/or negative markers, for example, by neomycin resistance and/or acyclovir and/or gancyclovir resistance. Those cells which show the desired phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, PCR, or the like. By identifying fragments which show the presence of the lesion(s) at the target locus, cells in which homologous recombination has occurred to inactivate a copy of the target locus are identified.

[0072] Furthermore, it is shown that upon immunization, the murine and human VH regions in the afore-mentioned transgenic mice but not the VL regions are capable of undergoing somatic hypermutations to generate high affinity antibodies. Advantageously, these antibodies encoded by germline VL regions are predicted to contribute to lower immunogenicity when applied in humans and result in more stable antibodies that are less prone to aggregation and thus safer for therapeutic use in humans.

[0073] MAbs derived from the afore-mentioned non-human transgenic animals or cells all share the same identical human VL regions. It has been described that mAbs that share the same identical VL region may be co-expressed in a single clonal cell for the production of mixtures of recombinant antibodies with functional binding sites (see the incorporated WO04106375 and WO05068622). Thus, provided is a platform for the generation of specific and high affinity mAbs that constitute the basis for mixtures of mAbs produced by clonal cells.

[0074] It is preferred that mAbs derived from the afore-mentioned non-human transgenic animals or cells are directed against cellular targets. Preferred targets are human surface-expressed or soluble proteins or carbohydrate molecules. Further preferred targets are surface-expressed proteins or carbohydrate molecules that are expressed on the surface of bacteria, viruses, and other pathogens, especially of humans.

[0075] More specifically, preferred targets include cytokines and chemokines, including but not limited to InterLeukin 1beta (IL1beta), IL2, IL4, IL5, IL7, IL8, IL12, IL13, IL15, IL18, IL21, IL23 and chemokines such as, for example, CXC chemokines, CC chemokines, C chemokines (or γ chemokines) such as XCL1 (lymphotactin-α) and XCL2 (lymphotactin-β), and CX3C chemokines. Further included as preferred targets are receptor molecules of the cytokines and chemokines, including type I cytokine receptors such as, for example, the IL-2 receptor, type II cytokine receptors such as, for example, interferon receptors, immunoglobulin (Ig) superfamily receptors, tumor necrosis factor receptor family including receptors for CD40, CD27 and CD30, serine/threonine-protein kinase receptors such as TGF beta receptors, G-protein coupled receptors such as CXCR1-CXCR7, and tyrosine kinase receptors such as fibroblast growth factor receptor (FGFR) family members, EGF receptor family members including erbB1 (EGF-R; HER1), erbB2, (HER2), erbB3 (HER3), and erbB4 (HER4), insulin receptor family members including IGF-R1 and IGF-RII, PDGF receptor family members, Hepatocyte growth factor receptor family members including c-Met (HGF-R), Trk receptor family members, AXL receptor family members, LTK receptor family members, TIE receptor family members, ROR receptor family members, DDR receptor family members, KLG receptor family members, RYK receptor family members, MuSK receptor family members, and vascular endothelial growth factor receptor (VEGFR) family members.

[0076] Further preferred targets are targets that are over-expressed or selectively expressed in tumors such as, for example, VEGF, CD20, CD38, CD33, CEA, EpCAM, PSMA, CD54, Lewis Y, CD52, CD40, CD22, CD51/CD61, CD74, MUC-1, CD38, CD19, CD262 (TRAIL-R2), RANKL, CTLA4, and CD30; targets that are involved in chronic inflammation such as, for example, CD25, CD11a, TNF, CD4, CD80, CD23, CD3, CD14, IFNgamma, CD40L, CD50, CD122, TGFbeta and TGFalpha.

[0077] Preferred surface-expressed proteins or carbohydrate molecules that are expressed on the surface of bacteria, viruses, and other parasitic pathogens, especially of humans, include surface markers of influenza A and B viruses such as hemagglutinin (HA) and neuraminidase (NA), filoviruses such as Ebola virus, rabies, measles, rubella, mumps, flaviviruses such as Dengue virus types 1-4, tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and Yellow fever virus, Paramyxoviruses including Paramyxovirus such as Parainfluenza 1, 3, Rubulavirus such as Mumpsvirus and Parainfluenza 2, 4, Morbillivirus, and Pneumovirus such as Respiratory syncytial virus, Vaccinia, small pox, coronaviruses, including Severe Acute Respiratory Syndrome (SARS) virus, hepatitis virus A, B and C, Human Immunodeficiency Virus, Herpes viruses, including cytomegalovirus, Epstein Barr virus, Herpes simplex virus, and Varicella zoster virus, parvoviruses such as, for example, B19; *Legionella pneumophila; Listeria monocytogenes; Campylobacter jejuni; Staphylococcus aureus; E. coli* O157:H7; *Borrelia burgdorferi; Helicobacter pylori; Ehrlichia chaffeensis; Clostridium difficile; Vibrio cholera; Salmonella enterica* Serotype *Typhimurium; Bartonella henselae; Streptococcus pyogenes* (Group A Strep); *Streptococcus agalactiae* (Group B Strep); Multiple drug resistant *S. aureus* (e.g., MRSA); *Chlamydia pneumoniae; Clostridium botulinum; Vibrio vulnificus; Parachlamydia* pneumonia; *Corynebacterium amycolatum; Klebsiella pneumonia*; Linezolid-resistant *enterococci* (*E. faecalis* and *E. faecium*); and Multiple drug resistant *Acinetobacter baumannii.*

[0078] Most preferred targets are IL-6 and its receptor, IL-6Ralpha, glycoprotein-denominated gp130, RSV, especially the surface proteins F, G and SH and non-structural proteins such as N and M, and receptor tyrosine kinases, in particular erbB1 (EGF-R; HER1), erbB2, (HER2), erbB3 (HER3), erbB4 (HER4), IGF-R1 and IGF-RII, c-Met (HGF-R).

[0079] Therefore, provided is a platform for the generation of specific and high affinity mAbs against the above mentioned targets that constitute the basis for mixtures of mAbs produced by clonal cells. In certain embodiments, the specific and high affinity mAbs comprise mAbs that are directed against different epitopes on at least one of the targets. In a further preferred embodiment, the specific and high affinity mAbs comprise mAbs that are directed against different targets, such as, for example, one or more members of the EGF-receptor family, including erbB1 (EGF-R; HER1), erbB2, (HER2), erbB3 (HER3) and erbB4 (HER4).

[0080] Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required

by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001)), which is incorporated herein by reference. The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

DESCRIPTION OF THE DRAWINGS

[0081] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0082] FIG. **1**: A topology map of the annealing locations of mouse specific VH primers and the position of required restriction sites that are introduced by overhanging sequences at the 3' end of primers.

[0083] FIG. **2**: PCR amplification steps (Amplification, Intermediate and Site introduction). The location and names of the mouse VH amplification primers (and mixtures of primers) are indicated per step.

[0084] FIG. **3**: Topology of the MV1043 vector. This vector is used for the cloning of human or murine VH fragments. O12 (IGKV1-39) is indicated as the VL gene. Products of this vector in combination with helper phages in *E. coli* cells allow the generation of phages that display Fab fragments on the surface of the phage particles as a fusion product to the g3 protein and presence of the vector in the phage as the genetic content (F1 ORI).

[0085] FIG. **4**: The topology of the mouse Ckappa locus downstream of the J-segments. Both enhancers and Ckappa region are indicated. The lower arrow indicates the region that is removed in order to silence the locus.

[0086] FIG. **5**: The topology of the mouse C-lambda locus. All three active V-regions are indicated (Igl-V1, V2 and V3) as are the J-segments (Igl-J1, Igl-J2, Igl-J3, Igl-J4 and the pseudo segment Igl-J3p) and constant regions (Igl-C1, Igl-C2, Igl-C3 and Igl-C4). The regions that are deleted in order to silence the locus are indicated by deletion markers. These deletions include all active V genes (1, 2 and 3) and the intergenic segment between V2 and V3.

[0087] FIG. **6**: Construct topology of IGKV1-39/J-Ck with an intron located in the leader open reading frame (ORF).

[0088] FIG. **7**: Construct topology of IGLV2-14/J-Ck with an intron located in the leader open reading frame (ORF).

[0089] FIG. **8**: Construct topology of VkP-IGKV1-39/J-Ck (VkP-O12). The promoter originates from the IGKV1-39 gene and is placed directly in front of the required elements for efficient transcription and translation. Intergenic sequences (including the enhancers) are derived from mice and obtained from BAC clones. The C-kappa sequence codes for the kappa constant region of rat.

[0090] FIG. **9**: Construct topology of VkP-IGLV2-14/J-Ck (VkP-2a2). The promoter originates from the IGKV1-39 gene and is placed directly in front of the required elements for efficient transcription and translation. Intergenic sequences (including the enhancers) are derived from mice and obtained from BAC clones. The C-kappa sequence codes for the kappa constant region of rat.

[0091] FIG. **10**: Construct topology of VkP-IGKV1-39/J-Ck-Δ1 (VkP-O12-de11) is identical to VkP-IGKV1-39/J-Ck from FIG. **9** except that the intron enhancer region is removed.

[0092] FIG. **11**: Construct topology of VkP-IGKV1-39/J-Ck-Δ2 VkP-O12-de12) is identical to VkP-IGKV1-39/J-Ck-Δ1 from FIG. **10** except that a large piece of the intergenic region between the Ck gene and 3' enhancer is deleted. In addition, the 3' enhancer is reduced in size from 809 bp to 125 bp.

[0093] FIG. **12**: Overview of the sequences used or referred to in this application: Human germline IGKV1-39/J DNA (SEQ ID NO:84); human germline IGKV1-39/J Protein (SEQ ID NO:85); human germline IGLV2-14/J DNA (SEQ ID NO:86); human germline IGLV2-14/J Protein (SEQ ID NO:87); Rat IGCK allele a DNA (SEQ ID NO:88); Rat IGCK allele a protein (SEQ ID NO:89); IGKV1-39/J-Ck (SEQ ID NO:90); IGLV2-14/J-Ck (SEQ ID NO:91); VkP-IGKV1-39/J-Ck (SEQ ID NO:92); VkP-IGKV1-39/J-Ck-Δ1 (SEQ ID NO:93); VkP-IGKV1-39/J-Ck-Δ2 (SEQ ID NO:94); VkP-IGLV2-14/J-Ck (SEQ ID NO:95); pSELECT-IGKV1-39/J-Ck (SEQ ID NO:96); pSelect-IGLV2-14/J-Ck (SEQ ID NO:97); MV1043 (SEQ ID NO:98); and MV1057 (SEQ ID NO:99).

[0094] FIGS. **13**A-C: Generation of Rosa26-IgVk1-39 KI allele. FIG. **13**A Schematic drawing of the pCAGGS-IgVK1-39 targeting vector. FIG. **13**B Nucleotide sequence of the pCAGGS-IgVK1-39 targeting vector (SEQ ID NO:100). FIG. **13**C Targeting strategy.

[0095] FIGS. **14**A-C: FIG. **14**A Southern blot analysis of genomic DNA of ES clones comprising an insertion of the pCAGGS-IgVK1-39 targeting vector. Genomic DNA of four independent clones was digested with AseI and probed with 5e1 indicating the 5'-border of the targeting vector. All clones comprise a correct insertion of the targeting vector at the 5' end. FIG. **14**B Southern blot analysis of genomic DNA of ES clones comprising an insertion of the pCAGGS-IgVK1-39 targeting vector. Genomic DNA of four independent clones was digested with MscI and probed with 3e1 indicating the 3'-border of the targeting vector. All clones comprise a correct insertion of the targeting vector at the 3' end. FIG. **14**C Southern blot analysis of genomic DNA of ES clones comprising an insertion of the pCAGGS-IgVK1-39 targeting vector. Genomic DNA of four independent clones was digested with BamHI and probed with an internal Neo

probe indicating the 5'-border of the targeting vector. All clones comprise a correct, single insertion of the targeting vector.

[0096] FIGS. **15**A-C: Generation of Rosa26-IgV12-14 KI allele. FIG. **15**A Schematic drawing of the pCAGGS-IgVL2-14 targeting vector. FIG. **15**B Nucleotide sequence of the pCAGGS-IgVL2-14 targeting vector containing the CAGGS expression insert (SEQ ID NO:101) based on the rearranged germline IGLV2-14/J V lambda region (IGLV2-14/J-Ck). FIG. **15**C Targeting strategy.

[0097] FIGS. **16**A-C: Epibase® profile of IGKV1-39 residues 1-107 (SEQ ID NO:85). FIG. **16**A displays the binding strength for DRB1 allotypes, while FIG. **16**C displays the binding strength for DRB3/4/5, DQ and DP allotypes. The values in the figure represent dissociation constants (Kds) and are plotted on a logarithmic scale in the range 0.01 μM-0.1 μM (very strong binders may have run off the plot). For medium binding peptides, qualitative values are given only, and weak and non-binders are not shown. Values are plotted on the first residue of the peptide in the target sequence (the peptide itself extends by another nine residues). Importantly, only the strongest binding receptor for each peptide is shown: cross-reacting allotypes with lower affinity are not visible in this plot. The strongest binding receptor is indicated by its serotypic name. Finally, any germline-filtered peptides are plotted with a lighter color in the epitope map (in this case, no non-self epitopes were found). FIG. **16**B shows the HLA binding promiscuity for every decameric peptide (Y-axis: the number of HLA allotypes recognizing critical epitopes in each of the peptides starting at the indicated residue shown on the X-axis). The promiscuity is measured as the number of allotypes out of the total of 47 for which the peptide is a critical binder. White columns refer to self-peptides, and black columns (absent here) to non-self peptides.

[0098] FIG. **17**: Epitope map of IGKV1-39 showing the presence of peptide binders predicted in the sequence of IGKV1-39 by serotype in the 15-mer format. Each 15-mer is numbered as indicated in the top of the figure. The full sequence of the corresponding 15-mer is listed in Table 7. Black boxes indicate the presence of one or more critical self-epitopes in the 15-mer for the serotype listed on the left. Critical epitopes are operationally defined as strong or medium DRB1 binders and strong DRB3/4/5 or DP or DQ binders.

[0099] FIGS. **18**A-B: Constitutive knock-out (KO) of the Ig kappa locus. FIG. **18**A Targeting strategy. FIG. **18**B Schematic drawing of the pIgKappa targeting vector.

[0100] FIGS. **19**A-B: Constitutive KO of the Ig lambda locus. FIG. **19**A First step of the targeting strategy. FIG. **19**B Second step of the targeting strategy.

[0101] FIGS. **20**A-C: Schematic drawing of targeting vectors. FIG. **20**A pVkP-O12 (VkP-IGKV1-39/J-Ck); FIG. **20**B pVkP-O12-de11 (VkP-IGKV1-39/J-Ck-Δ1); FIG. **20**C pVkP-O12-de12 (VkP-IGKV1-39/J-Ck-Δ2).

[0102] FIGS. **21**A-C: Targeting strategies for insertion of transgene into the Rosa26 locus by targeted transgenesis using RMCE. FIG. **21**A VkP-O12 (VkP-IGKV1-39/J-Ck); FIG. **21**B VkP-O12-de11 (VkP-IGKV1-39/J-Ck-Δ1); FIG. **21**C VkP-O12-de12 (VkP-IGKV1-39/J-Ck-Δ2).

[0103] FIG. **22**: Topology of the MV1057 vector. Replacing the indicated stuffer fragment with a VH fragment yields an expression vector that can be transfected to eukaryotic cells for the production of IgG1 antibodies with light chains containing an O12 (IGKV1-39) VL gene.

[0104] FIG. **23**: Lack of transgenic human Vk1 light chain expression in non-B cell populations of the spleen.

[0105] FIG. **24**: Transgenic human Vk1 light chain is expressed in all B cell populations of the spleen.

[0106] FIG. **25**: Transgenic human Vk1 light chain is expressed in B1 cells of the peritoneal cavity.

[0107] FIGS. **26**A-B: Transgenic human Vk1 light chain is not expressed in pro- and pre-B cells but in the immature and recirculating populations B cells in the bone marrow. FIG. **26**A Gating of bone marrow cells. FIG. **26**B Histograms of transgene expression with overlay from one WT control.

[0108] FIG. **27**: Transgenic human Vk1 light chain is directly correlated with endogenous light chain and IgM expression in circulating B cells in the blood.

[0109] FIG. **28**: Parameters of stability for stable clones containing the germline IGKV1-39 gene.

[0110] FIG. **29**A-B: Antibody mixtures used for staining of lymphocyte populations. BM=bone marrow, PC=peritoneal cavity, PP=Peyer's patches.

DETAILED DESCRIPTION OF THE INVENTION

Examples

Example 1: Human Light Chain V-Gene Clones

[0111] This example describes the rationale behind the choice of two human light chain V-genes, one gene of the kappa type and one gene of the lambda type, that are used as a proof of concept for light chain expressing transgenic mice. De Wildt et al. 1999 (de Wildt et al. (1999), *J. Mol. Biol.* 285(3):895) analyzed the expression of human light chains in peripheral IgG-positive B-cells. Based on these data, IGKV1-39 (O12) and IGLV2-14 (2a2) were chosen as light chains as they were well represented in the B-cell repertoire. The J-segment sequence of the light chains has been chosen based upon sequences as presented in GenBank ABA26122 for IGKV1-39 (B. J. Rabquer, S. L. Smithson, A. K. Shriner and M. A. J. Westerink) and GenBank AAF20450 for IGLV2-14 (O. Ignatovich, I. M. Tomlinson, A. V. Popov, M. Bruggemann and G. J. Winter, *J. Mol. Biol.* 294 (2):457-465 (1999)).

[0112] All framework segments are converted into germline amino acid sequences to provide the lowest immunogenicity possible in potential clinical applications.

Example 2: Obtaining Mouse Heavy Chain V-Genes that Pair with Human IGKV1-39 Gene Segment to Form Functional Antibody Binding Sites

[0113] This example describes the identification of mouse heavy chain V-genes that are capable of pairing with a single, rearranged human germline IGKV1-39/J region. A spleen VH repertoire from mice that were immunized with tetanus toxoid was cloned in a phage display Fab vector with a single human IGKV1-39-C kappa light chain and subjected to panning against tetanus toxoid. Clones obtained after a single round of panning were analyzed for their binding specificity. The murine VH genes encoding tetanus toxoid-specific Fab fragments were subjected to sequence analysis to identify unique clones and assign VH, DH and JH utilization.

[0114] Many of the protocols described here are standard protocols for the construction of phage display libraries and the panning of phages for binding to an antigen of interest and described in Antibody Phage Display: *Methods and Protocols* (editor(s): Philippa M. O'Brien and Robert Aitken).

Immunizations

[0115] BALB/c mice received one immunization with tetanus toxoid and were boosted after six weeks with tetanus toxoid.

Splenocyte Isolation

[0116] Preparation of spleen cell suspension. After dissection, the spleen was washed with PBS and transferred to a 60 mm Petri dish with 20 ml PBS. A syringe capped with 20 ml PBS and a G20 needle was used to repeatedly flush the spleen. After washing the flushed cells with PBS, the cells were carefully brought into suspension using 20 ml PBS and left on a bench for five minutes to separate the splenocytes from the debris and cell clusters. The splenocytes suspension was transferred on top of a Ficoll-Paque™ PLUS-filled tube and processed according to the manufacturer's procedures for lymphocyte isolation (Amersham Biosciences).

RNA Isolation and cDNA Synthesis

[0117] After isolation and pelleting of lymphocytes, the cells were suspended in TRIzol LS Reagent (Invitrogen) for the isolation of total RNA according to the accompanying manufacturer's protocol and subjected to reverse transcription reaction using 1 microgram of RNA, Superscript III RT in combination with dT20 according to manufacturer's procedures (Invitrogen).

PCR Amplification of cDNA

[0118] The cDNA was amplified in a PCR reaction using primer combinations that allow the amplification of approximately 110 different murine V-genes belonging to 15 VH families (Table 1; RefSeq NG_005838; Thiebe et al. 1999, *European Journal of Immunology* 29:2072-2081). In the first round, primer combinations that bind to the 5' end of the V-genes and 3' end of the J regions were used. In the second round, PCR products that were generated with the MJH-Rev2 primer were amplified in order to introduce modifications in the 3' region to enable efficient cloning of the products. In the last round of amplification, all PCR products were amplified using primers that introduce a SfiI restriction site at the 5' end and a BstEII restriction site at the 3' end (see FIGS. **1** and **2**, and Table 1).

[0119] Reaction conditions for 1st round PCR: four different reactions combining all 25 forward primers (MVH1 to MVH25, Table 1 and FIG. **2**) and one reverse primer per reaction (MJH-Rev1, MJH-Rev2, MJH-Rev3 or MJH-Rev4; see Table 1 and FIG. **2**). Fifty microliters PCR volumes were composed of 2 microliters cDNA (from RT reactions), 10 microliters 5* Phusion polymerase HF buffer, 40 nM of each of the 25 forward primers (total concentration of 1 micromolar), 1 micromolar reverse primer, 1 microliter 10 mM dNTP stock, 1.25 unit Phusion polymerase and sterile MQ water. The thermocycler program consisted of a touch down program: one cycle 98° C. for 30 seconds, 30 cycles 98° C. for ten seconds, 58° C. decreasing 0.2° C. per cycle ten seconds, 72° C. 20 seconds and one cycle 72° C. for three minutes. The second round PCR program was set up only for the products of the first PCR that contain the MJH-Rev2 primer: two different reactions combining either the Ext-MVH-1 or ExtMVH-2 primers (Table 1 and FIG. **2**) in combination with the reverse primer ExtMJH-Rev2int (Table 1 and FIG. **2**). Fifty microliters PCR volumes were composed of 50 ng PCR product (from first PCR round), 10 microliters 5* Phusion polymerase HF buffer, 500 nM of each forward primer, 1 micromolar reverse primer, 1 microliter 10 mM dNTP stock, 1.25 unit Phusion polymerase and sterile MQ water. The thermocycler program consisted of a touch down program followed by a regular amplification step: one cycle 98° C. for 30 seconds, ten cycles 98° C. for ten seconds, 65° C. decreasing 1.5° C. per cycle ten seconds, 72° C. 20 seconds, ten cycles 98° C. for ten seconds, 55° C. ten seconds, 72° C. 20 seconds and one cycle 72° C. for three minutes. The third round PCR program was setup as described in FIG. **2**. Fifty microliters PCR volumes were composed of 50 ng PCR product (from earlier PCR rounds, FIG. **2**), 10 microliters 5* Phusion polymerase HF buffer, 1 micromolar forward primer (Table 1 and FIG. **2**), 1 micromolar reverse primer, 1 microliter 10 mM dNTP stock, 1.25 unit Phusion polymerase and sterile MQ water. The program consists of a touch down program followed by a regular amplification step: one cycle 98° C. for 30 seconds, ten cycles 98° C. for ten seconds, 65° C. decreasing 1.5° C. per cycle ten seconds, 72° C. 20 seconds, ten cycles 98° C. for ten seconds, 55° C. ten seconds, 72° C. 20 seconds and one cycle 72° C. for three minutes. After PCR amplifications, all PCR products were gel purified using Qiaex II according to the manufacturer's protocols.

Restriction Enzyme Digestions

[0120] Purified products were digested with BstEII and SfiI in two steps. First 1 microgram of DNA was digested in 100 microliters reactions consisting of 10 microliters of 10* NEB buffer 3 (New England Biolabs), 1 microliter 100* BSA, 12.5 unit BstEII and sterile water for six hours at 60° C. in a stove. The products were purified using Qiaquick PCR Purification kit from Qiagen according to the manual instructions and eluted in 40 microliters water. Next all products were further digested with SfiI in 100 microliters reactions consisting of 10 microliters of 10* NEB buffer 2 (New England Biolabs), 1 microliter 100* BSA, 12.5 unit SfiI and sterile water for 12 hours at 50° C. in a stove. The digested fragments were purified by Qiaquick Gel Extraction kit following gel separation on a 20 cm 1.5% agarose TBE plus ethidium bromide gel at 80 V. 100 micrograms of the acceptor vector (MV1043, FIGS. **3** and **12**) was digested with 50 units Eco91I in 600 microliters under standard conditions (Tango buffer) and next purified on a 0.9% agarose gel. After a second digestion step under prescribed conditions with 400 units SfiI in 500 microliters for 12 hours, 100 units BsrGI were added for three hours at 50° C.

Ligations

[0121] Each PCR product was ligated separately according to the following scheme: 70 ng digested PCR products, 300 ng digested acceptor vector, 100 units T4 Ligase (NEB), 1* ligase buffer in 30 microliters for 16 hours at 12° C. The ligation reactions were purified with phenol/chloroform/isoamyl alcohol extractions followed by glycogen precipitations (Sigma Aldrich #G1767) according to the manufacturer's protocol and finally dissolved in 25 microliters sterile water.

Transformations and Library Storage

[0122] The purified ligation products were transformed by electroporation using 1200 microliters TG1 electrocompetent bacteria (Stratagene #200123) per ligation batch and plated on LB carbenicillin plates containing 4% glucose. Libraries were harvested by scraping the bacteria in 50 ml LB carbenicillin. After centrifugation at 2000 g for 20 minutes at 4° C., the bacterial pellets were resuspended carefully in 2 ml ice cold 2*TY/30% glycerol on ice water and frozen on dry ice/ethanol before storage at −80° C.

Library Amplification

[0123] Libraries were grown and harvested according to procedures as described by Kramer et al. 2003 (Kramer et al. (2003), *Nucleic Acids Res.* 31(11):e59) using VCSM13 (Stratagene) as helper phage strain.

Selection of Phages on Coated Immunotubes

[0124] Tetanus toxoid was dissolved in PBS in a concentration of 2 μg/ml and coated to MAXISORP™ Nunc-Immuno Tube (Nunc 444474) overnight at 4° C. After discarding the coating solution, the tubes were blocked with 2% skim milk (ELK) in PBS (blocking buffer) for one hour at RT. In parallel, 0.5 ml of the phage library was mixed with 1 ml blocking buffer and incubated for 20 minutes at room temperature. After blocking the phages, the phage solution was added to the tetanus toxoid-coated tubes and incubated for two hours at RT on a slowly rotating platform to allow binding. Next, the tubes were washed ten times with PBS/0.05% TWEEN™-20 detergent followed by phage elution by an incubation with 1 ml 50 mM glycine-HCl pH 2.2 ten minutes at RT on rotating wheel and directly followed by neutralization of the harvested eluent with 0.5 ml 1 M Tris-HCl pH 7.5.

Harvesting Phage Clones

[0125] Five ml XL1-Blue MRF (Stratagene) culture at O.D. 0.4 was added to the harvested phage solution and incubated for 30 minutes at 37° C. without shaking to allow infection of the phages. Bacteria were plated on Carbenicillin/Tetracycline 4% glucose 2*TY plates and grown overnight at 37° C.

Phage Production

[0126] Phages were grown and processed as described by Kramer et al. 2003 (Kramer et al. 2003, *Nucleic Acids Res.* 31(11):e59) using VCSM13 as helper phage strain.

Phage ELISA

[0127] ELISA plates were coated with 100 microliters tetanus toxoid per well at a concentration of 2 micrograms/ml in PBS overnight at 4° C. Plates coated with 100 microliters thyroglobulin at a concentration of 2 micrograms/ml in PBS were used as a negative control. Wells were emptied, dried by tapping on a paper towel, filled completely with PBS-4% skimmed milk (ELK) and incubated for one hour at room temperature to block the wells. After discarding the block solution, phage minipreps premixed with 50 μl blocking solution were added and incubated for one hour at RT. Next five washing steps with PBS-0.05% Tween-20 removed unbound phages. Bound phages were detected by incubating the wells with 100 microliters anti-M13-HRP antibody conjugate (diluted 1/5000 in blocking buffer) for one hour at room temperature. Free antibody was removed by repeating the washing steps as described above, followed by TMB substrate incubation until color development was visible. The reaction was stopped by adding 100 microliters of 2 M H_2SO_4 per well and analyzed on an ELISA reader at 450 nm emission wavelength (Table 2). Higher numbers indicate stronger signals and thus higher incidence of specific binding of the phage-Fab complex.

Sequencing

[0128] Clones that gave signals at least three times above the background signal (Table 2) were propagated, used for DNA miniprep procedures (see procedures Qiagen miniPrep manual) and subjected to nucleotide sequence analysis. Sequencing was performed according to the Big Dye 1.1 kit accompanying manual (Applied Biosystems) using a reverse primer (CH1_Rev1, Table 1) recognizing a 5' sequence of the CH1 region of the human IgG1 heavy chain (present in the Fab display vector MV1043, FIGS. **3** and **12**). Mouse VH sequences of 28 tetanus toxoid binding clones are depicted in Table 3. The results show that the selected murine VH genes belong to different gene families, and different individual members from these gene families are able to pair with the rearranged human IGKV1-39/J VH region to form functional tetanus toxoid-specific antibody binding sites. From the sequence analyses, it was concluded that the murine VH regions utilize a diversity of DH and JH gene segments.

Example 3: Silencing of the Mouse Kappa Light Chain Locus

[0129] This example describes the silencing of the mouse endogenous kappa light chain locus. The endogenous kappa locus is modified by homologous recombination in ES cells, followed by the introduction of genetically modified ES cells in mouse embryos to obtain genetically adapted offspring.

[0130] A vector that contains an assembled nucleotide sequence consisting of a part comprising the J-region to 338 bp downstream of the J5 gene segment fused to a sequence ending 3' of the 3' CK enhancer is used for homologous recombination in ES cells. The assembled sequence is used to delete a genomic DNA fragment spanning from 3' of the JK region to just 3' of the 3' CK enhancer. As a consequence of this procedure, the CK constant gene, the 3' enhancer and some intergenic regions are removed (see FIGS. **4** and **18**A-B).

Construction of the Targeting Vector

[0131] A vector that received 4.5-8 kb flanking arms on the 3' and 5' end fused to the deletion segment was used for targeted homologous recombination in an ES cell line. Both arms were obtained by PCR means ensuring maximum homology. The targeting strategy allows generation of constitutive KO allele. The mouse genomic sequence encompassing the Igk intronic enhancer, Igk constant region and the Igk 3' enhancer was replaced with a PuroR cassette, which was flanked by F3 sites and inserted downstream of the Jk elements. Flp-mediated removal of the selection marker resulted in a constitutive KO allele. The replacement of the Igk MiEk-Igk C-Igk 3'E genomic region (approxi-

mately 10 kb) with a F3-Puro cassette (approx. 3 kb) was likely to decrease the efficiency of homologous recombination. Therefore, the arms of homology were extended accordingly and more ES cell colonies were analyzed after transfection in order to identify homologous recombinant clones.

Generation of ES Cells Bearing the Deleted Kappa Fragment

[0132] The generation of genetically modified ES cells was essentially performed as described (Seibler et al. (2003), *Nucleic Acids Res*. February 15; 31(4):e12). See also Example 14 for a detailed description.

Generation of ES Mice by Tetraploid Embryo Complementation

[0133] The production of mice by tetraploid embryo complementation using genetically modified ES cells was essentially performed as described (Eggan et al., *PNAS* 98:6209-6214; J. Seibler et al. (2003), *Nucleic Acids Res*. February 15; 31(4):e12; Hogan et al. (1994), Summary of mouse development, *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y., pp. 253-289).

Example 4: Silencing of the Mouse Lambda Light Chain Locus

[0134] This example describes the silencing of the mouse endogenous lambda light chain locus. The endogenous lambda locus is modified by homologous recombination in ES cells followed by the introduction of genetically modified ES cells in mouse embryos to obtain genetically adapted offspring.

[0135] Two regions of the murine lambda locus that together contain all functional lambda V regions are subject to deletion.

[0136] The first region targeted for homologous recombination-based deletion is a region that is located 408 bp upstream of the start site of the IGLV2 gene segment and ends 215 bp downstream of IGLV3 gene segment, including the intergenic sequence stretch between these IGLV gene segments. The second region that is subject to a deletion involves the IGLV1 gene segment consisting of a fragment spanning from 392 bp upstream to 171 bp downstream of the IGLV1 gene segment. As a consequence of these two deletion steps, all functional V-lambda genes segments are deleted, rendering the locus functionally inactive (FIGS. **5** and **19**A-B).

Construction of the Targeting Vectors

[0137] Vectors that received 3-9.6 kb flanking arms on the 3' and 5' end fused to the deletion segment were used for targeted homologous recombination in an ES cell line. Both arms were obtained by PCR means ensuring maximum homology. In a first step, the mouse genomic sequence encompassing the Igl V2-V3 regions were replaced with a PuroR cassette flanked by F3 sites, which yields a constitutive KO allele after Flp-mediated removal of selection marker (see FIG. **19**A). In a second step, the mouse genomic sequence encompassing the Igl V1 region was replaced with a Neo cassette in ES cell clones which already carried a deletion of the Igl V2-V3 regions (see FIG. **19**B). The selection marker (NeoR) was flanked by FRT sites. A constitutive KO allele was obtained after Flp-mediated removal of selection markers.

Generation of ES Cells Bearing the Deleted Lambda Fragment

[0138] The generation of genetically modified ES cells was essentially performed as described (J. Seibler, B. Zevnik, B. Küter-Luks, S. Andreas, H. Kern, T. Hennek, A. Rode, C. Heimann, N. Faust, G. Kauselmann, M. Schoor, R. Jaenisch, K. Rajewsky, R. Kühn, F. Schwenk (2003), *Nucleic Acids Res*., February 15; 31(4):e12). See also, Example 14 for a detailed description. To show that both targeting events occurred on the same chromosome several double targeted clones were selected for the in vitro deletion with pCMV C31deltaCpG. The clones were expanded under antibiotic pressure on a mitotically inactivated feeder layer comprised of mouse embryonic fibroblasts in DMEM High Glucose medium containing 20% FCS (PAN) and 1200 μ/mL Leukemia Inhibitory Factor (Millipore ESG 1107). 1×10^7 cells from each clone were electroporated with 20 μg of circular pCMV C31deltaCpG at 240 V and 500 μF and plated on four 10 cm dishes each. Two to three days after electroporation, cells were harvested and analyzed by PCR. Primers used were:

2005_5:	CCCTTTCCAATCTTTATGGG	(SEQ ID NO: 1)
2005_7:	AGGTGGATTGGTGTCTTTTTCTC	(SEQ ID NO: 2)
2005_9:	GTCATGTCGGCGACCCTACGCC	(SEQ ID NO: 3)

[0139] PCR reactions were performed in mixtures comprising 5 μl PCR Buffer 10× (Invitrogen), 2 μl $MgCl_2$ (50 mM), 1 μl dNTPs (10 mM), 1 μl first primer (5 μM), 1 μl second primer (5 μM), 0.4 μl Taq (5 U/ul, Invitrogen), 37.6 μl H_2O, and 2 μl DNA. The program used was 95° C. for five minutes; followed by 35 cycles of 95° C. for 30 seconds; 60° C. for 30 seconds; 72° C. for 1 minute; followed by 72° C. for ten minutes.

Generation of ES Mice by Tetraploid Embryo Complementation

[0140] The production of mice by tetraploid embryo complementation using genetically modified ES cells was essentially performed as described (Eggan et al., *PNAS* 98:6209-6214; J. Seibler, B. Zevnik, B. Küter-Luks, S. Andreas, H. Kern, T. Hennek, A. Rode, C. Heimann, N. Faust, G. Kauselmann, M. Schoor, R. Jaenisch, K. Rajewsky, R. Kühn, and F. Schwenk (2003), *Nucleic Acids Res*., February 15; 31(4):e12; Hogan et al. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y.), pp. 253-289).

Example 5: Construction of the CAGGS Expression Insert Based on a Rearranged Human Germline IGKV1-39/J-Ck Gene (IGKV1-39/J-Ck)

[0141] This example describes the construction of a CAGGS expression cassette incorporating the rearranged human germline IGKV1-39/J region. This insert expression cassette encompasses cloning sites, a Kozak sequence, a leader sequence containing an intron, an open reading frame of the rearranged IGKV1-39 region, a rat CK constant region from allele a and a translational stop sequence (IGKV1-39/J-Ck; FIG. **6**). The primary construct consists of

naturally occurring sequences and has been analyzed and optimized by removing undesired cis acting elements like internal TATA-boxes, poly adenylation signals, chi-sites, ribosomal entry sites, AT-rich or GC-rich sequence stretches, ARE-, INS- and CRS sequence elements, repeat sequences, RNA secondary structures, (cryptic) splice donor and acceptor sites and splice branch points (GeneArt GmbH). In addition, the codon usage in the open reading frame regions is optimized for expression in mice. The intron sequence is unchanged and thus represents the sequence identical to the coding part of the human IGKV1-39 leader intron.

[0142] At the 5' end of the expression cassette, a NotI site was introduced and on the 3' site a NheI site. Both sites are used for cloning in the CAGGS expression module. After gene assembly according to methods used by GeneArt, the insert is digested with NotI-NheI and cloned into the expression module containing a CAGGS promoter, a stopper sequence flanked by LoxP sites ("foxed"), a polyadenylation signal sequence and, at the 5' and 3' end, sequences to facilitate homologous recombination into the Rosa26 locus of mouse ES cell lines. Promoter and/or cDNA fragments were amplified by PCR, confirmed by sequencing and/or cloned directly from delivered plasmids into an RMCE exchange vector harboring the indicated features. A schematic drawing and the confirmed sequence of the final targeting vector pCAGGS-IgVK1-39 are shown in FIGS. **13**A and **13**B. The targeting strategy is depicted in FIG. **13**C.

Example 6: CAGGS Expression Insert Based on the Rearranged Germline IGLV2-14/J V Lambda Region (IGLV2-14/J-Ck)

[0143] This example describes the sequence and insertion of an expression cassette incorporating the rearranged germline IGLV2-14/J V lambda region. This insert encompasses cloning sites, a Kozak sequence, a leader sequence containing an intron, an open reading frame of the rearranged IGLV2-14/J region, a rat CK constant region from allele a and a translational stop sequence (IGLV2-14/J-Ck; FIG. **7**). The primary construct consists of naturally-occurring sequences and has been analyzed and optimized by removing undesired cis acting elements like: internal TATA-boxes, poly adenylation signals, chi-sites, ribosomal entry sites, AT-rich or GC-rich sequence stretches, ARE-, INS- and CRS sequence elements, repeat sequences, RNA secondary structures, (cryptic) splice donor and acceptor sites and splice branch points (GeneArt GmbH). In addition, the codon usage in the open reading frame regions was optimized for expression in mice. The intron sequence is unchanged and thus represents the sequence identical to the human IGKV1-39 leader intron.

[0144] At the 5' end of the expression cassette, a NotI site was introduced and on the 3' site a NheI site. Both sites are used for cloning in the CAGGS expression module as described by TaconicArtemis. After gene assembly according to methods used by GeneArt, the insert was digested with NotI-NheI and cloned into the expression module containing a CAGGS promoter, a stopper sequence flanked by LoxP sites ("foxed"), a polyadenylation signal sequence and, at the 5' and 3' end, sequences to facilitate homologous recombination into the Rosa26 locus of mouse ES cell lines. To construct the final ROSA26 RMCE targeting vector, promoter and/or cDNA fragments were amplified by PCR. Amplified products were confirmed by sequencing and/or cloned directly from delivered plasmids into an RMCE exchange vector harboring the indicated features. A schematic drawing and the confirmed sequence of the final targeting vector pCAGGS-IgVL2-14 is shown in FIGS. **15**A and **15**B. The targeting strategy is depicted in FIG. **15**C.

Example 7: Expression of IGKV1-39/J-Ck in HEK293 Cell Lines (pSELECT-IGKV1-39/J-Ck)

[0145] This example describes a method to verify that the IGKV1-39/J-Ck constructs described in Example 5 enable expression and detection of the IGKV1-39/J-Ck L chain in HEK293 cells. The IGKV1-39/J insert (FIG. **6**) was modified at the 5' end by changing the NotI site into a SalI site. This change is required for cloning of the product into the expression cassette plasmid pSELECT-hygro (InvivoGen). The CAGGS expression insert IGKV1-39/J-Ck and pSELECT-hygro were digested with SalI and NheI, ligated and used to transform competent XL1-Blue cells using standard techniques. Colonies were picked and DNA purified using Qiagen Midi-prep columns according to the manufacturer's procedures. The resulting light chain (LC) expressing vector named 0817676_pSELECT_0815426 was used to transfect HEK293 cells with Fugene6 (Roche) according to the manufacturer's protocols. Supernatants were screened for the presence of IGKV1-39/J-Ck light chains by ELISA and western blot using anti-rat-Ck antibodies (Beckton Dickinson #550336 and 553871) and protocols used in the art.

[0146] The VH of anti-tetanus toxoid (TT) IgG MG1494 was cloned into IgG expression vector MV1056 using restriction sites SfiI and BstEII. The resulting clone was sequence verified. HEK293T cells were transfected with five different vector combinations as shown in Table 4 (see Example 8 for details of vector 0817678_pSELECT_0815427). Supernatants were harvested and IgG concentrations determined (see Table 4). No IgG could be detected for supernatants A and B containing light chain only as expected (detection antibody recognized Fc part of IgG). IgG concentration in supernatants C and D was comparable to that of positive control supernatant E, indicating correct expression of the light chain constructs.

[0147] Binding to TT was analyzed by ELISA to check functionality of the produced antibodies, using hemoglobin as negative control antigen. No TT-specific binding could be detected for supernatants A and B containing light chain only, as expected. TT-specific binding for supernatants C and D was at least as good as for positive control supernatant E, confirming correct expression of the light chain constructs and functional assembly with heavy chain. Antibodies were detected not only using an anti-human IgG secondary antibody, but also an anti-rat Ckappa light chain secondary antibody. The results confirm that the anti-rat Ckappa antibody (BD Pharmingen #553871, clone MRK-1) recognizes the light chain expressed by the pSELECT vectors.

[0148] Supernatants were analyzed by non-reducing SDS-PAGE and Western blot (not shown). Detection using an anti-human IgG heavy chain antibody did not show bands for supernatants A and B containing light chain only, as expected. Results for supernatants C and D were comparable to positive control supernatant E, with a band close to the 170 kD marker as expected for intact IgG. Additional lower molecular weight bands were observed as well for supernatants C, D and E, which might represent degradation prod-

ucts, IgG fragments resulting from (partial) reduction and/or irrelevant protein bands due to non-specific binding of the detection antibody.

[0149] Detection using an anti-rat Ckappa light chain antibody showed a band close to the 26 kD marker for supernatants A and B, as expected for light chain only. This band was much more intense for A compared to B, indicating that the free IGKV1-39 light chain may be better expressed and/or more stable than the free IGLV2-14 light chain. No bands were detected for control supernatant E as expected, since the expressed IgG contains a human Ckappa light chain. For supernatants C and D, expected bands close to the 170 kD marker were observed; lower molecular weight bands were also observed, but to a lesser extent than above using the anti-human IgG antibody.

[0150] In conclusion, transfection of the light chain expression constructs combined with the heavy chain of anti-tetanus toxoid (TT) IgG MG1494 resulted in IgG production comparable to the positive control construct for both the pSELECT kappa and lambda light chain constructs. Both IgG productions yielded ELISA signals in a TT ELISA that were better than or comparable to the control IgG. SDS-PAGE and Western blot analysis confirmed the presence of intact IgG. The tested anti-rat Ckappa antibody worked efficiently in both ELISA and Western blot. Culture supernatant from cells transfected with light chain constructs only did not result in detectable IgG production nor in detectable TT-specific binding, while free light chain was detected on Western blot.

Example 8: Expression of IGLV2-14/J-Ck in HEK293 Cell Lines (pSELECT-IGLV2-14/J-Ck)

[0151] This example describes a method to verify that the IGLV2-14/J constructs described in Example 6 enable expression and detection of the IGLV2-14/J-Ck L chain in HEK293 cells. The IGLV2-14/J-Ck insert (FIG. **7**) was modified at the 5' end by changing the NotI site into a SalI site. This change is required for cloning of the product into the expression cassette plasmid pSELECT-hygro (InvivoGen). The CAGGS expression insert IGLV2-14/J-Ck and pSELECT-hygro were digested with SalI and NheI ligated and used to transform competentXL1-Blue cells using standard techniques. Colonies were picked and DNA purified using Qiagen Midi-prep columns according to the manufacturer's procedures. The resulting light chain (LC) expressing vector named 0817678_pSELECT_0815427 was used to transfect HEK293 cells with Fugene6 (Roche) according to the manufacturer's protocols. Supernatants were screened for the presence of IGLV2-14/J-Ck light chains by ELISA and western blot using anti-rat-Ck antibodies (Becton Dickinson #550336 and 553871) and protocols used in the art. See Example 7 for details and results.

Example 9: Construction of a VK Promoter-Driven Expression Construct Containing an IGKV1-39/J Insert and Multiple Enhancer Elements Derived from the Murine CK Locus (VkP-IGKV1-39/J-Ck; VkP-O12)

[0152] This example describes the construction of an expression cassette that contains relevant elements to enable B-cell and developmental/differentiation stage-specific expression of the rearranged human IGKV1-39 VK region, based on the IGKV1-39 VK promoter region, leader containing an intron, germline V-gene, CDR3, IGKJ segment, mouse intergenic region located between Jk and CK, rat Ck allele a open reading frame, and a mouse intergenic fragment from the 3' end of the mouse CK gene ending just 3' of the 3' CK enhancer.

[0153] Optimized open reading frames of the leader, IGKV1-39 rearranged gene, and rat CK allele a gene, as described in Example 5, was used for the construction of the expression cassette. The VK promoter region was obtained by gene synthesis procedures (GeneArt, GmbH) and is almost identical to the sequence of the human IGKV1-39 region between −500 bp and the ATG (start site) of the gene. The only deviation from the natural sequence is the introduction of a GCCACCATGG Kozak sequence (SEQ ID NO:102) at the ATG (start) site in order to promote translation. A genomic fragment from a mouse BAC clone (TaconicArtemis) is used as the basis for the introduction of individual elements. This fragment is identical to the sequence of the mouse VK locus starting with the intron donor site located directly 3' of the JK5 region and ending just 3' of the 3' CK enhancer and covers approximately 12.5 kb.

[0154] The final construct contains from 5' to 3' end the following elements: human genomic IGKV1-39 promoter (500 bp), a Kozak sequence, a human IGKV1-39 leader part 1 (optimized), a human IGKV1-39 leader intron, a human IGKV1-39 leader part 2 (optimized), a human IGKV1-39 germline gene (optimized), a human J-region (optimized), a mouse intergenic region including the intron enhancer element, a rat (*Rattus norvegicus*) kappa constant region (optimized), and a mouse intergenic region including the 3' kappa enhancer. The elements of this expression cassette are shown in FIG. **8** and named VkP-IGKV1-39/J-Ck (VkP-O12). An outline of the pVkP-O12 vector and the targeting strategy is depicted in FIGS. **20**A and **21**A. The vector was introduced into ES cells following standard procedures (see Example 14).

Example 10: Construction of a VK Promoter-Driven Expression Construct Containing an IGLV2-14/J Clone and Multiple CK Locus-Derived Enhancer Elements (VkP-IGLVL2-14/J-Ck; VkP-2a2)

[0155] This example describes the same construct as described in Example 9, except that the IGKV1-39 gene and J-region are replaced by the optimized human IGLV2-14 germline gene including a unique V-J region (VkP-IGLV2-14/J-Ck; VkP-2a2; FIG. **9**).

Example 11: Construction of a VK Promoter-Driven Expression Construct Containing an IGKV1-39 Clone Lacking the CK Intron Enhancer Element (VkP-IGKV1-39/J-Ck-Δ1; VkP-O12-de11)

[0156] The construct described in Example 9 was modified by removing the CK intron enhancer element, located in the intergenic region between the human J region and the rat CK region by standard PCR modification and DNA cloning methodologies (GeneArt, GmBH). The resulting expression cassette is shown in FIG. **10** and named VkP-IGKV1-39/J-Ck-Δ1 (VkP-O12-de11).

[0157] An outline of the pVkP-O12-de11 vector and the targeting strategy is depicted in FIGS. **20**B and **21**B. The

vector was introduced into ES cells following standard procedures (see Example 14).

Example 12: Construction of a VK Promoter-Driven Expression Construct Containing an IGKV1-39 Clone Lacking the CK Intron Enhancer Element and a Truncated 3' CK Enhancer Element (VkP-IGKV1-39/J-Ck-Δ2; VkP-O12-de12)

[0158] The construct described in Example 11 was modified by truncating the 3' CK enhancer element and deleting part of the intergenic region 3' of the rat Ck gene, to remove potential inhibitory elements. This was achieved by removing the intergenic sequence between an EcoRV site (located 3' of the rat Ck gene) and the NcoI site present in the 3' enhancer (5993 bp) and further removing the sequence between the 3' enhancer BstXI site and the BstXI site 3' of the 3' enhancer (474 bp) using standard methods. The resulting expression cassette is shown in FIG. **11** and named VkP-IGKV1-39/J-Ck-Δ2 (VkP-O12-de12).

[0159] An outline of the pVkP-O12-de12 vector and the targeting strategy is depicted in FIGS. **20**C and **21**C. The vector was introduced into ES cells following standard procedures (see Example 14).

Example 13: Expression of Vk Constructs in Cell Lines

[0160] The constructs described in Examples 9-12 are tested for their ability to produce light chain proteins in the myeloma cell lines MPC11 (ATCC CCL167), B-cell lymphoma WEHI231 (ATCC CRL-1702), the T-cell lymphoma EL4 (ATCC TIB-39) and in HEK293 (ATCC CRL1573). The enhancer and promoter elements in the construct enable expression in the B-cell lines but not in cell lines derived from other tissues. After transfection of the cell lines using purified linearized DNA and Fugene6 (Roche) cells are cultured for transient expression. Cells and supernatant are harvested and subjected to SDS-PAGE analysis followed by western blotting using a specific anti-rat-C-kappa antibody. Supernatants are analyzed in ELISA for secreted L chains using the anti-rat CK antibody (Beckton Dickinson #550336).

Example 14: Generation of Transgenic ES Lines

[0161] All constructs as described in Examples 3, 4, 5, 6, 9, 10, 11 and 12 were used to generate individual stable transgenic ES lines by means of homologous recombination. The methods for generation of transgenic ES lines via homologous recombination are known in the field (e.g., Eggan et al., *PNAS* 98:6209-6214; J. Seibler, B. Zevnik, B. Küter-Luks, S. Andreas, H. Kern, T. Hennek, A. Rode, C. Heimann, N. Faust, G. Kauselmann, M. Schoor, R. Jaenisch, K. Rajewsky, R. Kühn, F. Schwenk (2003), *Nucleic Acids Res*., February 15; 31(4):e12; Hogan et al. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y.), pp. 253-289).

[0162] For all constructs described in Examples 5 and 6, and Examples 9-12, the RMCE ES cell line (derived from mouse strain 129S6B6F1-Gt(ROSA)26Sortm10Arte) was grown on a mitotically inactivated feeder layer comprised of mouse embryonic fibroblasts (MEF) in DMEM High Glucose medium containing 15% FBS (PAN 1302-P220821). Leukemia Inhibitory Factor (Chemicon ESG 1107) was added to the medium at a concentration of 900 U/mL. For manipulation, 2×10^5 ES-cells were plated on 3.5 cm dishes in 2 ml medium. Directly before transfection, 2 ml fresh medium was added to the cells. Three μl Fugene6 Reagent (Roche; Catalog No. 1 814 443) was mixed with 100 μl serum free medium (OptiMEM I with Glutamax I; Invitrogen; Catalog No. 51985-035) and incubated for five minutes. One hundred μl of the Fugene/OptiMEM solution was added to 2 μg circular vector and 2 μg CAGGS-Flp and incubated for 20 minutes. This transfection complex was added dropwise to the cells and mixed. Fresh medium was added to the cells the following day. From day 2 onwards, the medium was replaced daily with medium containing 250 μg/mL G418 (Geneticin; Invitrogen; Catalog No. 10131-019). Seven days after transfection, single clones were isolated, expanded, and molecular analyzed by Southern blotting according to standard procedures.

[0163] For each construct, analysis of multiple clones by restriction enzyme digestion of genomic DNA of single clones followed by hybridization with 5' probes, 3' probes, and internal probes resulted in clones that comprised a correct, single insertion at the correct position in the Rosa26 locus. An example is provided in FIGS. **14**A-C.

Example 15: Generation of Transgenic Mouse Strains

[0164] All ES cell lines that were generated and verified for their modifications as described in Example 14 were used to generate stable transgenic mice by means of tetraploid recombination. The methods are known in the field. In general, after administration of hormones, superovulated Balb/c females were mated with Balb/c males. Blastocysts were isolated from the uterus at dpc 3.5. For microinjection, blastocysts were placed in a drop of DMEM with 15% FCS under mineral oil. A flat tip, piezo actuated microinjection-pipette with an internal diameter of 12-15 micrometers was used to inject 10-15 targeted C57BL/6 N.tac ES cells into each blastocyst. After recovery, injected blastocysts were transferred to each uterine horn of 2.5 days post coitum, pseudopregnant NMRI females. Chimerism was measured in chimeras (G0) by coat color contribution of ES cells to the Balb/c host (black/white). Highly chimeric mice were bred to strain C57BL/6 females. Depending on the project requirements, the C57BL/6 mating partners are non-mutant (W) or mutant for the presence of a recombinase gene (Flp-Deleter or Cre-deleter or CreER inducible deleter or combination of Flp-deleter/CreER). Germline transmission was identified by the presence of black, strain C57BL/6, offspring (G1).

[0165] For example, ESC clone IgVK1-39 2683 8 (see Examples 5 and 14) was injected in a total of 62 blastocysts in three independent experiments. Three litters were obtained with a total of six pups. All pups were chimeric. Three heterozygous offspring pups were obtained that were used for further crossing.

[0166] ESC Clone Kappa 2692 A-C10 (see Examples 3 and 14) was injected in a total of 54 blastocysts in three independent experiments. Three litters were obtained with a total of eleven pups, of which ten were chimeric. Eight heterozygous offspring pups were obtained that were used for further crossing.

[0167] ESC Clone Kappa 2692 B-C1 (see Examples 3 and 14) was injected in a total of 51 blastocysts in three independent experiments. Two litters were obtained with a

total of six pups, of which four were chimeric. Three heterozygous offspring pups were obtained that were used for further crossing.

Example 16: Breeding

[0168] This example describes the breeding for obtaining mice that contain transgenic expression cassettes as described Example 14 and knock-out mice in which the endogenous lambda and kappa loci have been silenced. The localization of V-lambda on chromosome 16 and CD19 on chromosome 7 allow standard breeding procedures. The breeding of the co-localized Vk locus and Rosa26 locus on chromosome 6 with a distance of about 24 cM requires special attention during the screening as only a percentage of the offspring shows crossover in a way that both modifications are brought together on one chromosome.

[0169] All four loci have to be combined in a single mouse strain that is homo- or heterozygous for CD19-cre (not described) and modified Rosa26 transgene and homozygous for the other loci. Breeding is performed by standard breeding and screening techniques as appropriate and offered by commercial breeding companies (e.g., TaconicArtemis).

Example 17: Immunizations of Mice

[0170] Primary and booster immunization of mice are performed using standard protocols.

[0171] To validate the transgenic expression of human rearranged Vκ O12 (IGKV1-39)-rat Cκ light chains (see Examples 5, 14-16) in B cells from CD19-HuVκ1 mice and to assess its impact on VH repertoire size, diversity of VH family usage and V(D)J recombination after immunization, the CD19-HuVκ1 transgenic mice are immunized with tetanus toxin vaccine (TT vaccine) and VH sequence diversity of randomly picked clones from CD19-HuVκ1 mice are compared with TT-immunized wt mice and CD19-Cre HuVk1 negative littermates. Data on the SHM frequency of the human Vκ O12 transgene in the immunized mice are obtained. A diverse collection of at least 40 TT-specific, clonally-unrelated mAbs containing the human Vκ O12 are recovered from CD19-HuVκ1 mice by phage display.

[0172] For this, three adult CD19-HuVκ1 mice are vaccinated with TT vaccine using standard immunization procedures. After immunization, serum titers are measured using TT specific ELISA (TT: Statens Serum Institute, Art. no. 2674) and spleen suspensions subjected to cell sorting by the FACS procedure after staining with a rat Cκ-specific monoclonal antibody to isolate transgenic B cells (clone RG7/9.1; BD Pharmingen#553901, Lot#06548). RNA from rat Cκ-positive B cells are extracted and the resulting cDNA material used for library building and SHM analysis.

[0173] The standard monoclonal mouse anti-rat Cκ antibody (clone RG7/9.1; BD Pharmingen#553901, Lot#06548) is used in FACS analysis of transgene expressing B cells (Meyer et al. (1996), *Int. Immunol.* 8:1561). The clone RG7/9.1 antibody reacts with a monotypic (common) kappa chain determinant. This anti-rat Cκ antibody (clone RG7/9.1 (BD Pharmingen#553901, Lot#06548) is labeled with R-phycoerythrin (PE) using the LYNX rapid conjugation kit according to the manufacturer's instructions for FACS analysis and sorting. The labeled antibody is firstly tested by flow cytometry for binding to rat Cκ-containing functional light chain proteins produced into transiently transfected HEK-293T cells; the un-conjugated antibody serves as a positive control. Two other antibodies shown to bind to rat Cκ by ELISA and Western-blot (see Example 7) are tested as well by flow cytometry.

[0174] Fab-phage display library building is carried out with a set of optimized degenerate PCR primers designed to amplify C57BL/6 VH genes; the minimal library size is 10^6 clones, and minimal insert frequency is 80%. The vector used, MV1043 (FIGS. **3** and **12**), contains the human Vκ O12 fused to a human Cκ Region. The rat Cκ is therefore exchanged for the human counterpart in the library generation process.

[0175] Before selection, VH sequencing of 96 randomly picked clones is performed to validate VH repertoire diversity that is compared to diversity obtained from an unselected library previously generated using the same procedures from BALB/c mice immunized with TT. A library from C57Bl/6 wt mice that are immunized in the same way allows diversity comparison between two preselected libraries sharing the same vaccine and the same genetic background.

[0176] Several independent selections are performed on TT coated in immunotubes. Variables that may be included are selections using biotinylated antigens in solution or selections on captured TT. Based on the number and diversity of ELISA-positive clones obtained in the first selections, decisions on additional rounds of selection are made. Clones are considered positive when >3× positive over a negative control clone. Positive clones are analyzed by ELISA against a panel of negative control antigens to verify antigen specificity. The aim is to identify at least 40 unique VH regions, as based on unique CDR3 sequences and V_HDJ_H rearrangements.

[0177] Amplification of the cDNA material from rat Cκ-positive sorted B cells is performed with a PCR forward primer specific to the human leader sequence and a PCR reverse primer specific to the rat Cκ sequence, in a region not redundant with the mouse Cκ sequence, as reported in a recent study (Brady et al. (2006), *JIM* 315:61). Primer combinations and annealing temperatures are firstly tested on cDNA from HEK-293T cells transfected with 0817676_pSELECT_0815426=pSELECT vector with IGKV1-39 DNA cassette (see Example 7).

[0178] The amplification products is cloned in pJET-1 vector and after XL1-blue transformation, 96 colonies are sequenced for assessing VL SHM frequency by direct comparison to the Vκ O12 (IGKV1-39) germline sequence. The R/S ratio method, as described in our study on human TT-specific antibodies (de Kruif et al. (2009), *J. Mol. Biol.* 387:548) allows discrimination between random mutations and antigen-driven mutations that occurred on VL sequences.

Example 18: Immunofluorescent Analysis of B Cell Populations in Transgenic Mouse Lines

[0179] This example describes the use of antibodies and flow cytometry to analyze B cell populations in primary (bone marrow) and secondary (spleen, peritoneal) lymphoid organs and blood. Methods and reagents are described in Middendorp et al. (2002), *J. Immunol.* 168:2695; and Middendorp et al. (2004), *J. Immunol.* 172:1371. For analysis of early B cell development in bone marrow, cells were surface stained with combinations of antibodies (Becton Dickinson) specific for B220, CD19, CD25, IgM, IgD, mouse Ckappa, mouse Clambda and rat Ckappa to detect pro-B cells, pre-B

cells, large pre-B cells, early and late immature B cells and recirculating B cell populations expressing the transgene on their surface. DAPI staining (Invitrogen) was included to exclude dead cells from the analysis and FC block (Becton Dickinson) to inhibit antibody interaction with Fc receptors on myeloid cells. For analysis of surface transgene expression on B cell populations in peripheral lymphoid organs and blood, cells were stained with combinations of antibodies (Becton Dickinson) specific for B220, CD5, CD19, CD21, CD23, IgM, IgD, mouse Ckappa, mouse Clambda and rat Ckappa. DAPI staining was included to exclude dead cells from the analysis and FC block to inhibit antibody interaction with Fc receptors on myeloid cells. In addition, combinations of antibodies (Becton Dickinson) specific for CD3, CD4, CD11b, CD11c and NK1.1 were included to determine if transgene expression occurred in cell types outside of the B cell compartment.

[0180] Three mice heterozygous for the human IGKV1-39/rat Ckappa transgene and heterozygous for the CD19-Cre transgene on a C57BL6 background (HuVk1/CD19-Cre) were analyzed. As controls for the FACS analysis, three littermate mice wild-type for the human IGKV1-39/rat Ckappa transgene and heterozygous for the CD19-Cre transgene on a C57BL6 background (CD19-Cre) and two C57BL6/NTac mice (Wt) were included. All animals were allowed to acclimatize in the animal facility for one week before analysis and all mice were male and six weeks of age. Lymphocytes were isolated from the femurs, spleens, peritoneal cavity and blood of mice using conventional techniques as previously described (Middendorp et al. (2002), *J. Immunol.* 168:2695; and Middendorp et al. (2004), *J. Immunol.* 172:1371). Antibodies were pre-combined as shown in FIG. **29**A-B and staining was carried out in 96-well plates. Incubation with the PE-conjugated anti-rat C kappa (described above) was carried out before staining with the rat anti-murine antibodies to avoid non-specific binding. After completion of cell staining, labeled cells were analyzed on a Becton Dickinson LSR II FACS machine and the acquired data analyzed with FlowJo software (v6.4.7).

[0181] Transgenic mice were similar in weight, appearance and activity to wild-type mice. No gross anatomical alterations were observed during the harvesting of tissues. No difference was observed in the numbers of B cells in the bone marrow (BM) and spleen (Table 9) or in the numbers of B cells, T cells and myeloid cells in peripheral organs between transgenic and wild-type mice. In addition, the frequency or proportion of the cells in the different lymphocyte developmental pathways was not altered in transgenic mice when compared to wild-type mice. Thus in the double transgenic (HuVk1/CD19-Cre) and transgenic (CD19-Cre) mice lymphoid and most importantly B cell development was indistinguishable from wild-type mice.

[0182] In the peripheral lymphoid organs, staining with the transgene specific antibody (anti-ratCkappa-PE) was only observed in the B cell populations. T cell, myeloid cell and NK cell populations were all negative for surface expression of the transgene in the spleen (FIG. **23**). In contrast, in cells stained with the pan B cell markers B220 and CD19 all cells were shifted to the right in the FACS plot indicating cell surface expression of the transgene (FIG. **24**). A similar transgene-specific staining was measured in $CD5^+$ B1 cells of the peritoneum, a developmentally distinct population of B cells (FIG. **25**).

[0183] Differentiation of B cells from multilineage precursors to mature B cells occurs in the bone marrow. In the lymphocytes analyzed from the bone marrow, extracellular and transgene expression was not detectable in the earliest B cell progenitors the pro- and pre-B cell consistent with the pattern of normal light chain expression (FIGS. **26**A-B). Transgene expression first becomes detectable in immature B cells, the developmental stage at which the germline murine light chain undergoes rearrangement and is expressed at the cell surface in the context of the preselected heavy chain (FIGS. **26**A-B). Consistent with the staining in the spleen transgenic light chain expression is also detected on mature recirculating B cells (FIGS. **26**A-B). Thus the CD19-Cre driven expression of the transgene is consistent with the normal pattern of light chain expression. The staining with the endogenous light chain-specific antibody is more intense than that of the transgene-specific light chain antibody. This may indicate a higher expression level of the endogenous light chain, a more sensitive staining with the endogenous light chain-specific antibody or a combination of both. Importantly, the intensity of the surface expression of the transgenic light chain is correlated with both endogenous light chain and IgM surface expression as observed in staining of circulating B cells in the blood (FIG. **27**).

[0184] Thus, overall this analysis demonstrates that expression of the human IGKV1-39/Ckappa transgene is restricted to the B cell compartment and the temporal regulation of its expression is similar to the endogenous kappa and lambda light chains resulting in normal development of all B cell populations. The apparent lower level of expression of the transgene could be explained by the strength of the promoter in comparison to the promoter and enhancers present on endogenous light chain genes or by a delay in transgene expression that gives the endogenous light chains a competitive advantage in pairing with the rearranged heavy chain. This is consistent with the observation that as B cells mature the relative intensity of transgene staining increases compared to the endogenous light chains. In addition, the observation that B cells numbers are normal and that every surface Ig+ B cell co-expresses an endogenous and transgenic light chain supports the conclusion that the IGKV1-39 variable region is capable of pairing with a normal repertoire of different murine heavy chain variable regions. We conclude from this analysis that insertion of the IGKV1-39/rat Ckappa transgene driven by the CD19-Cre activated CAGGS promoter in the Rosa locus facilitates timely and B cell-specific expression of the transgene and that the transgene is capable of pairing with a normal repertoire of murine heavy chains.

Example 19: Epibase® T-Cell Epitope Profile for IGKV1-39

[0185] The protein sequence of IGKV1-39 (FIG. **12**, human germline IGKV1-39/J Protein) was scanned for the presence of putative HLA class II restricted epitopes, also known as T_H-epitopes. For this, Algonomics' Epibase® platform was applied to IGKV1-39. In short, the platform analyzes the HLA binding specificities of all possible 10-mer peptides derived from a target sequence (Desmet et al. (1992), *Nature* 356:539-542; Desmet et al. (1997), *FASEB J.* 11:164-172; Desmet et al. (2002), *Proteins* 48:31-43; Desmet et al. (2005), *Proteins* 58:53-69). Profiling is done at the allotype level for 20 DRB1, 7 DRB3/4/5, 13 DQ and 7 DP, i.e., 47 HLA class II receptors in total (see Table

5). Epibase® calculates a quantitative estimate of the free energy of binding ΔG_{BIND} of a peptide for each of the 47 HLA class II receptors. These data were then further processed as follows:

[0186] Free energies were converted into Kd-values through ΔG_{bind}=RT ln(Kd).

[0187] Peptides were classified as strong (S), medium (M), weak and non (N) binders. The following cutoffs were applied:

[0188] S: strong binder: Kd<0.1 μM.

[0189] M: medium binder: 0.1 μM≤Kd<0.8 μM.

[0190] N: weak and non-binder: 0.8 μM≤Kd.

[0191] Peptides corresponding to self-peptides were treated separately. The list of self-peptides was taken from 293 antibody germline sequences. They are referred to as "germline-filtered" peptides.

[0192] S- and M-peptides are mapped onto the target sequence in so-called epitope maps; S-affinities are plotted quantitatively; M-values are presented qualitatively. As a general overview of the results, Table 6 lists the number of strong and medium binders in the analyzed proteins, for the groups of HLA class II receptors corresponding to the DRB1, DQ, DP and DRB3/4/5 genes. Counting was done separately for strong and medium affinity binders. Peptides binding to multiple allotypes of the same group were counted as one. Values between brackets refer to germline-filtered peptides. In Table 7, the sequence is shown in a format suitable for experimental work. The sequence is broken down in consecutive 15-mers overlapping by 12 residues. For each 15-mer, the promiscuity is listed (the number of allotypes out of a total of 47 for which the 15-mer contains a critical binder), as well as the implied serotypes. The Epibase® profile and epitope maps are shown in FIGS. **16**A-C and **17**.

[0193] It was concluded that IGKV1-39 contains no strong non-self DRB1 binders. Typically, significantly more binders were found for DRB1 than for other HLA genes. This is in agreement with experimental evidence that allotypes belonging to the DRB1 group are more potent peptide binders. Medium strength epitopes for DRB1 allotypes are expected to contribute to the population response, and cannot be disregarded. Again, no non-self DRB1 binders were found in IGKV1-39.

[0194] In the humoral response raised against an antigen, the observed T_H cell activation/proliferation is generally interpreted in terms of the DRB1 specificity. However, one cannot ignore the possible contribution of the DRB3/4/5, DQ and DP genes. Given the lower expression levels of these genes as compared to DRB1, the focus was on the class of strong epitopes for DRB3/4/5, DQ and DP. "Critical epitopes" are those epitopes that are strong binders for any DRB1, DRB3/4/5, DQ or DP allotype or are medium binders for DRB1. IGKV1-39 contains no strong or medium non-self binders for DRB3/4/5, DQ, or DP.

[0195] A number of peptides are also present in germline sequences (values between brackets in Table 6). Such peptides may very well bind to HLA but they are assumed to be self and, hence, non-immunogenic. In total, six strong and 16 medium germline-filtered DRB1 binders were found in IGKV1-39. Framework region 1 up to framework region 3 is an exact match for germline V-segment VKI 2-1-(1) O12 (VBase), a.k.a. IGKV1-39*01 (IMGT). Framework region 4 is an exact match for germline J-segment JK1 (V-base) a.k.a. IGKJ1*01(IMGT). It is hardly surprising that these segments do not contain any non-self epitopes.

Example 20: Production Characteristics of IGKV1-39

[0196] There is a great demand for antibody discovery platforms that yield therapeutic antibodies that are thermodynamically stable and give good expression yields. These characteristics are important in ensuring the stability of the drug substance during production and after injection of the drug product into the patient. In addition good expression yields impact directly on the cost of drug manufacture and thus pricing, patient access and profitability. Virtually all therapeutic antibodies in clinical use today are composed of human IgG1 and kappa constant regions but use different heavy and light chain variable regions that confer specificity. Human variable heavy and light chain domains can be divided into families that have greater than 80% sequence divergence. When rearranged examples of these families in germline configuration are combined and compared for stability and yield it is clear that the gene families are not equal in terms of biophysical properties. In particular V_H3, V_H1 and V_H5 have favourable stability for the heavy chains and Vk1 and Vk3 have the best stability and yield of light chains. In addition when mutations are introduced as part of the somatic hypermutation process they can interfere with V_H/V_L pairing. To assess the effect that different light chain genes with different rates of mutation have on the production characteristics of a fixed V_H chain, a Fab phage display library was built of light chains (kappa and lambda) from six naïve healthy donors combined with a panel of 44 TT binding heavy chains from immunized donors. After one round of selection TT binding Fab clones were isolated. Several of these shared the same V_H gene as the TT clone PG1433 in combination with different light chains. The Fab light chain fragments were recloned into a kappa expression vector and transfected in combination with DNA encoding the heavy chain of PG1433 into 293 cells and specific IgG production measured by ELISA. As demonstrated in Table 8 the selected clones containing PG1433 V_H combined with different light chains had between five- and ten-fold lower protein expression PG1433 V_H combined with IGKV1-39. Note that all of the light chains contained amino acid mutations within their coding regions that might disrupt V_H paring and reduce production stability. Thus, in addition to reducing the chances of unwanted immunogenicity, it is expected that the use of the light chain IGKV1-39 without mutations contributes to improved production stability and yields of various specificity-contributing V_H genes. Indeed stable clones generated by the transfection of different V_H genes all paired with IGKV1-39 are able to be passaged extensively and still retain robust production characteristics as shown in FIG. **28**.

Example 21: Generation of Mice Expressing Fully Human VH and VL Regions

[0197] Transgenic mice described herein are crossed with mice that already contain a human VH locus. Examples of appropriate mice comprising a human VH locus are disclosed in Taylor et al. (1992), *Nucleic Acids Res.* 20:6287-95; Lonberg et al. (1994), *Nature* 368:856-9; Green et al. (1994), *Nat. Genet.* 7:13-21; Dechiara et al. (2009), *Methods Mol. Biol.* 530:311-24.).

[0198] After crossing and selecting for mice that are at least heterozygous for the IGKV1-39 transgene and the human VH locus, selected mice are immunized with a target. VH genes are harvested as described hereinabove. This method has the advantage that the VH genes are already fully human and thus do not require humanization.

Example 22: Isolation, Characterization, Oligoclonics Formatting and Production of Antibodies Targeting Human IL6 for Treatment of Chronic Inflammatory Diseases Such as Rheumatoid Arthritis

[0199] A spleen VH repertoire from transgenic mice that are immunized with human recombinant IL6 is cloned in a phage display Fab vector with a single human IGKV1-39-C kappa light chain (identical to the mouse transgene) and subjected to panning against the immunogen human IL6. Clones that are obtained after two to four rounds of panning are analyzed for their binding specificity. VH genes encoding IL6-specific Fab fragments are subjected to sequence analysis to identify unique clones and assign VH, DH and JH utilization. The Fab fragments are reformatted as IgG1 molecules and transiently expressed. Unique clones are then grouped based on non-competition in binding assays and subjected to affinity and functional analysis. The most potent anti-IL6 IgG1 mAbs are subsequently expressed as combinations of two, three, four or five heavy chains comprising different VH-regions in the Oligoclonics format, together with one IGKV1-39-C-based kappa light chain and tested in vitro for complex formation with IL-6. The Oligoclonics are also tested in vivo for clearance of human IL-6 from mice. An Oligoclonic with the most potent clearance activity is chosen and the murine VH genes humanized according to conventional methods. The humanized IgG1 are transfected into a mammalian cell line to generate a stable clone. An optimal subclone is selected for the generation of a master cell bank and the generation of clinical trial material.

[0200] Many of the protocols described here are standard protocols for the construction of phage display libraries and the panning of phages for binding to an antigen of interest and are described, for example, in *Antibody Phage Display: Methods and Protocols* (2002), Editor(s) Philippa M. O'Brien, Robert Aitken, Humana Press, Totowa, N.J., USA.

Immunizations

[0201] Transgenic mice receive three immunizations with human IL6 every two weeks using the adjuvant Sigma titerMax according to manufacturer's instructions.

RNA Isolation and cDNA Synthesis

[0202] Three days after the last immunization, spleens and lymphnodes from the mice are removed and passed through a 70 micron filter into a tube containing PBS pH 7.4 to generate a single cell suspension. After washing and pelleting of lymphocytes, cells are suspended in TRIzol LS Reagent (Invitrogen) for the isolation of total RNA according to the manufacturer's protocol and subjected to reverse transcription reaction using 1 microgram of RNA, Superscript III RT in combination with dT20 according to manufacturer's procedures (Invitrogen).

[0203] The generation of Fab phage display libraries is carried out as described in Example 2.

Selection of Phages on Coated Immunotubes

[0204] Human recombinant IL6 is dissolved in PBS in a concentration of 5 μg/ml and coated to MAXISORP™ Nunc-Immuno Tube (Nunc 444474) overnight at 4° C. After discarding the coating solution, the tubes are blocked with 2% skim milk (ELK) in PBS (blocking buffer) for one hour at Room Temperature (RT). In parallel, 0.5 ml of the phage library is mixed with 1 ml blocking buffer and incubated for 20 minutes at room temperature. After blocking the phages, the phage solution is added to the IL6-coated tubes and incubated for two hours at RT on a slowly rotating platform to allow binding. Next, the tubes are washed ten times with PBS/0.05% TWEEN™-20 detergent followed by phage elution by incubating with 1 ml 50 mM glycine-HCl pH 2.2 ten minutes at RT on rotating wheel and directly followed by neutralization of the harvested eluent with 0.5 ml 1 M Tris-HCl pH 7.5.

Harvesting Phage Clones

[0205] A 5 ml XL1-Blue MRF (Stratagene) culture at O.D. 0.4 is added to the harvested phage solution and incubated for 30 minutes at 37° C. without shaking to allow infection of the phages. Bacteria are plated on Carbenicillin/Tetracycline 4% glucose 2*TY plates and grown overnight at 37° C.

Phage Production

[0206] Phages are grown and processed as described by Kramer et al. 2003 (Kramer et al. 2003, *Nucleic Acids Res.* 31(11):e59) using VCSM13 as helper phage strain.

Phage ELISA

[0207] ELISA plates are coated with 100 microliters human recombinant IL6 per well at a concentration of 2.5 micrograms/ml in PBS overnight at 4° C. Plates coated with 100 microliters thyroglobulin at a concentration of 2 micrograms/ml in PBS are used as a negative control. Wells are emptied, dried by tapping on a paper towel, filled completely with PBS-4% skimmed milk (ELK) and incubated for one hour at room temperature to block the wells. After discarding the block solution, phage minipreps pre-mixed with 50 μl blocking solution are added and incubated for one hour at RT. Unbound phages are subsequently removed by five washing steps with PBS-0.05% Tween-20. Bound phages are detected by incubating the wells with 100 microliters anti-M13-HRP antibody conjugate (diluted $\frac{1}{5000}$ in blocking buffer) for one hour at room temperature. Free antibody is removed by repeating the washing steps as described above, followed by TMB substrate incubation until color development was visible. The reaction is stopped by adding 100 microliters of 2 M H2SO4 per well and analyzed on an ELISA reader at 450 nm emission wavelength.

Sequencing

[0208] Clones that give signals at least three times above the background signal are propagated, used for DNA miniprep procedures (see procedures Qiagen miniPrep manual) and subjected to nucleotide sequence analysis. Sequencing is performed according to the Big Dye 1.1 kit accompanying manual (Applied Biosystems) using a reverse primer (CH1_Rev1, Table 1) recognizing a 5' sequence of the CH1 region of the human IgG1 heavy chain (present in the Fab display

vector MV1043, FIGS. **3** and **12**). The sequences of the murine VH regions are analyzed for diversity of DH and JH gene segments.

Construction and Expression of Chimeric IgG1

[0209] Vector MV1057 (FIGS. **12** and **22**) was generated by cloning the transgene (IGKV1-39) L chain fragment into a derivative of vector pcDNA3000Neo (Crucell, Leiden, The Netherlands) that contains the human IgG1- and kappa constant regions. VH regions are cloned into MV1057 and nucleotide sequences for all constructs are verified according to standard techniques. The resulting constructs are transiently expressed in HEK293T cells and supernatants containing chimeric IgG1 are obtained and purified using standard procedures as described before (M. Throsby 2006, *J. Virol.* 80:6982-92).

IgG1 Binding and Competition Analysis

[0210] IgG1 antibodies are titrated in ELISA using IL6-coated plates as described above and an anti-human IgG peroxidase conjugate. Competition ELISAs to group antibodies based on epitope recognition are performed by incubating Fab phages together with IgG1 or with commercial antibodies against IL6 (e.g., Abcam cat. no. ab9324) in IL6-coated plates, followed by detection of bound Fab phage using an anti-M13 peroxidase conjugate.

IgG1 Affinity Measurements

[0211] The affinities of the antibodies to IL6 are determined with the Quantitative kinetic protocol on the Octet (ForteBio). Antibodies are captured onto an Anti-Human IgG Fc Capture biosensor and exposed to free IL6 and analyzed using proprietary software to calculate the Kd of each antibody.

Functional Activity of IL6 Antibodies

[0212] To test the ability of the selected antibodies to inhibit binding between IL6 and IL6 receptor (IL6R), an ELISA based assay is used. Various concentrations of antibody are mixed with a fixed concentration (10 ng/ml) of biotinylated IL6 as described by Naoko et al. 2007, *Can. Res.* 67:817-875. The IL6-antibody immune complex is added to immobilized IL6R. The binding of biotinylated IL6 to IL6R is detected with horseradish peroxidase-conjugated streptavidin. The reduction of ELISA signal is a measurement of inhibition. As positive control for inhibition of binding between IL6 and IL6R either anti-IL6R antibody (Abcam cat. no. ab34351; clone B-R6) or anti IL6 antibody (Abcam cat. no. ab9324) is used.

[0213] In vitro blocking activity of the selected anti-IL6 antibodies is measured in a proliferation assay using the IL6-dependent cell line 7TD1. Briefly, cells are incubated with different concentrations of human IL6 with or without the anti-IL6 antibody. The available amount of IL6 determines the degree of proliferation. Thus if an added antibody blocks IL6 binding the proliferation readout is reduced compared to a non binding antibody control. Proliferation is measured by the incorporation of 5-bromo-2'-deoxy-uridine (BrdU) into the DNA using the BrdU proliferation kit (Roche cat. no. 11444611001) according to the manufacturer's instructions.

Generation of Anti-IL6 Oligoclonics

[0214] The most potent anti-IL6 antibodies are selected from each epitope group. The expression constructs expressing these antibodies are transfected into HEK293T cells in non-competing groups of three in different ratios (1:1:1; 3:1:1; 1:3:1; 1:1:3; 3:3:1; 1:3:3; 3:1:3; 10:1:1; 1:10:1; 1:1:10; 10:10:1; 1:10:10; 10:1:10; 3:10:1; 10:3:1; 1:10:3; 3:1:10; 10:1:3; 1:3:10). Antibody containing supernatants are harvested and purified and characterized as above.

Complex Formation and In Vivo Clearance of Anti-IL6 Oligoclonics

[0215] To measure the ability of anti-IL6 Oligoclonics to form immune complexes and to analyze these complexes Size Exclusion Chromatography (SEC) is used according to the approach disclosed by Min-Soo Kim et al. (2007), *JMB* 374:1374-1388, to characterize the immune-complexes formed with different antibodies to TNFα. Different molar ratios of the anti-IL6 Oligoclonics are mixed with human IL6 and incubated for 20 hours at 4° C. or 25° C. The mixture is analyzed on an HPLC system fitted with a size exclusion column; different elution times are correlated to molecular weight using a molecular weight standards.

[0216] The ability of antibodies to form complexes with IL6 is correlated with their ability to rapidly clear the cytokine from the circulation in vivo. This is confirmed by measuring the clearance of radiolabelled IL6 from mice. Briefly, female, six- to eight-week-old Balb/c mice are obtained and 18 hours before the experiment, the animals are injected intravenously (IV) via the lateral tail vein with different doses of purified anti-IL6 Oligoclonics. On day 0, the mice are injected IV with 50 microliters of radiolabeled IL-6 (1×10E7 cpm/mL) under the same conditions. Blood samples (approximately 50 microliters) are collected at several time intervals and stored at 4° C. The samples are centrifuged for five minutes at 4000×g and the radioactivity of the serum determined. All pharmacokinetic experiments are performed simultaneously with three animals for each treatment.

Generation of Anti-IL6 Oligoclonics Stable Clones and Preclinical Development

[0217] A lead anti-IL6 Oligoclonic is selected based on the in vitro and in vivo potency as determined above. The murine VH genes are humanized according to standard methods and combined with the fully human IGKV1-39 light chain in an expression vector as described above. Examples of humanization methods include those based on paradigms such as resurfacing (E. A. Padlan et al. (1991), *Mol. Immunol.* 28:489), superhumanization (P. Tan, D. A., et al. (2002), *J. Immunol.* 169:1119) and human string content optimization (G. A. Lazar et al. (2007), *Mol. Immunol.* 44:1986). The three constructs are transfected into PER.C6 cells at the predetermined optimal ratio (described above) under the selective pressure of G418 according to standard methods. A stable high producing anti-IL6 Oligoclonic clone is selected and a working and qualified master cell bank generated.

TABLE 1

List of primers

DO-	Primer	Sequence
0012	CH1_ Rev1	TGCCAGGGGGAAGACCGATG (SEQ ID NO: 4)
0656	MVH-1	GCCGGCCATGGCC**GAGGTRMAGCTTCAGGAGTCAGGAC** (SEQ ID NO: 5)
0657	MVH-2	GCCGGCCATGGCC**GAGGTSCAGCTKCAGCAGTCAGGAC** (SEQ ID NO: 6)
0658	MVH-3	GCCGGCCATGGCC**CAGGTGCAGCTGAAGSASTCAGG** (SEQ ID NO: 7)
0659	MVH-4	GCCGGCCATGGCC**GAGGTGCAGCTTCAGGAGTCSGGAC** (SEQ ID NO: 8)
0660	MVH-5	GCCGGCCATGGCC**GARGTCCAGCTGCAACAGTCYGGAC** (SEQ ID NO: 9)
0661	MVH-6	GCCGGCCATGGCC**CAGGTCCAGCTKCAGCAATCTGG** (SEQ ID NO: 10)
0662	MVH-7	GCCGGCCATGGCC**CAGSTBCAGCTGCAGCAGTCTGG** (SEQ ID NO: 11)
0663	MVH-8	GCCGGCCATGGCC**CAGGTYCAGCTGCAGCAGTCTGGRC** (SEQ ID NO: 12)
0664	MVH-9	GCCGGCCATGGCC**CAGGTYCAGCTYCAGCAGTCTGG** (SEQ ID NO: 13)
0665	MVH-10	GCCGGCCATGGCC**GAGGTCCARCTGCAACAATCTGG ACC** (SEQ ID NO: 14)
0666	MVH-11	GCCGGCCATGGCC**CAGGTCCACGTGAAGCAGTCTGGG** (SEQ ID NO: 15)
0667	MVH-12	GCCGGCCATGGCC**GAGGTGAASSTGGTGGAATCTG** (SEQ ID NO: 16)
0668	MVH-13	GCCGGCCATGGCC**GAVGTGAAGYTGGTGGAGTCTG** (SEQ ID NO: 17)
0669	MVH-14	GCCGGCCATGGCC**GAGGTGCAGSKGGTGGAGTCTGGGG** (SEQ ID NO: 18)
0670	MVH-15	GCCGGCCATGGCC**GAKGTGCAMCTGGTGGAGTCTGGG** (SEQ ID NO: 19)
0671	MVH-16	GCCGGCCATGGCC**GAGGTGAAGCTGATGGARTCTGG** (SEQ ID NO: 20)
0672	MVH-17	GCCGGCCATGGCC**GAGGTGCARCTTGTTGAGTCTGGTG** (SEQ ID NO: 21)
0673	MVH-18	GCCGGCCATGGCC**GARGTRAAGCTTCTCGAGTCTGGA** (SEQ ID NO: 22)
0674	MVH-19	GCCGGCCATGGCC**GAAGTGAARSTTGAGGAGTCTGG** (SEQ ID NO: 23)
0675	MVH-20	GCCGGCCATGGCC**GAAGTGATGCTGGTGGAGTCTGGG** (SEQ ID NO: 24)
0676	MVH-21	GCCGGCCATGGCC**CAGGTTACTCTRAAAGWGTSTGGCC** (SEQ ID NO: 25)
0677	MVH-22	GCCGGCCATGGCC**CAGGTCCAACTVCAGCARCCTGG** (SEQ ID NO: 26)

TABLE 1-continued

List of primers

DO-	Primer	Sequence
0678	MVH-23	GCCGGCCATGGCC**CAGGTYCARCTGCAGCAGTCTG** (SEQ ID NO: 27)
0679	MVH-24	GCCGGCCATGGCC**GATGTGAACTTGGAAGTGTCTGG** (SEQ ID NO: 28)
0680	MVH-25	GCCGGCCATGGCC**GAGGTGAAGGTCATCGAGTCTGG** (SEQ ID NO: 29)
0681	ExtMVH-1	CAGTCACAGATCCTCGCGAATT*GGCCCA**GCCGGCC*** **ATGGCCSANG** (SEQ ID NO: 30)
0682	ExtMVH-2	CAGTCACAGATCCTCGCGAATT*GGCCCA**GCCGGCC*** **ATGGCCSANC** (SEQ ID NO: 31)
0683	MJH-Rev1	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACC*** **GTGG** (SEQ ID NO: 32)
0684	MJH-Rev2	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***TGTGAGA*** **GTGG** (SEQ ID NO: 33)
0685	MJH-Rev3	GGGGGTGTCGT**TTTGGCTGCAGAGAC** ***AGTGACC*** **AGAG** (SEQ ID NO: 34)
0686	MJH-Rev4	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACT*** **GAGG** (SEQ ID NO: 35)
0687	ExtMJH-Rev1 &	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACC*** **GTGG** (SEQ ID NO: 36)
0688	ExtMJH-Rev2in	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACA*** **GTGG** (SEQ ID NO: 37)
0690	ExtMJH-Rev3	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACC*** **AGAG** (SEQ ID NO: 38)
0691	ExtMJH-Rev4	GGGGGTGTCGT**TTTGGCTGAGGAGAC** ***GGTGACC*** **GAGG** (SEQ ID NO: 39)

TABLE 2

Phage ELISA signal levels as measured at 450 nm. TT-coated plates represent plates that were coated with tetanus toxoid. Thyroglobulin-coated plates are used as negative controls. 10/10 and 15/15 indicate the number of wash steps with PBS-Tween during panning procedures. The 10/10 tetanus toxoid and 10/10 thyroglobulin plates and the 15/15 tetanus toxoid and 15/15 thyroglobulin plates are duplicates from each other except for the coating agent. OD values higher than three times the background are assumed specific.

	1	2	3	4	5	6	7	8	9	10	11	12
TT-coated plate 10/10 washings												
A	0.139	0.093	0.089	0.121	0.117	0.598	0.146	0.115	0.18	0.155	0.543	0.601
B	0.136	0.404	0.159	0.187	0.489	0.134	0.216	0.092	0.222	0.108	0.181	0.484
C	0.197	0.526	0.09	0.213	0.395	0.155	0.108	0.12	0.183	0.136	0.092	0.866
D	0.143	0.258	0.101	0.422	0.088	0.243	0.485	0.251	0.304	0.198	0.478	0.091
E	0.445	0.169	0.526	0.481	0.206	0.285	0.111	0.119	0.128	0.2	0.118	0.098
F	0.237	0.291	0.594	0.139	0.206	0.565	0.543	0.091	0.136	0.227	0.228	0.099
G	0.459	0.102	0.152	0.659	0.203	0.452	0.152	0.133	0.094	0.102	0.375	0.098
H	0.341	0.623	0.745	0.415	0.682	0.527	0.655	0.114	0.258	0.284	0.685	0.113
TT-coated plate 15/15 washings												
A	0.247	0.582	0.421	0.428	0.133	0.082	0.262	0.079	0.343	0.414	0.095	0.292
B	0.065	0.364	0.073	0.042	0.049	0.071	0.046	0.103	0.078	0.057	0.048	0.155
C	0.081	0.044	0.066	0.082	0.225	0.444	0.203	0.362	0.122	0.047	0.052	0.309
D	0.092	0.11	0.59	0.22	0.33	0.544	0.058	0.159	0.047	0.174	0.086	0.05
E	0.469	0.577	0.206	0.304	0.13	0.749	0.431	0.062	0.167	0.049	0.056	0.049
F	0.846	0.07	0.561	0.656	0.882	0.094	0.383	0.13	0.152	0.098	0.134	0.048
G	0.537	0.052	0.49	0.105	0.337	0.193	0.514	0.294	0.068	0.35	0.525	0.05
H	0.061	0.306	0.157	0.853	0.054	0.534	0.102	0.235	0.441	0.412	0.565	0.061
Thyroglobulin-coated plate 10/10 washings												
A	0.047	0.051	0.045	0.043	0.051	0.044	0.046	0.042	0.047	0.048	0.049	0.05
B	0.042	0.042	0.042	0.042	0.043	0.041	0.041	0.042	0.043	0.045	0.042	0.046
C	0.044	0.043	0.043	0.044	0.043	0.044	0.043	0.042	0.043	0.041	0.044	0.046
D	0.045	0.044	0.044	0.044	0.045	0.046	0.045	0.056	0.045	0.049	0.048	0.73
E	0.046	0.045	0.046	0.044	0.045	0.044	0.044	0.044	0.047	0.046	0.047	0.926
F	0.048	0.045	0.044	0.046	0.044	0.043	0.044	0.046	0.046	0.046	0.046	0.792
G	0.051	0.048	0.045	0.045	0.044	0.043	0.048	0.045	0.048	0.051	0.045	0.053
H	0.064	0.05	0.049	0.047	0.05	0.051	0.047	0.046	0.047	0.047	0.047	0.056
Thyroglobulin-coated plate 15/15 washings												
A	0.036	0.049	0.045	0.044	0.046	0.047	0.046	0.042	0.042	0.043	0.042	0.041
B	0.045	0.042	0.041	0.043	0.043	0.043	0.045	0.045	0.047	0.048	0.044	0.045
C	0.049	0.047	0.047	0.046	0.046	0.046	0.045	0.047	0.046	0.045	0.045	0.052
D	0.047	0.049	0.048	0.048	0.048	0.048	0.047	0.052	0.048	0.046	0.048	0.456
E	0.049	0.047	0.047	0.047	0.047	0.049	0.047	0.048	0.047	0.046	0.048	0.412
F	0.05	0.047	0.046	0.046	0.046	0.046	0.046	0.046	0.046	0.047	0.048	0.528
G	0.05	0.048	0.045	0.045	0.046	0.049	0.048	0.046	0.053	0.049	0.05	0.057
H	0.057	0.05	0.046	0.045	0.047	0.049	0.047	0.047	0.046	0.047	0.053	0.048

TABLE 3

Protein sequence analysis of ELISA positive tetanus toxoid binders. CDR3 sequence, CDR3 length, VH family members and specific name, JH origin and DH origin of the clones is indicated.

CDR3/SEQ ID NO:	CDR3 length	VH	DH	JH	V Gene family
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183

TABLE 3-continued

Protein sequence analysis of ELISA positive tetanus toxoid binders. CDR3 sequence, CDR3 length, VH family members and specific name, JH origin and DH origin of the clones is indicated.

CDR3/SEQ ID NO:	CDR3 length	VH	DH	JH	V Gene family
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183

TABLE 3-continued

Protein sequence analysis of ELISA positive tetanus toxoid binders. CDR3 sequence, CDR3 length, VH family members and specific name, JH origin and DH origin of the clones is indicated.

CDR3/SEQ ID NO:	CDR3 length	VH	DH	JH	V Gene family
HGAYYTYDEKAWFAY (SEQ ID NO: 40)	15	musIGHV 192	DSP2.11	JH3 mouse	VH7183
HGAFYTYDEKPWFAY (SEQ ID NO: 41)	15	musIGHV 192	IGHD2-14*01	JH3 mouse	VH7183
HISYYRYDEEVSFAY (SEQ ID NO: 42)	15	musIGHV 192	IGHD2-14*01	JH3 mouse	VH7183
HISYYRYDEEVSFAY (SEQ ID NO: 42)	15	musIGHV 192	IGHD2-14*01	JH3 mouse	VH7183
GWRAFAY (SEQ ID NO: 43)	7	musIGHV 131	DSP2.9	JH3 mouse	VH7183
GWRAFAY (SEQ ID NO: 43)	7	musIGHV 131	DSP2.9	JH3 mouse	VH7183
GWRAFAY (SEQ ID NO: 43)	7	musIGHV 131	DSP2.9	JH3 mouse	VH7183
DRGNYYGMDY (SEQ ID NO: 44)	10	musIGHV 178	DSP2.1	JH4 mouse	VH7183
LGDYYVDWFFAV (SEQ ID NO: 45)	12	musIGHV 165	DFL16.1	JH1 mouse	VH7183

TABLE 3-continued

Protein sequence analysis of ELISA positive tetanus toxoid binders. CDR3 sequence, CDR3 length, VH family members and specific name, JH origin and DH origin of the clones is indicated.

CDR3/SEQ ID NO:	CDR3 length	VH	DH	JH	V Gene family
SFTPVPFYYGYDWYF DV (SEQ ID NO: 47)	17	musIGHV 532	DSP2.3	JH1 mouse	VJH558
SFTPVPFYYGYDWYF DV (SEQ ID NO: 47)	17	musIGHV 532	DSP2.3	JH1 mouse	VJH558
SDYDWYFDV (SEQ ID NO: 48)	9	musIGHV 286	DSP2.2	JH1 mouse	VJH558
SDYDWYFDV (SEQ ID NO: 48)	9	musIGHV 286	DSP2.2	JH1 mouse	VJH558
DSKWAYYFDY (SEQ ID NO: 49)	10	musIGHV 532	DST4.3	JH2 mouse	VJH558
GDYTGYGMDY (SEQ ID NO: 50)	10	musIGHV 125	DSP2.13	JH4 mouse	VHSM7
GDYTGYGMDY (SEQ ID NO: 50)	10	musIGHV 125	DSP2.13	JH4 mouse	VHSM7
GGYDGYWFPY (SEQ ID NO: 51)	10	musIGHV 125	DSP2.9	JH3 mouse	VHSM7

TABLE 4

Vector combinations that were transfected to HEK293T.

Code	HC vector	LC vector	Combined vector	Prep name	Conc. (μg/ml)
A	x	0817676_pSELECT_0815426 (IGKV1-39)	x	PIGKV1-39/P1	—
B	x	0817678_pSELECT_0815427 (IGLV2-14)	x	PIGLV2-14/P1	—
C	MV1110	0817676_pSELECT_0815426 (IGKV1-39)	x	PMV1110/IGKV1-39/P1	11.0
D	MV1110	0817678_pSELECT_0815427 (IGLV2-14)	x	PMV1110/IGLV2-14/P1	15.4
E	x	x	MG1494	MG1494/P2	16.1

TABLE 3-continued

Protein sequence analysis of ELISA positive tetanus toxoid binders. CDR3 sequence, CDR3 length, VH family members and specific name, JH origin and DH origin of the clones is indicated.

CDR3/SEQ ID NO:	CDR3 length	VH	DH	JH	V Gene family
NFPAWFAF (SEQ ID NO: 46)	8	musIGHV 547	DST4.3 inv	JH3 mouse	VJH558
NFPAWFAY (SEQ ID NO: 46)	8	musIGHV 547	DSP2.1	JH3 mouse	VJH558
NFPAWFVY (SEQ ID NO: 46)	8	musIGHV 547	DSP2.1	JH3 mouse	VJH558

TABLE 5

HLA allotypes considered in T_H-epitope profiling. The corresponding serotypes are shown, as well as allotype frequencies in the Caucasian population (Klitz et al. (2003), *Tissue Antigens* 62: 296-307; Gjertson and Terasake (eds) in: HLA 1997; Gjertson and Terasake (eds) in: HLA 1998; Castelli et al. (2002), *J. Immunol.* 169: 6928-6934). Frequencies can add up to more than 100% since each individual has two alleles for each gene. If all allele frequencies of a single gene were known, they would add up to slightly less than 200% due to homozygous individuals.

HLA type	Serotype	Population %
DRB1*0101	DR1	17.4
DRB1*0102	DR1	4.9
DRB1*0301	DR17(3)	21.2
DRB1*0401	DR4	11.5
DEB1*0402	DR4	3.1
DRB1*0404	DR4	5.5
DRB1*0405	DR4	2.2

TABLE 5-continued

HLA allotypes considered in T_H-epitope profiling. The corresponding serotypes are shown, as well as allotype frequencies in the Caucasian population (Klitz et al. (2003), *Tissue Antigens* 62: 296-307; Gjertson and Terasake (eds) in: HLA 1997; Gjertson and Terasake (eds) in: HLA 1998; Castelli et al. (2002), *J. Immunol.* 169: 6928-6934). Frequencies can add up to more than 100% since each individual has two alleles for each gene. If all allele frequencies of a single gene were known, they would add up to slightly less than 200% due to homozygous individuals.

HLA type	Serotype	Population %
DRB1*0407	DR4	<2
DRB1*0701	DR7	23.4
DRB1*0801	DR8	3.3
DRB1*0802	DR8	<2
DRB1*0901	DR9	<2
DRB1*1101	DR11(5)	17
DRB1*1104	DR11(5)	5.7
DRB1*1201	DR12(5)	3.1
DRB1*1301	DR13(6)	15.4
DRB1*1302	DR13(6)	10.8
DRB1*1401	DR14(6)	4.2
DRB1*1501	DR15(2)	13.2
DRB1*1601	DR16(2)	5.5
DRB3*0101	DR52	24.6
DRB3*0202	DR52	43
DRB3*0301	DR52	10
DRB4*0101	DR53	25.5
DRB4*0103	DR53	21
DRB5*0101	DR51	15.8
DRB5*0202	DR51	5.7
DQA1*0101/DQB1*0501	DQ5(1)	20.5
DQA1*0102/DQB1*0502	DQ5(1)	2.6
DQA1*0102/DQB1*0602	DQ6(1)	26.5
DQA1*0102/DQB1*0604	DQ6(1)	6.7
DQA1*0103/DQB1*0603	DQ6(1)	11
DQA1*0104/DQB1*0503	DQ5(1)	4
DQA1*0201/DQB1*0202	DQ2	20.9
DQA1*0201/DQB1*0303	DQ9(3)	7.2
DQA1*0301/DQB1*0301	DQ7(3)	12.5
DQA1*0301/DQB1*0302	DQ8(3)	18.3
DQA1*0401/DQB1*0402	DQ4	4.5
DQA1*0501/DQB1*0201	DQ2	24.6
DQA1*0501/DQB1*0301	DQ7(3)	20.9
DPA1*0103/DPB1*0201	DPw2	19.9
DPA1*0103/DPB1*0401	DPw4	65.1
DPA1*0103/DPB1*0402	DPw4	24.3
DPA1*0201/DPB1*0101	DPw1	6.3
DPA1*0201/DPB1*0301	DPw3	<2
DPA1*0201/DPB1*0501	DPw5	<2
DPA1*0201/DPB1*0901	—	2.4

TABLE 7

Mapping of Epibase ® predictions for Merus IGKV1-39 in the classical 15-mer peptide format. This table shows the allotype count of critical epitopes (SEQ ID NOs: 52-83) and implicated serotypes for each of the 15-mers spanning the Merus IGKV1-39 sequence.

15mer	Start Position	15-mer sequence	Allotype count	Implicated serotypes
1	1	DIQMTQSPSSLSASV	6	DR1, DR4, DR7, DR9
2	4	MTQSPSSLSASVGDR	5	DR1, DR4, DR9
3	7	SPSSLSASVGDRVTI	0	
4	10	SLSASVGDRVTITCR	0	
5	13	ASVGDRVTITCRASQ	0	
6	16	GDRVTITCRASQSIS	2	DR11(5), DR7
7	19	VTITCRASQSISSYL	4	DQ2, DR11(5), DR4, DR7
8	22	TCRASQSISSYLNWY	2	DQ2, DR4
9	25	ASQSISSYLNWYQQK	5	DR13(6), DR15(2), DR4
10	28	SISSYLNWYQQKPGK	8	DR12(5), DR13(6), DR15(2), DR16(2), DR4, DR8
11	31	SYLNWYQQKPGKAPK	10	DR1, DR12(5), DR16(2), DR4, DR51, DR8
12	34	NWYQQKPGKAPKLLI	9	DR1, DR15(2), DR4, DR51, DR8
13	37	QQKPGKAPKLLIYAA	7	DQ4, DR1, DR11(5), DR15(2), DR51, DR8
14	40	PGKAPKLLIYAASSL	7	DQ4, DR1, DR11(5), DR4, DR8
15	43	APKLLIYAASSLQSG	15	DR1, DR11(5), DR12(5), DR13(6), DR14(6), DR15(2), DR4, DR51, DR8, DR9

TABLE 6

T_H epitope counts for IGKV1-39. Peptides binding to multiple HLAs of the same group (DRB1, DRB3/4/5, DP, DQ) are counted as one. Values between brackets refer to germline-filtered peptides.

	DRB1		DRB3/4/5		DQ		DP	
	Strong	Medium	Strong	Medium	Strong	Medium	Strong	Medium
Merus IGKV1-39	0 (+6)	0 (+16)	0 (+0)	0 (+5)	0 (+3)	0 (+9)	0 (+0)	0 (+9)

TABLE 7-continued

Mapping of Epibase ® predictions for Merus IGKV1-39 in the classical 15-mer peptide format. This table shows the allotype count of critical epitopes (SEQ ID NOs: 52-83) and implicated serotypes for each of the 15-mers spanning the Merus IGKV1-39 sequence.

15mer	Start Position	15-mer sequence	Allotype count	Implicated serotypes
16	46	LLIYAASSLQSGVPS	15	DR1, DR11(5), DR12(5), DR13(6), DR14(6), DR15(2), DR4, DR51, DR8, DR9
17	49	YAASSLQSGVPSRFS	1	DR15(2)
18	52	SSLQSGVPSRFSGSG	1	DR15(2)
19	55	QSGVPSRFSGSGSGT	0	
20	58	VPSRFSGSGSGTDFT	0	
21	61	RFSGSGSGTDFTLTI	0	
22	64	GSGSGTDFTLTISSL	1	DR52
23	67	SGTDFTLTISSLQPE	4	DR4, DR52, DR7, DR9
24	70	DFTLTISSLQPEDFA	4	DQ2, DR4, DR7, DR9
25	73	LTISSLQPEDFATYY	1	DQ2
26	76	SSLQPEDFATYYCQQ	0	
27	79	QPEDFATYYCQQSYS	1	DR4
28	82	DFATYYCQQSYSTPP	5	DR4, DR51, DR7
29	85	TYYCQQSYSTPPTFG	4	DR4, DR51, DR7
30	88	CQQSYSTPPTFGQGT	0	
31	91	SYSTPPTFGQGTKVE	0	
32	94	TPPTFGQGTKVEIK	0	

TABLE 8

The V_H gene from PG1433 paired with various light chain genes with differing rates of amino acid mutation were compared for production levels with the original clone containing the IGKV1-39 gene.

IgG name	Light chain gene	Number of amino acid mutations	concentration (μg/ml)
PG1433	1-39	0	63, 45.5, 38.6 (avg = 49)
PG1631	1-12	4	10.5
PG1632	1-27	7	9.3
PG1634	1D-12	10	10.8
PG1635	1D-33	6	10.2
PG1642	1-5	8	7.1
PG1644	1-9	3	7.8
PG1650	1D-39	3	9.1
PG1652	2D-28	3	7.1
PG1653	3-15	14	7
PG1654	3-20	2	5.2
PG1674	1-40	7	8.2
PG1678	2-11	2	8.1
PG1680	2-14	15	10.8
PG1682	3-1	13	9.9
PG1683	6-57	6	13.9

TABLE 9

Numbers of lymphocytes harvested from the bone marrow and spleen of wild-type and transgenic mice

	*10e6/ml cells	total vol (ml)	total cells $*10^6$
Bone Marrow			
Wt	18.82	5.05	95.0
Wt	19.24	4.96	95.4
CD19-Cre	23.42	5.08	119.0
CD19-Cre	20.58	4.82	99.2
CD19-Cre	25.77	5.15	132.7
CD19-Cre/HuVk1	17.71	5.06	89.6
CD19-Cre/HuVk1	12.60	5.33	67.2
CD19-Cre/HuVk1	18.13	5.27	95.5
Spleen			
Wt	41.70	5.36	223.5
Wt	37.85	4.71	178.3
CD19-Cre	60.19	3.77	226.9
CD19-Cre	35.06	3.66	128.3
CD19-Cre	80.69	4.60	371.2
CD19-Cre/HuVk1	51.67	4.48	231.5
CD19-Cre/HuVk1	58.80	6.24	366.9
CD19-Cre/HuVk1	24.37	6.25	152.3

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 102

<210> SEQ ID NO 1
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 1

ccctttccaa tctttatggg 20

-continued

<210> SEQ ID NO 2
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 2

aggtggattg gtgtcttttt ctc 23

<210> SEQ ID NO 3
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 3

gtcatgtcgg cgaccctacg cc 22

<210> SEQ ID NO 4
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 4

tgccaggggg aagaccgatg 20

<210> SEQ ID NO 5
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 5

gccggccatg gccgaggtrm agcttcagga gtcaggac 38

<210> SEQ ID NO 6
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 6

gccggccatg gccgaggtsc agctkcagca gtcaggac 38

<210> SEQ ID NO 7
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

gccggccatg gcccaggtgc agctgaagsa stcagg 36

<210> SEQ ID NO 8
<211> LENGTH: 38
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 8

gccggccatg gccgaggtgc agcttcagga gtcsggac 38

<210> SEQ ID NO 9
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 9

gccggccatg gccgargtcc agctgcaaca gtcyggac 38

<210> SEQ ID NO 10
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 10

gccggccatg gcccaggtcc agctkcagca atctgg 36

<210> SEQ ID NO 11
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 11

gccggccatg gcccagstbc agctgcagca gtctgg 36

<210> SEQ ID NO 12
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 12

gccggccatg gcccaggtyc agctgcagca gtctggrc 38

<210> SEQ ID NO 13
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

gccggccatg gcccaggtyc agctycagca gtctgg 36

<210> SEQ ID NO 14
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

-continued

<400> SEQUENCE: 14

gccggccatg gccgaggtcc arctgcaaca atctggacc 39

<210> SEQ ID NO 15
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 15

gccggccatg gcccaggtcc acgtgaagca gtctggg 37

<210> SEQ ID NO 16
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 16

gccggccatg gccgaggtga asstggtgga atctg 35

<210> SEQ ID NO 17
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 17

gccggccatg gccgavgtga agytggtgga gtctg 35

<210> SEQ ID NO 18
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 18

gccggccatg gccgaggtgc agskggtgga gtctgggg 38

<210> SEQ ID NO 19
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 19

gccggccatg gccgakgtgc amctggtgga gtctggg 37

<210> SEQ ID NO 20
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 20

gccggccatg gccgaggtga agctgatgga rtctgg 36

-continued

<210> SEQ ID NO 21
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 21

gccggccatg gccgaggtgc arcttgttga gtctggtg 38

<210> SEQ ID NO 22
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 22

gccggccatg gccgargtra agcttctcga gtctgga 37

<210> SEQ ID NO 23
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 23

gccggccatg gccgaagtga arsttgagga gtctgg 36

<210> SEQ ID NO 24
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 24

gccggccatg gccgaagtga tgctggtgga gtctggg 37

<210> SEQ ID NO 25
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 25

gccggccatg gcccaggtta ctctraaagw gtstggcc 38

<210> SEQ ID NO 26
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 26

gccggccatg gcccaggtcc aactvcagca rcctgg 36

<210> SEQ ID NO 27
<211> LENGTH: 35
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 27

gccggccatg gcccaggtyc arctgcagca gtctg 35

<210> SEQ ID NO 28
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 28

gccggccatg gccgatgtga acttggaagt gtctgg 36

<210> SEQ ID NO 29
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 29

gccggccatg gccgaggtga aggtcatcga gtctgg 36

<210> SEQ ID NO 30
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (44)..(44)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 30

cagtcacaga tcctcgcgaa ttggcccagc cggccatggc csang 45

<210> SEQ ID NO 31
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (44)..(44)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 31

cagtcacaga tcctcgcgaa ttggcccagc cggccatggc csanc 45

<210> SEQ ID NO 32
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 32

gggggtgtcg ttttggctga ggagacggtg accgtgg 37

-continued

<210> SEQ ID NO 33
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 33

gggggtgtcg ttttggctga ggagactgtg agagtgg 37

<210> SEQ ID NO 34
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 34

gggggtgtcg ttttggctgc agagacagtg accagag 37

<210> SEQ ID NO 35
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 35

gggggtgtcg ttttggctga ggagacggtg actgagg 37

<210> SEQ ID NO 36
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 36

gggggtgtcg ttttggctga ggagacggtg accgtgg 37

<210> SEQ ID NO 37
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 37

gggggtgtcg ttttggctga ggagacggtg acagtgg 37

<210> SEQ ID NO 38
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 38

gggggtgtcg ttttggctga ggagacggtg accagag 37

<210> SEQ ID NO 39
<211> LENGTH: 37
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 39

ggggggtgtcg ttttggctga ggagacggtg accgagg 37

<210> SEQ ID NO 40
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 40

His Gly Ala Tyr Tyr Thr Tyr Asp Glu Lys Ala Trp Phe Ala Tyr
1 5 10 15

<210> SEQ ID NO 41
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 41

His Gly Ala Phe Tyr Thr Tyr Asp Glu Lys Pro Trp Phe Ala Tyr
1 5 10 15

<210> SEQ ID NO 42
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 42

His Ile Ser Tyr Tyr Arg Tyr Asp Glu Glu Val Ser Phe Ala Tyr
1 5 10 15

<210> SEQ ID NO 43
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 43

Gly Trp Arg Ala Phe Ala Tyr
1 5

<210> SEQ ID NO 44
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 44

Asp Arg Gly Asn Tyr Tyr Gly Met Asp Tyr
1 5 10

<210> SEQ ID NO 45
<211> LENGTH: 12

-continued

<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 45

Leu Gly Asp Tyr Tyr Val Asp Trp Phe Phe Ala Val
1 5 10

<210> SEQ ID NO 46
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 46

Asn Phe Pro Ala Trp Phe Ala Phe
1 5

<210> SEQ ID NO 47
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 47

Ser Phe Thr Pro Val Pro Phe Tyr Tyr Gly Tyr Asp Trp Tyr Phe Asp
1 5 10 15

Val

<210> SEQ ID NO 48
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 48

Ser Asp Tyr Asp Trp Tyr Phe Asp Val
1 5

<210> SEQ ID NO 49
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 49

Asp Ser Lys Trp Ala Tyr Tyr Phe Asp Tyr
1 5 10

<210> SEQ ID NO 50
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 50

Gly Asp Tyr Thr Gly Tyr Gly Met Asp Tyr
1 5 10

-continued

<210> SEQ ID NO 51
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR3

<400> SEQUENCE: 51

Gly Gly Tyr Asp Gly Tyr Trp Phe Pro Tyr
1 5 10

<210> SEQ ID NO 52
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: epitope IGKV1-39

<400> SEQUENCE: 52

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
1 5 10 15

<210> SEQ ID NO 53
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: epitope IGKV1-39

<400> SEQUENCE: 53

Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg
1 5 10 15

<210> SEQ ID NO 54
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: epitope IGKV1-39

<400> SEQUENCE: 54

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile
1 5 10 15

<210> SEQ ID NO 55
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: epitope IGKV1-39

<400> SEQUENCE: 55

Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
1 5 10 15

<210> SEQ ID NO 56
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 56

-continued

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
1 5 10 15

<210> SEQ ID NO 57
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 57

Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser
1 5 10 15

<210> SEQ ID NO 58
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 58

Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu
1 5 10 15

<210> SEQ ID NO 59
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 59

Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr
1 5 10 15

<210> SEQ ID NO 60
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 60

Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys
1 5 10 15

<210> SEQ ID NO 61
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 61

Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
1 5 10 15

<210> SEQ ID NO 62
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

-continued

<400> SEQUENCE: 62

Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
1 5 10 15

<210> SEQ ID NO 63
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 63

Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
1 5 10 15

<210> SEQ ID NO 64
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 64

Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala
1 5 10 15

<210> SEQ ID NO 65
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 65

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu
1 5 10 15

<210> SEQ ID NO 66
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 66

Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly
1 5 10 15

<210> SEQ ID NO 67
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 67

Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
1 5 10 15

<210> SEQ ID NO 68
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 68

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
1 5 10 15

<210> SEQ ID NO 69
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 69

Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly
1 5 10 15

<210> SEQ ID NO 70
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 70

Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
1 5 10 15

<210> SEQ ID NO 71
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 71

Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

<210> SEQ ID NO 72
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 72

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
1 5 10 15

<210> SEQ ID NO 73
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 73

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
1 5 10 15

<210> SEQ ID NO 74
<211> LENGTH: 15
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 74

Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
1 5 10 15

<210> SEQ ID NO 75
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 75

Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala
1 5 10 15

<210> SEQ ID NO 76
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 76

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
1 5 10 15

<210> SEQ ID NO 77
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 77

Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
1 5 10 15

<210> SEQ ID NO 78
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 78

Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser
1 5 10 15

<210> SEQ ID NO 79
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 79

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
1 5 10 15

<210> SEQ ID NO 80

-continued

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 80

Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly
1 5 10 15

<210> SEQ ID NO 81
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 81

Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr
1 5 10 15

<210> SEQ ID NO 82
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 82

Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu
1 5 10 15

<210> SEQ ID NO 83
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope IGKV1-39

<400> SEQUENCE: 83

Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> SEQ ID NO 84
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(321)

<400> SEQUENCE: 84

gac atc cag atg acc cag agc ccc agc agc ctg agc gcc agc gtg ggc 48
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

gac aga gtg acc atc acc tgc aga gcc agc cag agc atc agc agc tac 96
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

ctg aac tgg tat cag cag aag ccc ggc aag gcc ccc aag ctg ctg atc 144
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

tac gcc gcc agc tcc ctg cag agc ggc gtg ccc agc aga ttc agc ggc 192
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

-continued

```
agc ggc tcc ggc acc gac ttc acc ctg acc atc agc agc ctg cag ccc      240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80

gag gac ttc gcc acc tac tac tgc cag cag agc tac agc acc ccc ccc      288
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
                85                  90                  95

acc ttc ggc cag ggc acc aag gtg gag atc aag                          321
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
            100                 105


<210> SEQ ID NO 85
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 85

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
            20                  25                  30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
        35                  40                  45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
                85                  90                  95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
            100                 105


<210> SEQ ID NO 86
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(330)

<400> SEQUENCE: 86

cag tct gcc ctg acc cag ccc gcc tct gtg tct ggc agc cct ggc cag       48
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1               5                   10                  15

agc atc acc atc agc tgc acc ggc acc agc agc gac gtg ggc ggc tac       96
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
            20                  25                  30

aac tac gtg tcc tgg tat cag cag cac ccc ggc aag gcc ccc aag ctg      144
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
        35                  40                  45

atg atc tac gag gtg tcc aac aga ccc agc ggc gtg agc aac aga ttc      192
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
    50                  55                  60

agc ggc agc aag agc ggc aac acc gcc agc ctg acc atc agc ggc ctc      240
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65                  70                  75                  80

cag gct gag gac gag gcc gac tac tac tgc agc agc tac acc agc agc      288
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
                85                  90                  95
```

-continued

```
tcc acc ctg gtg ttt ggc ggc gga aca aag ctg acc gtg ctg            330
Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105                 110


<210> SEQ ID NO 87
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 87

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1               5                   10                  15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
            20                  25                  30

Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
        35                  40                  45

Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
    50                  55                  60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65                  70                  75                  80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
                85                  90                  95

Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
            100                 105                 110


<210> SEQ ID NO 88
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Rattus norvegicus
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(321)

<400> SEQUENCE: 88

aga gcc gac gcc gct ccc acc gtg tcc atc ttc ccc ccc agc atg gaa       48
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Met Glu
1               5                   10                  15

cag ctg acc tct ggc gga gcc acc gtg gtc tgc ttc gtg aac aac ttc       96
Gln Leu Thr Ser Gly Gly Ala Thr Val Val Cys Phe Val Asn Asn Phe
            20                  25                  30

tac ccc aga gac atc agc gtg aag tgg aag atc gac ggc agc gag cag      144
Tyr Pro Arg Asp Ile Ser Val Lys Trp Lys Ile Asp Gly Ser Glu Gln
        35                  40                  45

agg gac ggc gtg ctg gac agc gtg acc gac cag gac agc aag gac tcc      192
Arg Asp Gly Val Leu Asp Ser Val Thr Asp Gln Asp Ser Lys Asp Ser
    50                  55                  60

acc tac agc atg agc agc acc ctg agc ctg acc aag gtg gag tac gag      240
Thr Tyr Ser Met Ser Ser Thr Leu Ser Leu Thr Lys Val Glu Tyr Glu
65                  70                  75                  80

agg cac aac ctg tac acc tgc gag gtg gtg cac aag acc agc tcc agc      288
Arg His Asn Leu Tyr Thr Cys Glu Val Val His Lys Thr Ser Ser Ser
                85                  90                  95

ccc gtg gtc aag tcc ttc aac cgg aac gag tgt                          321
Pro Val Val Lys Ser Phe Asn Arg Asn Glu Cys
            100                 105


<210> SEQ ID NO 89
<211> LENGTH: 107
```

-continued

<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE: 89

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Met Glu
1 5 10 15

Gln Leu Thr Ser Gly Gly Ala Thr Val Val Cys Phe Val Asn Asn Phe
20 25 30

Tyr Pro Arg Asp Ile Ser Val Lys Trp Lys Ile Asp Gly Ser Glu Gln
35 40 45

Arg Asp Gly Val Leu Asp Ser Val Thr Asp Gln Asp Ser Lys Asp Ser
50 55 60

Thr Tyr Ser Met Ser Ser Thr Leu Ser Leu Thr Lys Val Glu Tyr Glu
65 70 75 80

Arg His Asn Leu Tyr Thr Cys Glu Val Val His Lys Thr Ser Ser Ser
85 90 95

Pro Val Val Lys Ser Phe Asn Arg Asn Glu Cys
100 105

<210> SEQ ID NO 90
<211> LENGTH: 865
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: IGKV1-39/J-Ck

<400> SEQUENCE: 90

ggtaccgcgg ccgccaccat ggacatgaga gtgcccgccc agctcctggg gctcctgcta 60

ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt gtgctcagta 120

ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa tatttgtttt 180

tatgtttcca atctcaggtg ccagatgtga catccagatg acccagagcc ccagcagcct 240

gagcgccagc gtgggcgaca gagtgaccat cacctgcaga gccagccaga gcatcagcag 300

ctacctgaac tggtatcagc agaagcccgg caaggccccc aagctgctga tctacgccgc 360

cagctccctg cagagcggcg tgcccagcag attcagcggc agcggctccg gcaccgactt 420

caccctgacc atcagcagcc tgcagcccga ggacttcgcc acctactact gccagcagag 480

ctacagcacc ccccccacct tcggccaggg caccaaggtg gagatcaaga gagccgacgc 540

cgctcccacc gtgtccatct tcccccccag catggaacag ctgacctctg gcggagccac 600

cgtggtctgc ttcgtgaaca acttctaccc cagagacatc agcgtgaagt ggaagatcga 660

cggcagcgag cagagggacg gcgtgctgga cagcgtgacc gaccaggaca gcaaggactc 720

cacctacagc atgagcagca ccctgagcct gaccaaggtg gagtacgaga ggcacaacct 780

gtacacctgc gaggtggtgc acaagaccag ctccagcccc gtggtcaagt ccttcaaccg 840

gaacgagtgt tgagctagcg agctc 865

<210> SEQ ID NO 91
<211> LENGTH: 874
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: IGLV2-14/J-Ck

<400> SEQUENCE: 91

-continued

ggtaccgcgg ccgccaccat ggacatgaga gtgcccgccc agctcctggg gctcctgcta 60

ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt gtgctcagta 120

ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa tatttgtttt 180

tatgtttcca atctcaggtg ccagatgtca gtctgccctg acccagcccg cctctgtgtc 240

tggcagccct ggccagagca tcaccatcag ctgcaccggc accagcagcg acgtgggcgg 300

ctacaactac gtgtcctggt atcagcagca ccccggcaag gcccccaagc tgatgatcta 360

cgaggtgtcc aacagaccca gcggcgtgag caacagattc agcggcagca agagcggcaa 420

caccgccagc ctgaccatca gcggcctcca ggctgaggac gaggccgact actactgcag 480

cagctacacc agcagctcca ccctggtgtt tggcggcgga acaaagctga ccgtgctgag 540

agccgacgcc gctcccaccg tgtccatctt ccccccccagc atggaacagc tgacctctgg 600

cggagccacc gtggtctgct tcgtgaacaa cttctacccc agagacatca gcgtgaagtg 660

gaagatcgac ggcagcgagc agagggacgg cgtgctggac agcgtgaccg accaggacag 720

caaggactcc acctacagca tgagcagcac cctgagcctg accaaggtgg agtacgagag 780

gcacaacctg tacacctgcg aggtggtgca caagaccagc tccagccccg tggtcaagtc 840

cttcaaccgg aacgagtgtt gagctagcga gctc 874

<210> SEQ ID NO 92
<211> LENGTH: 13373
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VkP-IGKV1-39/J-Ck

<400> SEQUENCE: 92

ggccggccca catgaaacaa tgggaaccat gtgacaatca cagaggtgtt gttactatag 60

caaaagggat tgttactctc cacatccctt taagtaactt gaaggcctga tagacccacc 120

ctctaagact tcattagaca ttccctacga atggttatac tctcctgtat actcccaata 180

caactctaaa atatattatt ccatatagtc cttaggtttg tattaaagtt tgacttttt 240

ccttcaaaat atctcttgtc acaacagcgg ctctagagag aaatacattc cctccaggca 300

aatctatgct gcgctggtct gacctgggac cctggggaca ttgcccctgt gctgagttac 360

taagatgagc cagccctgca gctgtgctca gcctgcccca tgccctgctg attgatttgc 420

atgttccaga gcacagcccc ctgccctgaa gacttttta tgggctggtc gcaccctgtg 480

caggagtcag tctcagtcag gagccaccat ggacatgaga gtgcccgccc agctcctggg 540

gctcctgcta ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt 600

gtgctcagta ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa 660

tatttgtttt tatgtttcca atctcaggtg ccagatgtga catccagatg acccagagcc 720

ccagcagcct gagcgccagc gtgggcgaca gagtgaccat cacctgcaga gccagccaga 780

gcatcagcag ctacctgaac tggtatcagc agaagcccgg caaggccccc aagctgctga 840

tctacgccgc cagctccctg cagagcggcg tgcccagcag attcagcggc agcggctccg 900

gcaccgactt caccctgacc atcagcagcc tgcagcccga ggacttcgcc acctactact 960

gccagcagag ctacagcacc ccccccacct tcggccaggg caccaaggtg gagatcaaac 1020

gtaagtacac ttttctcatc ttttttttatg tgtaagacac aggttttcat gttaggagtt 1080

-continued

aaagtcagtt cagaaaatct tgagaaaatg gagagggctc attatcagtt gacgtggcat 1140

acagtgtcag attttctgtt tatcaagcta gtgagattag gggcaaaaag aggctttagt 1200

tgagaggaaa gtaattaata ctatggtcac catccaagag attggatcgg agaataagca 1260

tgagtagtta ttgagatctg ggtctgactg caggtagcgt ggtcttctag acgtttaagt 1320

gggagatttg gaggggatga ggaatgaagg aacttcagga tagaaaaggg ctgaagtcaa 1380

gttcagctcc taaaatggat gtgggagcaa actttgaaga taaactgaat gacccagagg 1440

atgaaacagc gcagatcaaa gaggggcctg gagctctgag aagagaagga gactcatccg 1500

tgttgagttt ccacaagtac tgtcttgagt tttgcaataa aagtgggata gcagagttga 1560

gtgagccgta ggctgagttc tctcttttgt ctcctaagtt tttatgacta caaaaatcag 1620

tagtatgtcc tgaaataatc attaagctgt ttgaaagtat gactgcttgc catgtagata 1680

ccatggcttg ctgaataatc agaagaggtg tgactcttat tctaaaattt gtcacaaaat 1740

gtcaaaatga gagactctgt aggaacgagt ccttgacaga cagctcaagg ggtttttttc 1800

ctttgtctca tttctacatg aaagtaaatt tgaaatgatc ttttttatta taagagtaga 1860

aatacagttg ggtttgaact atatgtttta atggccacgg ttttgtaaga catttggtcc 1920

tttgttttcc cagttattac tcgattgtaa ttttatatcg ccagcaatgg actgaaacgg 1980

tccgcaacct cttctttaca actgggtgac ctcgcggctg tgccagccat ttggcgttca 2040

ccctgccgct aagggccatg tgaacccccg cggtagcatc ccttgctccg cgtggaccac 2100

tttcctgagg cacagtgata ggaacagagc cactaatctg aagagaacag agatgtgaca 2160

gactacacta atgtgagaaa aacaaggaaa gggtgactta ttggagattt cagaaataaa 2220

atgcatttat tattatattc ccttatttta attttctatt agggaattag aaagggcata 2280

aactgcttta tccagtgtta tattaaaagc ttaatgtata taatctttta gaggtaaaat 2340

ctacagccag caaaagtcat ggtaaatatt ctttgactga actctcacta aactcctcta 2400

aattatatgt catattaact ggttaaatta atataaattt gtgacatgac cttaactggt 2460

taggtaggat atttttcttc atgcaaaaat atgactaata ataatttagc acaaaaatat 2520

ttcccaatac tttaattctg tgatagaaaa atgtttaact cagctactat aatcccataa 2580

ttttgaaaac tatttattag cttttgtgtt tgacccttcc ctagccaaag gcaactattt 2640

aaggaccctt taaaactctt gaaactactt tagagtcatt aagttattta accactttta 2700

attactttaa aatgatgtca attccctttt aactattaat ttattttaag gggggaaagg 2760

ctgctcataa ttctattgtt tttcttggta aagaactctc agttttcgtt tttactacct 2820

ctgtcaccca agagttggca tctcaacaga ggggactttc cgagaggcca tctggcagtt 2880

gcttaagatc agaagtgaag tctgccagtt cctcccaggc aggtggccca gattacagtt 2940

gacctgttct ggtgtggcta aaaattgtcc catgtggtta caaaccatta gaccagggtc 3000

tgatgaattg ctcagaatat ttctggacac ccaaatacag accctggctt aaggccctgt 3060

ccatacagta ggtttagctt ggctacacca aaggaagcca tacagaggct aatatcagag 3120

tattcttgga agagacagga gaaaatgaaa gccagtttct gctcttacct tatgtgcttg 3180

tgttcagact cccaaacatc aggagtgtca gataaactgg tctgaatctc tgtctgaagc 3240

atggaactga aaagaatgta gtttcaggga agaaaggcaa tagaaggaag cctgagaata 3300

tcttcaaagg gtcagactca atttactttc taaagaagta gctaggaact agggaataac 3360

-continued

ttagaaacaa caagattgta tatatgtgca tcctggcccc attgttcctt atctgtaggg 3420

ataagcgtgc ttttttgtgt gtctgtatat aacataactg tttacacata atacactgaa 3480

atggagccct tccttgttac ttcataccat cctctgtgct tccttcctca ggggccgacg 3540

ccgctcccac cgtgtccatc ttccccccca gcatggaaca gctgacctct ggcggagcca 3600

ccgtggtctg cttcgtgaac aacttctacc ccagagacat cagcgtgaag tggaagatcg 3660

acggcagcga gcagagggac ggcgtgctgg acagcgtgac cgaccaggac agcaaggact 3720

ccacctacag catgagcagc accctgagcc tgaccaaggt ggagtacgag aggcacaacc 3780

tgtacacctg cgaggtggtg cacaagacca gctccagccc cgtggtcaag tccttcaacc 3840

ggaacgagtg ttgaagacaa aggtcctgag acgccaccac cagctcccca gctccatcct 3900

atcttccctt ctaaggtctt ggaggcttcc ccacaagcga cctaccactg ttgcggtgct 3960

ccaaacctcc tccccacctc cttctcctcc tcctcccttt ccttggcttt tatcatgcta 4020

atatttgcag aaaatattca ataaagtgag tctttgcact tgagatctct gtctttctta 4080

ctaaatggta gtaatcagtt gtttttccag ttacctgggt ttctcttcta aagaagttaa 4140

atgtttagtt gccctgaaat ccaccacact taaaggataa ataaaaccct ccacttgccc 4200

tggttggctg tccactacat ggcagtcctt tctaaggttc acgagtacta ttcatggctt 4260

atttctctgg gccatggtag gtttgaggag gcatacttcc tagttttctt cccctaagtc 4320

gtcaaagtcc tgaaggggga cagtctttac aagcacatgt tctgtaatct gattcaacct 4380

acccagtaaa cttggcgaag caaagtagaa tcattatcac aggaagcaaa ggcaacctaa 4440

atgtgcaagc aataggaaaa tgtggaagcc catcatagta cttggacttc atctgctttt 4500

gtgccttcac taagttttta aacatgagct ggctcctatc tgccattggc aaggctgggc 4560

actacccaca acctacttca aggacctcta taccgtgaga ttacacacat acatcaaaat 4620

ttgggaaaag ttctaccaag ctgagagctg atcaccccac tcttaggtgc ttatctctgt 4680

acaccagaaa ccttaagaag caaccagtat tgagagactc atttatgaaa gtctaaaact 4740

ggatacaacc aaaatgtcca ccaacagtta aattatgaca tgttcacaat tgagctatta 4800

cttaataagg agaattaata aaataaaact taagagcata gtttaatctc ataaacaaga 4860

taataagcaa aacaaaacat tttttcatcc atgtaagttt aaaagcaggt aaaatttaaa 4920

attaagagag acataagttt tgaggtagca agatggaaac tctggggctt ggggaatgtt 4980

ctgtctctct gtatgggatg tgaaagttac tattgtggaa ttgggatcta tgttcttcct 5040

gtatatattg tatacttcat aataacttca cctaaagaaa tatctaatac ccagtgcata 5100

cataaaagag gatacaagga atgaatcata cgtcaaggcc agaaagacaa taaagtaggg 5160

gatccaggat caaatctccc acaaccttga gccttctact attctgcctt ccagagctca 5220

aagtacaaaa cacataattc aaacacatga tccctccttg gggtctcttc cttcatgcat 5280

cgaattagaa atagccatgt ataaaatgag atagaagaga ccttcatcaa caggtcaaag 5340

aatataggta attttgtctg ggtatgaaga gcccacgtat caaaggttac attagggaag 5400

gaagaggaca ctaacagtga ctttcattct ccccctcttc ctggaggccc ctgcatttag 5460

tccctcgtgg gctcatccac tcagcacaca tttactaagc atcttctcag cctacactct 5520

gaaggcagtg cagaataatg ttagtgtccc ttcccccagt taatatgcag tccagtttcc 5580

ctgctccttc cctttctcag tccacataag gatgatggga aaggacagtc accaaatagg 5640

-continued

agagggcaac cctttgcctt cctacctctt gagaatgtac attattatcc actttttgaa 5700

acttctttta attgcttttt tttaatttgt cttttcaaat agcataacct tgttcatcca 5760

tttctgggaa ccaaatttat caatcaacag tgcctctaat ctggctatta atacaaaaat 5820

gcctcctcaa aatatatatg ttcgagtctt atctaaaaca gaacccacaa taaaaaagaa 5880

gaaagaatac atataagcat ttatataatt ctgagcaacc ttgtgctttg tgaaaaaaat 5940

ataatctaat gtcacatgct gtattctttt tatttaacac tggtgaaatt ataccattag 6000

agagaaagag gacagatcac tgatcctagg atctagggat gttacagata agaaaacaaa 6060

tgtgacaaag agctgtcaca aggaggatct tcaaggtcac agaatcactg tcttgatttc 6120

agtggtggtt acatacattt aaatatgtga taaaatgttg ttgaactata ttcatatatt 6180

gtaccaatgt caaatgctta attttggctc tatagtataa ttatgcacta aataactatt 6240

tggacaaaga aaatgatgtt tacatcaaag gtgaggccat atttgttagg aacataactt 6300

aaaaaccatt ttggataact aatgaaaagc cattttgtgt gccttggcat atcatgccta 6360

agctgtcacc agatagatct aataagacct aagcctcaga agcaagcccc tgcccagcaa 6420

gcaggcagca cagataagag ctaaacccag gacaggccat gatatgctaa tgaactacct 6480

tcaaggtggt gttgctgacc tagtgaacca gccccaagct gtgagcccca atagcacaaa 6540

gctactgccc aaagaaatta tacaaaaatt ggaactttgg gaatggtgtg caggatcgct 6600

ctgctgtatg cctggaacac agcttctcta tgttttgtat tgataccagt ctagaagctt 6660

ccaaaacttt ctcactgaag aagattcccc atgtgggacc cctacagact cttttgccca 6720

aacaactgct tccctcctgg tgtgatatct gttttgcttt tatgttagca taatattata 6780

aggaatgttt gtgtgaataa accaaacata ttttaaaagc aaatattgta tgcacatcct 6840

aattgctaaa aagtttacag ctaatagtcc catgctctcc acaatactgg atccaaataa 6900

gtcctaattt caatgttggg catctttaca gagagaaaga cattaaaaat gaagagacat 6960

gcagagagtg caccatgcca tcgtggagac agactgaagt gacacaactg ttagtcaaag 7020

aggattaagg acttccagaa gccaccaaag gaaggaggta tgaagtggtt tctccctcag 7080

agtatccaga ggagactaaa ccaaccaaca ccttttttgct taagacttct tgccttcagg 7140

actgtgagaa ggtagcttcc tattgttcta agccccagta tgtggcattt tgttaaggta 7200

gagtcaagaa accaataaaa tgcagacaga caaaaggata gctgagtttt ccaggccctt 7260

ccttcttatt tttggttttg ttggtggtgg tggtggtggt ggtgatggtg gtggttttgt 7320

ttatgttttg tttggggagt tttttggggt ttttttgggt tttgtttttg ttgttgtttt 7380

gggggttttt gttgttgttg ttgtttgctt ttttgttttt tgttttttgt ttttttgaga 7440

cagtgtttct ctgtatagcc ctggctgtcc tggagttcct tctatctcta atgtctacat 7500

ctcagagggg atcctctaat ttcaaatgag cagtagctct ccatttttag ctcttattta 7560

ttcatttatt tacttactta cttattgtct gtagatgaaa gaattttgga gtgggaaagg 7620

gttcatgagc ccccagcaac taatgaggag ctacagacaa ttgatgtttc tggggaaagg 7680

agactcagtt tctttgagag tatagcttct gatgggtcaa ccatgttcct gtggctgatg 7740

tcacacccag gagtatgcag acaacagaaa ctggagttaa tgagttgttt taaaaataaa 7800

aaagggcatg aagcttggga tagaaattaa ggataaatac aattaaatac aggaaattct 7860

gaaagaatta ataaaaacat ttctttttttt aaaaaaaaat ccagaattag ctatgcttct 7920

-continued

tcaaaattgc ttctggagaa ctttacaagt taaataagtt atattgtaga aaaggtagag 7980

aggagaatag tggaagagag agataaggag acttcaaaag gagtggaggg agatagagga 8040

ggagaaagca gaagcaatgg ctgatagaca caggataaga gggaacagaa aggagaaaga 8100

ggaagccagg atgggtattt ctttgcctat ctgtgacttg cacatggtct tggcaattat 8160

tgatgagttc aaggcttaat tcttcacttg tgccaactca acagagtctt tctttcttat 8220

aaccaggccc ccagtatgct catgtatgta tcaggtcctc ttatctcctt atagcaatcc 8280

tgtttataac tgggtaactt tgtgaaggga aggaagtgca cactgagatg tgctacaact 8340

ttttaataca aaattttgaa gagtttgtac aatgtatgta taattaataa ttaatattat 8400

gcactttaga ttttgatttc aactcaagat actaattcta tatatatggg ttaaatcaat 8460

atattaataa gtttaatttc acatgcttat ttttattgtg gttttcgaga cagggtttct 8520

ctgtatagcc ctggctgtcc tggaacccac tttgtagacc aggctggcct caaactcaga 8580

aacctacctg cctctgcctc tgcctctgcc tctgcctctg cctctgcctc tgcctctgcc 8640

tctgcctctg cctctgcctc tgcctctgcc tctgcctctg cctctgcctc tgcctctgcc 8700

tctgcctctg cctctgcctc tgcctctgcc tctgcctctg cctctgcctc tgcctctgcc 8760

tctgcctagt gctggaatta aaggtttgcg ccaccacgcc cggtgaaatt tttaaacttt 8820

atatatgtct cattctattt ctatcagata ggactgtgta gactgtgcta aactaataaa 8880

tgtgccctca aaagtaatcg caagttgtat tgttgttgtt ttgctttgct ttgctttgct 8940

ttgctttgct ttgctttgct ttgctttgct ttgctttgct ttgctttgct ttgctttgct 9000

ttgctttgct ttgctttgct ttgcttttt gttttgggtt tttttccggg ggagggaggg 9060

tggagaaaga atcttactat gaagctctga ctgtcctggg aactcactat atagatcagg 9120

cttgattcaa ctcatagaga tctgccttct tctgcctccc aagtgctggg aataaaggca 9180

tacacctcca tgcccagata gtgatcccaa gttttagcaa aagtttctag acttgacatt 9240

aatcgatgga gatagacatg aattacacaa agaactaatg tggagtttac ctgaatcata 9300

ctctatactt tatcagagat taaattaaca tttaataatc cagtgccagg ctagaggcac 9360

cattcaatgg cagtgtttgc catcatgcat aggcttagtc ttcagtgctg aaaggcattg 9420

ggggcaatat tactcattat acagatgaga aactgggaaa gacttgcctc agattctcta 9480

ctgaaaggct gagtttgtgg cttctagaaa atcttttact ttcaatattt ttaatgtata 9540

attttttttat ttccactgat tttatttttt atttttaaca tttataagaa ataaatgcaa 9600

taaaccaaat acatggacaa aaaaatacaa gaatcatatg atcacctcaa tggaaggaaa 9660

aaaaaagaaa gaaaaagtct ttgataagat tcaacattca ttctttttttt attagatatt 9720

ttcttcattt acatttcaaa tgctatcccc aaagcccccc ataccttccc ctgccctgct 9780

ccccaaccca cccactcctg ctttctggcc ctggcattcc tctgtactga ggcatatgat 9840

cttcaaaaaa ccaagggcct ctcctctcat tggtggccga ctattaggcc atcttttgct 9900

acatatgcaa ctagagacac agctctgggg gttactggtt agttcatatt gttagtcctc 9960

ctatagagtt gcagacccct ttagctcctt ggatactttc tctagttcct tcattagggg 10020

ccctgtgtcc catccaatag atgactgtga gcatccactt ctgtatttgc caggcactgg 10080

catagcctca cgagaaagag agagctatgt caggatcctg tcagtaaaat ctttctggca 10140

tatgcaatag tatctgggtt tggtggttgt atatgggatg gatccccaag tggagcagtc 10200

-continued

tctgaatggt ccttccttcc atctcagctc caaactttgt ctctataact ccttccatgg 10260

gtattttgtt ccccattcta agaaggagtg aagaatccac actttggtct tccttcttct 10320

tgagtttcat atgttgcatc ttggatattc taagtttctg ggttaatatc cacgtatcag 10380

tgagtgcata tcatgcgtgt tattttgtga ttagtttacc tcactcagga tgatatcctc 10440

cagatgcatc catttgccta agaatttcat taattcactg tttttaattg ctgaatagta 10500

ctccattgtg taaatgtacc acattttctg tatccattcc tctgttgagg ggcatctggg 10560

ttctttccag cttctggcta ttataaataa ggctgctatg agcatagcgg agcatgtgtc 10620

cttatcaagt tggaacatct tctaggtata tgcccaggag aggaattgct ggatcttccg 10680

gtagtaccat caacatgcat tcttaataaa agccctagaa caaggaggac tgtaggaaac 10740

atattccaac ataataaagg ttatgtatga caaactcatg accaatatca tcctaaatga 10800

atgaaaccat taataagctc cattaaaatc agaggactgc ccactatccc tacttctcat 10860

ccataatgag attgaagcat tagctggagc aataaggcaa gagaagggat acaaatggga 10920

aaatattaag tcaaattgtt ttcaattgaa gattatatta tcttataccc aatgacctca 10980

aattttgact agaaaaattg tagaaattat caataatttc agcaaagtgt tatgatgcac 11040

cacatcctta ttcttctccc cagcttctgc ttgcttctct cttcttgctc ttcatccttt 11100

ctgtccttcc atctgcctgc actcttgtct caagactgag tgcagcgtgt aactctcctg 11160

tgactgagta tctcacaaaa cgttctacct gccaaacctg gatgagccct ttgtctttct 11220

gaagctatga ggctctctac atagactcaa gaaggaaatg acagggagga ggtaataatg 11280

aagtggggaa ggctgacatt agcattgctc ctgtgtggct ccttaatttc tcatacttca 11340

cactgagatg ttattaactg tgactcatag gtgaagaagc cagagctaag gttctcatat 11400

ttgagtgtta tagaatgagt agagcagtag ttctcaaact atgggtcatg actcctttat 11460

gggtcaaact acccttttcac acaggttgca tatcagatat cctaatttta tatacatata 11520

tatatgcata tgtatatata tatatttcac aacagtagga aaattattta gtaatcattt 11580

tatagttgtg ggtcatggca acatgaggaa ctgtattaaa gggttgcagc attaggaatg 11640

ttgagaccca ctgtaataga gaatgaggct taaggcaggg ctataaagcc caatggacca 11700

tgtgcctttt ccaacatttg ccacatggta agctctgtat agacttttta aagaacattg 11760

gtttgtaatt ttaaatggat aagggtcttc actgtctatc acccatctat ataataaata 11820

cataagtttt gattccacca tggattcaaa tgcaaaaatc ctcaacctaa gacatagcag 11880

tgaaacattg atgaccaaat aggaaatcca tgtagagacc ttctatcttc tgatggctcc 11940

acaggcacca tcttgcaaca gagttctact ttgctaccag taatgaatac agtgtctcaa 12000

ctcctgccat tgaatcttca ggaagcccct gaaatgactt gtactacacc atttcttaaa 12060

gacagaaaag ctaagactta gagggaataa atgtcatgcc tgagatcatg caaccaatta 12120

agtccaactt ggcctgatca agaggcacaa ttcaaaagca atgttgttcc ttcactagct 12180

cttgtgtatg gttgctgatt ccggaagcaa agtatcagtg aatatcccta gtgggaaaag 12240

acttggaaat caaatgtctc atttaacaga ttaggagatg aaacggtaga ctctgtgtag 12300

ttgtacaccc ctgtgatccc atcgctagga agactgaggc aggaagtcct cgagctcaaa 12360

ccagcttagg ctacacagag aaactatcta aaaaataatt actaactact taataggaga 12420

ttggatgtta agatctggtc actaagaggc agaattgaga ttcgaagcca gtattttcta 12480

-continued

cctggtatgt tttaaattgc agtaaggatc taagtgtaga tatataataa taagattcta 12540

ttgatctctg caacaacaga gagtgttaga tttgtttgga aaaaaatatt atcagccaac 12600

atcttctacc atttcagtat agcacagagt acccacccat atctccccac ccatccccca 12660

taccagactg gttattgatt ttcatggtga ctggcctgag aagattaaaa aaagtaatgc 12720

taccttattg ggagtgtccc atggaccaag atagcaactg tcatagctac cgtcacactg 12780

ctttgatcaa gaagaccctt tgaggaactg aaaacagaac cttaggcaca tctgttgctt 12840

tcgctcccat cctcctccaa cagcctgggt ggtgcactcc acacccttc aagtttccaa 12900

agcctcatac acctgctccc taccccagca cctggccaag gctgtatcca gcactgggat 12960

gaaaatgata ccccacctcc atcttgtttg atattactct atctcaagcc ccaggttagt 13020

ccccagtccc aatgcttttg cacagtcaaa actcaacttg gaataatcag tatccttgaa 13080

gagttctgat atggtcactg ggcccatata ccatgtaaga catgtggaaa agatgtttca 13140

tggggcccag acacgttcta gaagtacctg agagtggcaa aaaatagttg tgctaaatag 13200

tttggccatc tttaggctga gagactagga aatacagcga tggactatat cagcattgca 13260

ggatagttgt cagtaaacac cccacaaccc ataacagaag tattctcttc tttctatatc 13320

ccttttccat ccatgtagat ggctgtcttc atatttgttc tagacggccg gcc 13373

<210> SEQ ID NO 93
<211> LENGTH: 12892
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VkP-IGKV1-39/J-Ck-delta1

<400> SEQUENCE: 93

ggccggccca catgaaacaa tgggaaccat gtgacaatca cagaggtgtt gttactatag 60

caaaagggat tgttactctc cacatccctt taagtaactt gaaggcctga tagacccacc 120

ctctaagact tcattagaca ttccctacga atggttatac tctcctgtat actcccaata 180

caactctaaa atatattatt ccatatagtc cttaggtttg tattaaagtt tgacttttt 240

ccttcaaaat atctcttgtc acaacagcgg ctctagagag aaatacattc cctccaggca 300

aatctatgct gcgctggtct gacctgggac cctggggaca ttgcccctgt gctgagttac 360

taagatgagc cagccctgca gctgtgctca gcctgcccca tgccctgctg attgatttgc 420

atgttccaga gcacagcccc ctgccctgaa gacttttta tgggctggtc gcaccctgtg 480

caggagtcag tctcagtcag gagccaccat ggacatgaga gtgcccgccc agctcctggg 540

gctcctgcta ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt 600

gtgctcagta ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa 660

tatttgtttt tatgtttcca atctcaggtg ccagatgtga catccagatg acccagagcc 720

ccagcagcct gagcgccagc gtgggcgaca gagtgaccat cacctgcaga gccagccaga 780

gcatcagcag ctacctgaac tggtatcagc agaagcccgg caaggccccc aagctgctga 840

tctacgccgc cagctccctg cagagcggcg tgcccagcag attcagcggc agcggctccg 900

gcaccgactt caccctgacc atcagcagcc tgcagcccga ggacttcgcc acctactact 960

gccagcagag ctacagcacc ccccccacct tcggccaggg caccaaggtg gagatcaaac 1020

gtaagtacac ttttctcatc tttttttatg tgtaagacac aggttttcat gttaggagtt 1080

-continued

aaagtcagtt cagaaaatct tgagaaaatg gagagggctc attatcagtt gacgtggcat 1140

acagtgtcag attttctgtt tatcaagcta gtgagattag gggcaaaaag aggctttagt 1200

tgagaggaaa gtaattaata ctatggtcac catccaagag attggatcgg agaataagca 1260

tgagtagtta ttgagatctg ggtctgactg caggtagcgt ggtcttctag acgtttaagt 1320

gggagatttg gaggggatga ggaatgaagg aacttcagga tagaaaaggg ctgaagtcaa 1380

gttcagctcc taaaatggat gtgggagcaa actttgaaga taaactgaat gacccagagg 1440

atgaaacagc gcagatcaaa gaggggcctg gagctctgag aagagaagga gactcatccg 1500

tgttgagttt ccacaagtac tgtcttgagt tttgcaataa aagtgggata gcagagttga 1560

gtgagccgta ggctgagttc tctcttttgt ctcctaagtt tttatgacta caaaaatcag 1620

tagtatgtcc tgaaataatc attaagctgt ttgaaagtat gactgcttgc catgtagata 1680

ccatggcttg ctgaataatc agaagaggtg tgactcttat tctaaaattt gtcacaaaat 1740

gtcaaaatga gagactctgt aggaacgagt ccttgacaga cagctcaagg ggtttttttc 1800

ctttgtctca tttctacatg aaagtaaatt tgaaatgatc ttttttatta taagagtaga 1860

aatacagttg ggtttgaact atatgtttta atggccacgg ttttgtaaga catttggtcc 1920

tttgttttcc cagttattac tcgattgtaa ttttatatcg ccagcaatgg actgaaacgg 1980

tccgcaacct cttctttaca actgggtgac ctcgcggctg tgccagccat ttggcgttca 2040

ccctgccgct aagggccatg tgaacccccg cggtagcatc ccttgctccg cgtggaccac 2100

tttcctgagg cacagtgata ggaacagagc cactaatctg aagagaacag agatgtgaca 2160

gactacacta atgtgagaaa aacaaggaaa gggtgactta ttggagattt cagaaataaa 2220

atgcatttat tattatattc ccttatttta attttctatt agggaattag aaagggcata 2280

aactgcttta tccagtgtta tattaaaagc ttaatgtata taatctttta gaggtaaaat 2340

ctacagccag caaaagtcat ggtaaatatt ctttgactga actctcacta aactcctcta 2400

aattatatgt catattaact ggttaaatta atataaattt gtgacatgac cttaactggt 2460

taggtaggat atttttcttc atgcaaaaat atgactaata ataatttagc acaaaaatat 2520

ttcccaatac tttaattctg tgatagaaaa atgtttaact cagctactat aatcccataa 2580

ttttgaaaac tatttatttg gctacaccaa aggaagccat acagaggcta atatcagagt 2640

attcttggaa gagacaggag aaaatgaaag ccagtttctg ctcttacctt atgtgcttgt 2700

gttcagactc ccaaacatca ggagtgtcag ataaactggt ctgaatctct gtctgaagca 2760

tggaactgaa aagaatgtag tttcagggaa gaaaggcaat agaaggaagc ctgagaatat 2820

cttcaaaggg tcagactcaa tttactttct aaagaagtag ctaggaacta gggaataact 2880

tagaaacaac aagattgtat atatgtgcat cctggcccca ttgttcctta tctgtaggga 2940

taagcgtgct tttttgtgtg tctgtatata acataactgt ttacacataa tacactgaaa 3000

tggagccctt ccttgttact tcataccatc ctctgtgctt ccttcctcag gggccgacgc 3060

cgctcccacc gtgtccatct tccccccccag catggaacag ctgacctctg gcggagccac 3120

cgtggtctgc ttcgtgaaca acttctaccc cagagacatc agcgtgaagt ggaagatcga 3180

cggcagcgag cagagggacg gcgtgctgga cagcgtgacc gaccaggaca gcaaggactc 3240

cacctacagc atgagcagca ccctgagcct gaccaaggtg gagtacgaga ggcacaacct 3300

gtacacctgc gaggtggtgc acaagaccag ctccagcccc gtggtcaagt ccttcaaccg 3360

-continued

gaacgagtgt tgaagacaaa ggtcctgaga cgccaccacc agctccccag ctccatccta 3420

tcttcccttc taaggtcttg gaggcttccc cacaagcgac ctaccactgt tgcggtgctc 3480

caaacctcct ccccacctcc ttctcctcct cctccctttc cttggctttt atcatgctaa 3540

tatttgcaga aaatattcaa taaagtgagt ctttgcactt gagatctctg tctttcttac 3600

taaatggtag taatcagttg tttttccagt tacctgggtt tctcttctaa agaagttaaa 3660

tgtttagttg ccctgaaatc caccacactt aaaggataaa taaaaccctc cacttgccct 3720

ggttggctgt ccactacatg gcagtccttt ctaaggttca cgagtactat tcatggctta 3780

tttctctggg ccatggtagg tttgaggagg catacttcct agttttcttc ccctaagtcg 3840

tcaaagtcct gaaggggggac agtctttaca agcacatgtt ctgtaatctg attcaaccta 3900

cccagtaaac ttggcgaagc aaagtagaat cattatcaca ggaagcaaag gcaacctaaa 3960

tgtgcaagca ataggaaaat gtggaagccc atcatagtac ttggacttca tctgcttttg 4020

tgccttcact aagtttttaa acatgagctg gctcctatct gccattggca aggctgggca 4080

ctacccacaa cctacttcaa ggacctctat accgtgagat tacacacata catcaaaatt 4140

tgggaaaagt tctaccaagc tgagagctga tcaccccact cttaggtgct tatctctgta 4200

caccagaaac cttaagaagc aaccagtatt gagagactca tttatgaaag tctaaaactg 4260

gatacaacca aaatgtccac caacagttaa attatgacat gttcacaatt gagctattac 4320

ttaataagga gaattaataa aataaaactt aagagcatag tttaatctca taaacaagat 4380

aataagcaaa acaaaacatt ttttcatcca tgtaagttta aaagcaggta aaatttaaaa 4440

ttaagagaga cataagtttt gaggtagcaa gatggaaact ctggggcttg gggaatgttc 4500

tgtctctctg tatgggatgt gaaagttact attgtggaat tgggatctat gttcttcctg 4560

tatatattgt atacttcata ataacttcac ctaaagaaat atctaatacc cagtgcatac 4620

ataaaagagg atacaaggaa tgaatcatac gtcaaggcca gaaagacaat aaagtagggg 4680

atccaggatc aaatctccca caaccttgag ccttctacta ttctgccttc cagagctcaa 4740

agtacaaaac acataattca aacacatgat ccctccttgg ggtctcttcc ttcatgcatc 4800

gaattagaaa tagccatgta taaaatgaga tagaagagac cttcatcaac aggtcaaaga 4860

atataggtaa ttttgtctgg gtatgaagag cccacgtatc aaaggttaca ttagggaagg 4920

aagaggacac taacagtgac tttcattctc cccctcttcc tggaggcccc tgcatttagt 4980

ccctcgtggg ctcatccact cagcacacat ttactaagca tcttctcagc ctacactctg 5040

aaggcagtgc agaataatgt tagtgtccct tcccccagtt aatatgcagt ccagtttccc 5100

tgctccttcc ctttctcagt ccacataagg atgatgggaa aggacagtca ccaaatagga 5160

gagggcaacc ctttgccttc ctacctcttg agaatgtaca ttattatcca ctttttgaaa 5220

cttcttttaa ttgctttttt ttaatttgtc ttttcaaata gcataacctt gttcatccat 5280

ttctgggaac caaatttatc aatcaacagt gcctctaatc tggctattaa tacaaaaatg 5340

cctcctcaaa atatatatgt tcgagtctta tctaaaacag aacccacaat aaaaaagaag 5400

aaagaataca tataagcatt tatataattc tgagcaacct tgtgctttgt gaaaaaaata 5460

taatctaatg tcacatgctg tattcttttt atttaacact ggtgaaatta taccattaga 5520

gagaaagagg acagatcact gatcctagga tctagggatg ttacagataa gaaaacaaat 5580

gtgacaaaga gctgtcacaa ggaggatctt caaggtcaca gaatcactgt cttgatttca 5640

-continued

gtggtggtta catacattta aatatgtgat aaaatgttgt tgaactatat tcatatattg 5700

taccaatgtc aaatgcttaa ttttggctct atagtataat tatgcactaa ataactattt 5760

ggacaaagaa aatgatgttt acatcaaagg tgaggccata tttgttagga acataactta 5820

aaaaccattt tggataacta atgaaaagcc attttgtgtg ccttggcata tcatgcctaa 5880

gctgtcacca gatagatcta ataagaccta agcctcagaa gcaagcccct gcccagcaag 5940

caggcagcac agataagagc taaacccagg acaggccatg atatgctaat gaactacctt 6000

caaggtggtg ttgctgacct agtgaaccag ccccaagctg tgagccccaa tagcacaaag 6060

ctactgccca aagaaattat acaaaaattg gaactttggg aatggtgtgc aggatcgctc 6120

tgctgtatgc ctggaacaca gcttctctat gttttgtatt gataccagtc tagaagcttc 6180

caaaactttc tcactgaaga agattcccca tgtgggaccc ctacagactc ttttgcccaa 6240

acaactgctt ccctcctggt gtgatatctg ttttgctttt atgttagcat aatattataa 6300

ggaatgtttg tgtgaataaa ccaaacatat tttaaaagca aatattgtat gcacatccta 6360

attgctaaaa agtttacagc taatagtccc atgctctcca caatactgga tccaaataag 6420

tcctaatttc aatgttgggc atctttacag agagaaagac attaaaaatg aagagacatg 6480

cagagagtgc accatgccat cgtggagaca gactgaagtg acacaactgt tagtcaaaga 6540

ggattaagga cttccagaag ccaccaaagg aaggaggtat gaagtggttt ctccctcaga 6600

gtatccagag gagactaaac caaccaacac ctttttgctt aagacttctt gccttcagga 6660

ctgtgagaag gtagcttcct attgttctaa gccccagtat gtggcatttt gttaaggtag 6720

agtcaagaaa ccaataaaat gcagacagac aaaaggatag ctgagttttc caggcccttc 6780

cttcttattt ttggttttgt tggtggtggt ggtggtggtg gtgatggtgg tggttttgtt 6840

tatgttttgt ttggggagtt ttttggggtt tttttgggtt ttgtttttgt tgttgttttg 6900

ggggtttttg ttgttgttgt tgtttgcttt tttgtttttt gttttttgtt tttttgagac 6960

agtgtttctc tgtatagccc tggctgtcct ggagttcctt ctatctctaa tgtctacatc 7020

tcagagggga tcctctaatt tcaaatgagc agtagctctc catttttagc tcttatttat 7080

tcatttattt acttacttac ttattgtctg tagatgaaag aattttggag tgggaaaggg 7140

ttcatgagcc cccagcaact aatgaggagc tacagacaat tgatgtttct ggggaaagga 7200

gactcagttt ctttgagagt atagcttctg atgggtcaac catgttcctg tggctgatgt 7260

cacacccagg agtatgcaga caacagaaac tggagttaat gagttgtttt aaaaataaaa 7320

aagggcatga agcttgggat agaaattaag gataaataca attaaataca ggaaattctg 7380

aaagaattaa taaaaacatt tctttttttа aaaaaaaatc cagaattagc tatgcttctt 7440

caaaattgct tctggagaac tttacaagtt aaataagtta tattgtagaa aaggtagaga 7500

ggagaatagt ggaagagaga gataaggaga cttcaaaagg agtggaggga gatagaggag 7560

gagaaagcag aagcaatggc tgatagacac aggataagag ggaacagaaa ggagaaagag 7620

gaagccagga tgggtatttc tttgcctatc tgtgacttgc acatggtctt ggcaattatt 7680

gatgagttca aggcttaatt cttcacttgt gccaactcaa cagagtcttt ctttcttata 7740

accaggcccc cagtatgctc atgtatgtat caggtcctct tatctcctta tagcaatcct 7800

gtttataact gggtaacttt gtgaagggaa ggaagtgcac actgagatgt gctacaactt 7860

tttaatacaa aattttgaag agtttgtaca atgtatgtat aattaataat taatattatg 7920

-continued

cactttagat tttgatttca actcaagata ctaattctat atatatgggt taaatcaata 7980

tattaataag tttaatttca catgcttatt tttattgtgg ttttcgagac agggtttctc 8040

tgtatagccc tggctgtcct ggaacccact ttgtagacca ggctggcctc aaactcagaa 8100

acctacctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct gcctctgcct 8160

ctgcctctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct gcctctgcct 8220

ctgcctctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct gcctctgcct 8280

ctgcctagtg ctggaattaa aggtttgcgc caccacgccc ggtgaaattt ttaaacttta 8340

tatatgtctc attctatttc tatcagatag gactgtgtag actgtgctaa actaataaat 8400

gtgccctcaa aagtaatcgc aagttgtatt gttgttgttt tgctttgctt tgctttgctt 8460

tgctttgctt tgctttgctt tgctttgctt tgctttgctt tgctttgctt tgctttgctt 8520

tgctttgctt tgctttgctt tgctttgctt ttttgggttt ttttccgggg gagggagggt 8580

ggagaaagaa tcttactatg aagctctgac tgtcctggga actcactata tagatcaggc 8640

ttgattcaac tcatagagat ctgccttctt ctgcctccca agtgctggga ataaaggcat 8700

acacctccat gcccagatag tgatcccaag ttttagcaaa agtttctaga cttgacatta 8760

atcgatggag atagacatga attacacaaa gaactaatgt ggagtttacc tgaatcatac 8820

tctatacttt atcagagatt aaattaacat ttaataatcc agtgccaggc tagaggcacc 8880

attcaatggc agtgtttgcc atcatgcata ggcttagtct tcagtgctga aaggcattgg 8940

gggcaatatt actcattata cagatgagaa actgggaaag acttgcctca gattctctac 9000

tgaaaggctg agtttgtggc ttctagaaaa tcttttactt tcaatatttt taatgtataa 9060

tttttttatt tccactgatt ttatttttta tttttaacat ttataagaaa taaatgcaat 9120

aaaccaaata catggacaaa aaaatacaag aatcatatga tcacctcaat ggaaggaaaa 9180

aaaaagaaag aaaaagtctt tgataagatt caacattcat tctttttta ttagatattt 9240

tcttcattta catttcaaat gctatcccca aagcccccta taccttcccc tgccctgctc 9300

cccaacccac ccactcctgc tttctggccc tggcattcct ctgtactgag gcatatgatc 9360

ttcaaaaaac caagggcctc tcctctcatt ggtggccgac tattaggcca tcttttgcta 9420

catatgcaac tagagacaca gctctggggg ttactggtta gttcatattg ttagtcctcc 9480

tatagagttg cagacccctt tagctccttg gatactttct ctagttcctt cattaggggc 9540

cctgtgtccc atccaataga tgactgtgag catccacttc tgtatttgcc aggcactggc 9600

atagcctcac gagaaagaga gagctatgtc aggatcctgt cagtaaaatc tttctggcat 9660

atgcaatagt atctgggttt ggtggttgta tatgggatgg atccccaagt ggagcagtct 9720

ctgaatggtc cttccttcca tctcagctcc aaactttgtc tctataactc cttccatggg 9780

tattttgttc cccattctaa gaaggagtga agaatccaca ctttggtctt ccttcttctt 9840

gagtttcata tgttgcatct tggatattct aagtttctgg gttaatatcc acgtatcagt 9900

gagtgcatat catgcgtgtt attttgtgat tagtttacct cactcaggat gatatcctcc 9960

agatgcatcc atttgcctaa gaatttcatt aattcactgt ttttaattgc tgaatagtac 10020

tccattgtgt aaatgtacca cattttctgt atccattcct ctgttgaggg gcatctgggt 10080

tctttccagc ttctggctat tataaataag gctgctatga gcatagcgga gcatgtgtcc 10140

ttatcaagtt ggaacatctt ctaggtatat gcccaggaga ggaattgctg gatcttccgg 10200

-continued

tagtaccatc aacatgcatt cttaataaaa gccctagaac aaggaggact gtaggaaaca 10260

tattccaaca taataaaggt tatgtatgac aaactcatga ccaatatcat cctaaatgaa 10320

tgaaaccatt aataagctcc attaaaatca gaggactgcc cactatccct acttctcatc 10380

cataatgaga ttgaagcatt agctggagca ataaggcaag agaagggata caaatgggaa 10440

aatattaagt caaattgttt tcaattgaag attatattat cttataccca atgacctcaa 10500

attttgacta gaaaaattgt agaaattatc aataatttca gcaaagtgtt atgatgcacc 10560

acatccttat tcttctcccc agcttctgct tgcttctctc ttcttgctct tcatcctttc 10620

tgtccttcca tctgcctgca ctcttgtctc aagactgagt gcagcgtgta actctcctgt 10680

gactgagtat ctcacaaaac gttctacctg ccaaacctgg atgagccctt tgtctttctg 10740

aagctatgag gctctctaca tagactcaag aaggaaatga cagggaggag gtaataatga 10800

agtggggaag gctgacatta gcattgctcc tgtgtggctc cttaatttct catacttcac 10860

actgagatgt tattaactgt gactcatagg tgaagaagcc agagctaagg ttctcatatt 10920

tgagtgttat agaatgagta gagcagtagt tctcaaacta tgggtcatga ctcctttatg 10980

ggtcaaacta ccctttcaca caggttgcat atcagatatc ctaattttat atacatatat 11040

atatgcatat gtatatatat atatttcaca acagtaggaa aattatttag taatcatttt 11100

atagttgtgg gtcatggcaa catgaggaac tgtattaaag ggttgcagca ttaggaatgt 11160

tgagacccac tgtaatagag aatgaggctt aaggcagggc tataaagccc aatggaccat 11220

gtgccttttc caacatttgc cacatggtaa gctctgtata gacttttaa agaacattgg 11280

tttgtaattt taaatggata agggtcttca ctgtctatca cccatctata taataaatac 11340

ataagttttg attccaccat ggattcaaat gcaaaaatcc tcaacctaag acatagcagt 11400

gaaacattga tgaccaaata ggaaatccat gtagagacct tctatcttct gatggctcca 11460

caggcaccat cttgcaacag agttctactt tgctaccagt aatgaataca gtgtctcaac 11520

tcctgccatt gaatcttcag gaagcccctg aaatgacttg tactacacca tttcttaaag 11580

acagaaaagc taagacttag agggaataaa tgtcatgcct gagatcatgc aaccaattaa 11640

gtccaacttg gcctgatcaa gaggcacaat tcaaaagcaa tgttgttcct tcactagctc 11700

ttgtgtatgg ttgctgattc cggaagcaaa gtatcagtga atatccctag tgggaaaaga 11760

cttggaaatc aaatgtctca tttaacagat taggagatga aacggtagac tctgtgtagt 11820

tgtacacccc tgtgatccca tcgctaggaa gactgaggca ggaagtcctc gagctcaaac 11880

cagcttaggc tacacagaga aactatctaa aaaataatta ctaactactt aataggagat 11940

tggatgttaa gatctggtca ctaagaggca gaattgagat tcgaagccag tattttctac 12000

ctggtatgtt ttaaattgca gtaaggatct aagtgtagat atataataat aagattctat 12060

tgatctctgc aacaacagag agtgttagat ttgtttggaa aaaaatatta tcagccaaca 12120

tcttctacca tttcagtata gcacagagta cccacccata tctccccacc catcccccat 12180

accagactgg ttattgattt tcatggtgac tggcctgaga agattaaaaa aagtaatgct 12240

accttattgg gagtgtccca tggaccaaga tagcaactgt catagctacc gtcacactgc 12300

tttgatcaag aagacccttt gaggaactga aaacagaacc ttaggcacat ctgttgcttt 12360

cgctcccatc ctcctccaac agcctgggtg gtgcactcca caccctttca agtttccaaa 12420

gcctcataca cctgctccct accccagcac ctggccaagg ctgtatccag cactgggatg 12480

-continued

aaaatgatac cccacctcca tcttgtttga tattactcta tctcaagccc caggttagtc 12540

cccagtccca atgcttttgc acagtcaaaa ctcaacttgg aataatcagt atccttgaag 12600

agttctgata tggtcactgg gcccatatac catgtaagac atgtggaaaa gatgtttcat 12660

ggggcccaga cacgttctag aagtacctga gagtggcaaa aaatagttgt gctaaatagt 12720

ttggccatct ttaggctgag agactaggaa atacagcgat ggactatatc agcattgcag 12780

gatagttgtc agtaaacacc ccacaaccca taacagaagt attctcttct ttctatatcc 12840

cttttccatc catgtagatg gctgtcttca tatttgttct agacggccgg cc 12892

<210> SEQ ID NO 94
<211> LENGTH: 6425
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VkP-IGKV1-39/J-Ck-delta2

<400> SEQUENCE: 94

ggccggccca catgaaacaa tgggaaccat gtgacaatca cagaggtgtt gttactatag 60

caaaagggat tgttactctc cacatccctt taagtaactt gaaggcctga tagacccacc 120

ctctaagact tcattagaca ttccctacga atggttatac tctcctgtat actcccaata 180

caactctaaa atatattatt ccatatagtc cttaggtttg tattaaagtt tgacttttt 240

ccttcaaaat atctcttgtc acaacagcgg ctctagagag aaatacattc cctccaggca 300

aatctatgct gcgctggtct gacctgggac cctggggaca ttgcccctgt gctgagttac 360

taagatgagc cagccctgca gctgtgctca gcctgcccca tgccctgctg attgatttgc 420

atgttccaga gcacagcccc ctgccctgaa gacttttta tgggctggtc gcaccctgtg 480

caggagtcag tctcagtcag gagccaccat ggacatgaga gtgcccgccc agctcctggg 540

gctcctgcta ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt 600

gtgctcagta ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa 660

tatttgtttt tatgtttcca atctcaggtg ccagatgtga catccagatg acccagagcc 720

ccagcagcct gagcgccagc gtgggcgaca gagtgaccat cacctgcaga gccagccaga 780

gcatcagcag ctacctgaac tggtatcagc agaagcccgg caaggccccc aagctgctga 840

tctacgccgc cagctccctg cagagcggcg tgcccagcag attcagcggc agcggctccg 900

gcaccgactt caccctgacc atcagcagcc tgcagcccga ggacttcgcc acctactact 960

gccagcagag ctacagcacc ccccccacct tcggccaggg caccaaggtg gagatcaaac 1020

gtaagtacac ttttctcatc ttttttttatg tgtaagacac aggttttcat gttaggagtt 1080

aaagtcagtt cagaaaatct tgagaaaatg gagagggctc attatcagtt gacgtggcat 1140

acagtgtcag attttctgtt tatcaagcta gtgagattag gggcaaaaag aggctttagt 1200

tgagaggaaa gtaattaata ctatggtcac catccaagag attggatcgg agaataagca 1260

tgagtagtta ttgagatctg ggtctgactg caggtagcgt ggtcttctag acgtttaagt 1320

gggagatttg gaggggatga ggaatgaagg aacttcagga tagaaaaggg ctgaagtcaa 1380

gttcagctcc taaaatggat gtgggagcaa actttgaaga taaactgaat gacccagagg 1440

atgaaacagc gcagatcaaa gaggggcctg gagctctgag aagagaagga gactcatccg 1500

tgttgagttt ccacaagtac tgtcttgagt tttgcaataa aagtgggata gcagagttga 1560

-continued

gtgagccgta ggctgagttc tctcttttgt ctcctaagtt tttatgacta caaaaatcag 1620

tagtatgtcc tgaaataatc attaagctgt ttgaaagtat gactgcttgc catgtagata 1680

ccatggcttg ctgaataatc agaagaggtg tgactcttat tctaaaattt gtcacaaaat 1740

gtcaaaatga gagactctgt aggaacgagt ccttgacaga cagctcaagg ggtttttttc 1800

ctttgtctca tttctacatg aaagtaaatt tgaaatgatc ttttttatta taagagtaga 1860

aatacagttg ggtttgaact atatgtttta atggccacgg ttttgtaaga catttggtcc 1920

tttgttttcc cagttattac tcgattgtaa ttttatatcg ccagcaatgg actgaaacgg 1980

tccgcaacct cttctttaca actgggtgac ctcgcggctg tgccagccat ttggcgttca 2040

ccctgccgct aagggccatg tgaacccccg cggtagcatc ccttgctccg cgtggaccac 2100

tttcctgagg cacagtgata ggaacagagc cactaatctg aagagaacag agatgtgaca 2160

gactacacta atgtgagaaa aacaaggaaa gggtgactta ttggagattt cagaaataaa 2220

atgcatttat tattatattc ccttatttta attttctatt agggaattag aaagggcata 2280

aactgcttta tccagtgtta tattaaaagc ttaatgtata taatctttta gaggtaaaat 2340

ctacagccag caaaagtcat ggtaaatatt ctttgactga actctcacta aactcctcta 2400

aattatatgt catattaact ggttaaatta atataaattt gtgacatgac cttaactggt 2460

taggtaggat atttttcttc atgcaaaaat atgactaata ataatttagc acaaaaatat 2520

ttcccaatac tttaattctg tgatagaaaa atgtttaact cagctactat aatcccataa 2580

ttttgaaaac tatttatttg gctacaccaa aggaagccat acagaggcta atatcagagt 2640

attcttggaa gagacaggag aaaatgaaag ccagtttctg ctcttacctt atgtgcttgt 2700

gttcagactc ccaaacatca ggagtgtcag ataaactggt ctgaatctct gtctgaagca 2760

tggaactgaa aagaatgtag tttcagggaa gaaaggcaat agaaggaagc ctgagaatat 2820

cttcaaaggg tcagactcaa tttacttttct aaagaagtag ctaggaacta gggaataact 2880

tagaaacaac aagattgtat atatgtgcat cctggcccca ttgttcctta tctgtaggga 2940

taagcgtgct tttttgtgtg tctgtatata acataactgt ttacacataa tacactgaaa 3000

tggagccctt ccttgttact tcataccatc ctctgtgctt ccttcctcag gggccgacgc 3060

cgctcccacc gtgtccatct tccccccag catggaacag ctgacctctg gcggagccac 3120

cgtggtctgc ttcgtgaaca acttctaccc cagagacatc agcgtgaagt ggaagatcga 3180

cggcagcgag cagagggacg gcgtgctgga cagcgtgacc gaccaggaca gcaaggactc 3240

cacctacagc atgagcagca ccctgagcct gaccaaggtg gagtacgaga ggcacaacct 3300

gtacacctgc gaggtggtgc acaagaccag ctccagcccc gtggtcaagt ccttcaaccg 3360

gaacgagtgt tgaagacaaa ggtcctgaga cgccaccacc agctccccag ctccatccta 3420

tcttcccttc taaggtcttg gaggcttccc cacaagcgac ctaccactgt tgcggtgctc 3480

caaacctcct ccccacctcc ttctcctcct cctccctttc cttggctttt atcatgctaa 3540

tatttgcaga aaatattcaa taaagtgagt ctttgcactt gagatctctg tctttcttac 3600

taaatggtag taatcagttg tttttccagt tacctgggtt tctcttctaa agaagttaaa 3660

tgtttagttg ccctgaaatc caccacactt aaaggataaa taaaaccctc cacttgccct 3720

ggttggctgt ccactacatg gcagtccttt ctaaggttca cgagtactat tcatggctta 3780

tttctctggg ccatggtagg tttgaggagg catacttcct agttttcttc ccctaagtcg 3840

-continued

tcaaagtcct gaagggggac agtctttaca agcacatgtt ctgtaatctg attcaaccta 3900

cccagtaaac ttggcgaagc aaagtagaat cattatcaca ggaagcaaag gcaacctaaa 3960

tgtgcaagca ataggaaaat gtggaagccc atcatagtac ttggacttca tctgcttttg 4020

tgccttcact aagtttttaa acatgagctg gctcctatct gccattggca aggctgggca 4080

ctacccacaa cctacttcaa ggacctctat accgtgagat tacacacata catcaaaatt 4140

tgggaaaagt tctaccaagc tgagagctga tcaccccact cttaggtgct tatctctgta 4200

caccagaaac cttaagaagc aaccagtatt gagagactca tttatgaaag tctaaaactg 4260

gatacaacca aaatgtccac caacagttaa attatgacat gttcacaatt gagctattac 4320

ttaataagga gaattaataa aataaaactt aagagcatag tttaatctca taaacaagat 4380

aataagcaaa acaaaacatt ttttcatcca tgtaagttta aaagcaggta aaatttaaaa 4440

ttaagagaga cataagtttt gaggtagcaa gatggaaact ctggggcttg gggaatgttc 4500

tgtctctctg tatgggatgt gaaagttact attgtggaat tgggatctat gttcttcctg 4560

tatatattgt atacttcata ataacttcac ctaaagaaat atctaatacc cagtgcatac 4620

ataaaagagg atacaaggaa tgaatcatac gtcaaggcca gaaagacaat aaagtagggg 4680

atccaggatc aaatctccca caaccttgag ccttctacta ttctgccttc cagagctcaa 4740

agtacaaaac acataattca aacacatgat ccctccttgg ggtctcttcc ttcatgcatc 4800

gaattagaaa tagccatgta taaaatgaga tagaagagac cttcatcaac aggtcaaaga 4860

atataggtaa ttttgtctgg gtatgaagag cccacgtatc aaaggttaca ttagggaagg 4920

aagaggacac taacagtgac tttcattctc cccctcttcc tggaggcccc tgcatttagt 4980

ccctcgtggg ctcatccact cagcacacat ttactaagca tcttctcagc ctacactctg 5040

aaggcagtgc agaataatgt tagtgtccct tcccccagtt aatatgcagt ccagtttccc 5100

tgctccttcc ctttctcagt ccacataagg atgatgggaa aggacagtca ccaaatagga 5160

gagggcaacc ctttgccttc ctacctcttg agaatgtaca ttattatcca ctttttgaaa 5220

cttcttttaa ttgctttttt ttaatttgtc ttttcaaata gcataacctt gttcatccat 5280

ttctgggaac caaatttatc aatcaacagt gcctctaatc tggctattaa tacaaaaatg 5340

cctcctcaaa atatatatgt tcgagtctta tctaaaacag aacccacaat aaaaaagaag 5400

aaagaatata tataagcatt tatataattc tgagcaacct tgtgctttgt gaaaaaaata 5460

taatctaatg tcacatgctg tattcttttt atttaacact ggtgaaatta taccattaga 5520

gagaaagagg acagatcact gatcctagga tctagggatg ttacagataa gaaaacaaat 5580

gtgacaaaga gctgtcacaa ggaggatctt caaggtcaca gaatcactgt cttgatttca 5640

gtggtggtta catacattta aatatgtgat aaaatgttgt tgaactatat tcatatattg 5700

taccaatgtc aaatgcttaa ttttggctct atagtataat tatgcactaa ataactattt 5760

ggacaaagaa aatgatgttt acatcaaagg tgaggccata tttgttagga acataactta 5820

aaaaccattt tggataacta atgaaaagcc attttgtgtg ccttggcata tcatgcctaa 5880

gctgtcacca gatagatcta ataagaccta agcctcagaa gcaagcccct gcccagcaag 5940

caggcagcac agataagagc taaacccagg acaggccatg atatgctaat gaactacctt 6000

caaggtggtg ttgctgacct agtgaaccag ccccaagctg tgagccccaa tagcacaaag 6060

ctactgccca aagaaattat acaaaaattg gaactttggg aatggtgtgc aggatcgctc 6120

-continued

tgctgtatgc ctggaacaca gcttctctat gttttgtatt gataccagtc tagaagcttc 6180

caaaactttc tcactgaaga agattcccca tgtgggaccc ctacagactc ttttgcccaa 6240

acaactgctt ccctcctggt gtgatcatgg accaagatag caactgtcat agctaccgtc 6300

acactgcttt gatcaagaag acccttttgag gaactgaaaa cagaacctta ggcacatctg 6360

ttgctttcgc tcccatcctc ctccaacagc atggctgtct tcatatttgt tctagacggc 6420

cggcc 6425

<210> SEQ ID NO 95
<211> LENGTH: 13382
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: VkP-IGLV2-14/J-Ck

<400> SEQUENCE: 95

ggccggccca catgaaacaa tgggaaccat gtgacaatca cagaggtgtt gttactatag 60

caaaagggat tgttactctc cacatccctt taagtaactt gaaggcctga tagacccacc 120

ctctaagact tcattagaca ttccctacga atggttatac tctcctgtat actcccaata 180

caactctaaa atatattatt ccatatagtc cttaggtttg tattaaagtt tgacttttt 240

ccttcaaaat atctcttgtc acaacagcgg ctctagagag aaatacattc cctccaggca 300

aatctatgct gcgctggtct gacctgggac cctggggaca ttgcccctgt gctgagttac 360

taagatgagc cagccctgca gctgtgctca gcctgcccca tgccctgctg attgatttgc 420

atgttccaga gcacagcccc ctgccctgaa gacttttta tgggctggtc gcaccctgtg 480

caggagtcag tctcagtcag gagccaccat ggacatgaga gtgcccgccc agctcctggg 540

gctcctgcta ctctggctcc gaggtaagga tggagaacac taggaattta ctcagccagt 600

gtgctcagta ctgactggaa cttcagggaa gttctctgat aacatgatta atagtaagaa 660

tatttgtttt tatgtttcca atctcaggtg ccagatgtca gtctgccctg acccagcccg 720

cctctgtgtc tggcagccct ggccagagca tcaccatcag ctgcaccggc accagcagcg 780

acgtgggcgg ctacaactac gtgtcctggt atcagcagca ccccggcaag gcccccaagc 840

tgatgatcta cgaggtgtcc aacagaccca gcggcgtgag caacagattc agcggcagca 900

agagcggcaa caccgccagc ctgaccatca gcggcctcca ggctgaggac gaggccgact 960

actactgcag cagctacacc agcagctcca ccctggtgtt tggcggcgga acaaagctga 1020

ccgtgctgcg taagtacact tttctcatct ttttttatgt gtaagacaca ggttttcatg 1080

ttaggagtta aagtcagttc agaaaatctt gagaaaatgg agagggctca ttatcagttg 1140

acgtggcata cagtgtcaga ttttctgttt atcaagctag tgagattagg ggcaaaaaga 1200

ggctttagtt gagaggaaag taattaatac tatggtcacc atccaagaga ttggatcgga 1260

gaataagcat gagtagttat tgagatctgg gtctgactgc aggtagcgtg gtcttctaga 1320

cgtttaagtg ggagatttgg aggggatgag gaatgaagga acttcaggat agaaaagggc 1380

tgaagtcaag ttcagctcct aaaatggatg tgggagcaaa ctttgaagat aaactgaatg 1440

acccagagga tgaaacagcg cagatcaaag aggggcctgg agctctgaga agagaaggag 1500

actcatccgt gttgagtttc cacaagtact gtcttgagtt ttgcaataaa agtgggatag 1560

cagagttgag tgagccgtag gctgagttct ctcttttgtc tcctaagttt ttatgactac 1620

-continued

aaaaatcagt agtatgtcct gaaataatca ttaagctgtt tgaaagtatg actgcttgcc 1680

atgtagatac catggcttgc tgaataatca gaagaggtgt gactcttatt ctaaaatttg 1740

tcacaaaatg tcaaaatgag agactctgta ggaacgagtc cttgacagac agctcaaggg 1800

gtttttttcc tttgtctcat ttctacatga aagtaaattt gaaatgatct tttttattat 1860

aagagtagaa atacagttgg gtttgaacta tatgttttaa tggccacggt tttgtaagac 1920

atttggtcct ttgttttccc agttattact cgattgtaat tttatatcgc cagcaatgga 1980

ctgaaacggt ccgcaacctc ttctttacaa ctgggtgacc tcgcggctgt gccagccatt 2040

tggcgttcac cctgccgcta agggccatgt gaacccccgc ggtagcatcc cttgctccgc 2100

gtggaccact ttcctgaggc acagtgatag gaacagagcc actaatctga agagaacaga 2160

gatgtgacag actacactaa tgtgagaaaa acaaggaaag ggtgacttat tggagatttc 2220

agaaataaaa tgcatttatt attatattcc cttatttttaa ttttctatta gggaattaga 2280

aagggcataa actgctttat ccagtgttat attaaaagct taatgtatat aatcttttag 2340

aggtaaaatc tacagccagc aaaagtcatg gtaaatattc tttgactgaa ctctcactaa 2400

actcctctaa attatatgtc atattaactg gttaaattaa tataaatttg tgacatgacc 2460

ttaactggtt aggtaggata tttttcttca tgcaaaaata tgactaataa taatttagca 2520

caaaaatatt tcccaatact ttaattctgt gatagaaaaa tgtttaactc agctactata 2580

atcccataat tttgaaaact atttattagc ttttgtgttt gacccttccc tagccaaagg 2640

caactattta aggacccttt aaaactcttg aaactacttt agagtcatta agttatttaa 2700

ccacttttaa ttactttaaa atgatgtcaa ttccctttta actattaatt tattttaagg 2760

ggggaaaggc tgctcataat tctattgttt ttcttggtaa agaactctca gttttcgttt 2820

ttactacctc tgtcacccaa gagttggcat ctcaacagag gggactttcc gagaggccat 2880

ctggcagttg cttaagatca gaagtgaagt ctgccagttc ctcccaggca ggtggcccag 2940

attacagttg acctgttctg gtgtggctaa aaattgtccc atgtggttac aaaccattag 3000

accagggtct gatgaattgc tcagaatatt tctggacacc caaatacaga ccctggctta 3060

aggccctgtc catacagtag gtttagcttg gctacaccaa aggaagccat acagaggcta 3120

atatcagagt attcttggaa gagacaggag aaaatgaaag ccagtttctg ctcttacctt 3180

atgtgcttgt gttcagactc ccaaacatca ggagtgtcag ataaactggt ctgaatctct 3240

gtctgaagca tggaactgaa aagaatgtag tttcagggaa gaaaggcaat agaaggaagc 3300

ctgagaatat cttcaaaggg tcagactcaa tttacttttct aaagaagtag ctaggaacta 3360

gggaataact tagaaacaac aagattgtat atatgtgcat cctggcccca ttgttcctta 3420

tctgtaggga taagcgtgct tttttgtgtg tctgtatata acataactgt ttacacataa 3480

tacactgaaa tggagccctt ccttgttact tcataccatc ctctgtgctt ccttcctcag 3540

gggccgacgc cgctcccacc gtgtccatct tccccccccag catggaacag ctgacctctg 3600

gcggagccac cgtggtctgc ttcgtgaaca acttctaccc cagagacatc agcgtgaagt 3660

ggaagatcga cggcagcgag cagagggacg gcgtgctgga cagcgtgacc gaccaggaca 3720

gcaaggactc cacctacagc atgagcagca ccctgagcct gaccaaggtg gagtacgaga 3780

ggcacaacct gtacacctgc gaggtggtgc acaagaccag ctccagcccc gtggtcaagt 3840

ccttcaaccg gaacgagtgt tgaagacaaa ggtcctgaga cgccaccacc agctccccag 3900

-continued

ctccatccta tcttcccttc taaggtcttg gaggcttccc cacaagcgac ctaccactgt 3960

tgcggtgctc caaacctcct ccccacctcc ttctcctcct cctccctttc cttggctttt 4020

atcatgctaa tatttgcaga aaatattcaa taaagtgagt ctttgcactt gagatctctg 4080

tcttttcttac taaatggtag taatcagttg ttttttccagt tacctgggtt tctcttctaa 4140

agaagttaaa tgtttagttg ccctgaaatc caccacactt aaaggataaa taaaaccctc 4200

cacttgccct ggttggctgt ccactacatg gcagtccttt ctaaggttca cgagtactat 4260

tcatggctta tttctctggg ccatggtagg tttgaggagg catacttcct agttttcttc 4320

ccctaagtcg tcaaagtcct gaaggggggac agtctttaca agcacatgtt ctgtaatctg 4380

attcaaccta cccagtaaac ttggcgaagc aaagtagaat cattatcaca ggaagcaaag 4440

gcaacctaaa tgtgcaagca ataggaaaat gtggaagccc atcatagtac ttggacttca 4500

tctgcttttg tgccttcact aagtttttaa acatgagctg gctcctatct gccattggca 4560

aggctgggca ctacccacaa cctacttcaa ggacctctat accgtgagat tacacacata 4620

catcaaaatt tgggaaaagt tctaccaagc tgagagctga tcaccccact cttaggtgct 4680

tatctctgta caccagaaac cttaagaagc aaccagtatt gagagactca tttatgaaag 4740

tctaaaactg gatacaacca aaatgtccac caacagttaa attatgacat gttcacaatt 4800

gagctattac ttaataagga gaattaataa aataaaactt aagagcatag tttaatctca 4860

taaacaagat aataagcaaa acaaaacatt ttttcatcca tgtaagttta aaagcaggta 4920

aaatttaaaa ttaagagaga cataagtttt gaggtagcaa gatggaaact ctggggcttg 4980

gggaatgttc tgtctctctg tatgggatgt gaaagttact attgtggaat tgggatctat 5040

gttcttcctg tatatattgt atacttcata ataacttcac ctaaagaaat atctaatacc 5100

cagtgcatac ataaaagagg atacaaggaa tgaatcatac gtcaaggcca gaaagacaat 5160

aaagtagggg atccaggatc aaatctccca caaccttgag ccttctacta ttctgccttc 5220

cagagctcaa agtacaaaac acataattca aacacatgat ccctccttgg ggtctcttcc 5280

ttcatgcatc gaattagaaa tagccatgta taaaatgaga tagaagagac cttcatcaac 5340

aggtcaaaga atataggtaa ttttgtctgg gtatgaagag cccacgtatc aaaggttaca 5400

ttagggaagg aagaggacac taacagtgac tttcattctc cccctcttcc tggaggcccc 5460

tgcatttagt ccctcgtggg ctcatccact cagcacacat ttactaagca tcttctcagc 5520

ctacactctg aaggcagtgc agaataatgt tagtgtccct tcccccagtt aatatgcagt 5580

ccagtttccc tgctccttcc ctttctcagt ccacataagg atgatgggaa aggacagtca 5640

ccaaatagga gagggcaacc ctttgccttc ctacctcttg agaatgtaca ttattatcca 5700

ctttttgaaa cttcttttaa ttgctttttt ttaatttgtc ttttcaaata gcataacctt 5760

gttcatccat ttctgggaac caaatttatc aatcaacagt gcctctaatc tggctattaa 5820

tacaaaaatg cctcctcaaa atatatatgt tcgagtctta tctaaaacag aacccacaat 5880

aaaaaagaag aaagaatata tataagcatt tatataattc tgagcaacct tgtgctttgt 5940

gaaaaaaata taatctaatg tcacatgctg tattcttttt atttaacact ggtgaaatta 6000

taccattaga gagaaagagg acagatcact gatcctagga tctagggatg ttacagataa 6060

gaaaacaaat gtgacaaaga gctgtcacaa ggaggatctt caaggtcaca gaatcactgt 6120

cttgatttca gtggtggtta catacattta aatatgtgat aaaatgttgt tgaactatat 6180

-continued

tcatatattg taccaatgtc aaatgcttaa ttttggctct atagtataat tatgcactaa 6240

ataactattt ggacaaagaa aatgatgttt acatcaaagg tgaggccata tttgttagga 6300

acataactta aaaaccattt tggataacta atgaaaagcc attttgtgtg ccttggcata 6360

tcatgcctaa gctgtcacca gatagatcta ataagaccta agcctcagaa gcaagcccct 6420

gcccagcaag caggcagcac agataagagc taaacccagg acaggccatg atatgctaat 6480

gaactacctt caaggtggtg ttgctgacct agtgaaccag ccccaagctg tgagccccaa 6540

tagcacaaag ctactgccca aagaaattat acaaaaattg gaactttggg aatggtgtgc 6600

aggatcgctc tgctgtatgc ctggaacaca gcttctctat gttttgtatt gataccagtc 6660

tagaagcttc caaaactttc tcactgaaga agattcccca tgtgggaccc ctacagactc 6720

ttttgcccaa acaactgctt ccctcctggt gtgatatctg ttttgctttt atgttagcat 6780

aatattataa ggaatgtttg tgtgaataaa ccaaacatat tttaaaagca aatattgtat 6840

gcacatccta attgctaaaa agtttacagc taatagtccc atgctctcca caatactgga 6900

tccaaataag tcctaatttc aatgttgggc atctttacag agagaaagac attaaaaatg 6960

aagagacatg cagagagtgc accatgccat cgtggagaca gactgaagtg acacaactgt 7020

tagtcaaaga ggattaagga cttccagaag ccaccaaagg aaggaggtat gaagtggttt 7080

ctccctcaga gtatccagag gagactaaac caaccaacac ctttttgctt aagacttctt 7140

gccttcagga ctgtgagaag gtagcttcct attgttctaa gccccagtat gtggcatttt 7200

gttaaggtag agtcaagaaa ccaataaaat gcagacagac aaaaggatag ctgagttttc 7260

caggcccttc cttcttattt ttggttttgt tggtggtggt ggtggtggtg gtgatggtgg 7320

tggttttgtt tatgttttgt ttggggagtt ttttggggtt tttttgggtt ttgtttttgt 7380

tgttgttttg ggggtttttg ttgttgttgt tgtttgcttt tttgtttttt gttttttgtt 7440

tttttgagac agtgtttctc tgtatagccc tggctgtcct ggagttcctt ctatctctaa 7500

tgtctacatc tcagagggga tcctctaatt tcaaatgagc agtagctctc catttttagc 7560

tcttatttat tcatttattt acttacttac ttattgtctg tagatgaaag aattttggag 7620

tgggaaaggg ttcatgagcc cccagcaact aatgaggagc tacagacaat tgatgtttct 7680

ggggaaagga gactcagttt ctttgagagt atagcttctg atgggtcaac catgttcctg 7740

tggctgatgt cacacccagg agtatgcaga caacagaaac tggagttaat gagttgtttt 7800

aaaaataaaa aagggcatga agcttgggat agaaattaag gataaataca attaaataca 7860

ggaaattctg aaagaattaa taaaaacatt tctttttta aaaaaaaatc cagaattagc 7920

tatgcttctt caaaattgct tctggagaac tttacaagtt aaataagtta tattgtagaa 7980

aaggtagaga ggagaatagt ggaagagaga gataaggaga cttcaaaagg agtggaggga 8040

gatagaggag gagaaagcag aagcaatggc tgatagacac aggataagag ggaacagaaa 8100

ggagaaagag gaagccagga tgggtatttc tttgcctatc tgtgacttgc acatggtctt 8160

ggcaattatt gatgagttca aggcttaatt cttcacttgt gccaactcaa cagagtcttt 8220

ctttcttata accaggcccc cagtatgctc atgtatgtat caggtcctct tatctcctta 8280

tagcaatcct gtttataact gggtaacttt gtgaagggaa ggaagtgcac actgagatgt 8340

gctacaactt tttaatacaa aattttgaag agtttgtaca atgtatgtat aattaataat 8400

taatattatg cactttagat tttgatttca actcaagata ctaattctat atatatgggt 8460

-continued

taaatcaata tattaataag tttaatttca catgcttatt tttattgtgg ttttcgagac 8520

agggtttctc tgtatagccc tggctgtcct ggaacccact ttgtagacca ggctggcctc 8580

aaactcagaa acctacctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct 8640

gcctctgcct ctgcctctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct 8700

gcctctgcct ctgcctctgc ctctgcctct gcctctgcct ctgcctctgc ctctgcctct 8760

gcctctgcct ctgcctagtg ctggaattaa aggtttgcgc caccacgccc ggtgaaattt 8820

ttaaacttta tatatgtctc attctatttc tatcagatag gactgtgtag actgtgctaa 8880

actaataaat gtgccctcaa aagtaatcgc aagttgtatt gttgttgttt tgctttgctt 8940

tgctttgctt tgctttgctt tgctttgctt tgctttgctt tgctttgctt tgctttgctt 9000

tgctttgctt tgctttgctt tgctttgctt tgctttttttg ttttgggttt ttttccgggg 9060

gagggagggt ggagaaagaa tcttactatg aagctctgac tgtcctggga actcactata 9120

tagatcaggc ttgattcaac tcatagagat ctgccttctt ctgcctccca agtgctggga 9180

ataaaggcat acacctccat gcccagatag tgatcccaag ttttagcaaa agtttctaga 9240

cttgacatta atcgatggag atagacatga attacacaaa gaactaatgt ggagtttacc 9300

tgaatcatac tctatacttt atcagagatt aaattaacat ttaataatcc agtgccaggc 9360

tagaggcacc attcaatggc agtgtttgcc atcatgcata ggcttagtct tcagtgctga 9420

aaggcattgg gggcaatatt actcattata cagatgagaa actgggaaag acttgcctca 9480

gattctctac tgaaaggctg agtttgtggc ttctagaaaa tcttttactt tcaatatttt 9540

taatgtataa ttttttttatt tccactgatt ttatttttta tttttaacat ttataagaaa 9600

taaatgcaat aaaccaaata catggacaaa aaaatacaag aatcatatga tcacctcaat 9660

ggaaggaaaa aaaaagaaag aaaaagtctt tgataagatt caacattcat tctttttta 9720

ttagatattt tcttcattta catttcaaat gctatcccca aagcccccta taccttcccc 9780

tgccctgctc cccaacccac ccactcctgc tttctggccc tggcattcct ctgtactgag 9840

gcatatgatc ttcaaaaaac caagggcctc tcctctcatt ggtggccgac tattaggcca 9900

tcttttgcta catatgcaac tagagacaca gctctggggg ttactggtta gttcatattg 9960

ttagtcctcc tatagagttg cagacccctt tagctccttg gatactttct ctagttcctt 10020

cattaggggc cctgtgtccc atccaataga tgactgtgag catccacttc tgtatttgcc 10080

aggcactggc atagcctcac gagaaagaga gagctatgtc aggatcctgt cagtaaaatc 10140

tttctggcat atgcaatagt atctgggttt ggtggttgta tatgggatgg atccccaagt 10200

ggagcagtct ctgaatggtc cttccttcca tctcagctcc aaactttgtc tctataactc 10260

cttccatggg tattttgttc cccattctaa gaaggagtga agaatccaca ctttggtctt 10320

ccttcttctt gagtttcata tgttgcatct tggatattct aagtttctgg gttaatatcc 10380

acgtatcagt gagtgcatat catgcgtgtt attttgtgat tagtttacct cactcaggat 10440

gatatcctcc agatgcatcc atttgcctaa gaatttcatt aattcactgt ttttaattgc 10500

tgaatagtac tccattgtgt aaatgtacca cattttctgt atccattcct ctgttgaggg 10560

gcatctgggt tctttccagc ttctggctat tataaataag gctgctatga gcatagcgga 10620

gcatgtgtcc ttatcaagtt ggaacatctt ctaggtatat gcccaggaga ggaattgctg 10680

gatcttccgg tagtaccatc aacatgcatt cttaataaaa gccctagaac aaggaggact 10740

-continued

gtaggaaaca tattccaaca taataaaggt tatgtatgac aaactcatga ccaatatcat 10800

cctaaatgaa tgaaaccatt aataagctcc attaaaatca gaggactgcc cactatccct 10860

acttctcatc cataatgaga ttgaagcatt agctggagca ataaggcaag agaagggata 10920

caaatgggaa aatattaagt caaattgttt tcaattgaag attatattat cttataccca 10980

atgacctcaa attttgacta gaaaaattgt agaaattatc aataatttca gcaaagtgtt 11040

atgatgcacc acatccttat tcttctcccc agcttctgct tgcttctctc ttcttgctct 11100

tcatcctttc tgtccttcca tctgcctgca ctcttgtctc aagactgagt gcagcgtgta 11160

actctcctgt gactgagtat ctcacaaaac gttctacctg ccaaacctgg atgagccctt 11220

tgtctttctg aagctatgag gctctctaca tagactcaag aaggaaatga cagggaggag 11280

gtaataatga agtggggaag gctgacatta gcattgctcc tgtgtggctc cttaatttct 11340

catacttcac actgagatgt tattaactgt gactcatagg tgaagaagcc agagctaagg 11400

ttctcatatt tgagtgttat agaatgagta gagcagtagt tctcaaacta tgggtcatga 11460

ctcctttatg ggtcaaacta ccctttcaca caggttgcat atcagatatc ctaattttat 11520

atacatatat atatgcatat gtatatatat atatttcaca acagtaggaa aattatttag 11580

taatcatttt atagttgtgg gtcatggcaa catgaggaac tgtattaaag ggttgcagca 11640

ttaggaatgt tgagacccac tgtaatagag aatgaggctt aaggcagggc tataaagccc 11700

aatggaccat gtgccttttc caacatttgc cacatggtaa gctctgtata gacttttttaa 11760

agaacattgg tttgtaattt taaatggata agggtcttca ctgtctatca cccatctata 11820

taataaatac ataagttttg attccaccat ggattcaaat gcaaaaatcc tcaacctaag 11880

acatagcagt gaaacattga tgaccaaata ggaaatccat gtagagacct tctatcttct 11940

gatggctcca caggcaccat cttgcaacag agttctactt tgctaccagt aatgaataca 12000

gtgtctcaac tcctgccatt gaatcttcag gaagcccctg aaatgacttg tactacacca 12060

tttcttaaag acagaaaagc taagacttag agggaataaa tgtcatgcct gagatcatgc 12120

aaccaattaa gtccaacttg gcctgatcaa gaggcacaat tcaaaagcaa tgttgttcct 12180

tcactagctc ttgtgtatgg ttgctgattc cggaagcaaa gtatcagtga atatccctag 12240

tgggaaaaga cttggaaatc aaatgtctca tttaacagat taggagatga aacggtagac 12300

tctgtgtagt tgtacacccc tgtgatccca tcgctaggaa gactgaggca ggaagtcctc 12360

gagctcaaac cagcttaggc tacacagaga aactatctaa aaaataatta ctaactactt 12420

aataggagat tggatgttaa gatctggtca ctaagaggca gaattgagat tcgaagccag 12480

tattttctac ctggtatgtt ttaaattgca gtaaggatct aagtgtagat atataataat 12540

aagattctat tgatctctgc aacaacagag agtgttagat ttgtttggaa aaaaatatta 12600

tcagccaaca tcttctacca tttcagtata gcacagagta cccacccata tctccccacc 12660

catcccccat accagactgg ttattgattt tcatggtgac tggcctgaga agattaaaaa 12720

aagtaatgct accttattgg gagtgtccca tggaccaaga tagcaactgt catagctacc 12780

gtcacactgc tttgatcaag aagacccttt gaggaactga aaacagaacc ttaggcacat 12840

ctgttgcttt cgctcccatc ctcctccaac agcctgggtg gtgcactcca cacccttca 12900

agtttccaaa gcctcataca cctgctccct accccagcac ctggccaagg ctgtatccag 12960

cactgggatg aaaatgatac cccacctcca tcttgtttga tattactcta tctcaagccc 13020

-continued

caggttagtc cccagtccca atgcttttgc acagtcaaaa ctcaacttgg aataatcagt 13080

atccttgaag agttctgata tggtcactgg gcccatatac catgtaagac atgtggaaaa 13140

gatgtttcat ggggcccaga cacgttctag aagtacctga gagtggcaaa aaatagttgt 13200

gctaaatagt ttggccatct ttaggctgag agactaggaa atacagcgat ggactatatc 13260

agcattgcag gatagttgtc agtaaacacc ccacaaccca taacagaagt attctcttct 13320

ttctatatcc cttttccatc catgtagatg gctgtcttca tatttgttct agacggccgg 13380

cc 13382

<210> SEQ ID NO 96
<211> LENGTH: 4638
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pSELECT-IGKV1-39/J-Ck

<400> SEQUENCE: 96

gcggccgcaa taaaatatct ttattttcat tacatctgtg tgttggtttt ttgtgtgaat 60

cgtaactaac atacgctctc catcaaaaca aaacgaaaca aaacaaacta gcaaaatagg 120

ctgtccccag tgcaagtgca ggtgccagaa catttctcta tcgaaggatc tgcgatcgct 180

ccggtgcccg tcagtgggca gagcgcacat cgcccacagt ccccgagaag ttgggggggag 240

gggtcggcaa ttgaacgggt gcctagagaa ggtggcgcgg ggtaaactgg gaaagtgatg 300

tcgtgtactg gctccgcctt tttcccgagg gtgggggaga accgtatata agtgcagtag 360

tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacagctg aagcttcgag 420

gggctcgcat ctctccttca cgcgcccgcc gccctacctg aggccgccat ccacgccggt 480

tgagtcgcgt tctgccgcct cccgcctgtg gtgcctcctg aactgcgtcc gccgtctagg 540

taagtttaaa gctcaggtcg agaccgggcc tttgtccggc gctcccttgg agcctaccta 600

gactcagccg gctctccacg ctttgcctga ccctgcttgc tcaactctac gtctttgttt 660

cgttttctgt tctgcgccgt tacagatcca agctgtgacc ggcgcctacc tgagatcacc 720

ggcgtgtcga cgccaccatg gacatgagag tgcccgccca gctcctgggg ctcctgctac 780

tctggctccg aggtaaggat ggagaacact aggaatttac tcagccagtg tgctcagtac 840

tgactggaac ttcagggaag ttctctgata acatgattaa tagtaagaat atttgttttt 900

atgtttccaa tctcaggtgc cagatgtgac atccagatga cccagagccc cagcagcctg 960

agcgccagcg tgggcgacag agtgaccatc acctgcagag ccagccagag catcagcagc 1020

tacctgaact ggtatcagca gaagcccggc aaggccccca agctgctgat ctacgccgcc 1080

agctccctgc agagcggcgt gcccagcaga ttcagcggca gcggctccgg caccgacttc 1140

accctgacca tcagcagcct gcagcccgag gacttcgcca cctactactg ccagcagagc 1200

tacagcaccc cccccacctt cggccagggc accaaggtgg agatcaagag agccgacgcc 1260

gctcccaccg tgtccatctt ccccccccagc atggaacagc tgacctctgg cggagccacc 1320

gtggtctgct tcgtgaacaa cttctacccc agagacatca gcgtgaagtg gaagatcgac 1380

ggcagcgagc agagggacgg cgtgctggac agcgtgaccg accaggacag caaggactcc 1440

acctacagca tgagcagcac cctgagcctg accaaggtgg agtacgagag gcacaacctg 1500

tacacctgcg aggtggtgca caagaccagc tccagccccg tggtcaagtc cttcaaccgg 1560

-continued

aacgagtgtt gagctagctg gccagacatg ataagataca ttgatgagtt tggacaaacc 1620

acaactagaa tgcagtgaaa aaaatgcttt atttgtgaaa tttgtgatgc tattgcttta 1680

tttgtaacca ttataagctg caataaacaa gttaacaaca acaattgcat tcattttatg 1740

tttcaggttc agggggaggt gtgggaggtt ttttaaagca agtaaaacct ctacaaatgt 1800

ggtatggaat tctaaaatac agcatagcaa aactttaacc tccaaatcaa gcctctactt 1860

gaatcctttt ctgagggatg aataaggcat aggcatcagg ggctgttgcc aatgtgcatt 1920

agctgtttgc agcctcacct tctttcatgg agtttaagat atagtgtatt ttcccaaggt 1980

ttgaactagc tcttcatttc tttatgtttt aaatgcactg acctcccaca ttccctttt 2040

agtaaaatat tcagaaataa tttaaatata tcattgcaat gaaaataaat gttttttatt 2100

aggcagaatc cagatgctca aggcccttca taatatcccc cagtttagta gttggactta 2160

gggaacaaag gaacctttaa tagaaattgg acagcaagaa agcgagcttc tagcgaattc 2220

tcgactcatt cctttgccct cggacgagtg ctggggcgtc ggtttccact atcggcgagt 2280

acttctacac agccatcggt ccagacggcc gcgcttctgc gggcgatttg tgtacgcccg 2340

acagtcccgg ctccggatcg gacgattgcg tcgcatcgac cctgcgccca agctgcatca 2400

tcgaaattgc cgtcaaccaa gctctgatag agttggtcaa gaccaatgcg gagcatatac 2460

gcccggagcc gcggcgatcc tgcaagctcc ggatgcctcc gctcgaagta gcgcgtctgc 2520

tgctccatac aagccaacca cggcctccag aagaagatgt tggcgacctc gtattgggaa 2580

tccccgaaca tcgcctcgct ccagtcaatg accgctgtta tgcggccatt gtccgtcagg 2640

acattgttgg agccgaaatc cgcgtgcacg aggtgccgga cttcggggca gtcctcggcc 2700

caaagcatca gctcatcgag agcctgcgcg acggacgcac tgacggtgtc gtccatcaca 2760

gtttgccagt gatacacatg gggatcagca atcgcgcata tgaaatcacg ccatgtagtg 2820

tattgaccga ttccttgcgg tccgaatggg ccgaacccgc tcgtctggct aagatcggcc 2880

gcagcgatcg catccatgag ctccgcgacg ggttgcagaa cagcgggcag ttcggtttca 2940

ggcaggtctt gcaacgtgac accctgtgca cggcgggaga tgcaataggt caggctctcg 3000

ctgaattccc caatgtcaag cacttccgga atcgggagcg cggccgatgc aaagtgccga 3060

taaacataac gatctttgta gaaaccatcg gcgcagctat ttacccgcag gacatatcca 3120

cgccctccta catcgaagct gaaagcacga gattcttcgc cctccgagag ctgcatcagg 3180

tcggagacgc tgtcgaactt ttcgatcaga aacttctcga cagacgtcgc ggtgagttca 3240

ggctttttca tgatggccct cctatagtga gtcgtattat actatgccga tatactatgc 3300

cgatgattaa ttgtcaaaac agcgtggatg gcgtctccag cttatctgac ggttcactaa 3360

acgagctctg cttatataga cctcccaccg tacacgccta ccgcccattt gcgtcaatgg 3420

ggcggagttg ttacgacatt ttggaaagtc ccgttgattt actagtcaaa acaaactccc 3480

attgacgtca atggggtgga gacttggaaa tccccgtgag tcaaaccgct atccacgccc 3540

attgatgtac tgccaaaacc gcatcatcat ggtaatagcg atgactaata cgtagatgta 3600

ctgccaagta ggaaagtccc ataaggtcat gtactgggca taatgccagg cgggccattt 3660

accgtcattg acgtcaatag ggggcgtact tggcatatga tacacttgat gtactgccaa 3720

gtgggcagtt taccgtaaat actccaccca ttgacgtcaa tggaaagtcc ctattggcgt 3780

tactatggga acatacgtca ttattgacgt caatgggcgg gggtcgttgg gcggtcagcc 3840

-continued

aggcgggcca tttaccgtaa gttatgtaac gcctgcaggt taattaagaa catgtgagca 3900

aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg 3960

ctccgccccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg 4020

acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt 4080

ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt 4140

tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc 4200

tgtgtgcacg aacccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt 4260

gagtccaacc cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt 4320

agcagagcga ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc 4380

tacactagaa gaacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa 4440

agagttggta gctcttgatc cggcaaacaa accaccgctg gtagcggtgg ttttttgtt 4500

tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct 4560

acggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt catggctagt 4620

taattaacat ttaaatca 4638

<210> SEQ ID NO 97
<211> LENGTH: 5349
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pSelect-IGVL2-14/J-Ck

<400> SEQUENCE: 97

gcggccgcaa taaaatatct ttattttcat tacatctgtg tgttggtttt ttgtgtgaat 60

cgtaactaac atacgctctc catcaaaaca aaacgaaaca aaacaaacta gcaaaatagg 120

ctgtccccag tgcaagtgca ggtgccagaa catttctcta tcgaaggatc tgcgatcgct 180

ccggtgcccg tcagtgggca gagcgcacat cgcccacagt ccccgagaag ttgggggggag 240

gggtcggcaa ttgaacgggt gcctagagaa ggtggcgcgg ggtaaactgg gaaagtgatg 300

tcgtgtactg gctccgcctt tttcccgagg gtgggggaga accgtatata agtgcagtag 360

tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacagctg aagcttcgag 420

gggctcgcat ctctccttca cgcgcccgcc gccctacctg aggccgccat ccacgccggt 480

tgagtcgcgt tctgccgcct cccgcctgtg gtgcctcctg aactgcgtcc gccgtctagg 540

taagtttaaa gctcaggtcg agaccgggcc tttgtccggc gctcccttgg agcctaccta 600

gactcagccg gctctccacg ctttgcctga ccctgcttgc tcaactctac gtctttgttt 660

cgttttctgt tctgcgccgt tacagatcca agctgtgacc ggcgcctacc tgagatcacc 720

ggcgtgtcga cgccaccatg gacatgagag tgcccgccca gctcctgggg ctcctgctac 780

tctggctccg aggtaaggat ggagaacact aggaatttac tcagccagtg tgctcagtac 840

tgactggaac ttcagggaag ttctctgata acatgattaa tagtaagaat atttgttttt 900

atgtttccaa tctcaggtgc cagatgtcag tctgccctga cccagcccgc ctctgtgtct 960

ggcagccctg gccagagcat caccatcagc tgcaccggca ccagcagcga cgtgggcggc 1020

tacaactacg tgtcctggta tcagcagcac cccggcaagg cccccaagct gatgatctac 1080

gaggtgtcca acagacccag cggcgtgagc aacagattca gcggcagcaa gagcggcaac 1140

-continued

accgccagcc tgaccatcag cggcctccag gctgaggacg aggccgacta ctactgcagc 1200

agctacacca gcagctccac cctggtgttt ggcggcggaa caaagctgac cgtgctgaga 1260

gccgacgccg ctcccaccgt gtccatcttc ccccccagca tggaacagct gacctctggc 1320

ggagccaccg tggtctgctt cgtgaacaac ttctacccca gagacatcag cgtgaagtgg 1380

aagatcgacg gcagcgagca gagggacggc gtgctggaca gcgtgaccga ccaggacagc 1440

aaggactcca cctacagcat gagcagcacc ctgagcctga ccaaggtgga gtacgagagg 1500

cacaacctgt acacctgcga ggtggtgcac aagaccagct ccagccccgt ggtcaagtcc 1560

ttcaaccgga acgagtgttg agctagctgg ccagacatga taagatacat tgatgagttt 1620

ggacaaacca caactagact gactcagcct gcctccgtgt ctgggtctcc tggacagtcg 1680

atcaccatct cctgcactgg aaccagcagt gacgttggtg gttataacta tgtctcctgg 1740

taccaacagc acccaggcaa agcccccaaa ctcatgattt atgaggtcag taatcggccc 1800

tcaggggttt ctaatcgctt ctctggctcc aagtctggca acacggcctc cctgaccatc 1860

tctgggctcc aggctgagga cgaggctgat tattactgca gctcatatac aagcagcagc 1920

actctcgtat tcggcggagg gaccaagctg accgtcctac gggctgatgc tgcaccaact 1980

gtatccatct tcccaccatc catggaacag ttaacatctg gaggtgccac agtcgtgtgc 2040

ttcgtgaaca acttctatcc cagagacatc agtgtcaagt ggaagattga tggcagtgaa 2100

caacgagatg gtgtcctgga cagtgttact gatcaggaca gcaaagacag cacgtacagc 2160

atgagcagca ccctctcgtt gaccaaggtt gaatatgaaa ggcataacct ctatacctgt 2220

gaggttgttc ataagacatc atcctcaccc gtcgtcaaga gcttcaacag gaatgagtgt 2280

taggctagct ggccagacat gataagatac attgatgagt ttggacaaac cacaactaga 2340

atgcagtgaa aaaaatgctt tatttgtgaa atttgtgatg ctattgcttt atttgtaacc 2400

attataagct gcaataaaca agttaacaac aacaattgca ttcattttat gtttcaggtt 2460

caggggagg tgtgggaggt tttttaaagc aagtaaaacc tctacaaatg tggtatggaa 2520

ttctaaaata cagcatagca aaactttaac ctccaaatca agcctctact tgaatccttt 2580

tctgagggat gaataaggca taggcatcag gggctgttgc caatgtgcat tagctgtttg 2640

cagcctcacc ttctttcatg gagtttaaga tatagtgtat tttcccaagg tttgaactag 2700

ctcttcattt ctttatgttt taaatgcact gacctcccac attccctttt tagtaaaata 2760

ttcagaaata atttaaatac atcattgcaa tgaaaataaa tgtttttttat taggcagaat 2820

ccagatgctc aaggcccttc ataatatccc ccagtttagt agttggactt agggaacaaa 2880

ggaaccttta atagaaattg gacagcaaga aagcgagctt ctagcgaatt ctcgactcat 2940

tcctttgccc tcggacgagt gctggggcgt cggtttccac tatcggcgag tacttctaca 3000

cagccatcgg tccagacggc cgcgcttctg cgggcgattt gtgtacgccc gacagtcccg 3060

gctccggatc ggacgattgc gtcgcatcga ccctgcgccc aagctgcatc atcgaaattg 3120

ccgtcaacca agctctgata gagttggtca agaccaatgc ggagcatata cgcccggagc 3180

cgcggcgatc ctgcaagctc cggatgcctc cgctcgaagt agcgcgtctg ctgctccata 3240

caagccaacc acggcctcca gaagaagatg ttggcgacct cgtattggga atccccgaac 3300

atcgcctcgc tccagtcaat gaccgctgtt atgcggccat tgtccgtcag gacattgttg 3360

gagccgaaat ccgcgtgcac gaggtgccgg acttcggggc agtcctcggc ccaaagcatc 3420

-continued

agctcatcga gagcctgcgc gacggacgca ctgacggtgt cgtccatcac agtttgccag 3480

tgatacacat ggggatcagc aatcgcgcat atgaaatcac gccatgtagt gtattgaccg 3540

attccttgcg gtccgaatgg gccgaacccg ctcgtctggc taagatcggc cgcagcgatc 3600

gcatccatga gctccgcgac gggttgcaga acagcgggca gttcggtttc aggcaggtct 3660

tgcaacgtga caccctgtgc acggcgggag atgcaatagg tcaggctctc gctgaattcc 3720

ccaatgtcaa gcacttccgg aatcgggagc gcggccgatg caaagtgccg ataaacataa 3780

cgatctttgt agaaaccatc ggcgcagcta tttacccgca ggacatatcc acgccctcct 3840

acatcgaagc tgaaagcacg agattcttcg ccctccgaga gctgcatcag gtcggagacg 3900

ctgtcgaact tttcgatcag aaacttctcg acagacgtcg cggtgagttc aggctttttc 3960

atgatggccc tcctatagtg agtcgtatta tactatgccg atatactatg ccgatgatta 4020

attgtcaaaa cagcgtggat ggcgtctcca gcttatctga cggttcacta aacgagctct 4080

gcttatatag acctcccacc gtacacgcct accgcccatt tgcgtcaatg gggcggagtt 4140

gttacgacat tttggaaagt cccgttgatt tactagtcaa aacaaactcc cattgacgtc 4200

aatggggtgg agacttggaa atccccgtga gtcaaaccgc tatccacgcc cattgatgta 4260

ctgccaaaac cgcatcatca tggtaatagc gatgactaat acgtagatgt actgccaagt 4320

aggaaagtcc cataaggtca tgtactgggc ataatgccag gcgggccatt taccgtcatt 4380

gacgtcaata gggggcgtac ttggcatatg atacacttga tgtactgcca agtgggcagt 4440

ttaccgtaaa tactccaccc attgacgtca atggaaagtc cctattggcg ttactatggg 4500

aacatacgtc attattgacg tcaatgggcg ggggtcgttg ggcggtcagc caggcgggcc 4560

atttaccgta agttatgtaa cgcctgcagg ttaattaaga acatgtgagc aaaaggccag 4620

caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag gctccgcccc 4680

cctgacgagc atcacaaaaa tcgacgctca agtcagaggt ggcgaaaccc gacaggacta 4740

taaagatacc aggcgtttcc ccctggaagc tccctcgtgc gctctcctgt tccgaccctg 4800

ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc 4860

tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac 4920

gaaccccccg ttcagcccga ccgctgcgcc ttatccggta actatcgtct tgagtccaac 4980

ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg 5040

aggtatgtag gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga 5100

agaacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa aagagttggt 5160

agctcttgat ccggcaaaca aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag 5220

cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc tacggggtct 5280

gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatggctag ttaattaaca 5340

tttaaatca 5349

<210> SEQ ID NO 98
<211> LENGTH: 6772
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: MV1043

<400> SEQUENCE: 98

-continued

cttgatttgg gtgatggttc acgtagtggg ccatcgccct gatagacggt ttttcgccct 60

ttgacgttgg agtccacgtt ctttaatagt ggactcttgt tccaaactgg aacaacactc 120

aactctatct cgggctattc ttttgattta taagggattt tgccgatttc ggtctattgg 180

ttaaaaaatg agctgattta acaaaaattt aacgcgaatt ttaacaaaat attaacgttt 240

acaatttttat ggtgcagtct cagtacaatc tgctctgatg ccgcatagtt aagccagccc 300

cgacacccgc caacacccgc tgacgcgccc tgacgggctt gtctgctccc ggcatccgct 360

tacagacaag ctgtgaccgt ctccgggagc tgcatgtgtc agaggttttc accgtcatca 420

ccgaaacgcg cgagacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 480

ataataatgg tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct 540

atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga 600

taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc 660

cttattccct tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg 720

aaagtaaaag atgctgaaga tcagttgggt gcccgagtgg gttacatcga actggatctc 780

aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact 840

tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc 900

ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag 960

catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat 1020

aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 1080

ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa 1140

gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc 1200

aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 1260

gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt 1320

gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 1380

gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat 1440

gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca 1500

gaccaagttt actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg 1560

atctaggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg 1620

ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tccttttttt 1680

ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg 1740

ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata 1800

ccaaatactg ttcttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca 1860

ccgcctacat acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag 1920

tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 1980

tgaacggggg gttcgtgcat acagcccagc ttggagcgaa cgacctacac cgaactgaga 2040

tacctacagc gtgagctatg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg 2100

tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac 2160

gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg 2220

tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 2280

-continued

ttcctggcct tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct 2340

gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc 2400

gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc 2460

cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg 2520

ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 2580

cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 2640

ggaaacagct atgaccatga ttacgccaag ctttggagcc tttttttgg agattttcaa 2700

cgtgaaaaaa ttattattcg caattccttt agttgttcct ttctattctc acagtgcaca 2760

gatccaaatg acccagtctc catcctccct gtctgcatct gtaggagaca gagtcaccat 2820

cacttgccgg gcaagtcaga gcattagcag ctacttaaat tggtatcagc agaaaccagg 2880

gaaagcccct aagctcctga tctatgctgc atccagtttg caaagtgggg tcccatcaag 2940

gttcagtggc agtggatctg ggacagattt cactctcacc atcagcagtc tgcaacctga 3000

agattttgca acttactact gtcaacagag ttacagtacc cctccaacgt tcggccaagg 3060

gaccaagctc gagatcaaac gtactgtggc tgcaccatct gtcttcatct tcccgccatc 3120

tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctatcc 3180

cagagaggcc aaagtacagt ggaaggtgga taacgccctc caatcgggta actcccagga 3240

gagtgtcaca gagcaggaca gcaaggacag cacctacagc ctcagcagca ccctgacgct 3300

gagcaaagca gactacgaga aacacaaagt ctacgcctgc gaagtcaccc atcagggcct 3360

gagctcgccc gtcacaaaga gcttcaacag gggagagtgt tagtaaggcg cgccaattct 3420

atttcaagga gacagtcata atgaaatacc tattgcctac ggcagccgct ggattgttat 3480

tactcgcggc ccagccggcc atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg 3540

ccgcttttct ggattcatcg actgtggccg gctgggtgtg gcggaccgct atcaggacat 3600

agcgttggct acccgtgata ttgctgaaga gcttggcggc gaatgggctg accgcttcct 3660

cgtgctttac ggtatcgccg ctcccgattc gcagcgcatc gccttctatc gccttcttga 3720

cgagttcttc tgagcgggac tctggggttc ggtgctacga gatttcgatt ccaccgccgc 3780

cttctatgaa aggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca 3840

gcgcggggat ctcatgctgg agttcttcgc ccaccccaac ttgtttattg cagcttataa 3900

tggttacaaa taaagcaata gcatcacaaa tttcacaaat aaagcatttt tttcactgca 3960

ttctagttgt ggtttgtcca aactcatcaa tgtatcttat catgtctgta taccgtcgac 4020

ctctagctag agcttggcgt aatcatggtc atagctgttt cctgtgtgaa attgttatcc 4080

gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaagcct ggggtgccta 4140

atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 4200

cctgtcgtgc cagaattgca tgaagaatct gcttagggtt aggcgttttg cgctgcttcg 4260

ctaggtggtc aatattggcc attagccata ttattcattg gttatatagc ataaatcaat 4320

attggctatt ggccattgca tacgttgtat ccatatcata atatgtacat ttatattggc 4380

tcatgtccaa cattaccgcc atgttgacat tgattattga ctagttatta atagtaatca 4440

attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta 4500

aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat 4560

-continued

gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 4620

taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac 4680

gtcaatgacg gtcaccgtct caagcgcctc caccaagggc ccatcggtct tccccctggc 4740

accctcctcc aagagcacct ctgggggcac agcggccctg ggctgcctgg tcaaggacta 4800

cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc ctgaccagcg gcgtccacac 4860

cttccccggct gtcctacagt cctcaggact ctactccctc agcagcgtag tgaccgtgcc 4920

ctccagcagc ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac 4980

caaggtggac aagaaagttg agcccaaatc ttgtgcggcc gcacatcatc atcaccatca 5040

cggggccgca gaacaaaaac tcatctcaga agaggatctg aatggggccg catagactgt 5100

tgaaagttgt ttagcaaaac ctcatacaga aaattcattt actaacgtct ggaaagacga 5160

caaaacttta gatcgttacg ctaactatga gggctgtctg tggaatgcta caggcgttgt 5220

ggtttgtact ggtgacgaaa ctcagtgtta cggtacatgg gttcctattg ggcttgctat 5280

ccctgaaaat gagggtggtg gctctgaggg tggcggttct gagggtggcg gttctgaggg 5340

tggcggtact aaacctcctg agtacggtga tacacctatt ccgggctata cttatatcaa 5400

ccctctcgac ggcacttatc cgcctggtac tgagcaaaac cccgctaatc ctaatccttc 5460

tcttgaggag tctcagcctc ttaatacttt catgtttcag aataataggt tccgaaatag 5520

gcagggtgca ttaactgttt atacgggcac tgttactcaa ggcactgacc ccgttaaaac 5580

ttattaccag tacactcctg tatcatcaaa agccatgtat gacgcttact ggaacggtaa 5640

attcagagac tgcgctttcc attctggctt taatgaggat ccattcgttt gtgaatatca 5700

aggccaatcg tctgacctgc ctcaacctcc tgtcaatgct ggcggcggct ctggtggtgg 5760

ttctggtggc ggctctgagg gtggcggctc tgagggtggc ggctctgagg gtggcggttc 5820

tgagggtggc ggctctgagg gtggcggttc cggtggcggc tccggttccg gtgattttga 5880

ttatgaaaaa atggcaaacg ctaataaggg ggctatgacc gaaaatgccg atgaaaacgc 5940

gctacagtct gacgctaaag gcaaacttga ttctgtcgct actgattacg gtgctgctat 6000

cgatggtttc attggtgacg tttccggcct tgctaatggt aatggtgcta ctggtgattt 6060

tgctggctct aattcccaaa tggctcaagt cggtgacggt gataattcac ctttaatgaa 6120

taatttccgt caatatttac cttctttgcc tcagtcggtt gaatgtcgcc cttatgtctt 6180

tggcgctggt aaaccatatg aattttctat tgattgtgac aaaataaact tattccgtgg 6240

tgtctttgcg tttcttttat atgttgccac ctttatgtat gtattttcga cgtttgctaa 6300

catactgcgt aataaggagt cttaataaga attcactggc cgtcgtttta caacgtcgtg 6360

actgggaaaa ccctggcgtt acccaactta atcgccttgc agcacatccc cctttcgcca 6420

gctggcgtaa tagcgaagag gcccgcaccg atcgcccttc ccaacagttg cgcagcctga 6480

atggcgaatg gcgcctgatg cggtattttc tccttacgca tctgtgcggt atttcacacc 6540

gcatacgtca aagcaaccat agtacgcgcc ctgtagcggc gcattaagcg cggcgggtgt 6600

ggtggttacg cgcagcgtga ccgctacact tgccagcgcc ttagcgcccg ctcctttcgc 6660

tttcttccct tcctttctcg ccacgttcgc cggctttccc cgtcaagctc taaatcgggg 6720

gctcccttta gggttccgat ttagtgcttt acggcacctc gaccccaaaa aa 6772

<210> SEQ ID NO 99

-continued

<211> LENGTH: 10293
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: MV1057

<400> SEQUENCE: 99

tactcttcct ttttcaatat tattgaagca tttatcaggg ttattgtctc atgagcggat 60

acatatttga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 120

aagtgccacc tgacgtcgac ggatcgggag atctcccgat cccctatggt gcactctcag 180

tacaatctgc tctgatgccg catagttaag ccagtatctg ctccctgctt gtgtgttgga 240

ggtcgctgag tagtgcgcga gcaaaattta agctacaaca aggcaaggct tgaccgacaa 300

ttgcatgaag aatctgctta gggttaggcg ttttgcgctg cttcgctagg tggtcaatat 360

tggccattag ccatattatt cattggttat atagcataaa tcaatattgg ctattggcca 420

ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg tccaacatta 480

ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac ggggtcatta 540

gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc 600

tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc catagtaacg 660

ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg 720

gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa tgacggtaaa 780

tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac 840

atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta catcaatggg 900

cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga cgtcaatggg 960

agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca 1020

ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag agctcgttta 1080

gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca tagaagacac 1140

cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaagcttggt accggtgaat 1200

tggccggccc gcgccgtcga ggttatcgat ccgaccgacg cgttcgcgag aggccgcaat 1260

tccctagcca ccatgggatg gagctgtatc atcctcttct tggtactgct gctggcccag 1320

ccggccatgg ggcggagaat gggcggaact gggcggagtt aggggcggga tgggcggagt 1380

taggggcggg actatggttg ctgactaatt gagatgcgga tccgctggca cgacaggttt 1440

cccgactgga aagcgggcag tgagcgcaac gcaattaatg tgagttagct cactcattag 1500

gcaccccagg ctttacactt tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga 1560

taacaatttc acacaggaaa cagctatgac catgattacg ccaagcttgg gctgcaggtt 1620

ctttccgcct cagaagccat agagcccacc gcatccccag catgcctgct attgtcttcc 1680

caatcctccc ccttgctgtc ctgccccacc ccacccccca gaatagaatg acacctactc 1740

agacaatgcg atgcaatttc ctcattttat taggaaagga cagtgggagt ggcaccttcc 1800

agggtcaagg aaggcacggg ggaggggcaa acaacagatg gctggcaact agaaggcaca 1860

gtcgaggctg atcagcgagc tctagatcat cgatgcatgg ggtcgtgcgc tcctttcggt 1920

cgggcgctgc gggtcgtggg gcgggcgtca ggcaccgggc ttgcgggtca tgcaccaggt 1980

gcgcggtcct tcgggcacct cgacgtcggc ggtgacggtg aagccgagcc gctcgtagaa 2040

-continued

ggggaggttg cggggcgcgg aggtctccag gaaggcgggc accccggcgc gctcggccgc 2100

ctccactccg gggagcacga cggcgctgcc cagacccttg ccctggtggt cgggcgagac 2160

gccgacggtg gccaggaacc acgcgggctc cttgggccgg tgcggcgcca ggaggccttc 2220

catctgttgc tgcgcggcca gccgggaacc gctcaactcg gccatgcgcg ggccgatctc 2280

ggcgaacacc gcccccgctt cgacgctctc cggcgtggtc cagaccgcca ccgcggcgcc 2340

gtcgtccgcg acccacacct tgccgatgtc gagcccgacg cgcgtgagga agagttcttg 2400

cagctcggtc accgtctcca gtgctagcac caagggccca tcggtcttcc ccctggcacc 2460

ctcctccaag agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt 2520

ccccgaaccg gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt 2580

cccggctgtc ctacagtcct caggactcta ctccctcagc agcgtcgtga ccgtgccctc 2640

cagcagcttg ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa 2700

ggtggacaag agagttggtg agaggccagc acagggaggg agggtgtctg ctggaagcca 2760

ggctcagcgc tcctgcctgg acgcatcccg gctatgcagt cccagtccag ggcagcaagg 2820

caggccccgt ctgcctcttc acccggaggc ctctgcccgc cccactcatg ctcagggaga 2880

gggtcttctg gctttttccc caggctctgg gcaggcacag gctaggtgcc cctaacccag 2940

gccctgcaca caaaggggca ggtgctgggc tcagacctgc caagagccat atccgggagg 3000

accctgcccc tgacctaagc ccaccccaaa ggccaaactc tccactccct cagctcggac 3060

accttctctc ctcccagatt ccagtaactc ccaatcttct ctctgcagag cccaaatctt 3120

gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg ggaccgtcag 3180

tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc cctgaggtca 3240

catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac tggtacgtgg 3300

acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac aacagcacgt 3360

accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc aaggagtaca 3420

agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc tccaaagcca 3480

aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggag gagatgacca 3540

agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac atcgccgtgg 3600

agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc gtgctggact 3660

ccgacggctc cttcttcctc tatagcaagc tcaccgtgga caagagcagg tggcagcagg 3720

ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac acgcagaaga 3780

gcctctccct gtctccgggt aaatgagttt aacggatctt aattaatccg agctcggtac 3840

caagcttaag tttaaaccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg 3900

ttgtttgccc ctccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt 3960

cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg 4020

gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg catgctgggg 4080

atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct aggggtatc 4140

cccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 4200

ccgctacact tgccagcgcc tagcgcccgc tcctttcgct ttcttccctt cctttctcgc 4260

cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttccgatt 4320

-continued

tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatggtt cacgtagtgg 4380

gccatcgccc tgatagacgg tttttcgccc tttgacgttg gagtccacgt tctttaatag 4440

tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgattt 4500

ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt 4560

taacgcgaat taattctgtg gaatgtgtgt cagttagggt gtggaaagtc cccaggctcc 4620

ccagcaggca gaagtatgca aagcatgcat ctcaattagt cagcaaccag gtgtggaaag 4680

tccccaggct ccccagcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc 4740

atagtcccgc ccctaactcc gcccatcccg cccctaactc cgcccagttc cgcccattct 4800

ccgccccatg gctgactaat ttttttatt tatgcagagg ccgaggccgc ctctgcctct 4860

gagctattcc agaagtagtg aggaggcttt tttggaggcc taggcttttg caaaaagctc 4920

ccgggagctt ggatatccat tttcggatct gatcaagaga caggatgagg atcgtttcgc 4980

atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 5040

ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 5100

gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 5160

caggacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 5220

ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 5280

gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 5340

cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 5400

atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 5460

gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgcg catgcccgac 5520

ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 5580

ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 5640

atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 5700

ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 5760

gacgagttct tctgagcggg actctggggt tcggtgctac gagatttcga ttccaccgcc 5820

gccttctatg aaaggttggg cttcggaatc gttttccggg acgccggctg gatgatcctc 5880

cagcgcgggg atctcatgct ggagttcttc gcccacccca acttgtttat tgcagcttat 5940

aatggttaca ataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 6000

cattctagtt gtggtttgtc caaactcatc aatgtatctt atcatgtctg tataccgtcg 6060

acctctagct agagcttggc gtaatcatgg tcatagctgt ttcctgtgtg aaattgttat 6120

ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc ctggggtgcc 6180

taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga 6240

aacctgtcgt gccagaattg catgaagaat ctgcttaggg ttaggcgttt tgcgctgctt 6300

cgctaggtgg tcaatattgg ccattagcca tattattcat tggttatata gcataaatca 6360

atattggcta ttggccattg catacgttgt atccatatca taatatgtac atttatattg 6420

gctcatgtcc aacattaccg ccatgttgac attgattatt gactagttat taatagtaat 6480

caattacggg gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg 6540

taaatggccc gcctggctga ccgcccaacg acccccgccc attgacgtca ataatgacgt 6600

-continued

atgttcccat agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttac 6660

ggtaaactgc ccacttggca gtacatcaag tgtatcatat gccaagtacg ccccctattg 6720

acgtcaatga cggtaaatgg cccgcctggc attatgccca gtacatgacc ttatgggact 6780

ttcctacttg gcagtacatc tacgtattag tcatcgctat taccatggtg atgcggtttt 6840

ggcagtacat caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccacc 6900

ccattgacgt caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtc 6960

gtaacaactc cgccccattg acgcaaatgg gcggtaggcg tgtacggtgg gaggtctata 7020

taagcagagc tcgtttagtg aaccgtcaga tcgcctggag acgccatcca cgctgttttg 7080

acctccatag aagacaccgg gaccgatcca gcctccgcgg ccgggaacgg tgcattggaa 7140

gcttggtacc ggtgaattag gcgcgccgtc gaggttatcg atccgaccga cgcgttcgcg 7200

agaggccgca attccctagc caccatggca tgccctggct tcctgtgggc acttgtgatc 7260

tccacctgtc ttgaattctc catggctgac atccagatga cccagtctcc atcctccctg 7320

tctgcatctg taggagacag agtcaccatc acttgccggg caagtcagag cattagcagc 7380

tacttaaatt ggtatcagca gaaaccaggg aaagccccta agctcctgat ctatgctgca 7440

tccagtttgc aaagtggggt cccatcaagg ttcagtggca gtggatctgg gacagatttc 7500

actctcacca tcagcagtct gcaacctgaa gattttgcaa cttactactg tcaacagagt 7560

tacagtaccc ctccaacgtt cggccaaggg accaaggtgg agatcaaacg taagtgcact 7620

ttgcggccgc taggaagaaa ctcaaaacat caagatttta aatacgcttc ttggtctcct 7680

tgctataatt atctgggata agcatgctgt tttctgtctg tccctaacat gccctgtgat 7740

tatccgcaaa caacacaccc aagggcagaa ctttgttact taaacaccat cctgtttgct 7800

tctttcctca ggaactgtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca 7860

gttgaaatct ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc 7920

caaagtacag tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac 7980

agagcaggac agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc 8040

agactacgag aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc 8100

cgtcacaaag agcttcaaca ggggagagtg ttaggtttaa cggatccgag ctcggtacca 8160

agctcaagtt taaaccgctg atcagcctcg actgtgcctt ctagttgcca gccatctgtt 8220

gtttgccccc cccccgtgcc ttccttgacc ctggaaggtg ccactcccac tgtcctttcc 8280

taataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat tctgggggggt 8340

ggggtggggc aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat 8400

gcggtgggct ctatggcttc tgaggcggaa agaaccagct gcattaatga atcggccaac 8460

gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc 8520

tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt 8580

tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 8640

ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc cccctgacg 8700

agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 8760

accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 8820

ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct 8880

-continued

gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc 8940

ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa 9000

gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 9060

taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag 9120

tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt 9180

gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 9240

cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 9300

agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca 9360

cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 9420

cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat 9480

ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 9540

taccatctgg ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt 9600

tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 9660

ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 9720

atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9780

gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 9840

tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 9900

cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 9960

taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10020

ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 10080

ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 10140

cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 10200

ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 10260

gaataagggc gacacggaaa tgttgaatac tca 10293

<210> SEQ ID NO 100
<211> LENGTH: 8179
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pCAGGS-IgVK1-39 targeting vector

<400> SEQUENCE: 100

atccaggcgc ggatcaataa aagatcatta ttttcaatag atctgtgtgt tggtttttg 60

tgtgccttgg gggaggggga ggccagaatg aggcgcggcc aaggggagg gggaggccag 120

aatgaccttg ggggaggggg aggccagaat gaccttgggg gaggggagg ccagaatgag 180

gcgcggatcc ggagaagttc ctattccgaa gttcctattc ttcaaatagt ataggaactt 240

cgctcgaggg atcggccatt gaacaagatg gattgcacgc aggttctccg gccgcttggg 300

tggagaggct attcggctat gactgggcac aacagacaat cggctgctct gatgccgccg 360

tgttccggct gtcagcgcag gggcgcccgg ttctttttgt caagaccgac ctgtccggtg 420

ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg acgggcgttc 480

cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg ctattgggcg 540

-continued

aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa gtatccatca 600

tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca ttcgaccacc 660

aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt gtcgatcagg 720

atgatctgga cgaagagcat caggggctcg cgccagccga actgttcgcc aggctcaagg 780

cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc ttgccgaata 840

tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg ggtgtggcgg 900

accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt ggcggcgaat 960

gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag cgcatcgcct 1020

tctatcgcct tcttgacgag ttcttctgag gggatcgatc cgctgtaagt ctgcagaaat 1080

tgatgatcta ttaaacaata aagatgtcca ctaaaatgga agtttttcct gtcatacttt 1140

gttaagaagg gtgagaacag agtacctaca ttttgaatgg aaggattgga gctacggggg 1200

tgggggtggg gtgggattag ataaatgcct gctctttact gaaggctctt tactattgct 1260

ttatgataat gtttcatagt tggatatcat aatttaaaca agcaaaacca aattaagggc 1320

cagctcattc ctcccactca tgatctatag atctatagat ctctcgtggg atcattgttt 1380

ttctcttgat tcccactttg tggttctaag tactgtggtt tccaaatgtg tcagtttcat 1440

agcctgaaga acgagatcag cagcctctgt tccacataca cttcattctc agtattgttt 1500

tgccaagttc taattccatc agaagctgac tctagatggc gcgtatgcag gttttcgaca 1560

ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc atagcccata 1620

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga 1680

cccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt 1740

ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt 1800

gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca 1860

ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt 1920

catcgctatt accatggtcg aggtgagccc cacgttctgc ttcactctcc ccatctcccc 1980

cccctcccca cccccaattt tgtatttatt tatttttaa ttattttgtg cagcgatggg 2040

ggcgggggggg ggggggcgc gcgccaggcg gggcggggcg gggcgagggg cggggcgggg 2100

cgaggcggag aggtgcggcg gcagccaatc agagcggcgc gctccgaaag tttccttta 2160

tggcgaggcg gcggcggcgg cggccctata aaaagcgaag cgcgcggcgg gcgggagtcg 2220

ctgcgttgcc ttcgccccgt gccccgctcc gcgccgcctc gcgccgcccg ccccggctct 2280

gactgaccgc gttactccca caggtgagcg ggcgggacgg cccttctcct ccgggctgta 2340

attagcgctt ggtttaatga cggctcgttt cttttctgtg gctgcgtgaa agccttaaag 2400

ggctccggga gggccctttg tgcgggggggg agcggctcgg ggggtgcgtg cgtgtgtgtg 2460

tgcgtgggga gcgccgcgtg cggcccgcgc tgcccggcgg ctgtgagcgc tgcgggcgcg 2520

gcgcggggct ttgtgcgctc cgcgtgtgcg cgaggggagc gcggccgggg gcggtgcccc 2580

gcggtgcggg ggggctgcga ggggaacaaa ggctgcgtgc ggggtgtgtg cgtgggggggg 2640

tgagcagggg gtgtgggcgc ggcggtcggg ctgtaacccc cccctgcacc cccctccccg 2700

agttgctgag cacggcccgg cttcgggtgc ggggctccgt gcggggcgtg gcgcggggct 2760

cgccgtgccg ggcgggggggt ggcggcaggt gggggtgccg ggcggggcgg ggccgcctcg 2820

-continued

ggccggggag ggctcggggg aggggcgcgg cggccccgga gcgccggcgg ctgtcgaggc 2880

gcggcgagcc gcagccattg ccttttatgg taatcgtgcg agagggcgca gggacttcct 2940

ttgtcccaaa tctgtgcgga gccgaaatct gggaggcgcc gccgcacccc ctctagcggg 3000

cgcggggcga agcggtgcgg cgccggcagg aaggaaatgg gcggggaggg ccttcgtgcg 3060

tcgccgcgcc gccgtcccct tctccctctc cagcctcggg gctgtccgcg gggggacggc 3120

tgccttcggg ggggacgggg cagggcgggg ttcggcttct ggcgtgtgac cggcggctct 3180

agaagcgttg gggtgagtac tccctctcaa aagcgggcat gacttctgcg ctaagattgt 3240

cagtttccaa aaacgaggag gatttgatat tcacctggcc cgcggtgatg cctttgaggg 3300

tggccgcgtc catctggtca gaaaagacaa tctttttgtt gtcaagcttg aggtgtggca 3360

ggcttgagat ctggccatac acttgagtga cattgacatc cactttgcct ttctctccac 3420

aggtgtccac tcccagggcg gcctccggag cgatcgccga tccgcctagg caattgttta 3480

aatcggccgg ccataacttc gtataatgta tgctatacga agttatggat cctcacagta 3540

ggtggcatcg ttccttttctg actgcccgcc ccccgcatgc cgtcccgcga tattgagctc 3600

cgaacctctc gccctgccgc cgccggtgct ccgtcgccgc cgcgccgcca tggaatcgaa 3660

gccaccatgg atcttaccgg aaaactcgac gcaagaaaaa tcagagagat cctcataaag 3720

gtcaagaagg gcggaaagat cgccgtgtaa ttctagaccg gttcgagatc caggcgcgga 3780

tcaataaaag atcattattt tcaatagatc tgtgtgttgg ttttttgtgt gccttggggg 3840

aggggaggc cagaatgagg cgcggccaag ggggaggggg aggccagaat gaccttgggg 3900

gaggggagg ccagaatgac cttgggggag ggggaggcca gaatgaggcg cgccctccgt 3960

cgacctataa cttcgtataa tgtatgctat acgaagttat ggcggccgcc accatggaca 4020

tgagagtgcc cgcccagctc ctggggctcc tgctactctg gctccgaggt aaggatggag 4080

aacactagga atttactcag ccagtgtgct cagtactgac tggaacttca gggaagttct 4140

ctgataacat gattaatagt aagaatattt gtttttatgt ttccaatctc aggtgccaga 4200

tgtgacatcc agatgaccca gagccccagc agcctgagcg ccagcgtggg cgacagagtg 4260

accatcacct gcagagccag ccagagcatc agcagctacc tgaactggta tcagcagaag 4320

cccggcaagg cccccaagct gctgatctac gccgccagct ccctgcagag cggcgtgccc 4380

agcagattca gcggcagcgg ctccggcacc gacttcaccc tgaccatcag cagcctgcag 4440

cccgaggact tcgccaccta ctactgccag cagagctaca gcacccccc caccttcggc 4500

cagggcacca aggtggagat caagagagcc gacgccgctc ccaccgtgtc catcttcccc 4560

cccagcatgg aacagctgac ctctggcgga gccaccgtgg tctgcttcgt gaacaacttc 4620

taccccagag acatcagcgt gaagtggaag atcgacggca gcgagcagag ggacggcgtg 4680

ctggacagcg tgaccgacca ggacagcaag gactccacct acagcatgag cagcaccctg 4740

agcctgacca aggtggagta cgagaggcac aacctgtaca cctgcgaggt ggtgcacaag 4800

accagctcca gccccgtggt caagtccttc aaccggaacg agtgttgagc tagcttaaga 4860

tttaaatagg ccggccgcgt cgacctcgag atccaggcgc ggatcaataa aagatcatta 4920

ttttcaatag atctgtgtgt tggttttttg tgtgccttgg gggaggggga ggccagaatg 4980

aggcgcggcc aaggggggagg gggaggccag aatgaccttg ggggaggggg aggccagaat 5040

gaccttgggg gaggggggagg ccagaatgag gcgcgccccc gggtaccgag ctcgaattag 5100

-continued

tggatcctca cagtaggtgg catcgttcct ttctgactgc ccgccccccg catgccgtcc 5160

cgcgatattg agctccgaac ctctcgccct gccgccgccg gtgctccgtc gccgccgcgc 5220

cgccatggaa tcgcgccggt aaccgaagtt cctatacttt ctagagaata ggaacttcgg 5280

aataggaact tcaagccggt acccagcttt tgttcccttt agtgagggtt aatttcgagc 5340

ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca 5400

cacaacatac gagccgggag cataaagtgt aaagcctggg gtgcctaatg agtgagctaa 5460

ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag 5520

ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc 5580

gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct 5640

cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg 5700

tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 5760

cataggctcc gccccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga 5820

aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct 5880

cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg 5940

gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag 6000

ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat 6060

cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac 6120

aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac 6180

tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttaccttc 6240

ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt 6300

tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 6360

ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg 6420

agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca 6480

atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca 6540

cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag 6600

ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac 6660

ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 6720

agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct 6780

agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc 6840

gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg 6900

cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc 6960

gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat 7020

tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag 7080

tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat 7140

aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg 7200

cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 7260

cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga 7320

aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 7380

-continued

ttccttttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 7440

tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg 7500

ccacctaaat tgtaagcgtt aatatttttgt taaaattcgc gttaaatttt tgttaaatca 7560

gctcattttt taaccaatag gccgaaatcg gcaaaatccc ttataaatca aaagaataga 7620

ccgagatagg gttgagtgtt gttccagttt ggaacaagag tccactatta aagaacgtgg 7680

actccaacgt caaagggcga aaaaccgtct atcagggcga tggcccacta cgtgaaccat 7740

caccctaatc aagttttttg gggtcgaggt gccgtaaagc actaaatcgg aaccctaaag 7800

ggagcccccg atttagagct tgacggggaa agccggcgaa cgtggcgaga aaggaaggga 7860

agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt agcggtcacg ctgcgcgtaa 7920

ccaccacacc cgccgcgctt aatgcgccgc tacagggcgc gtcccattcg ccattcaggc 7980

tgcgcaactg ttgggaaggg cgatcggtgc gggcctcttc gctattacgc cagctggcga 8040

aaggggatg tgctgcaagg cgattaagtt gggtaacgcc agggttttcc cagtcacgac 8100

gttgtaaaac gacggccagt gagcgcgcgt aatacgactc actatagggc gaattggggg 8160

taactaagta aggatcgag 8179

<210> SEQ ID NO 101
<211> LENGTH: 8188
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: pCAGGS-IgVL2-14 targeting vector

<400> SEQUENCE: 101

atccaggcgc ggatcaataa aagatcatta ttttcaatag atctgtgtgt tggtttttg 60

tgtgccttgg gggaggggga ggccagaatg aggcgcggcc aaggggagg gggaggccag 120

aatgaccttg ggggaggggg aggccagaat gaccttgggg gaggggagg ccagaatgag 180

gcgcggatcc ggagaagttc ctattccgaa gttcctattc ttcaaatagt ataggaactt 240

cgctcgaggg atcggccatt gaacaagatg gattgcacgc aggttctccg gccgcttggg 300

tggagaggct attcggctat gactgggcac aacagacaat cggctgctct gatgccgccg 360

tgttccggct gtcagcgcag gggcgcccgg ttctttttgt caagaccgac ctgtccggtg 420

ccctgaatga actgcaggac gaggcagcgc ggctatcgtg gctggccacg acgggcgttc 480

cttgcgcagc tgtgctcgac gttgtcactg aagcgggaag ggactggctg ctattgggcg 540

aagtgccggg gcaggatctc ctgtcatctc accttgctcc tgccgagaaa gtatccatca 600

tggctgatgc aatgcggcgg ctgcatacgc ttgatccggc tacctgccca ttcgaccacc 660

aagcgaaaca tcgcatcgag cgagcacgta ctcggatgga agccggtctt gtcgatcagg 720

atgatctgga cgaagagcat caggggctcg cgccagccga actgttcgcc aggctcaagg 780

cgcgcatgcc cgacggcgag gatctcgtcg tgacccatgg cgatgcctgc ttgccgaata 840

tcatggtgga aaatggccgc ttttctggat tcatcgactg tggccggctg ggtgtggcgg 900

accgctatca ggacatagcg ttggctaccc gtgatattgc tgaagagctt ggcggcgaat 960

gggctgaccg cttcctcgtg ctttacggta tcgccgctcc cgattcgcag cgcatcgcct 1020

tctatcgcct tcttgacgag ttcttctgag gggatcgatc cgctgtaagt ctgcagaaat 1080

tgatgatcta ttaaacaata aagatgtcca ctaaaatgga agtttttcct gtcatacttt 1140

-continued

gttaagaagg gtgagaacag agtacctaca ttttgaatgg aaggattgga gctacggggg 1200

tgggggtggg gtgggattag ataaatgcct gctctttact gaaggctctt tactattgct 1260

ttatgataat gtttcatagt tggatatcat aatttaaaca agcaaaacca aattaagggc 1320

cagctcattc ctcccactca tgatctatag atctatagat ctctcgtggg atcattgttt 1380

ttctcttgat tcccactttg tggttctaag tactgtggtt tccaaatgtg tcagtttcat 1440

agcctgaaga acgagatcag cagcctctgt tccacataca cttcattctc agtattgttt 1500

tgccaagttc taattccatc agaagctgac tctagatggc gcgtatgcag gttttcgaca 1560

ttgattattg actagttatt aatagtaatc aattacgggg tcattagttc atagcccata 1620

tatggagttc cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga 1680

cccccgccca ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt 1740

ccattgacgt caatgggtgg agtatttacg gtaaactgcc cacttggcag tacatcaagt 1800

gtatcatatg ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgcctggca 1860

ttatgcccag tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt 1920

catcgctatt accatggtcg aggtgagccc cacgttctgc ttcactctcc ccatctcccc 1980

cccctcccca cccccaattt tgtatttatt tatttttttaa ttattttgtg cagcgatggg 2040

ggcgggggggg ggggggcgc gcgccaggcg gggcggggcg gggcgagggg cggggcgggg 2100

cgaggcggag aggtgcggcg gcagccaatc agagcggcgc gctccgaaag tttccttta 2160

tggcgaggcg gcggcggcgg cggccctata aaaagcgaag cgcgcggcgg gcgggagtcg 2220

ctgcgttgcc ttcgccccgt gccccgctcc gcgccgcctc gcgccgcccg ccccggctct 2280

gactgaccgc gttactccca caggtgagcg ggcgggacgg cccttctcct ccgggctgta 2340

attagcgctt ggtttaatga cggctcgttt cttttctgtg gctgcgtgaa agccttaaag 2400

ggctccggga gggccctttg tgcgggggggg agcggctcgg ggggtgcgtg cgtgtgtgtg 2460

tgcgtgggga gcgccgcgtg cggcccgcgc tgcccggcgg ctgtgagcgc tgcgggcgcg 2520

gcgcggggct ttgtgcgctc cgcgtgtgcg cgaggggagc gcggccgggg gcggtgcccc 2580

gcggtgcggg ggggctgcga ggggaacaaa ggctgcgtgc ggggtgtgtg cgtgggggggg 2640

tgagcagggg gtgtgggcgc ggcggtcggg ctgtaacccc cccctgcacc cccctccccg 2700

agttgctgag cacggcccgg cttcgggtgc ggggctccgt gcggggcgtg gcgcggggct 2760

cgccgtgccg ggcgggggggt ggcggcaggt gggggtgccg ggcggggcgg ggccgcctcg 2820

ggccggggag ggctcgggggg aggggcgcgg cggccccgga gcgccggcgg ctgtcgaggc 2880

gcggcgagcc gcagccattg ccttttatgg taatcgtgcg agagggcgca gggacttcct 2940

ttgtcccaaa tctgtgcgga gccgaaatct gggaggcgcc gccgcacccc ctctagcggg 3000

cgcggggcga agcggtgcgg cgccggcagg aaggaaatgg gcggggaggg ccttcgtgcg 3060

tcgccgcgcc gccgtcccct tctccctctc cagcctcggg gctgtccgcg gggggacggc 3120

tgccttcggg ggggacgggg cagggcgggg ttcggcttct ggcgtgtgac cggcggctct 3180

agaagcgttg gggtgagtac tccctctcaa aagcgggcat gacttctgcg ctaagattgt 3240

cagtttccaa aaacgaggag gatttgatat tcacctggcc cgcggtgatg cctttgaggg 3300

tggccgcgtc catctggtca gaaaagacaa tctttttgtt gtcaagcttg aggtgtggca 3360

ggcttgagat ctggccatac acttgagtga cattgacatc cactttgcct ttctctccac 3420

-continued

aggtgtccac tcccagggcg gcctccggag cgatcgccga tccgcctagg caattgttta 3480

aatcggccgg ccataacttc gtataatgta tgctatacga agttatggat cctcacagta 3540

ggtggcatcg ttcctttctg actgcccgcc ccccgcatgc cgtcccgcga tattgagctc 3600

cgaacctctc gccctgccgc cgccggtgct ccgtcgccgc cgcgccgcca tggaatcgaa 3660

gccaccatgg atcttaccgg aaaactcgac gcaagaaaaa tcagagagat cctcataaag 3720

gtcaagaagg gcggaaagat cgccgtgtaa ttctagaccg gttcgagatc caggcgcgga 3780

tcaataaaag atcattattt tcaatagatc tgtgtgttgg ttttttgtgt gccttggggg 3840

agggggaggc cagaatgagg cgcggccaag ggggaggggg aggccagaat gaccttgggg 3900

gagggggagg ccagaatgac cttgggggag ggggaggcca gaatgaggcg cgccctccgt 3960

cgacctataa cttcgtataa tgtatgctat acgaagttat ggcggccgcc accatggaca 4020

tgagagtgcc cgcccagctc ctggggctcc tgctactctg gctccgaggt aaggatggag 4080

aacactagga atttactcag ccagtgtgct cagtactgac tggaacttca gggaagttct 4140

ctgataacat gattaatagt aagaatattt gtttttatgt ttccaatctc aggtgccaga 4200

tgtcagtctg ccctgaccca gcccgcctct gtgtctggca gccctggcca gagcatcacc 4260

atcagctgca ccggcaccag cagcgacgtg ggcggctaca actacgtgtc ctggtatcag 4320

cagcaccccg gcaaggcccc caagctgatg atctacgagg tgtccaacag acccagcggc 4380

gtgagcaaca gattcagcgg cagcaagagc ggcaacaccg ccagcctgac catcagcggc 4440

ctccaggctg aggacgaggc cgactactac tgcagcagct acaccagcag ctccaccctg 4500

gtgtttggcg gcggaacaaa gctgaccgtg ctgagagccg acgccgctcc caccgtgtcc 4560

atcttccccc ccagcatgga acagctgacc tctggcggag ccaccgtggt ctgcttcgtg 4620

aacaacttct accccagaga catcagcgtg aagtggaaga tcgacggcag cgagcagagg 4680

gacggcgtgc tggacagcgt gaccgaccag gacagcaagg actccaccta cagcatgagc 4740

agcaccctga gcctgaccaa ggtggagtac gagaggcaca acctgtacac ctgcgaggtg 4800

gtgcacaaga ccagctccag ccccgtggtc aagtccttca accggaacga gtgttgagct 4860

agcttaagat ttaaataggc cggccgcgtc gacctcgaga tccaggcgcg gatcaataaa 4920

agatcattat tttcaataga tctgtgtgtt ggtttttttgt gtgccttggg ggaggggggag 4980

gccagaatga ggcgcggcca agggggaggg ggaggccaga atgaccttgg gggaggggga 5040

ggccagaatg accttggggg agggggaggc cagaatgagg cgcgcccccg ggtaccgagc 5100

tcgaattagt ggatcctcac agtaggtggc atcgttcctt tctgactgcc cgccccccgc 5160

atgccgtccc gcgatattga gctccgaacc tctcgccctg ccgccgccgg tgctccgtcg 5220

ccgccgcgcc gccatggaat cgcgccggta accgaagttc ctatactttc tagagaatag 5280

gaacttcgga ataggaactt caagccggta cccagctttt gttcccttta gtgagggtta 5340

atttcgagct tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc 5400

acaattccac acaacatacg agccgggagc ataaagtgta aagcctgggg tgcctaatga 5460

gtgagctaac tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg 5520

tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg 5580

cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg 5640

gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga 5700

-continued

aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg 5760

gcgtttttcc ataggctccg ccccccctgac gagcatcaca aaaatcgacg ctcaagtcag 5820

aggtggcgaa acccgacagg actataaaga taccaggcgt ttcccccctgg aagctccctc 5880

gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg 5940

ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt 6000

cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc 6060

ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc 6120

actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg 6180

tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca 6240

gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 6300

ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 6360

cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt 6420

ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 6480

tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc 6540

agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 6600

gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata 6660

ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 6720

gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc 6780

cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct 6840

acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa 6900

cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt 6960

cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca 7020

ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac 7080

tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca 7140

atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 7200

tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc 7260

actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca 7320

aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata 7380

ctcatactct tccttttttca atattattga agcatttatc agggttattg tctcatgagc 7440

ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc 7500

cgaaaagtgc cacctaaatt gtaagcgtta atattttgtt aaaattcgcg ttaaattttt 7560

gttaaatcag ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa 7620

aagaatagac cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa 7680

agaacgtgga ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac 7740

gtgaaccatc accctaatca agtttttttgg ggtcgaggtg ccgtaaagca ctaaatcgga 7800

accctaaagg gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa 7860

aggaagggaa gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc 7920

tgcgcgtaac caccacaccc gccgcgctta atgcgccgct acagggcgcg tcccattcgc 7980

-continued

cattcaggct gcgcaactgt tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc 8040

agctggcgaa agggggatgt gctgcaaggc gattaagttg ggtaacgcca gggttttccc 8100

agtcacgacg ttgtaaaacg acggccagtg agcgcgcgta atacgactca ctatagggcg 8160

aattgggggt aactaagtaa ggatcgag 8188

<210> SEQ ID NO 102
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Kozak sequence

<400> SEQUENCE: 102

gccaccatgg 10

1. A method for producing a composition comprising at least two different antibodies or antigen-binding fragments thereof comprising paired variable regions, said at least two antibodies or antigen-binding fragments thereof having different binding specificities, comprising contacting at least one light chain variable region with at least two heavy chain variable regions under conditions allowing for pairing of light chain variable regions with heavy chain variable regions and harvesting antibodies or antigen-binding fragments thereof having binding specificities resulting from said pairing,

wherein said contacting takes place inside a cell; and

said variable regions are produced by expression of nucleic acid sequences encoding said variable regions, and

wherein said nucleic acids encode heavy chain variable regions expressed by B cells of transgenic non-human animals that have been immunized with antigens,

wherein the genome of the transgenic animals comprises a transgene comprising a immunoglobulin light chain germline V gene segment fused to a immunoglobulin light chain germline J gene segment such that there is no mutation due to said fusion, wherein the fused V/J gene segments encode a rearranged immunoglobulin light chain variable region and wherein the transgene comprises a light chain constant region gene segment or is operatively linked to an endogenous light chain constant region gene segment and

wherein said transgenic animals produce populations of B cells producing antigen-specific antibodies, wherein said antibodies comprise the rearranged light chain immunoglobulin variable region encoded by the fused V/J gene segments paired with a diversity of heavy chain variable regions.

2. The method of claim **1**, wherein said light chain variable region upon pairing does not significantly contribute to the resulting binding specificity of the resulting antibodies or antigen-binding fragments thereof.

3. The method of claim **1** for producing a composition of antibodies or antigen binding fragments thereof comprising at least three different binding specificities.

4. The method of claim **1**, wherein at least two different heavy chain variable regions are expressed from one or more nucleic acids encoding these variable regions, whereby expression of said different variable regions is under the direction of different control elements.

5. The method of claim **4**, wherein said differential expression is different in levels of expression and/or time of expression.

6. An expression system for carrying out the method of claim **1**, comprising nucleic acids encoding said variable regions together with elements required for gene expression and pairing.

7. Recombinant host cells that comprise the expression system of claim **6**.

8. The cells of claim **7** which are eukaryotic cells.

9. A method for identifying antibodies or antigen-binding fragments thereof having specific affinity for at least one target epitope, comprising contacting antibodies or antigen-binding fragments thereof produced by the cells of claim **7** with said target epitope and identifying antibodies or antigen-binding fragments thereof showing said specific affinity.

10. The method of claim **9**, wherein antibodies or antigen-binding fragments thereof having specific affinity for at least two target epitopes, are identified.

11. A composition comprising antibodies or antigen binding fragments thereof obtainable by the method of claim **1**.

12. The composition of claim **11**, wherein said antibodies or antigen-binding fragments thereof are directed to at least two target antigens and/or two target epitopes.

13. The composition of claim **12**, wherein the target epitopes are associated with a disease or disorder.

14. The composition of claim **13**, wherein antibodies or antigen-binding fragments thereof are human antibodies.

15. A pharmaceutical composition comprising the composition of claim **13**.

16. The composition of claim **11** comprising at least one monospecific antibody and at least one bispecific antibody.

17. The composition of claim **11** comprising at least two monospecific antibodies.

18. The composition of claim **13**, wherein at least one target antigen is a protein or carbohydrate expressed on the surface of bacteria, viruses, or other pathogen or is an endogenous animal protein.

19. The composition of claim **18**, wherein the target antigen comprises two or more epitopes derived from or two or more targets selected from proteins and carbohydrates expressed on the surface of bacteria, viruses, or other pathogen or are endogenous animal proteins.

20. The composition of claim **18**, wherein the target antigen is an EGF receptor family member including erbB1 (EGF-R; HER 1), erbB2, (HER2), erbB3 (HER3) or erbB4 (HER4), or is c-Met (HGF-R or is a vascular endothelial growth factor receptor (VEGFR) family member or is VEGF, CD20, CD38, CD33, CEA, EpCAM, PSMA, CD19, CTLA4 or TGFbeta.

21. The composition of claim **19**, wherein the target antigen comprises two or more epitopes derived from or two or more targets which are selected from an EGF receptor family member including erbB1 (EGF-R; HER 1), erbB2, (HER2), erbB3 (HER3), and erbB4 (HER4); c-Met (HGF-R; a vascular endothelial growth factor receptor (VEGFR) family member; VEGF, CD20, CD38, CD33, CEA, EpCAM, PSMA, CD19, CTLA4 and TGFbeta.

* * * * *